

USING REAL WORLD DATA AND DESIGNS TO OPTIMIZE DECISIONS

A stylized graphic of the Philadelphia skyline, including the Liberty Bell, Independence Hall, and various skyscrapers, set against a cityscape background.

INTERNATIONAL CONFERENCE ON PHARMACOEPIDEMIOLOGY & THERAPEUTIC RISK MANAGEMENT

35TH ICPE

AUGUST 24-28, 2019

PENNSYLVANIA CONVENTION CENTER • PHILADELPHIA, PA

SCIENTIFIC PROGRAM

JOINTLY SPONSORED BY



Login to my ispe conference to elevate your conference experience <https://www.pharmacoepi.org/meetings/35ICPE>

Board of Directors & Volunteer Leaders

ISPE Officers & Board of Directors

OFFICERS

Alison Bourke, FISPE, President
 Almut Winterstein, FISPE, President-Elect
 Jesper Hallas, FISPE, Immediate Past President
 Krista Huybrechts, FISPE, Vice President Finance
 James Vrac, Executive Secretary
 Mark Epstein, Executive Secretary, *Emeritus*

DIRECTORS

Dorothee Bartels, FISPE	Lisa Pont, FISPE
Pia Caduff-Janosa	June Raine
Vera Ehrenstein	Jennita Reefhuis
Cynthia Girman, FISPE	Rachel Sobel, FISPE
Chieko Ishiguro	Montse Soriano Gabarro
Michelle Jonsson Funk, FISPE	Darren Toh, FISPE
Olaf Klungel, FISPE	Jasmanda Wu, FISPE
Malcolm Maclure	Stanley Edlavitch, <i>Lifetime Emeritus</i>

2019 ICPE Scientific Program Committee

Vincent Lo Re, FISPE

CORE PROGRAM COMMITTEE

Jaclyn Bosco, FISPE	Bradley Layton
Corinne de Vries, FISPE	Charles Leonard
Ian Douglas	Jenny Lund
Sascha Dublin	Yola Moide, FISPE
Stanley A Edlavitch, <i>Conference Chair Emeritus</i>	Elaine Morato
Vera Ehrenstein	Syd Phillips
Mark H Epstein	Lisa Pont, FISPE
Tobias Gerhard, FISPE	June Raine
Rosa Gini	Mary Ritchey, FISPE
Susanna Gutthann-Perez, FISPE	Soko Setoguchi Iwata, FISPE
Christian Hampp, FISPE	Rachel Sobel, FISPE
Daniel Horton	Montse Soriano Gabarro
Krista Huybrechts, FISPE	Walter Straus
Solomon Iyasu	Til Sturmer, FISPE
Ursula Kirchmayer, FISPE	Almut Winterstein, FISPE
Olaf Klungel, FISPE	Lindsay Wong
	Jasmanda Wu, FISPE

2019 ICPE Local Host Committee

Daniel Horton, Chair	Charles Leonard
Quazi Ataher	James Lewis, FISPE
Kristen Bibeau	Nancy Lewis
Kourtney Davis	Longjian Liu
Kelly Filipksi	Vincent Lo Re, FISPE
Tobias Gerhard, FISPE	Eileen Ming, FISPE
Kevin Haynes, FISPE	Mary Ritchey, FISPE
Amalia Issa, FISPE	Ravy Vajravelu

Chairs/Co-Chairs & Liaisons

COMMITTEES

Bylaws & Policies

Stella Blackburn, FISPE
 Frank May, FISPE

Development

Doug Kou
 Nick Everage

Education

Jaclyn Bosco, FISPE
 Caitlin Knox
 Anton Pottegård

Fellowship & Awards

Jesper Hallas, FISPE

Finance

Krista Huybrechts, FISPE

Global Development

Arnold Chan, FISPE
 Wei Zhou, FISPE

History & Archives

Hugh Tilson, FISPE
 Eileen Ming, FISPE

Management Oversight

Jesper Hallas, FISPE

Membership

Alicia Gilseman

Nominating

Quazi Ataher

Public Policy & Ethics

Jesper Hallas, FISPE

Lisa Pont, FISPE

Meredith Smith

Kourtney Davis

Christine Ulbricht

Alison Bourke, FISPE

David Miller, FISPE

Almut Winterstein, FISPE

Publications & Communications

Scholarship

Strategic Planning

Kevin Lu

COUNCILS

Academic

Vicki Osborne

Ann McMahon

Government/Regulatory

John Acquavella, FISPE

Industry/Service Providers

Dan Fife, FISPE

Student

Lindsay Wong

Caroline Walsh

SPECIAL INTEREST GROUPS (SIGS)

Adherence

Julie Lauffenburger

Sarah-Jo Sinnott

Asian Pharmacoepidemiology Network (AsPEN)

Kenneth Mann

Nam-Kyong Choi

Edward Chia-Cheng Lai

Nicole Pratt

Benefit Risk Assessment, Communication And Evaluation (BRACE)

Annalisa Rubino

Brett Hauber

Elaine Morrato

Gianluca Trifirò

Michael Kelsh

Biologics & Biosimilars

Comparative Effectiveness Research (CER)

Elisabetta Patorno

Hongbo Yuan

Matthew Reynolds, FISPE

Daniel Prieto Alhambra, FISPE

Xiaofeng Zhou

Databases



Volunteer Leaders & Committees

Digital Epidemiology Drug Utilization Research

Dorothee Bartels, FISPE
Veronika Wirtz, FISPE
Douglas Steinke

Geriatric Pharmacoepidemiology

Kristina Johnell
Daniel Prieto-Alhambra, FISPE

Medical Devices

Macarius Donneyong
Christina Mack

Medications In Pregnancy & Lactation (MIPAL)

Hedvig Nordeng
Susan Sinclair

Molecular Epi/Biomarkers/Pharmacogenetics

Gillian Bartlett-Esquillant, FISPE
Leah Sansbury

Oncology

Andrew Freedman, FISPE
Dorian Murariu

Pediatrics

Lina Titievsky
Daniel Horton

Rare Disease

Jasmanda Wu, FISPE
Jieying Jiang

Vaccines

James Stark
Wan-Ting Huang
Catherine Panozzo

LIAISONS

Council of International Organizations for Medical Sciences (CIOMS)

Stella Blackburn, FISPE

European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENC&PP)

Yola Moride, FISPE

International Network for Epidemiology in Policy (INEP)

Lisa Pont, FISPE
Meredith Smith

US Food & Drug Administration (FDA)

Christian Hampf, FISPE

REGIONAL INTEREST GROUPS

Africa

Kwame Appenteng
Irene Berita Murimi

Brazil

Luciane C Lopes
Maribel Salas, FISPE
Claudia Gracia Serpa
Osório De Castro

FarmacoepiEnRed

Alejandro Arana, FISPE
Daniel Prieto-Alhambra, FISPE

Gulf Region

Tariq Alhawassi
Nasser Alqahtani

Latin America

Rene Soria Saucedo

STUDENT CHAPTERS

- Basel Pharmacoepidemiology Unit, University of Basel, Switzerland & The Boston Collaborative Drug Surveillance Program, Boston University, USA
- Brown University School of Public Health, USA
- Center for Drug Safety & Effectiveness, Department of Epidemiology, Johns Hopkins School of Public Health, USA
- Center for Drug Safety & Pharmaceutical Health Services Research Graduate Program, University of Maryland School of Pharmacy, USA

- Center For Pharmacoepidemiology Research and Training (CPeRT), Perelman School of Medicine at the University of Pennsylvania
- Clinical and Population Health Research Program, Department of Quantitative Health Sciences, University of Massachusetts Medical School, USA
- College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Canada
- College of Pharmacy, University of Cincinnati, USA
- College of Pharmacy & Pharmaceutical Sciences, Washington State University, USA
- Department of Epidemiology, Biostatistics, And Occupational Health & Department of Family Medicine, McGill University, Canada
- Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, USA
- Department of Pharmacy Systems, Outcomes And Policy, University of Illinois At Chicago, USA
- Department of Pharmacy Practice, KMCH College of Pharmacy, Coimbatore, India.
- Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Brazil
- Faculty of Pharmacy, JSS University, Mysore, India
- Graduate Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Canada
- Harvard University School of Public Health, USA
- Health Outcomes and Pharmacy Practice, The University of Texas at Austin, USA
- Pharmacoepidemiology and Pharmacoeconomics, University of Rhode Island, USA
- Pharmacoepidemiology Program, Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, USA
- Program for Clinical Pharmacy and Pharmaceutical Sciences, National Chen-Kung University, Taiwan
- Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, USA
- Talla Padmavathi College of Pharmacy, Warangal, Telangana, India
- Touro College of Pharmacy, New York City, USA
- University of Bordeaux, France

ISPE Development Committee

Amanda Anderson
Dimitri Bennett
Andrzej Czarnecki, FISPE
Mark Cziraky
Nancy Dreyer, FISPE
Mark H Epstein
Nick Everage, Co-Chair

Doug Kou, Chair
Kirk Midkiff
Susan Oliveria, FISPE
Syd Phillips
Maribel Salas, FISPE
Jasmanda Wu, FISPE



Organizational Members & In This Program

Organizational & Institutional Members

PHARMACEUTICALS

GlaxoSmithKline
Sanofi-Aventis
UCS Biosciences

SERVICE PROVIDERS

RTI Health Solutions

GOVERNMENT/REGULATORY/AGENCY

Department of Epidemiology, Lazio Regional Health Service

ACADEMIC PROGRAMS

- Center for Drug Safety & Effectiveness, Department of Epidemiology, Johns Hopkins School of Public Health
- Center for Pharmacoepidemiology Research and Training (CPeRT), Perelman School of Medicine at the University of Pennsylvania

- College of Pharmacy, University of South Carolina
- Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida
- Drug Safety Research Unit, Associated Department, School of Pharmacy, Portsmouth University
- Harvard School of Public Health
- McGill Pharmacoepidemiology Research Unit, McGill University
- Pharmacoepidemiology Program, Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill
- Rutgers, The State University of New Jersey
- University of Massachusetts Medical School, Clinical and Population Health Research

35TH ICPE AGENDA

Friday, August 23.....	12
Saturday, August 24.....	12
Sunday, August 25.....	22
Monday, August 26.....	31
Tuesday, August 27.....	44
Wednesday, August 28.....	57

35TH ICPE POSTERS

Poster Guidelines.....	69
Poster Session A.....	70
Poster Session B.....	90
Poster Session C.....	109

INDEXES

Abstract Index.....	128
Advertisers Index.....	148

SAVE THE DATES!

SAVE THE DATES!



Abstract Reviewers

Ali Abbasi
Victoria Abbing-
Karahagopian
Devin Abrahami
John Acquavella, FISPE
Michael Adena
Sruthi Adimadhyan
Thomas Ahern
Fariba Ahmadizar
Jessica Albano
Yasser Albogami
Silvia Alessi-Severini
Fawaz Alharbi
Tariq Alhawassi
Adel Alrwisan
Thamir Alshammari
Carlos Alves
Heather Anderson
Karolina Andersson
Sundell
Daniel Ankrah
Mary Anthony
Ippazio Cosimo Antonazzo
Eirini Apostolidou
Kwame Appenteng
Alejandro Arana, FISPE
Daniel Arhinful
Ariel Arias, FISPE
Janet Arrowsmith
Keiko Asao
Darren Ashcroft
Alex Asimwe
Magdalene Assimon
Quazi Ataher
Laurent Azoulay
Shahram Bahmanyar
Nicole Baker
Sulayman Balogun
Deepak Bandari
Gretchen Bandoli
Dorothee Bartels, FISPE
Gillian Bartlett-Esquillant,
FISPE
Claudia Bartolini
Brian Bateman
Daniel Beachler
Claudia Becker
Sigrid Behr
Irene Bezemer
Gouri Shankar
Bhattacharyya

Gage Billioti de Gage
Therese Bittermann
Patrick Blin
Lourens Bloem
Michael Blum
Priyanka Bobbili
Justin Bohn
Rhonda Bohn, FISPE
Reka Bordas
Jaclyn Bosco, FISPE
Naomi Boxall
Marie Bradley
Jaden Brandt
Benjamin Bray
Kimberly Brodovicz
Emily Brouwer
Jeremy Brown
Andrea Burden
Greta Bushnell
Anne Butler
Katsiaryna Bykov
Pia Caduff
Caitriona Cahir
Wendy Camelo Castillo
Tonya Campbell
Bruce Carleton, FISPE
Deborah Casso
Gillian Caughey
Irina Cazacu
Carolyn Cesta
Christina Chambers
Rebecca Chandler
Jen-Yu Chang
May Chan-Liston
Sarah Charlier
Chao Chen
Ju-Ling Chen
Nai-Yu Chen
Robert Chen, FISPE
Szu-Ta Chen
Teng-Chou Chen
Yingkai Cheng
Muhammad Abdul Baker
Chowdhury
Christian Christiansen
Danielle Chun
Te-yuan Chyou
Javier Cid Ruzafa
Noelle Cocoros
Jacqueline Cohen
Karen Cohen

Catherine Cohet
Alexander Cole
Susan Colilla
Paul Coplan, FISPE
Nicole Cossrow
Florence Coste
Deborah Covington, FISPE
James Crispo
Deirdre Cronin Fenton
Andrzej Czarnecki, FISPE
Benjamin Daniels
Chintan Dave
Kourtney Davis
Marie de Bruin
Cynthia De Luise
Sieta de Vries
Christina DeFilippo-Mack
Stephanie Dellicour
Kitaw Demissie
Petra Denig, FISPE
Anouk Deruaz Luyet
Nafeesa Dhalwani
Julia DiBello
Harriet Dickinson
Rachael DiSantostefano
Caitlin Dodd
Yaa-Hui Dong
Macarius Donneyong
Susan DosReis, FISPE
Ian Douglas
Antonios Douros
Cécile Droz-Perroteau
Sascha Dublin
Sarah Dutcher
Vera Ehrenstein
Alan Ellis
Soha Elmorsy
Cheryl Enger
Omotayo Fatokun
Veronika Fedirko
James Feinstein
Kristian Filion
Eva Flahavan
Joan Fornis
Michael Forstner
Joan Fortuny
Nadia Foskett
Matthew Francis
Lourdes Frau, FISPE
Andrew Freedman, FISPE

Thomas Frey
Kari Furu
Genevieve Gabb
Myriam Gagné
Steve Gao
Xabier Garcia de Albeniz
Claudia Garcia Serpa
Osorio de Castro
Maria Garcia-Gil
Helga Gardarsdottir, FISPE
Christiane Gasse
Nicolle Gatto, FISPE
Alicia Gayle
Wenzhen Ge
Stewart Geary
Tobias Gerhard, FISPE
Thijs Giezen
Alicia Gilsenan
Rosa Gini
Cynthia Girman, FISPE
Natasa Gisev
Gunnar Gislason
Danijela Gnjidic
Wim Goettsch
Catherine Goetzinger
Asieh Golozar
Diana Gomez
Amie Goodin
Hayley Gorton
Amandine Gouverneur
Elsie Grace
Sonia Grandi
Emily Granger
Jody Green
Marie Griffin
Carlos Grijalva
Qi Guan
Xiaodong Guan
Sandra Guedes
Line Guenette
Jason Guertin
Lia Gutierrez
Katarina Gvozdanovic
Katrina Hagberg
Eelko Hak
Gillian Hall, FISPE
Jesper Hallas, FISPE
Amani Hamad
Christian Hampp, FISPE
Sola Han

Abstract Reviewers

Janet Hardy
Ulrike Haug
Alys Havard
Samuel Hawley
Kunihiko Hayashi
Kevin Haynes, FISPE
Ying He
Maja Hellfritzsch
Sharon Hensley Alford
Inmaculada Hernandez
Jose Hernandez
Laura Hester
Blánaid Hicks
Ryan Hickson
Juan Hincapie Castillo
Maria Hoeltzenbein
Veena Hoffman
Mikael Hoffmann
Ken Hornbuckle, FISPE
Daniel Horton
Jason C. Hsu
Phyo Htoo
Jason Hu
Li Ying Huang
Ting-Ying Huang
Wan-Ting Huang
Consuelo Huerta
Phillip Hunt
Krista Huybrechts, FISPE
Luisa Ibanez
Janetta Iwanicki
Solomon Iyasu
Marie Joelle Jabagi
Jessica Jalbert
Aziza Jamal-Allial
Meghna Jani
Thomas Bo Jensen
Nakyung Jeon
Catherine Johannes
Cynthia Jones
MicheleJonsson Funk,
FISPE
Sophie Laurence Jouaville
Catherine Jutzeler
Dan Kajungu
Francis Kalemeera
Linda Kalilani
Lisa Kalisch Ellett
Yea-Huei Kao
Sigal Kaplan
Hugh Kawabata

Sara Khalid
Farzin Khosrow-Khavar
Dae Kim
Eunyoung Kim
Mikyung Kim
Seoyoung Kim
Tomomi Kimura
Ursula Kirchmayer, FISPE
Oksana Kirichek
Caitlin Knox
Monica Kobayashi
Tomoko Kobayashi
Joris Komen
Christos Kontogiorgis
Oleksii Korzh
Kaarina Kowalec
Erna Kristin
Kiyoshi Kubota, FISPE
Hiraku Kumamaru
Siyana Kurteva
Xavier Kurz
Edward Lai
Francois-Xavier Lamy
Suzanne Landi
Tamar Lasky, FISPE
Wallis Lau
Julie Lauffenburger
Deborah Layton
Bradley J Layton
Jacinthe Leclerc
Hankil Lee
Inyoung Lee
Meng-Sui Lee
Wanju Lee
Andreia Leite
Charles Leonard
Michael Lewis, FISPE
Hu Li
Xiaojuan Li
Yan Li
Huifang Liang
Fang-Ju Lin
Jennifer Hsiang-Ling Lin
Tzu-Chieh Lin
Shao-Hsien Liu
Vincent Lo Re III, FISPE
Weihsuan Jenny Lo-
Ciganic
John Logie
Feng-Hua Loh
Luciane Lopes

Jennifer Lund
Angela Lupattelli
Theodore Lystig
Marina Machado
Isla Mackenzie
Jacqueline Major
Atheline Major-Pedersen
Kenneth Man
Zachary Marcum
Andrea Margulis
Karine Marinier
Morgan Marks
Kayleigh Mason
Ilan Matok
Matreja Matreja
Zinhle Matsebula-Myeni
Shinichi Matsuda
Géric Maura
Ann McMahon
Cristiane Menezes
Anne-Marie Meyer
Alexander Michel
David Miller, FISPE
Jea Young Min
Daniel Mines
Eileen Ming, FISPE
Jingping Mo
Daniela Moga
Peter Mol
Yola Moride, FISPE
Elaine Morrato
Cristiano Moura
Jerald Mullersman
Isam Eldin Mustafa
Walter-Rodney Nagumo
Abdallah Naser
Prasad Nishtala
Francis Nissen
Hedvig Nordeng
Beth Nordstrom
Mette Norgaard
Fredrik Nyberg, FISPE
Josephine Ocran-Appiah
Charles Okafor
Denise Oleske
Sylvia Opanga
Ibrahim Oreagba
Vicki Osborne
Shilpa Palaksha
Kristin Palmsten
Antoine Pariente

Björn Pasternak
Ami Patel
Elisabetta Patorno
Catherine Patterson
David Pau
Alma Pedersen
Michael Peng
Dinci Pennap
Susana Perez-Gutthann,
FISPE
Rebecca Persson
Paul Petrarò
Hans Petri
Natalia Petruski-Ivleva
Payam Peymani
Tra My Pham
Thanh Phuong Pham
Nguyen
Syd Phillips
Simone Pinheiro
Federica Pisa
Manel Pladevall Vila
Robert Platt
Lisa Pont, FISPE
Anton Pottegård
Chih-Ying Pratt
Nicole Pratt
Daniel Prieto-Alhambra,
FISPE
Jingjing Qian
Sudha Raman
Darmendra Ramcharran
Adepu Ramesh
Cristina Rebordosa
Garcia
Suzanne Reed
Jennita Reefhuis
Mette Reilev
Adriano Reis
Christel Renoux
Christopher Rentsch
Shannon Reynolds
Margaret Richards
John Ripollone
Mary Ritchey, FISPE
Elena Rivero-Ferrer,
FISPE
Giuseppe Roberto
Danielle Robinson
Robert Romanelli
Julie Rouette

Abstract Reviewers

Elizabeth Roughead, FISPE
Jonathan Roux
Christopher Rowan
Debabrata Roy
Ana Ruigomez
Watcharee Rungapiromnan
Leo Russo
Veronica Russo
Patricia Saddier
McKayla Saine
Maribel Salas, FISPE
Nurrul Salwa Saleh
Catherine Saltus
Ramiro Sanchez-Huesca
Gabriel Sanfelix-Gimeno
Thibaut Sanglier
Yared Santa-Ana-Tellez
Surasak Saokaew
Ameet Sarpatwari
Lucie-Marie Scailteux
Andrea Schaffer
Jonathan Schelfhout
Tania Schink
Niklas Schmedt
Martin Schulz
Renate Schulze-Rath
Jodi Segal, FISPE
Harry Seifert, FISPE
Maurizio Sessa
Soko Setoguchi, FISPE
Ankitaben Shah
Yu-Hsuan Joni Shao
Odile Sheehy
Ju-Young Shin
Shahar Shmuel
Jason Simeone
Scot Simpson
Sonal Singh
Sarah-Jo Sinnott
Jonathan Slaughter
Meredith Smith
Rachel Sobel, FISPE
Patrick Soverein
Julia Spöndlin
Chalasani Sri Harsha
Paul Stang, FISPE
Kathryn Starzyk
Michael Steinbuch, FISPE

Douglas Steinke
Lauren Stevens
Henrik Stovring
Victoria Strauss
Hae Sun Suh
Jenny Sun
Mina Tadrous
Yoshinori Takeuchi
Vesa Tapiainen
Katja Taxis, FISPE
John Tazare
Dana Teltsch
Sydney Thai
Thuy Thai
Darren Toh, FISPE
Sylvie Tomczyk
Massoud Toussi
Tanja Tran
Thierry Trenque
Ilse Truter
Nicole Tsao
Md Jamal Uddin
Anan Udombhornprabha
Christine Ulbricht
Marianne Ulcickas Yood, FISPE
Hisashi Urushihara
Patricia van den Bemt
Rianne van den Ham
Angela van der Salm
Marleen Van Gelder
Robert Vander Stichele
Brian VanderBeek
Catherine Vasilakis-Scaramozza
Freija Verdoodt
Patrice Verpillat
Arti Virkud
David Vizcaya
Caroline Walsh
Meng-Ting Wang
Shi-Heng Wang
Shirley Wang
Wei Wang
Xi Wang
Li Wei
Yu-Jung Wei
Lisa Weiss
Xuerong (Sheron) Wen
Madé Wenten

Bjorn Wettermark
Andrew Wiese
James Wilson
Jerome Wilson
Aaron N Winn
Veronika Wirtz, FISPE
Lesley Wise
Eric Wittbrodt
Lindsay Wong
Kimberley Wong
Nicole Woodcroft
Chuntao Wright
Jasmanda Hsiao-hui Wu, FISPE
Richard Wu
Takuhiro Wyss
Jeff Yamaguchi
Yu Yang

Wai Ping Yang
Zenas Yau
Mellissa Yiu
Muhammad Yong Williamson
Onchee Younus
Hongbo Yu
Zhong Yuan
Ismaeel Yuan
Siyan Yunusa
Dongmu Zhan
Zilu Zhang
Ke (Cindy) Zhang
Meijia Zhou
Wei Zhou, FISPE
Xiaofeng Zhou
Lin Zhou
Andrew Zullo

Newcomer Track Reviewers

Ian Douglas, Co-Director

Emily Brouwer

Harriet Dickinson

William Dixon


Kristian Filion

Candace Fuller

John Logie

Todd Miano

Daniel Morales



ICPE 2019 Exhibitors & Sponsors



ISPE gratefully acknowledges the generous support of the following organizations, institutions and programs.

Their contributions helped the Society advance the scientific program content and increase attendance at ISPE's 35th annual meeting (ICPE).

Exhibitors*

- Aarhus University, Department of Clinical Epidemiology
- Advera Health Analytics, Inc
- Aetion, Inc.
- Amgen, Inc.
- Analysis Group
- BHE
- Clinical Practice Research Datalink
- Commonwealth Informatics
- Drug Safety Research Unit
- Eu2P
- Evidera
- FDA/Division of Epidemiology
- FDA/Office of Women's Health
- HealthCore, Inc.
- IBM Watson Health
- ICON plc
- IQVIA
- Kantar
- Klein Health International
- OM1
- Optum
- Oxon Epidemiology
- PharmaLex and DGI, LLC
- PHARMO Institute
- PRA Health Sciences
- Primevigilance
- Regeneron Pharmaceuticals
- Risk Sciences International
- RTI Health Solutions
- Syneos Health
- TriNetX
- UBC
- Uppsala Monitoring Centre
- Veradigm

Badges

All attendees at the 2019 ICPE must wear their badge to all events and conference-related functions including the Welcome Reception/Academic Showcase, scientific sessions, exhibit/poster hall, and social event. Badges will be included in the registration material. In some cases, tickets for admission will be required; e.g., courses and guests.

Annual Meeting Sponsors*

PLATINUM

- HealthCore, Inc.
- Veradigm

GOLD

- Amgen
- Analysis Group
- AstraZeneca
- Bayer
- BHE
- Biogen
- Boehringer-Ingelheim International
- Commonwealth Informatics
- Eli Lilly & Company
- Epi Excellence, LLC
- Evidera
- IBM Watson Health
- ICON plc
- IQVIA
- Kantar Health
- Optum
- Pfizer
- PharmaLex and DGI, LLC
- RTI Health Solutions
- Servier
- UBC

SILVER

- Procter & Gamble

BRONZE

- Boston Collaborative Drug Surveillance Program
- Harvard Pilgrim Health Care Institute

*As of August 2, 2019

Poster Presentations during ICPE 2019

A Real-World Evidence Study of BRCA Mutations and Survival in HER2-negative Breast Cancer

Dalvi T, McLaurin K, Briceno J, Nordstrom B, Bennett J, Hettle R, Murphy B, Collins J, McCutcheon S

Calculating Prevalence of Spontaneous Abortion in Pregnancy Registries: Slippery Slope

Govington D, Veley K, Buus R, Churchill P

Development of an Integrated Research Network to Facilitate Non-Interventional Research

Reisinger S, Berger A, Chen D, Chick S, Kallenbach L, Vernon B, Payne K

The Occupational Hazards of Measuring Risk Tolerance: Convergent Validity in Preference Elicitation

SriBhashyan S, Marsh K, Quartel A, Gershman A

Using Different Look Back Periods to Calculate the Charlson Comorbidity Index (CCI) in NVAF Patients Treated with Oral Anticoagulants (OACs)

Graham S, Schultze A, Nordstrom B, Mehmud F, Ramagopalan S

Utilisation of Linaclotide in United Kingdom

Dhalwani N, Schultze A, Donaldson R, Ukah A, Weissman D, Wang J, Cid-Ruzafa J

Validity of Claims-Based Algorithms to Identify Acute Kidney Injury, Acute Liver Injury, Severe Complications of Urinary Tract Infections, Breast Cancer, and Bladder Cancer Among Patients with Type 2 Diabetes: A Pilot Study

Zhou CK, Dinh J, Danysh HE, Johannes C, Gutierrez L, Schmid R, Arana A, Kaye JA, Pladevall-Vila M, Garcia-Albeniz X, Gangemi K, Yin R, Cid-Rufaza J, Gilsenan A, Beachler DC



**Real-World
Evidence**

**Patient-Centered
Research**

**Evidence Synthesis,
Modeling &
Communication**

Market Access

Interventional Studies

Pragmatic Studies

Medical Writing

evidera.com



Meeting-At-A-Glance

Friday, August 23, 2019

7:00 am	8:00 am	9:00 am	10:00 am	11:00 am	12:00 pm	1:00 pm	2:00 pm	3:00 pm	4:00 pm	5:00 pm	6:00 pm	7:00 pm
							2:00pm-6:00pm	Speaker Ready Room		Room 303		
									4:00pm-6:00pm	Registration	Registration Bridge East	

Saturday, August 24, 2019

7:00 am	8:00 am	9:00 am	10:00 am	11:00 am	12:00 pm	1:00 pm	2:00 pm	3:00 pm	4:00 pm	5:00 pm	6:00 pm	7:00 pm
	7:30am-6:00pm	Speaker Ready Room		Room 303								
	7:30am-6:00pm	Mother's Room		Room 300								
	7:30am-6:00pm	Registration		Registration Bridge East								
	8:30am-12:30pm	Educational Sessions				12:30pm-2:00pm	Lunch on Your Own		2:00pm-6:00pm	Educational Sessions		
		Effective Risk Management	201A					Using Field Studies to Value-Add in Pharmacoepidemiology	201A			
		Adherence to Medication	201B					Cancer Pharmacoepidemiology and Genomics	201B			
		Introduction to Pharmacogenomics & Precision Medicine	201C					Comparative Effectiveness Research (CER)	201C			
		ISPE Newcomers/Early Stage Investigator Pharmacoepi Workshop	204A					Practical Skills in Protocol Writing and Statistical Analytic				
		Pharmacoepidemiology Considerations for Biologics & Biosimilars	204B					Programming Relevant to Pharmacoepidemiology	204A			
		Principles of Pharmacoepidemiology	202AB					Scientific Writing from the Reader's Perspective	204B			
		Rare Disease Epidemiology & Orphan Drug Approvals	204C					Pragmatic Trials	202AB			
						1:00pm-5:00pm	ISPE Board of Directors Meeting		Marriott Franklin Hall 1 - 2			
								Using Pharmacoepidemiology Database Resources to Address Drug Safety Research	204C			

Sunday, August 25, 2019

7:00 am	8:00 am	9:00 am	10:00 am	11:00 am	12:00 pm	1:00 pm	2:00 pm	3:00 pm	4:00 pm	5:00 pm	6:00 pm	7:00 pm
	7:30am-6:00pm	Speaker Ready Room		Room 303								
	7:30am-6:00pm	Mother's Room		Room 300								
	7:30am-6:30pm	Registration		Registration Bridge East								
	8:30am-12:30pm	Educational Sessions				12:30pm-2:00pm	Lunch on Your Own		2:00pm-6:00pm	Educational Sessions		
		Intermediate Pharmacoepidemiology	201A					Advanced Pharmacoepidemiology	201A			
		Epidemiology of Vaccine Safety	201B					Applied Sensitivity Analyses in Pharmacoepidemiology				
		Introduction to Drug Utilization Research	201C					Database Studies	201B			
		Modern Pregnancy Pharmacoepidemiology	204A					Advanced Drug Utilization Research	201C			
		Pharmacovigilance and Signal Detection	204B					Medical Device Epidemiology	204A			
		Propensity Scores in Pharmacoepidemiology	202AB					Pediatric Pharmacoepidemiology	204B			
		Prospective Research	204C					Regulatory Pharmacoepidemiology	202AB			
						12:30pm-2:00pm	New Member & Early Stage Investigator Luncheon		6:00pm-7:30pm			
								By invitation only; registration required)	Welcome Reception/Regional Interest Group & Academic Showcase			
								Weighing the Benefits & Risks: The Science and Methods of Benefit-Risk Assessment in Drug Development	204C			Grand Hall

Monday, August 26, 2019

7:00 am	8:00 am	9:00 am	10:00 am	11:00 am	12:00 pm	1:00 pm	2:00 pm	3:00 pm	4:00 pm	5:00 pm	6:00 pm	7:00 pm
7:00am-8:00am Continental Breakfast Hall A	7:00am-6:00pm	Speaker Ready Room		Room 303								8:00pm-10:00pm PDS Editorial Board (By invitation)
	7:30am-6:00pm	Mother's Room		Room 300								8:30pm-10:30pm Students/Early Career Professionals Meet & Greet (Off-site)
7:00am-8:00am Regional Interest Groups (Open to all participants) Brazil 203A Gulf Region 100A Latin America 101	7:00am-6:00pm	Registration		Registration Bridge East								
	7:30am-6:00pm	Exhibits/Poster Session A		Hall A								
8:00am-8:30am WELCOM E Ballroom B	8:30am-10:00am Keynote Session: The Role of Real World Evidence In Regulatory Decision Making Ballroom B	10:00am-10:30am Break/Posters/Exhibits Hall A	10:30am-Noon Symposia & Workshops What Does Replicable and Robust Non-Randomized Database Evidence Look Like? Ballroom B	Noon-1:30pm Lunch/Poster Session A/ Exhibits Hall A	Noon-1:30pm Committee Meetings (open to all participants; lunch available) Education Marriott 304-305 Finance Marriott 302-303 Membership Marriott 306	1:30pm-3:00pm Oral Presentations Show Us Your Money: Health Economics and Policy Ballroom B	3:00pm-3:30pm Break/Posters/Exhibits Hall A	3:30pm-5:00pm Symposia & Workshops The Ascension of Real-World Evidence: Heterogeneity and Validity in National and International Multi-Database Pharmacoepidemiologic Studies (MPES) 201A Thinking Globally While Acting Locally: Developing Time-on-Treatment Data in International Settings 201B Machine Learning to Improve Causal Inference in Pharmacoepidemiology 201C Measuring, Mapping, and Meshing of Genotype and Phenotype Data across Large Datasets 202AB	5:15pm-6:45pm Oral Presentations Where Is the Unbiased Comparison? Ballroom B	7:00pm-8:00pm Adherence SIG 201A Asian Pharmacoepidemiology Network (ASPEN) SIG 201B Benefits Risk Assessment, Communication and Evaluation (BRACE) SIG 201C Biologics & Biosimilars SIF 202AB Comparative Effectiveness Research (CER) SIG 204A Database SIG 204B Digital Epidemiology SIG 204C Drug Utilization/Health Services Research SIG 203A Geriatric Pharmacoepidemiology SIG 203B Medical Devices SIG 100A Medications in Pregnancy/Molecular Epi/Biomarkers/Pharmacogenetics SIG 100B Oncology SIG 104AB Pediatrics SIG Marriott 301 Rare Disease SIG Marriott 302-303 Vaccines SIG Marriott 304-305		



Tuesday, August 27, 2019

7:00 am	8:00 am	9:00 am	10:00 am	11:00 am	12:00 pm	1:00 pm	2:00 pm	3:00 pm	4:00 pm	5:00 pm	6:00 pm	7:00 pm
7:00am-8:00am Continental Breakfast Hall A	7:00am-6:00pm Registration Registration Bridge East	Speaker Ready Room Room 303										7:30pm-11:30pm Social Evening at the Kimmel Center for the Performing Arts
7:00am-8:00am ISPE Task Force - Using RWE for Regulatory Submission 106AB	7:30am-6:00pm Exhibits/Posters Session B Hall A	Mother's Room Room 300										
7:00am-8:00am African Regional Interest Group (Open to all participants) 107A	8:00am-9:30am Oral Presentations A Mummer's Parade of Analytic Methods To Bleed or Not to Bleed 201A We All Need Validation 201B What a Pain: Are We Making Progress with Opioids 201C CNS Drugs in Pregnancy 202AB	9:30am-10:00am Break/Posters/Exhibits Hall A	10:00am-11:30am Plenary Session: Implementation and Evaluation of Risk Minimization Measures: Challenges and Opportunities Ballroom B	11:30am-1:00pm Lunch/Poster Session B/ Exhibits Hall A	11:30am-1:00pm Committee Meetings (open to all participants) Development Marriott 304-305 Global Development Marriott 302-303 History & Archives Marriott 308 Publications & Communications Marriott 307 Public Policy Marriott 301	1:00pm-2:30pm Oral Presentations Around the Benefit Risk Assessment, Communication, & Evaluation Cycle Ballroom B Diabetes: Outcomes and Safety 201A Lightning Forum 201B ▪ Methods in Geriatric Pharmacoepidemiology ▪ Machine Learning for Risk Prediction ▪ Opioid Method Research How to Analyze Complex Longitudinal Exposures 201C Validity of RWE Data in Pregnancy 202AB Don't Tell the Antivaxers, Vaccines Work! 204C	2:40pm-3:50pm Annual Meeting of ISPE Members & Awards Ceremony Ballroom B	3:50pm-4:15pm Break/Posters/Exhibits Hall A	4:15pm-5:45pm Symposia & Workshops Replicating Clinical Trial Data Using RWD Ballroom B Data Diversity in Multi-Database Pharmacoepidemiologic Studies and Its Role in Outcome Misclassification 201A Characterizing Patient Experience Data in Medical Product Development 201B Existing Databases for Drug Utilization Research in Latin American and African Countries 201C Introducing Lactation Real World Data to ISPE 202AB	6:00pm-7:00pm Council Meetings (open to all participants) Academic Government/Regulatory 202AB Industry/Service Providers 204C Student 107B		
7:00am-8:00am Poster Session B Set-Up Hall A	7:00am-8:00am Your Brain on Drugs : Pharmacoepidemiology of CNS Agents 204C											
7:00am-8:00am Spotlight Poster Session B Set-Up West Bridge					11:45am-12:45pm Spotlight Poster Session B West Bridge							

Wednesday, August 28, 2019

7:00 am	8:00 am	9:00 am	10:00 am	11:00 am	12:00 pm	1:00 pm	2:00 pm	3:00 pm	4:00 pm	5:00 pm	6:00 pm	7:00 pm
7:00am-3:30pm Speaker Ready Room Room 303	7:00am-4:30pm Registration Registration Bridge East	7:30am-1:45pm Exhibits/Poster Session B Hall A										
7:00am-8:00am Continental Breakfast Hall A	7:30am-4:30pm Mother's Room Room 300											
7:00am-8:00am Poster Session C Set-Up Hall A	8:30am-10:00am Oral Presentations Around the World with DJR Validation and Performance - Methods and Pharmacovigilance 201A Revolutionary Study Designs Infectiously Interesting 201B Do Do Do Doac Vaccine Abstracts Gone Viral! 204C	10:00am-10:30am Break/Posters/Exhibits Hall A	10:30am-Noon Symposia & Workshops Analysis of Data from Distributed Pharmacoepidemiologic Networks Causal Inference in Pharmacoepidemiology 201A Pharmacoepidemiology and Rare Cancer Research 201B Emerging Solutions to Addressing Challenges in Measuring Adherence to Multiple Medications 201C Mixing It Up 202AB	Noon-1:30pm Lunch/Poster Session C/ Exhibits Hall A	Noon-1:30pm ISPE Board of Directors Luncheon Marriott Salon A	12:15pm-1:15pm Spotlight Poster Session C West Bridge	1:30pm-3:00pm Oral Presentations CER of DM Treatments Ballroom B Generating Real-World Evidence on Biologics 201A It's Complicated in the Old World Adherence: In for the Long-Term 201B Potpourri 202AB Slice and Device 204C	3:00pm-3:15pm Break/Posters/Exhibits Hall A	3:15pm-4:45pm Hot Topic Session: When You're a Single-Arm Trial or Extension, Can an External Control Make a Good Match? Ballroom B	4:45pm-5:30pm The Final Word Ballroom B		
7:00am-8:00am Spotlight Session C Set-Up West Bridge												
7:15am-8:15am 2020 Scientific Program Committee (Open to all participants) 203AB												

save the dates
april 18-21, 2020
 ispe's 2020 mid-year meeting
 Aging in The Sunshine State – Rising to The Challenges in Pharmacoepidemiology
 loew's royal pacific resort – orlando, florida

ispe International Society for Pharmacoepidemiology



Pre-Conference | Friday, August 23

2:00pm-6:00pm

Speaker Ready Room* Room 303

**Please arrive 24 hours before your presentation start time to upload or check your presentation.*

4:00pm-6:00pm

Registration

Registration Bridge East

**If you plan to attend a course on Saturday morning, it is strongly recommended that you register Friday evening to avoid delays on Saturday morning.*

Pre-Conference | Saturday, August 24

7:30am-6:00pm

Speaker Ready Room*

Room 303

**If you plan to attend a course on Saturday morning, it is strongly recommended that you register Friday evening to avoid delays on Saturday morning.*

7:30am-6:00pm

Mother's Room

Room 300

Sponsored by EPI Excellence, LLC

7:30am-6:00pm

Registration

Registration Bridge East

8:30am-12:30pm

EDUCATIONAL SESSIONS: HALF-DAY MORNING COURSES (Ticket Required)

Effective Risk Management: Best Practices for Designing, Implementing and Evaluating Risk Minimization Programs

201A

Content

This course presents an overview of risk management principles, with a focus on best practice methods for designing, implementing and evaluating risk minimization programs. The didactic section will feature experts from regulatory, industry, academia and research organizations who will present the regulatory context, methods, and examples of effective risk minimization program design, implementation and evaluation techniques. The interactive workshop section will provide an opportunity for participants to actively apply what they have learned via a case study approach.

Faculty

Doris Auth
Alicia Gilsonan
Elaine Morrato
Meredith Smith

Adherence to Medication

201B

Content

Adherence to medication is indispensable for achieving clinical goals. Non-adherence is a complex and multifactorial problem leading to poor clinical outcomes, increased morbidity and death rates, and unnecessary healthcare costs. Assessing (non-)adherence is challenging and both subjective and objective measures are applied. This course is aimed at introducing students to the various constructs of adherence behavior and techniques to evaluate (non-) adherence and data analysis.

Faculty

Jacqueline Hugtenburg
Petra Denig, FISPE
Jessie Franklin
Julie Lauffenburger
Robert Gross, FISPE

Generating **REAL-WORLD INSIGHT** into Drug Safety & Epidemiology

HealthCore combines proven epidemiology research expertise with one of the largest integrated research environments to uncover vital evidence on the safety and effectiveness of medications and devices in large, real-world populations.



Post-Marketing Requirements/ Post-Authorization Safety Studies

HealthCore designs and manages safety studies as the sole data partner and as coordinating center for studies requiring multiple databases. As an original Sentinel data partner, our intimate understanding of the development and use of electronic real-world data allows us to fulfill industry needs and regulatory requirements accurately and efficiently.



Validation Studies and Machine Learning

Our researchers leverage the **HealthCore Integrated Research Environment (HIRE®)** to validate clinical endpoints by linking administrative claims data to medical records, the National Death Index, and other data sources. We use machine learning methods to develop predictive models that target health conditions of interest with greater validity.

HealthCore®

www.healthcore.com

Visit us at
Booth 1005 for
more information
about these and
other services.

Pre-Conference | Saturday, August 24

8:30am-12:30pm

EDUCATIONAL SESSIONS: HALF-DAY MORNING COURSES (Ticket Required) (continued)**Introduction to Pharmacogenomics & Precision Medicine for Pharmacoepidemiologists**

201C

Content

This course, sponsored by the Molecular Epidemiology, Biomarkers, and Pharmacogenomics (MEBP) SIG, will focus on the essentials every pharmacoepidemiologist should know about real world applications of pharmacogenomics epidemiology including (1) the role of epidemiology in pharmacogenomics (pre-course video); (2) definitions of genetic terms and basic genetic concepts (pre-course video); (3) quality control and analytical procedures required in a pharmacogenetic analysis; (4) step-by-step planning guide to designing a pharmacogenomic analysis; (5) phenotyping considerations and breaking down examples of pharmacogenomic successes; (6) databases available to study pharmacogenomics; (7) designing a companion pharmacogenomic diagnostic in drug development; (8) designing a prospective observational cohort or case-control study of pharmacogenomics; (9) designing a clinical utility trial: a guide with examples; and (10) collecting health related quality of life data using an innovative role playing game.

Faculty

Amalia M. Issa, FISPE
 Gillian Bartlett-Esquillant, FISPE
 Bruce Carleton, FISPE
 Steve Kimmel, FISPE
 Leah Sansbury
 Anke-Hilse Maitland van der Zee, FISPE

ISPE Newcomers/Early Stage Investigator Pharmacoepidemiology Workshop

204A

Content

This course is aimed at early stage pharmacoepidemiologists that have been in the field for less than 3 years. Participation will lead to enhancement in research skills (i.e., grant writing, research presentation, and manuscript writing) and professional development (development of mentor-mentee relationships, enhancing creativity/productivity, and professional networking) that are crucial to early success in pharmacoepidemiology.

Faculty

Vincent Lo Re, FISPE
 Caitlin Knox
 Tarek Hammad, FISPE
 Sengwee Darren Toh, FISPE
 Almut G. Winterstein, FISPE
 Mary Ritchey, FISPE
 Quazi Ataher





8:30am-12:30pm

EDUCATIONAL SESSIONS: HALF-DAY MORNING COURSES (Ticket Required) (continued)**Pharmacoepidemiologic Considerations for Biologics and Biosimilars**

204B

Content

This workshop will provide participants with information on the following topics:

- Background on biologics, biosimilars and differences from small molecules
- Naming and traceability issues for biologicals and biosimilars
- Interchangeability, switching, and automatic substitution from a regulatory, methodological, and clinical perspective
- Review country-specific regulatory guidelines, particularly focused on post-marketing monitoring, pharmacovigilance, and risk management requirements for biologics and biosimilars
- Conducting observational studies of biologics and biosimilars, including primary data collection and secondary use of data sources for evaluating patterns of use as well as comparative safety and effectiveness of biologics and biosimilars
- Special emphasis will be given to the methodological issues concerning post-marketing assessment of the interchangeability of biologics and corresponding biosimilars

Faculty

Jaclyn Bosco, FISPE
Gerald Dal Pan, FISPE
Gianluca Trifirò

Principles of Pharmacoepidemiology

202AB

Content

This course will provide participants with a succinct introduction to the basic principles, concepts, and study designs of pharmacoepidemiology. The course includes lectures on (1) cohort studies, (2) case-control studies, as well as (3) confounding and other sources of bias.

Faculty

Almut Winterstein, FISPE
Anton Pottegard
Tobias Gerhard, FISPE

Rare Disease Epidemiology and Orphan Drug Approvals

204C

Content

There are over 7,000 rare diseases, which affect more than 350 million people worldwide, only 5% of rare conditions have an FDA approved drug treatment. Over the past years, an increasing number of companies have devoted clinical programs to develop new treatments for patients with rare disorders. This creates the need for rare disease epidemiology, as a sub-specialty within pharmacoepidemiology. This unit is aimed at introducing students to the current regulatory environments for rare disease drug approvals in the US and Europe, the specific methodologic issues arising in rare disease epidemiology, use of electronic medical records and claims databases for rare disease research, as well as practical approaches used to integrate pharmacoepidemiologic methods into rare disease drug development programs.

Faculty

Melanie Blank
Rima Izem
Siyan Zhan
Jasmanda Wu, FISPE
Cynthia Jones

Pre-Conference | Saturday, August 24

12:30pm-2:00pm

Lunch on Your Own

1:00pm-5:00pm

**ISPE Board of
Directors Meeting***
**Marriott Franklin Hall
1 - 2**

**Open to all ISPE members;
interested members should
contact info@pharmacoepi.org
if they would like to attend this
meeting.*

2:00pm-6:00pm

EDUCATIONAL SESSIONS: HALF-DAY AFTERNOON COURSES

(Ticket Required)

Using Field Studies to Value-Add in Pharmacoepidemiology

201A

Content

This course provides basic theory and practical tips in conducting pharmacoepidemiologic studies when required information is not captured in databases or when large databases are not available. Common study designs used to collect data through observations, medical records or questionnaires will be presented and the strengths and limitations of working without large databases discussed. Hands-on experience via a workshop will expose course participants to different study designs and rich discussions on how to answer relevant questions about safety and utilization of medicines in primary and secondary care settings using field studies.

Faculty

Veronika Wirtz, FISPE
Lisa Pont, FISPE
Katja Taxis, FISPE

Cancer Pharmacoepidemiology and Genomics: What You Should Know in the Era of Precision Medicine

201B

Content

This course, co-sponsored by the Molecular Epidemiology, Biomarkers, and Pharmacogenomics and Oncology SIGs, will focus on the essentials every pharmacoepidemiologist should know about study design and real-world applications of cancer personalized medicine including precision medicine, companion diagnostics, biomarkers and the biomarker development pipeline, diagnosis and treatment coding, drug and cancer risk associations and linking databases with genomic information.

Faculty

Gillian Bartlett-Esquilant, FISPE
Bruce Carleton, FISPE
Andrew Freedman, FISPE
Geoffrey Liu, FISPE
Anton Pottegard
Wei Zhou, FISPE
Mary Davis



2:00pm-6:00pm

EDUCATIONAL SESSIONS: HALF-DAY AFTERNOON COURSES (Ticket Required) (continued)

Comparative Effectiveness Research (CER)

201C

Content

There is growing interest in drug repurposing, which involves finding new uses for old drugs. In addition to various clinical and pharmacological approaches, the methods of comparative effectiveness research (CER) can play an important role in evaluating whether marketed medications may be beneficial for other indications before embarking on large and expensive randomized trials. The course will start with an overview of the role of CER in drug repurposing, describe CER methods for generating evidence to evaluate the benefits of existing medications for new indications, and will discuss the promises and challenges of CER in this space. Multiple case studies will be used to facilitate an interactive group discussion and will address how observational, real-world data can be used to evaluate medications for repurposing.

Faculty

Joshua Gagne
Shirley Wang

CHECK OUT YOUR NEWEST MEMBER BENEFIT - The ISPE Exchange



Welcome to The ISPE Exchange, ISPE's new online community. It is your newest, best way to connect with members, get involved with the Society, join the mentorship program, and connect with new people.

Plan on joining some ISPE communities. Communities allow you to participate in discussions and share resources with other members. ISPE Committees, Special Regional Interest Groups, Councils and Chapters all have communities on the Exchange.

Log-in today at community.pharmacoepi.org

Below are several basic question and responses.

Q: WHAT IS MY USERNAME/PASSWORD?

A: Your login credentials are the same username and password that you use to log in to the main site. If you have forgotten your login credentials or need assistance with your login information, Email: info@pharmacoepi.org

Q: HOW DO I JOIN/SUBSCRIBE TO A COMMUNITY AND THE AFFILIATED DISCUSSION GROUP?

A: Click on "Communities" in the main navigation and click on "All Communities" in order to see a list of available communities. Click on the community that you wish to join and simply click "Join," then choose a delivery option for posts (Real Time, Daily Digest or No Email).

Q: HOW DO I START A NEW DISCUSSION THREAD?

A: Go to "Participate" > "Post a message." From an email (HTML version) for a particular discussion forum, you can use the "Post Message" link located at the top of the discussion email.

Q: HOW DO I FIND RESOURCES THAT MAY HAVE BEEN UPLOADED BY OTHER MEMBERS?

A: If you know which library the resource might be located in, find the affiliated community via the All Communities page. Click through the community's landing page, then click on the "Library" tab. If you do not know where the resource might be, enter search terms in the main search box the same way you might enter search terms in Google or another search engine.

Pre-Conference | Saturday, August 24

2:00pm-6:00pm

EDUCATIONAL SESSIONS: HALF-DAY AFTERNOON COURSES (Ticket Required) (continued)

Practical Skills in Protocol Writing and Statistical Analytic Programming Relevant to Pharmacoepidemiology

204A

Content

Pharmacoepidemiologic studies that involve the use of electronic healthcare data have complex and unique characteristics that must be taken into consideration when planning and conducting these types of studies. This highly interactive course will engage participants in the following topics:

- Pre-specifying study components of a protocol, including design, analysis, and reporting of the study, along with a science-based rationale for the choices pertaining to these components
- Translating elements of the study protocol into a statistical analytic program.

Faculty

Chih-Ying Pratt
Christian Hampp, FISPE
Jessical Jalbert
Nicole Pratt
Chintan Dave



lilly.com

2019 CA Approved for External Use PRINTED IN USA ©2019, Eli Lilly and Company. ALL RIGHTS RESERVED.

LILLY FOR BETTER

At Lilly, we are constantly evolving the way we discover, develop and manufacture medicines to bring new treatments to the people who need them even faster – and to expand access to these medicines for even more people around the world.



Japan's Largest Claims Database.

Payer-based DB

Data source : claim, enrollment information and health checkup from 130 + payers
Data period : January 2005 – the latest
Data volume : about 7 million enrollments

Hospital-based DB

Data source : claim + DPC survey data from 190 + hospitals
Data period : April 2014 – the latest
Data volume : about 8 million patients

Our service

Data Provision service

Data Analysis service

JMDC Inc.

<https://www.jmdc.co.jp/>
pbmadmin@jmdc.co.jp
+81-3-5733-8614

Pre-Conference | Saturday, August 24

2:00pm-6:00pm

EDUCATIONAL SESSIONS: HALF-DAY AFTERNOON COURSES (Ticket Required) (continued)**Scientific Writing from the Reader's Perspective: A New Take on the Writing Process**

204B

Content

From graduate students to senior practicing pharmacoepidemiologists, our work requires that we communicate in writing. Success in securing funding, sharing research findings, and influencing key decision makers depends on the skill with which we present thoughts to the reader. Those accustomed to reading English prose bring implicit expectations for when and how information will be presented. Violate these unstated expectations and the reader becomes irritated, weary, and struggles to understand the writer's intended message. The same content presented in alignment with reader expectations allows the reader to focus on the writer's ideas.

Over the last 45 years, Dr Gopen has devoted himself to uncovering these reader expectations and understanding the implications for scientific writing. During that time, he has taught tens of thousands of undergraduates, PhDs, MDs, JDs and MBAs the world over – including many mid-to-senior level clinical scientists. In this workshop, Dr Gopen introduces participants to the rhetorical principles underlying this advanced approach to scientific writing and demonstrates key reader expectations well enough for them to be applied immediately.

As noted in Dr. Gopen's 1990 publication in American Scientist, "The results are substantive, not merely cosmetic: Improving the quality of writing actually improves the quality of thought."

Faculty

George D Gopen

Pragmatic Trials: Design, Methods, and Implementation

202AB

Content

Pragmatic randomized clinical trials (pRCTs) require the expertise of pharmacoepidemiologists that understand considerations and methodologic challenges that arise with more "pragmatic" RCTs compared with traditional "explanatory" RCTs. This course will highlight issues such as real-world site and patient identification, enrollment and retention, ethical review issues, approach to randomization, selection bias, and defining the appropriate comparator. In addition, choice of study design including cluster randomization, step wedge design or individual randomization, and associated analytic considerations will be highlighted. Randomizing patients to "standard of care (SOC)", accounting for changes in therapies over time, and other methodological considerations will also be discussed. Operational challenges and lessons learned from conducting pRCTs will be shared along with case examples.

Faculty

Jennifer Christian, FISPE
Priscilla Velentgas
Cynthia Girman, FISPE
Anne Trontell

2:00pm-6:00pm

EDUCATIONAL SESSIONS: HALF-DAY AFTERNOON COURSES (Ticket Required) (continued)

Using Pharmacoepidemiology Database Resources to Address Drug Safety Research

204C

Content

Pharmacoepidemiology requires the utilization of database resources to evaluate drug safety. This course will define the different types of data resources available for pharmacoepidemiology and the selection criteria to select the most appropriate resource. The course focuses on the Guidelines for good database selection and use in pharmacoepidemiology research, provides an overview of available resources, addresses the need for outcome validation, and highlights data linkage considerations.

Faculty

- Kevin Haynes, FISPE
- Gillian Hall, FISPE
- Matthew Reynolds, FISPE
- Keith Marsolo
- Daniel Beachler
- Sudha Raman

TRANSFORMING THE LANGUAGE OF LIFE INTO VITAL MEDICINES



At Amgen, we believe that the answers to medicine’s most pressing questions are written in the language of our DNA. As pioneers in biotechnology, we use our deep understanding of that language to create vital medicines that address the unmet needs of patients fighting serious illness—to dramatically improve their lives.

For more information about Amgen, our pioneering science and our vital medicines, please visit www.amgen.com

Amgen is a proud sponsor of the 35th International Conference on Pharmacoepidemiology and Therapeutic Risk Management. Epidemiologic research at Amgen focuses on benefiting patients with grievous illnesses and advancing knowledge in our field.

©2019 Amgen Inc. All rights reserved.

Pre-Conference | Sunday, August 25

7:30am-6:00pm

Speaker Ready Room*

Room 303

7:30am-6:00pm

Mother's Room

Room 300

Sponsored by EPI Excellence, LLC

7:30am-6:30pm

Registration

Registration Bridge East

8:30am-12:30pm

EDUCATIONAL SESSIONS: HALF-DAY MORNING COURSES

(Ticket Required)

Intermediate Pharmacoepidemiology: Approaches to Unmeasured Confounders

201A

Content

This interactive course will introduce students to multiple approaches to addressing unmeasured confounders through study design and analysis, the requirements and assumptions of each, and an opportunity to compare these approaches through facilitated discussion of a case-study.

Faculty

Michele Jonsson Funk, FISPE
Jennifer Lund
Sudha Raman
Mugdha Gokhale
Til Stürmer, FISPE

Epidemiology of Vaccine Safety

201B

Content

Vaccines are key tools for global public health. Increasingly, pharmacoepidemiological studies are providing critical evidence needed for risk-benefit assessment to inform immunization policy, both for mature immunization programs and for low- and middle-income countries (LMIC) for which innovative vaccines against challenging diseases (e.g., dengue fever, Ebola, malaria, etc.) are under development. The annual ICPE has had vaccine-specific sessions for >15 years and ISPE has had a Vaccine Special Interest Group (VAXSIG) since 2014. One of the VAXSIG goals is to offer educational activities on vaccine-related epidemiology, in collaboration with the ISPE Education Committee.

Faculty

Cathy Panozzo
Robert T Chen, FISPE
Martin Kulldorff
Catherine Cohet
Harry Seifert, FISPE
Katherine Yih




Science for a **better life**

How do you fight an enemy with many faces?

100 plus types of cancer exist

Up to **100** times faster analysis of data in the search for a cure

CanWeLiveBetter.com



Source 1: What is Cancer?: Types of Cancer. National Cancer Institute, 2015
Source 2: Exascale Computing Project Funds Three CI/Argonne Projects. Computation Institute & The University of Chicago, 2016

DEPARTMENT OF POPULATION MEDICINE



HARVARD
MEDICAL SCHOOL



Harvard Pilgrim
Health Care Institute

Come work with us!

**Pharmacoepidemiologists, Biostatisticians, SAS Programmers,
Research Analysts, Program Managers**

We are the home of the:

- FDA Sentinel Operations Center
- Reagan-Udall Foundation IMEDS Analytics Center
- PCORnet Query Fulfillment Center
- NIH Health Care Systems Research Collaboratory Distributed Research Network
- State of Massachusetts MDPHnet Coordinating Center

We look forward to meeting you here at ICPE – look for anyone with the 'Ask me about Sentinel' buttons or email us at TIDE@harvardpilgrim.org

Please visit our website for information about our research programs, career, and training opportunities.

www.populationmedicine.org

Pre-Conference | Sunday, August 25

8:30am-12:30pm

EDUCATIONAL SESSIONS: HALF-DAY MORNING COURSES (Ticket Required) (continued)**Introduction to Drug Utilization Research**

201C

Content

This educational session provides an overview of drug utilization research (DUR) and presents essential methods used. The session includes interaction with participants, question and answer sessions, and discussion during and at the end of each presentation. At the end of the session, the participant will be exposed to:

- Description of the theoretical framework and practical applications of different methods illustrated using selected examples
- Classification systems used in drug utilization monitoring and research
- Limitations of data sources and methods
- Interpretation of aggregate and individual-based data, variation and change
- Using drug utilization research for public health and implications for policy decisions

Faculty

Gillian Caughey
 Veronika Wirtz, FISPE
 Lisa Pont, FISPE
 Solveig Sakshaug
 Morten Andersen
 Jaden Brandt

Modern Pregnancy Pharmacoepidemiology: Selected Analytical Considerations in the Study of Drug Safety in Pregnancy

204A

Content

In this course, faculty will present and discuss selected analytical considerations that are relevant for drug safety research in pregnancy.

The content of this course has changed from previous years. In 2015, the course provided an overview of issues that are particular to drug safety research in pregnancy. In 2016, the course focused on challenges related to exposure measurement, in 2017 the focus was on maternal and neonatal outcomes, and in 2018, the course presented pros and cons of various study designs. This year, the focus will be on selected analytical aspects of relevance to pregnancy safety research.

Faculty

Brian Bateman
 Krista Huybrechts, FISPE
 Andrea Margulis
 Ken Rothman, FISPE



8:30am-12:30pm

EDUCATIONAL SESSIONS: HALF-DAY MORNING COURSES (Ticket Required) (continued)**Pharmacovigilance and Signal Detection**

204B

Content

This course will introduce participants to the principles of surveillance in pharmacovigilance with a focus on quantitative aspects and recent advances in the field. The course will cover classical pharmacovigilance signal detection using spontaneous adverse event reports, quantitative signal detection methods for electronic medical record and claims data, and international initiatives, including work in the US FDA's Sentinel program aimed at using routinely collected electronic healthcare data to conduct signal detection. Real-world examples will be used across the lecture sessions to illustrate and connect different concepts. Participants will engage in interactive discussions about contemporary issues in and challenges facing pharmacovigilance, such as the role of social media data and the use of the same data for both signal detection and subsequent evaluation.

Faculty

Joshua Gagne
Gianluca Trifirò
Manfred Hauben
Judith Maro

Propensity Scores in Pharmacoepidemiology

202AB

Content

Issues of bias and confounding relate to study design and analysis in the setting of non-random treatment assignment where compared subjects might differ substantially with respect to comorbidities. Failing to address a lack of balance in the covariates between treated and comparison groups can produce confounded estimates of treatment effect.

Faculty

John Seeger, FISPE
Jeremy Rassen

Prospective Research: Tips & Tricks for Today's Technologies

204C

Content

This course will provide an overview of the methods and applications for studies that use primary data collection for effectiveness and safety research, including regulatory submissions of real-world data for label approvals or expansions. Topics include data collection from clinicians, electronic health records, or directly from patients without use of clinicians, and will address methodological and logistical challenges with a focus on recruitment and retention. Examples will include working with patient communities, data collection through clinicians, call centers, and digital technologies, and integrating electronic health data, with applications in rheumatology, pregnancy and injury research, among others.

Faculty

Nancy Dreyer, FISPE
Nabarun Dasgupta
Jeff Curtis
Christina Mack
Kevin Haynes, FISPE

Pre-Conference | Sunday, August 25

12:30pm-2:00pm

Lunch on your own

12:30pm-2:00pm

New Member & Early Stage Investigator Luncheon* 203AB

*Ticket Required

By invitation only; registration required.



2:00pm-6:00pm

EDUCATIONAL SESSIONS: HALF-DAY AFTERNOON COURSES

(Ticket Required)

Advanced Pharmacoepidemiology

201A

Content

This interactive course will touch on multiple advanced pharmacoepidemiology methods with each lecture providing the necessary tools for the attendees to apply the discussed principles to their own research.

- Multi-group Comparisons
- Drug-drug Interaction Research
- Double Robustness
- Conditional Power

Moderators

Jaclyn Bosco
Caitlin Knox

Faculty

Olaf Klungel, FISPE
Katsiaryna Bykov
Eric Tchetgen
Alec Walker, FISPE

Applied Sensitivity Analyses in Pharmacoepidemiology Database Studies

201B

Content

It is widely recognized that sensitivity analyses of study design choices and analytic assumptions help to interpret the robustness of pharmacoepidemiology studies. To encourage increased use of well-described techniques, this workshop will provide an introduction and demonstrations of a range of sensitivity analyses typically applied in pharmacoepidemiology with hands-on exercises. The course is interactive and participants will be able to conduct their own sensitivity analyses during the course – **bring your computer!**

Part 1: Sensitivity analyses of study design choices will introduce typical variations in study designs, including variations in exposure risk window length, variations in covariate assessment window length, duration of minimum induction period, and variations in follow-up model (fixed time vs. as treated analysis).

Part 2: Quantitative confounding bias analysis will focus on testing the influence of external assumptions or outside data on our understanding of residual confounding in a specific study setting.

Faculty

Sebastian Schneeweiss, FISPE
Jeremy Rassen
Nicolle Gatto, FISPE
Xavier Kurz
Olaf Klungel, FISPE
Natalia Petrusik-Ivleva



KANTAR



DELIVERING REAL-WORLD EVIDENCE THAT KEEPS PATIENTS SAFE

Partnering with prescribers and key industry stakeholders, we develop international registries that meet real-world evidence needs and provide hybrid studies that go beyond the database.

Through a custom consulting engagement, we'll fully support your regulatory needs.

Our vast heritage consists of more than 20 years of experience in real-world, patient-centric PASS and PAES, and our team has developed innovative safety studies for AI influenced devices and medicines.

Meet our experts at booth 208/210.

kantar.com/health-zeg-berlin.de

Rapid Analytics. Actionable Insights. Instant Health Data (IHD)

ANALYZE DIVERSE,
REAL WORLD DATABASES



PERFORM ANALYSES IN
A FRACTION OF THE TIME



HIGHEST-QUALITY
RESEARCH RESULTS WITH
INTERNAL RESOURCES



RESPOND TO GROWING
DEMANDS FOR RWE

Come see us at booth #206 at ICPE 2019
www.bhei.com



Pre-Conference | Sunday, August 25

2:00pm-6:00pm

EDUCATIONAL SESSIONS: HALF-DAY AFTERNOON COURSES (Ticket Required) (continued)**Advanced Drug Utilization Research**

201C

Content

This interactive educational program includes presentations, question and answer sessions and a final discussion with the faculty panel. The session will involve participants in the:

- Methods for evaluating the effect of clinical or policy interventions
- Interpretation of the evaluation data and dissemination of results
- Application of principles derived from Health Services and Implementation Research to the design of a clinical intervention
- Use of drug utilization information from administrative health data to improve medicines use
- Use of prescribing data and quality measures to assess prescribing

Faculty

Gillian Caughey
 Katja Taxis, FISPE
 Lisa Kalisch Ellett
 Petra Denig, FISPE
 Yared Santa-Ana-Télllez

Medical Device Epidemiology

204A

Content

Over the past few years, there has been increased focus on generating real-world evidence for medical products. Thus, medical product epidemiology is gaining visibility outside of ISPE. Medical device epidemiology uses methodologies similar to those for medicines. However, alternative strategies are often implemented due to the nature of the products, data sources, and situational use. With the changing regulatory and reimbursement environments, it is more important than ever for pharmacoepidemiology researchers to better understand the methods and practice of medical device epidemiology, both for study of medical devices and combination products. Methods discussed will be applicable across therapeutic products and will provide deeper understanding of measuring benefits and risks in clinical context.

This course provides a foundation for medical device epidemiology and its current applications in actual clinical practice. The session will incorporate didactic lectures and interactive case studies that highlight novel medical devices and combination products.

Faculty

Mary Ritchey, FISPE
 Daniel Prieto Alhambra, FISPE
 Christina Mack
 Theodore Lystig
 Colin Anderson-Smits



2:00pm-6:00pm

EDUCATIONAL SESSIONS: HALF-DAY AFTERNOON COURSES (Ticket Required) (continued)

Pediatric Pharmacoepidemiology

204B

Content

The increasing use of medications by children and the history of excluding children from clinical trials have created the need for pediatric pharmacoepidemiology, a sub-specialty within pharmacoepidemiology. Unique challenges in studying children, accessing data, defining outcomes, and designing pediatric studies will be discussed. This course will introduce participants that have a good understanding of pharmacoepidemiology to the specific methodologic issues arising in pediatric pharmacoepidemiology and operational approaches used to study medications in children.

Faculty

Tamar Lasky, FISPE
Daniel B Horton
Steven Bird
Mehmet Burcu

Regulatory Pharmacoepidemiology

202AB

Content

Medical product regulation increasingly relies on pharmacoepidemiologic analyses to assess the safety of medical products once they are marketed. This course is aimed at describing how pharmacoepidemiologic analyses are used in regulatory decision making, and the challenges that regulators face when using such analyses.

Faculty

Gerald Dal Pan, FISPE
June Raine
Danica Marinac-Dabic, FISPE

Weighing the Benefits & Risks: The Science and Methods of Benefit-Risk Assessment in Drug Development

204 C

Content

Benefit-risk assessment is now a fundamental science for understanding and evaluating the development, approval, and continued marketing of drugs and devices. This course is aimed at introducing attendees to core concepts and tools of both the science and practice of benefit-risk assessment.

Faculty

Rebecca Noel
Tarek A Hammad, FISPE
Juhaeri Juhaeri
Brett Hauber

6:00pm-7:30pm

Welcome Reception/Regional Interest Group & Academic Showcase

Grand Hall

Sponsored by Veridigm

Daniel B. Horten, Chair, ICPE 2019 Local Host Committee
Alison Bourke, FISPE, ISPE President
Vincent Lo Re, FISPE, Chair, ICPE 2019 Scientific Program Committee
Brian D Works, Temple University Lewis Katz School of Medicine

African Regional Interest Group
Brazil Regional Interest Group
Brown University School of Public Health
Brigham & Women's Hospital - Harvard University Division of Pharmacoepidemiology
DSRU Pharmacovigilance
Johns Hopkins Center for Drug Safety and Effectiveness
McGill University, Pharmacoepidemiology Unit
Rutgers Center for Pharmacoepidemiology and Treatment Science
University of Florida, Department of Pharmaceutical Outcomes and Policy
University of North Carolina - Pharmacoepidemiology Dept
University of Manitoba - College of Pharmacy
A cash bar will be available.



Optimising Real World Data Use to Drive Effective Outcomes


ICON provides integrated services to identify, generate, synthesise and communicate real world evidence to drive healthcare and research decisions.

From interactive evidence planning workshops and strategy creation to implementation of innovative technology and RWD solutions, we ensure that you are on the clear path to commercial success, equipped with the right RWD assets to generate impactful evidence.

[ICONplc.com/realworldevidence](https://www.iconplc.com/realworldevidence)




Generate Evidence for Patient Safety using Global Healthcare Data



At UBC, our scientists analyze real-world healthcare data to provide rapid, reliable insight into the safe and effective use of products, pre- and post-marketing.

We never lose sight of the patients behind the data. Learn more by visiting [ubc.com/global-services](https://www.ubc.com/global-services).



©2019 United BioSource LLC. All Rights Reserved.



Main Conference | Monday, August 26

7:00am – 8:00am
Continental Breakfast Hall A
Sponsored by IBM Watson Health

7:00am – 8:00am
Regional Interest Groups (*Open to all participants*)
Brazil 203A
Gulf Region 100A
Latin America 101

7:00am – 8:00am
Poster Session A Set-up Hall A

7:00am – 8:00am
Spotlight Poster Session A Set-up West Bridge

7:00am – 6:00pm
Registration Registration Bridge East

7:00am – 6:00pm
Speaker Ready Room
(Please arrive 24 hours before your presentation start time to upload or check your presentation.) Room 303

7:30am – 6:00pm
Exhibits/Poster Session A Hall A

7:30am – 6:00pm
Mother's Room Room 300
Sponsored by EPI Excellence, LLC

8:00am-8:30am
Welcome Ballroom B

- **Vincent Lo Re**, FISPE, Chair, 2019 ICPE Scientific Program Committee
- **Daniel B. Horton**, Chair, 2019 ICPE Local Host Committee
- **Alison Bourke**, FISPE, ISPE President

8:30am – 10:00am
Keynote Session - The Role of Real World Evidence In Regulatory Decision Making Ballroom B

With the 21st Century Cures Act, U.S. Congress directed the FDA to explore how real-world evidence (RWE) can be used to support approval of new indications for existing drugs and to satisfy post-approval study requirements. To address this mandate, FDA committed to conducting pilot studies and developing guidance on how RWE can contribute to the assessment of safety and effectiveness in regulatory submissions. In this keynote address, the FDA speaker will discuss the current application of RWE in regulatory decision making, the development of evidence to support fitness for use, future directions, and the role of pharmacoepidemiology in the generation and evaluation of RWE. A panel of pharmacoepidemiologists will provide their own perspectives on the promises and challenges of using RWE to assess the safety and effectiveness of drugs and biologics.

Keynote Speaker

- **Jacqueline Corrigan-Curay**, JD, MD, FDA/CDER/OMP Director

Moderator

- **Vincent Lo Re**, FISPE, Associate Professor of Medicine & Epidemiology, Perelman School of Medicine, Center for Clinical Epidemiology & Biostatistics, University of Pennsylvania

Panelists

- **Brian Strom**, FISPE, Chancellor, Rutgers Biomedical & Health Sciences; Executive Vice President for Health Affairs; University Professor; Rutgers, the State University of New Jersey
- **Solomon Iyasu**, Vice President and Head of Pharmacoepidemiology, Merck & Company, Inc.
- **June M Raine**, Medicines and Healthcare Products Regulatory Agency, UK

10:00am – 10:30am
Break Hall A

10:30am – 12:00pm
CONCURRENT SESSIONS: SYMPOSIA AND WORKSHOPS

10:30am
What Does Replicable and Robust Non-Randomized Database Evidence Look Like? [1] Ballroom B
 Shirley Wang, Jeremy Rassen, Simone Pinheiro, Jesse Berlin, Sebastian Schneeweiss. (United States)

10:30am
How Do We Assess When Electronic Health Records or Claims Databases are Fit for a Specific Research or Regulatory Purpose? [2] 201A
 Cynthia J Girman, Mary E Ritchey, David Martin, Wei J Zhou, Nancy J Dreyer. (United States)

Main Conference | Monday, August 26

10:30am – 12:00pm

CONCURRENT SESSIONS: SYMPOSIA AND WORKSHOPS (continued)

10:30am

When Artificial Intelligence Meets Pharmacoepidemiology [3]

201B

Dorothee B Bartels, Jim Slattery, Antoine Pariente, John Rigg. (Germany) *Sponsored by the Digital Epidemiology Special Interest Group*

10:30am

Pregnancy Registries and Pregnancy Outcome Studies in Healthcare Databases: Trends and Complementary Research Approaches [4]

201C

Steve Gao, Krista Huybrechts, Leyla Sahin, John Seeger, Daina Esposito, Christina D. Chambers. (United States)

10:30am

Drugs and Germs: Dirty Details about Pharmacoepidemiology and the Microbiome [5]

202AB

Daniel B Horton, Peter J Turnbaugh, Scott E Plevy, Soko Setoguchi, Tobias Gerhard, James D Lewis. (United States)

12:00pm – 1:30pm

Lunch/Poster Session A/Exhibits

Hall A

12:00pm – 1:30pm

Committee Meetings (Open to all participants; lunch available)

- Education **Marriott 304-305**
- Finance **Marriott 302-303**
- Membership **Marriott 306**

12:15pm – 1:15pm

Spotlight Poster Session A:

West Bridge

- Adherence
- Asian Pharmacoepidemiology Network (AsPEN)
- Biologics & Biosimilars
- Comparative Effectiveness Research (CER)
- Geriatric Pharmacoepidemiology

1:30pm – 3:00pm

CONCURRENT SESSIONS: ORAL PRESENTATIONS**Show Us Your Money: Health Economics and Policy**

Ballroom B

Moderators: Daniel Arhinful & Kimberly Brodovicz

1:30pm

Scientific Evidence Supporting Benefits of Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2017 [6]

James Heyward, G Caleb Alexander, Thomas J Moore. (United States)

1:45pm

Cost-Effectiveness of First Line Tyrosine Kinase Inhibitor Initiation Strategies for Chronic Myeloid Leukemia [7]

Joehl T Nguyen, Ashley L Cole, Ashley A Leech, William A Wood, Stacie B Dusetzina. (United States)

2:00pm

Healthcare Resource Use and Expenditures in Patients Newly Diagnosed with Paroxysmal Supraventricular Tachycardia in the United States [8]

Naomi C Sacks, Katie Everson, Philip L Cyr, Madison T Preib, David R Wood, Sean D Pokorney. (United States)

2:15pm

The Economic Impact of the Introduction of Infliximab-Biosimilar: Preliminary Results from a Study on Rheumatologic Patients in Tuscany, Italy [9]

Valentina Lorenzoni, Leopoldo Trieste, Marta Mosca, Irma Convertino, Marco Tuccori, Ersilia Lucenteforte, Sara Ferraro, Luca Leonardi, Giuseppe Roberto, Nicoletta Luciano, Corrado Blandizzi, Rosa Gini, Giuseppe Turchetti. (Italy)

2:30pm

Antithrombotic Stewardship [10]

Albert Dreijer, Marieke JHA Kruij, Jeroen Diepstraten, Suzanne Polinder, Rolf Brouwer, Nanne Croles, Esther Kragten, Frank WG Leebeek, Patricia van den Bemt. (Netherlands)

2:45pm

Privacy versus Public Good: The Methodological Approach of the Belgian Healthdata.be Platform to Protect Individual Privacy in Health Research [11]

Kaatje Bollaerts, Maria Alexandridou, Simeon Wanyama, Kris Vranken. (Belgium)

1:30pm – 3:00pm

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)

Winning the Immunity Challenge

201A

Moderators: Seoyoung Kim & Maribel Salas, FISPE

1:30pm

Infant Infections after Maternal Anti-TNF Treatment in Pregnancy [12]

Gabriella Broms, Helle Kieler, Anders Ekbohm, Mika Gissler, Karin Hellgren, Maarit K Leinonen, Lars Pedersen, Marcus Schmitt-Egenolf, Henrik Toft Sørensen, Fredrik Granath. (Sweden)

1:45pm

The Association between Atopic Eczema and Cancer in England and Denmark: Two Cohort Studies [13]

Kathryn E Mansfield, Sigrún A Jóhannesdóttir Schmidt, Bianka Darvalics, Amy Mulick, Katrina Abuabara, Angel Wong, Henrik Toft Sørensen, Liam Smeeth, Krishnan Bhaskaran, Isabel dos Santos Silva, Richard J Silverwood, Sinéad M Langan. (United Kingdom)

2:00pm


The Association between Partner Bereavement and Incident Psoriasis or Atopic Dermatitis: A Matched Cohort Study [14]

Angel YS Wong, Harriet J Forbes, Amy Mulick, Kathryn Mansfield, Richard J Silverwood, Henrik T Sørensen, Liam Smeeth, Sigrún AJ Schmidt, Sinéad M Langan. (United Kingdom)

2:15pm

Risk of Liver Disease in Patients with Psoriasis, Psoriatic Arthritis, and Rheumatoid Arthritis Treated with Methotrexate [15]

Joy Wan, He Zhang, Alexis Ogdie, Alexander Egeberg, Joel M Gelfand. (United States)



AETION[®]

The biggest innovation you can make is a better decision

The Aetion Evidence Platform™ is the validated real-world evidence platform to determine the safety, effectiveness, and value of therapeutics.

- Regulatory-grade
- Efficient, transparent, and scalable
- Data connected across global sources

Visit us at booth #1019
www.aetion.com info@aetion.com

Main Conference | Monday, August 26

1:30pm – 3:00pm

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)

2:30pm

Prediction of Cardiovascular Events in Rheumatoid Arthritis Patients Using Protein Biomarkers and Clinical Factors [16]

Jeffrey R Curtis, Fenglong Xie, Lang Chen, Eric Sasso, Elena Hitraya, Jerry S Lanchbury, Darl Flake, Alexander Gutin, Cheryl Chin, Cynthia Crowson. (United States)

2:45pm

Induction Immunosuppression Practices in Liver Transplantation Are Variable and Predict Post-Transplant Outcomes [17]

Therese Bittermann, Rebecca A Hubbard, James D Lewis, David S Goldberg. (United States)

Medications and Birth Defects

201B

Moderators: Christina Chambers & Marleen VanGelder

1:30pm

Comparative Safety of Antiepileptic Drugs and Risk of Major Congenital Malformations [18]

Jacqueline M Cohen, Maarit K Leinonen, Silje Alvestad, Marte-Helene Bjørk, Carolyn E Cesta, Kristjana Einarsdóttir, Anders Engeland, Mika Gissler, Óskar Hálfðánarson, Øystein Karlstad, Helle Kieler, Kari Klungsoyr, Mette Nørgaard, Lars Pedersen, Randi Selmer, Helga Zoega, Kari Furu. (Norway)

1:45pm

Use of Oral Fluconazole during Pregnancy and Risks of Spontaneous Abortion, Stillbirth and Major Congenital Malformation: An International, Multi-Centre Cohort Study [19]

Colin Dormuth, Brandace Winquist, Anat Fisher, Fangyun Wu, Pauline Reynier, Matthew Dahl, Zhihai Ma, Xinya Lu, Jianguo Zhang, Colette Raymond, Kristian B Filion, Robert W Platt, Carolina Moriello, J Michael Paterson, CNODES Investigators. (Canada)

2:00pm

Oral Fluconazole Use in Pregnancy and the Risk of Birth Defects [20]

Yanmin Zhu, Brian T Bateman, Sonia Hernandez-Diaz, Kathryn J Gray, Helen Mogun, Krista F Huybrechts. (United States)

2:15pm

The Impact of In-Utero Prescription Opioid Exposure on Congenital Malformations [21]

Loren Straub, Krista F Huybrechts, Sonia Hernandez-Diaz, Helen Mogun, Brian T Bateman. (United States)

2:30pm

Risk of Neonatal Abstinence Syndrome Following Prenatal Exposure to Methadone vs Buprenorphine [22]

Mollie Wood, Milada Mahic, Marte Handal, Svetlana Skurtveit, Ingunn Olea Lund, Sonia Hernandez-Diaz. (United States)

2:45pm

Paternal Exposure to Finasteride - before and during Pregnancy [23]

Jon T Andersen, Thomas B Jensen, Henrik Horwitz, Stine S Clausen. (Denmark)



1:30pm – 3:00pm

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)

Confounding Methods

201C

Moderators: Deborah Layton & Jesper Hallas, FISPE

1:30pm

Modeling Effect Heterogeneity in the Presence of Heterogeneous Confounding: A Plasmode Simulation [24]

Mitchell M Conover, Virginia Pate, Michele Jonsson Funk. (United States)

1:45pm

A Little off the Sides: Propensity Score Trimming in the Presence of Heterogeneity [25]

Michael Webster-Clark, Robert Glynn, Til Stürmer. (United States)

Student Award Recipient – Best Methods Abstract Submitted by a Student/Post-Doc

2:00pm

Propensity Score Trimming - Lessons from a Study of Antipsychotic Augmentation for Depression [26]

Tobias Gerhard, Daniel Horton, Mark Olsson, T Scott Stroup, Soko Setoguchi, Brian L Strom. (United States)

2:15pm

Residual Confounding and Treatment Effect Heterogeneity: An Applied Example [27]

Mitchell M Conover, Virginia Pate, Michele Jonsson Funk. (United States)

2:30pm

Novel Approaches for Defining Binary Confounders in Claims Data: A Simulation Study [28]

John G Connolly, Sebastian Schneeweiss, Robert J Glynn, Joshua J Gagne. (United States)

2:45pm

An Empirical Evaluation of a Propensity Score Stratification Based Weighting Approach in Settings of More Than Two Treatment Groups [29]

Rishi J Desai, Kazuki Yoshida, Krista Huybrechts, Jessica Franklin. (United States)



Pfizer
Working together for a healthier world

Committed to bringing therapies to people that extend and significantly improve their lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

Pfizer Epidemiology is proud to support the 35th International Conference on Pharmacoepidemiology and Therapeutic Risk Management in Philadelphia, PA.

Main Conference | Monday, August 26

1:30pm – 3:00pm

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)**Not All Bad News on CVD Safety**

202AB

Moderators: Joris Komen & Marie de Bruin

1:30pm

Use of Stimulants in Adults and Risk of Cardiovascular Events: A Multi-Design Approach [30]

Mina Tadrous, Simon Greaves, Michael Paterson, Jennifer Watt, David N Juurlink, Diana Martins, Muhammad M Mamdani, Tara Gomes. (Canada)

1:45pm

Mirabegron and the Risk of Arrhythmias: A Population-Based Cohort Study [31]

Mina Tadrous, Rano Matta, Simon Greaves, David N Juurlink, Muhammad Mamdani, Tara Gomes. (Canada)

2:00pm

Risk of Major Cardiovascular Events Associated with Varenicline and Nicotine Replacement Therapy: An Australian Population-Based Study [32]

Alys Havard, Stephanie K Choi, Clara K Chow, Duong T Tran, Kristian B Filion. (Australia)

2:15pm

Cardiovascular Safety of Prucalopride for Chronic Constipation: A Multinational Population-Based Cohort Study [33]

Alicia Gilsean, Joan Fortuny, Miguel Cainzos-Achirica, Oscar F. Cantero, Robert W Flynn, Luis Garcia-Rodriguez, Abenah Harding, Bianca Kollhorst, Pär Karlsson, Love Linnér, Thomas M. MacDonald, Ingvild Odsbu, Estel Plana, Ana Ruigómez, Tania Schink, Ryan Ziemiecki, Elizabeth B Andrews. (United States)

2:30pm

Cardiotoxicity of Aromatase Inhibitors in Post-Menopausal Women with Breast Cancer: A Population-Based Cohort Study [34]

Farzin Khosrow-Khavar, Nathaniel Bouganim, Kristian B Filion, Samy Suissa, Laurent Azoulay. (Canada)

2:45pm

Diagnosis of Immune Checkpoint Inhibitor Associated Myocarditis: A Systematic Review of Case Reports and Observational Studies [35]

Richeek Pradhan, Amit Nautiyal, Sonal Singh. (United States)

Wear and Tear, Bad to the Bone and the Good Stuff

204C

Moderators: Andrew Zullo & Rachel Sobel, FISPE

1:30pm

Effects of Bisphosphonate Use on Knee Osteoarthritis Progression: An Analysis of the Osteoarthritis Initiative Study [36]

Kaleen N Hayes, Vasily Giannakeas, Andy Kin On Wong. (Canada)

1:45pm

The Effect of Beta Blocker Use on Bone Outcomes in the Framingham Osteoporosis Study [37]

Christine W Lary, Kathleen Nevola, Alexandra C Hinton, Theresa I Shireman, Katherine Motyl, Karen L Houseknecht, Frances L Lucas, Sarah Hallen, Andrew R Zullo, Sarah D Berry, Douglas P Kiel. (United States)

2:00pm

Sodium-Glucose Co-Transporter 2 Inhibitors and the Risk of Fractures among Patients with Type 2 Diabetes [38]

Devin Abrahami, Antonios Douros, Hui Yin, Oriana H Yu, Laurent Azoulay. (Canada)

3:00pm – 5:00pm

Break/Posters/Exhibits

Hall A



3:30pm – 5:00pm

CONCURRENT SESSIONS: SYMPOSIA AND WORKSHOPS

3:30pm

The Ascension of Real-World Evidence: Can (and Should) We Establish Thresholds for Validity? [42]

Ballroom B

Nicolle M Gatto, Cynthia Girman, Stephan Lanes, David Martin, Robert F Reynolds, Sebastian Schneeweiss, Jim Slattery. (United States)

3:30pm

Heterogeneity and Validity in National and International Multi-Database Pharmacoepidemiologic Studies (MPES): Lessons Learned in North America, Europe, and Asia [43]

201A

Edward Chia-Cheng Lai, Kenneth Man, Darren Toh, Robert Platt, Jesper Hallas, Soko Setoguchi. (Taiwan)

3:30pm

Thinking Globally While Acting Locally: Developing Time-on-Treatment Data in International Settings [44]

201B

Judith C. Maro, Kristian B Filion, Achim Wolf, Kevin Haynes, Michael D Nguyen. (United States)

3:30pm

Machine Learning to Improve Causal Inference in Pharmacoepidemiology [45]

201C

Jason Roy, Nandita Mitra. (United States)

3:30pm

Measuring, Mapping, and Meshing of Genotype and Phenotype Data across Large Datasets: Challenges of Combining and Mining Genotype and Phenotype Data [46]

202AB

Leah Sansbury, Meg Ehm, Marylyn Richie, Amalia Issa, Edgar Simard. (United States)

Sponsored by the Molecular Epidemiology, Biomarkers and Pharmacogenetics Special Interest Group

5:15pm – 6:45pm

CONCURRENT SESSIONS: ORAL PRESENTATIONS

Where Is the Unbiased Comparison?

Ballroom B

Moderators: Helga Gardarsdottir, FISPE, & Eric Wittbrodt

5:15pm

Using Negative Control Outcomes to Assess the Comparability of Osteoporosis Treatment Groups [47]

Leah J McGrath, Leslie Spangler, Jeffrey R Curtis, Vera Ehrenstein, Henrik Toft Sørensen, Bradley Saul, Sara Levintow, M. Alan Brookhart, Brian D. Bradbury. (United States)

5:30pm

Can Adjustment Fail? Confounder Misclassification in Single-Arm Studies with Real World Comparators [48]

Michael Webster-Clark, Mitchell Conover, Michele Jonsson-Funk, Til Stürmer. (United States)

5:45pm

Confounding by Indication in Drug-Cancer Association Studies: A Nested Case-Control Study of the Association between Calcium Channel Blockers and Renal Cell Carcinoma [49]

Kasper Bruun Kristensen, Laurel A Habel, Joshua J Gagne, Søren Friis, Jesper Hallas, Klaus Kaae Andersen, Anton Pottegård. (Denmark)

6:00pm

Visualization Tool of Variable Selection for Inverse Probability Weighted Estimator in High-Dimensional Covariates [50]

Ya-Hui Yu, Ashley I Naimi, Lisa M Bodnar, Kristian B Filion, Robert W Platt. (Canada)

6:15pm


A General Propensity Score for Signal Detection Using Tree-Based Scan Statistics [51]

Shirley V Wang, Joshua J Gagne, Judith C Maro, Sushama Kattinakere, Danijela Stojanovic, Efe Eworuke, Elande Baro, Rita Ouellet-Hellstrom, Michael Nguyen, Sandra DeLuccia, Ella Pestine, Martin Kulldorff. (United States)

6:30pm


Approaches to Overcome the Immeasurable Time Bias in Cohort Studies: Beta-Blockers and Risk of Mortality in Patients with Heart Failure [52]

In-sun Oh, Han Eol Jeong, Kristian B Filion, Ju-Young Shin. (Korea, Republic of)



RTI (h)(s)[™]

Health Solutions



Meet Us at ICPE.

FIND US AT:
booth #308

LEARN MORE:
rtihs.org/ICPE19

The power of **knowledge**. The value of **understanding**.

Our expert team of epidemiologists are no strangers to real-world evidence. We have long-standing research collaborations with over 20 research partners across Europe and North America. You can trust our background and expertise to guide you to the right evidence to help you answer your pharmacoepidemiology, risk management, benefit-risk, and real-world evidence questions.



ANALYSIS GROUP

ECONOMIC, FINANCIAL and STRATEGY CONSULTANTS

Drug Safety and Epidemiology

Raising the Standard in Pharmacoepidemiology

Analysis Group collaborates with prominent clinicians, academics, and industry thought leaders to develop innovative solutions for clients across North America, Europe, and emerging markets in the following areas:

- Real-world evidence generation and regulatory strategy for NDA, sNDA, BLA, and PMA submission
- Peri- and post-approval safety studies
- Pharmacovigilance and spontaneous report analyses
- Clinical trial data analyses
- Advanced methods in causal inference
- Machine learning and big data analytics
- Mass tort pharmaceutical liability litigation

Analysis Group is a proud Gold Sponsor of the 35th International Conference on Pharmacoepidemiology and Therapeutic Risk Management. Please visit booth #1105 to meet our team!

For more information, contact **Mei Sheng Duh, Sc.D., M.P.H.**, Managing Principal and Chief Epidemiologist, at mei.duh@analysisgroup.com or 617-425-8131, or visit www.analysisgroup.com/epidemiology

5:15pm – 6:45pm

CONCURRENT SESSIONS: ORAL PRESENTATION (continued)

How Do Exposed Pregnancies End?

201A

Moderators: Hedvig Nordeng & Alys Havard

5:15pm

Risk of Pregnancy Loss in Patients Exposed to Mycophenolate Compared to Azathioprine: A Retrospective Cohort Study [53]

Thuy N Thai, Amir Sarayani, Xi Wang, Yasser Albogami, Sonja Rasmussen, Almut G Winterstein. (United States)

Student Award Recipients – Second Best Abstract Submitted by a Student(s)/Post-Doc

5:30pm

Exposure to Antidepressants during Pregnancy and the Risk of Attention Deficit Hyperactivity Disorder in Offspring: Findings from a Nationwide Cohort Study with and without Sibling Design [54]

Buket Öztürk, Lars Pedersen, Vera Ehrenstein, Henrik T Sørensen. (Denmark)

5:45pm

Does the Type of Antihypertensive Medication Used in Pregnancy Affect Risk of Pre-Eclampsia? [55]

Sascha Dublin, Mary A Akosile, Lu Chen, Lyndsay A Avalos, T Craig Cheetham, Thomas Easterling, Victoria L Holt, Sylvia E Badon, Romain S Neugebauer, Kristi Reynolds, Rod L. Walker, Susan M Shortreed. (United States)

6:00pm

Prenatal Antidepressant Exposure and Perinatal Outcomes: An Analysis Utilizing Longitudinal Clustering Methods [56]

Gretchen Bandoli, Christina Chambers, Kristin Palmsten. (United States)

6:15pm

Incident Exposure to Benzodiazepine in Early Pregnancy and the Risk of Spontaneous Abortion [57]

Odile Sheehy, Anick Bérard, Jin-Ping Zhao. (Canada)

6:30pm

Ondansetron Use in Early Pregnancy and Miscarriage [58]

Elizabeth A Suarez, Kim Boggess, Stephanie M Engel, Jennifer L Lund, Til Stürmer, Michele Jonsson Funk. (United States)

Still Asking the Same Questions? Who, What, Where, When, How

201B

Moderators: Kenneth Man & Vicki Osborne

5:15pm

Use of Psychotropic Drugs in Children and Adolescents with Tic Disorders in Denmark: A Nationwide Drug-Utilization Study [59]

Lotte Rasmussen, Julie M Thrane, Niels Bilenberg, Anton Pottegård. (Denmark)

5:30pm

Patterns of Drug Utilisation over Age in Asthmatic Children [60]

Esmé Baan, Astrid Heeremans, Leila Karimi, Hettie M Janssens, Miriam Karimi, Johan C de Jongste, Lies Lahousse, Katia Verhamme. (Netherlands)

5:45pm

Methylphenidate Treatment during Childhood Is Continued in Adulthood in Half of the Study Population [61]

Chii Chyi Cheung, Katia M Verhamme, Ron M Herings, Loes E Visser, Bruno H Stricker. (Netherlands)

6:00pm

Unintended Consequences of a National Policy Intervention to Curb Inappropriate Alprazolam Prescribing in Australia [62]

Andrea L Schaffer, Nicholas A Buckley, Sallie Pearson. (Australia)

6:15pm

Prescribing Systemic Steroids for Acute Respiratory Tract Infections in US Outpatient Settings [63]

Kueiyu Joshua J Lin, Evan Dvorin, Aaron S Kesselheim. (United States)

6:30pm

Characteristics of Febuxostat and Allopurinol Initiators and Utilization Patterns in Real-World Settings [64]

Marie Bradley, Efe Eworuke, Austin Cosgrove, Laura Hou, Darren Toh. (United States)

5:15pm – 6:45pm

CONCURRENT SESSIONS: ORAL PRESENTATION (continued)

SGLT2 and Risk (?)

201C

Moderators: Charles Leonard & Edward Lai

5:15pm

Analysis of Sodium-Glucose-Cotransporter-2 Inhibitor Use in Patients with Type-1 Diabetes Mellitus and Rates of Diabetic Ketoacidosis [65]

Christian Hampp, Richard Swain, Casie Horgan, Elizabeth Dee, Yandong Qiang, Sarah Dutcher, Andrew Petrone, Rong Chen Tilney, Judith C Maro, Catherine A Panozzo. (United States)

5:30pm

Clinical Outcomes in Patients with Type 2 Diabetes Newly Initiating SGLT2 or DPP4 Inhibitors [66]

Sruthi Adimadhyam, Danielle Isaman, Andrew Weckstein, Emma Payne, Edward Yu, Anthony Louder, Shannon L Reynolds. (United States)

5:45pm

Incidence Rate of Fournier's Gangrene in Type-2 Diabetic Patients Using Second-Line Anti-Diabetic Drugs [67]

Sara Eapen, Sebastian Schneeweiss, Aditya Rajan, Natalia Petruski-Ivleva, Saira A Jan. (United States)

6:00pm

SGLT-2 Inhibitors and the Risk of Community-Acquired Pneumonia in Patients with Type-2 Diabetes [68]

Vanessa Brunetti, Pauline Reynier, Laurent Azoulay, Oriana H Yu, Pierre Ernst, Robert W Platt, Kristian B Filion. (Canada)

6:15pm

Risk of Inflammatory Bowel Disease with Sodium Glucose Co-Transporter-2 Inhibitors Compared to Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes [69]

Ghadeer K Dawwas, Steven M Smith. (United States)

6:30pm

Sodium-Glucose Co-Transporter 2 Inhibitors and the Risk of Venous Thromboembolism in Patients with Type 2 Diabetes: A Cohort Study [70]

Niklas Schmedt, Dirk Enders, Felix Müller, Jochen Walker, Edeltraut Garbe, Antonios Douros. (Germany)

Mental Health and Medicines

202AB

Moderators: Christine Ulbricht & Sudha Raman

5:15pm

Association of Aripiprazole with the Risk of Psychiatric Hospitalization, Self-Harm, or Suicide [71]

François Montastruc, Rui Nie, Simone Loo, Soham Rej, Sophie Dell'Aniello, Joelle Micallef, Samy Suissa, Christel Renoux. (Canada)

5:30pm

Changes in the Population Characteristics of U.S. Youth Receiving Psychotropic Polypharmacy: 1996 to 2016 [72]

Chengchen Zhang, O'Mareen Spence, Gloria Reeves, Susan dosReis. (United States)

5:45pm

Trends in Antipsychotic-Related Polypharmacy among U.S. Youth from 1996 to 2016 [73]

Chengchen Zhang, O'Mareen Spence, Gloria Reeves, Susan dosReis. (United States)

6:00pm

Off-Label Use of Antipsychotics among US Commercially-Insured Youth [74]

Kyungwan Hong, O'Mareen Spence, Susan dosReis. (United States)

6:15pm

Risk of Psychosis with Amphetamine versus Methylphenidate in Attention Deficit Hyperactivity Disorder [75]

Lauren V Moran, Dost Ongur, John Hsu, Victor M Castro, Roy H Perlis, Sebastian Schneeweiss. (United States)

6:30pm

The Occurrence of Suicide-Related Outcomes among Patients Initiating Tegaserod in Routine Clinical Practice [76]

John D Seeger, Sherry G Quinn, Heather Norman, Judy Wong. (United States)

Main Conference | Monday, August 26

5:15pm – 6:45pm

CONCURRENT SESSIONS: ORAL PRESENTATION (continued)**Risky Business in Cancer**

204C

Moderators: Andrew Freeman, FISPE, & Cynthia de Luise

5:15pm

Cholesterol-Lowering Medication and Breast Cancer Recurrence in Postmenopausal Women Treated with Adjuvant Aromatase Inhibitors: A Danish Population-Based Cohort Study [77]

Karl S Harborg, Uffe Heide-Jørgensen, Thomas P Ahern, Maj-Britt Jensen, Marianne Ewertz, Deirdre Cronin-Fenton, Signe Borgquist. (Denmark)

5:30pm

Association between Hydrochlorothiazide Exposure and Skin, Lip and Oral Cancer: A Series of Population-Based Nested Case-Control Studies [78]

Daniel R Morales, Alexandra Pacurariu, Xavier Kurz, Jim Slattery. (United Kingdom)

5:45pm

Voriconazole and Cutaneous Squamous Cell Carcinoma Risk among Lung Transplant Recipients [79]

Monica D'Arcy, Ruth Pfeiffer, Donna R Rivera, Sarah Aaron, Elizabeth Yanik, Isaac Brownell, Edward Cowen, Matthew Triplette, Greg Hess, Eric A Engels. (United States)

6:00pm

Detection of Prevalent Cancer among New Users without Routine Care [80]

Monica D'Arcy, Til Stürmer, Michele Jonsson Funk. (United States)

6:15pm

Automatic Detection of Drug-Drug Interactions in Cancer Patients: A French Population-Based Cohort Study [81]

Camille Morival, Clément Mathieu, Antoine Pariente, Mathieu Molimard, Amandine Gouverneur, Pernelle Noize. (France)

6:30pm

Treatment Pattern and Real World Effectiveness on Non Small Cell Lung Cancer Patients Harboring Major Single and Double EGFR Mutations [82]

W. Venus So, Xing Yang, Mathias Leddin, Lin-Chi Chen, Yvonne A Nagel. (United States)

7:00pm – 8:00pm

Special Interest Group Meetings (Open to all participants)

7:00pm – 8:00pm

Adherence SIG 201A

7:00pm – 8:00pm

Asian Pharmacoepidemiology Network (AsPEN) SIG 201B

7:00pm – 8:00pm

Benefits Risk Assessment, Communication and Evaluation (BRACE) SIG 201C

7:00pm – 8:00pm

Biologics & Biosimilars SIG 202AB

7:00pm – 8:00pm

Comparative Effectiveness Research (CER) SIG 204A

7:00pm – 8:00pm

Dababase SIG 204B

7:00pm – 8:00pm

Digital Epidemiology SIG 204C

7:00pm – 8:00pm

Drug Utilization/Health Services Research SIG 203A

7:00pm – 8:00pm

Geriatric Pharmacoepidemiology SIG 203B

7:00pm – 8:00pm

Medical Devices SIG 100A

7:00pm – 8:00pm

Medications in Pregnancy & Lactation SIG 101

7:00pm – 8:00pm

Molecular Epidemiology/Biomarkers/Pharmacogenetics SIG 100B

7:00pm – 8:00pm

Oncology SIG 104AB

7:00pm – 8:00pm

Pediatrics SIG **Marriott 301**

7:00pm – 8:00pm

Rare Disease SIG **Marriott 302-303**

7:00pm – 8:00pm

Vaccines SIG **Marriott 304-305**



Broaden your horizons.

Discover ***new*** data and analytics
for actionable insights.

Visit ICPE booth #1100-1102
and talk to our research team.



Main Conference | Tuesday, August 27

7:00am – 8:00am
Continental Breakfast Hall A

7:00am – 8:00am
African Regional Interest Group (Open to all participants) 107A

7:00am – 8:00am
Asian DURG Meeting (Open to all participants) 107B

7:00am – 8:00am
ISPE Task Force - Using RWE for Regulatory Submission (By Invitation) 106AB

7:00am – 8:00am
Poster Session B Set-up Hall A

7:00am – 8:00am
Spotlight Poster Session B Set-up West Bridge

7:00am – 6:00pm
Registration Registration Bridge East

7:30am – 6:00pm
Speaker Ready Room (Please arrive 24 hours before your presentation start time to upload or check your presentation.) Room 303

7:30am – 6:00pm
Exhibits/Poster Session B Hall A

7:30am – 6:00pm
Mother's Room Room 300
Sponsored by EPI Excellence, LLC

8:00am – 9:30am
CONCURRENT SESSIONS: ORAL PRESENTATIONS

A Mummer's Parade of Analytic Methods Ballroom B

Moderators: Cynthia Girman, FISPE, & Mina Tadrous

8:00am
Data-Driven Identification of Indication for Treatment in Electronic Medical Records Using Cluster Analysis in Combination with a Self-Controlled Cohort Analysis [411]

Tomas Bergvall, Birgitta Grundmark, Alison Bourke, Niklas Norén. (Sweden)

8:15am
Evaluation Framework to Guide Model Selection and Cohort Definition in Causal Inference [412]

Yishia Shimoni, Sivan Ravid, Ehud Karavani, Peter Bak, Marie Ng, Sharon Hensley Alford, Denise Meade, Ya'ara Goldschmidt. (United States)

8:30am
A R-Based Application to Perform Distributed Regression Analysis with Vertically Partitioned Data [413]

Qoua Her, Yuji Samizo, Thomas Kent, Mia Gallagher, Aleksandra Slavkovic, Sengwee Toh. (United States)

8:45am
Privacy-Protecting Estimation of Adjusted Risk Ratios Using Modified Poisson Regression in Multi-Center Studies [414]

Di Shu, Jessica G Young, Sengwee Darren Toh. (United States)

9:00am
Relying on RE-LY to Transport Effect Estimates to Patients in Routine Care [415]

Michael Webster-Clark, Til Stürmer, Jessie K Edwards, Charles Poole, Ross Simpson, Jennifer L Lund. (United States)

9:15am
An Online Tool for Correcting Risk Ratio or Cumulative Incidence Estimates for Bias Due to Outcome Misclassification [416]

Gillian C Hall, Stephan Lanes, Kaatje Bollaerts, Xiaofeng Zhou, Vinay Mehta, Germano Ferreira, Rosa Gini. (United Kingdom)

To Bleed or Not to Bleed 201A

Moderators: Rianne van den Ham & Lourens Bloem

8:00am
Clopidogrel Drug Interactions and Serious Bleeding: High-Throughput Screening Using the Self-Controlled Case Series Design [417]

Charles E Leonard, Meijia Zhou, Colleen M Brensinger, Warren B Bilker, Samantha E Soprano, Thanh Phuong Pham Nguyen, Young Hee Nam, Jordana B Cohen, Sean Hennessy. (United States)

8:15am
Statins and Risk of Venous Thromboembolism [418]

Nils Skajaa, Szimonetta K. Szépliget, Erzsébet Horváth-Puhó, Waleed Ghanima, John B Hansen, Henrik T. Sørensen. (Denmark)



8:00am– 9:30am

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)

8:30am

Antithrombotic Treatment Preceding Ischemic Stroke, Intracranial Hemorrhage, and Gastrointestinal Bleeds and Mortality in Patients with Atrial Fibrillation [419]

Joris J Komen, Tomas Forslund, Aukje K Mantel-Teeuwisse, Olaf H Klungel, Björn Wettermark, Paul Hjerdahl. (Netherlands)

8:45am

Pharmacoepidemiologic Screening of Potential Oral Anticoagulant Drug Interactions and Thromboembolic Events [420]

Meijia Zhou, Charles E Leonard, Colleen M Brensinger, Warren B Bilker, Stephen E Kimmel, Todd E Hecht, Sean Hennessy. (United States)

9:00am

Non-Vitamin K Antagonist Oral Anticoagulants and Angioedema: A Cohort and Case-Crossover Study [421]

John Connolly, Sebastian Schneeweiss, Robert J Glynn, Joshua J Gagne. (United States)

9:15am

Exposure to Dicloxacillin and Flucloxacillin during Warfarin Use and Risk of Ischemic Stroke and Systemic Embolism [422]

Maja Hellfritzsch, Lars Christian Lund, Zandra Ennis, Tore B Stage, Mette Bliddal, Peter B Jensen, Daniel P Henriksen, Martin T Ernst, Morten S Olesen, Anne Broe, Kasper B Kristensen, Per Damkier, Jesper Hallas, Anton Pottgård. (Denmark)

DEPARTMENT OF CLINICAL EPIDEMIOLOGY IN AARHUS, DENMARK

Better clinical care through research

VISIT US AT OUR BOOTH



AARHUS UNIVERSITY
DEPARTMENT OF CLINICAL EPIDEMIOLOGY



FOLLOW US ON TWITTER

@DCEAarhus

midt
Central Denmark Region

8:00am– 9:30am

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)**We All Need Validation**

201B

Moderators: Tania Schink & Anne-Marie Meyer

8:00am

Comparative Performance of CIDACS-RL Using Administrative Data Sources [423]

George C Barbosa, Mohamed S Ali, Bruno Araujo, Maria Y Ichihara, Sandra Reis, Samila Sena, Julia M Pescarini, Rosemeire L Fiaccone, Leila D Amorim, Robespierre Pita, Marcos E Barreto, Liam Smeeth, Mauricio L Barreto. (Brazil)

8:15am

Swedish National Registries versus Electronic Medical Records: Comparing the Completeness of Systemic Therapy Data Using Data from the Scan-Leaf Study [424]

Pia Horvat, Naomi Boxhall, Anne Mette-Kejs, Quratul Ann, Valeria Lascano, Benjamin Bray, Dony Patel, Simon Ekman, Laure Lacoïn, Ariadna Juarez-Garcia, Joseph Kim. (United Kingdom)

8:30am

Validation of Diagnostic Algorithms to Detect Type 1 Diabetes Mellitus Disease Using Administrative Data from a General Population from Southern Italy [425]

Ylenia Ingrasciotta, Andrea Fontana, Valentina Ientile, Salvatore Crisafulli, Maria Paola Bertuccio, Maurizio Pastorello, Vincenzo Provenzano, Alessandro Scorsoni, Gianluca Trifirò. (Italy)

8:45am

Validity of Claims-Based Definitions for Rheumatoid Arthritis, Selected Cancers and Infectious Diseases in Japan: Results from Validate - J Study [426]

Cynthia de Luise, Haoqian Chen, Edward Nonnenmacher, Naonobu Sugiyama, Ryota Hase, Mitsuyo Kinjo, Daisuke Suzuki, Kayoko Katayama, Takakazu Higuchi, Sadao Jinno, Yoshiya Tanaka, Toshitaka Morishima, Soko Setoguchi. (United States)

9:00am

ICD-9 TO ICD-10 Mapping for Research in Biologics and Biosimilars Using Administrative Healthcare Data [427]

Mengdong He, Adrian J Ortiz, James Marshall, Aaron B Mendelsohn, Jeffrey R Curtis, Charles E Barr, Catherine M Lockhart, Seoyoung C Kim. (United States)

9:15am

External Validation of an Algorithm to Identify Patients with High Data-Completeness in Electronic Health Records for Comparative Effectiveness Research [428]

Joshua K Lin, Yinzhu Jin, Robert J Glynn, Sebastian Schneeweiss. (United States)

What a Pain: Are We Making Progress with Opioids?

201C

Moderators: Paul Coplan, FISPE, & Silvia Alessi-Severini

8:00am

Incidence Rates of and Risk Factors for Opioid Overdoses in New Users of Prescription Opioids among US Medicaid Enrollees: A Cohort Study [429]

Young Hee Nam, Warren Bilker, Francesco DeMayo, Mark Neuman, Sean Hennessy. (United States)

8:15am

Risk of Opioid Overdose Associated with Concomitant Use of Opioids and Muscle Relaxants [430]

Yan Li, Yu-Jung Wei, Joshua Brown, Gary M Reisfield, Chris Delcher, Almut G Winterstein. (United States)

8:30am

The Association between Prescription Opioid Use and Bone Fracture: A Self-Controlled Case Series Study [431]

Emily Peach, Fiona Pearce, Janice Fuller, Andrew Cooper, Li-Chia Chen, Roger Knaggs. (United Kingdom)

8:45am

The Proportion of Patients in the United States Receiving Postsurgical Opioids Exceeding Recommended Thresholds Increased between 2006 and 2015 [432]

Jessica C Young, Brooke A Chidgey, Til Stürmer, Michele Jonsson Funk. (United States)

9:00am

Healthcare Utilization Associated with Chronic Opioid Use among Hospitalized Patients [433]

Siyana Kurteva, Daniala Weir, Todd Lee, Michal Abrahamowicz, Robyn Tamblyn. (Canada)

9:15am

High-Risk Opioid Utilization and Mortality among Hemodialysis Patients [434]

Matthew Daubresse, G Caleb Alexander, Deidra C Crews, Dorry L. Segev, Mara A McAdams-DeMarco. (United States)



8:00am– 9:30am

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)**CNS Drugs in Pregnancy**

202AB

Moderators: Mayura Shinde & Sascha Dublin

8:00am

Opioid Prescription Use after Vaginal Delivery and Subsequent Persistent Opioid Use and Misuse [435]

Yanmin Zhu, Krista F Huybrechts, Rishi J Desai, Alexis Krumme, Loreen Straub, Raisa Levin, Helen Mogun, Sonia Hernandez-Diaz, Brian T Bateman. (United States)

8:15am

Postpartum Opioid Prescribing and the Risk of Persistent Opioid Use [436]

Sarah S Osmundson, Jae Young Min, Andrew D Wiese, Robert E Hawley, Stephen W Patrick, Marie R Griffin, Carlos G Grijalva. (United States)

8:30am

Prevalence and Predictors of ADHD Medication Use in a Cohort of Pregnant Women [437]

Maxim Lemelin, Takoua Boukhris, Odile Sheehy, Anick Bérard. (Canada)

8:45am

Interrupted Time Series Analysis to Assess Prescription Filling around Conception and Implications for Misclassification of Medication Use in Pregnancy [438]

Jacqueline M Cohen, Randi Selmer, Kari Furu, Øystein Karlstad. (Norway)

9:00am

Trajectories of Antipsychotic Use before and during Pregnancy and Related Maternal and Birth Characteristics [439]

Andrea L Schaffer, Helga Zoega, Duong T Tran, Nicholas A Buckley, Sallie Pearson, Alys Havard. (Australia)

9:15am

Medication Use Patterns in Pregnant Women with Migraine [440]

Rohini K. Hernandez, Sonja Nakasian, Lisa Bollinger, Brian Bradbury, Susan Jick, Paul Muntner, Eric Ng, Victoria Chia. (United States)

Your Brain on Drugs: Pharmacoepidemiology of CNS Agents

204C

Moderators: Stanley Edlavitch & Paul Stang, FISPE

8:00am

Baclofen Decreases Alcohol Consumption in Real World Clinical Populations [441]

Christopher T Rentsch, David A Fiellin, Kendall J Bryant, Amy C Justice, Janet P Tate. (United Kingdom)

8:15am

Long-Term Effect of Interferon and Glatiramer Acetate in Real-World Settings Use on Multiple Sclerosis Disability Progression: Input of Time-Dependent Propensity Score [442]

Mathilde Lefort, Yohann Foucher, Rémi Lenain, Sandra Vukusic, Gilles Edan, Emmanuelle Leray. (France)

8:30am

Ethnic Inequalities in Prescribing Quality for Patients with Dementia: A Cohort Study Using Electronic Health Records [443]

Mary E Jones, Claudia Cooper, Cini Bhanu, Rosalind Raine, Gillian Manthorpe, Kate Walters, Irene Petersen. (United Kingdom)

8:45am

Nested Case-Control Study of Antidepressant Drug Use and Subdural Hematoma Risk [444]

David Gaist, Luis A García Rodríguez, Stine M Hald, Maja Hellfritzsch, Frantz R Poulsen, Bo Halle, Jesper Hallas, Anton Pottegård. (Denmark)

9:00am

Co-Occurring Neuropsychiatric Diagnoses and Use of Psychotropic Drugs in Children with Autism Spectrum Disorder [445]

Svetlana Skurtveit, Yury Kiselev, Marte Handal, Vidar Hjellvik, Ted Reichborn-Kjennerud, Camilla Stoltenberg, Pål Suren, Alexandra Havdahl. (Norway)

9:15am

Concurrent Use of Neurocognitively-active Medications and Alcohol Increases Risk of Community-Acquired Pneumonia [446]

Christopher T Rentsch, Janet P Tate, Kirsha S Gordon, Kathleen M Akgün, Supriya Krishnan, Alice Tseng, Julie A Womack, Maria C Rodriguez-Barradas, Cynthia L Gibert, Kendall J Bryant, E Jennifer Edelman, Amy C Justice. (United Kingdom)

9:30am – 10:00am

Break/Posters/Exhibits

Hall A



Main Conference | Tuesday, August 27

10:00am – 11:30am

PLENARY SESSION: IMPLEMENTATION AND EVALUATION OF RISK MINIMIZATION MEASURES: CHALLENGES AND OPPORTUNITIES BALLROOM B

In parallel with the global adoption of risk management planning, significant progress has been made in recent years in the area of risk minimization measures and evaluation of their effectiveness. Experts in the field now fully recognize the importance of integrating risk minimization and effectiveness as part of the evaluation of the benefit-risk profile throughout the therapeutic product lifecycle in order to ensure that better safety outcomes are met for the patient. However adoption of such measures has also been accompanied with certain challenges. Examples include how to harmonize the risk minimization programs with regional or country-specific requirements, when should effectiveness be evaluated and what is an acceptable threshold for success. In addition, more and more, it is recognized that evaluation of effectiveness should occur throughout the life cycle of a therapeutic product, and information is to be collected in real-world settings. This information in turn will inform on whether changes are needed to the product label or other terms of marketing, including removal of regulatory requirements.

Considering that 2019 coincides with the 10th anniversary of the global adoption of risk management planning worldwide (i.e., ICH E2E), the speakers will provide their perspective supported with case examples to illustrate real-world challenges and proposed solutions. These talks will

be followed with a moderated discussion with the audience and a podium discussion with the panelists to generate a discussion and ultimately share best practices that can be used in risk management planning.

Moderator

- **Rania Mouchantaf**, Manager, Marketed Health Products Directorate, Health Canada.

Speakers

- **Doris Auth**, Associate Director, Division of Risk Management, Office of Surveillance and Epidemiology/CDER/FDA
10 years of REMS: Evaluation Challenges and Opportunities
- **Meredith Smith**, Global Risk Management Officer, Global Patient Safety, Labeling & Pediatrics, Amgen, Inc.
Advancing the Field of Risk Minimization Through Application of Implementation Science: Current Status and Future State
- **Yola Moride, FISPE**, Professor, Faculty of Pharmacy, Université de Montréal
Evaluation of Effectiveness of Risk Minimization Interventions: Methodological Landscape and Lessons Learned Panelists

Panelists

- **June Raine**, Director, Vigilance and Risk Management, Medicines and Healthcare products Regulatory Agency UK.
- **Soonyoung Hahn**, President, Korea Institute of Drug Safety and Risk Management

11:30am – 1:00pm

Lunch/Poster Session B/Exhibits

Hall A

11:30am – 1:00 pm

Committee Meetings (Open to all participants; lunch available)

- | | | | |
|---------------------------------|-------------------------|--|---------------------|
| ■ Development Marriott | 304-305 | ■ Publications & Communications | Marriott 307 |
| ■ Global Development | Marriott 302-303 | ■ Public Policy | Marriott 301 |
| ■ History & Archives | Marriott 308 | | |

11:45am – 12:45pm

Spotlight Poster Session B:

West Bridge

- | | |
|---|-----------------------------|
| ■ Benefit Risk Assessment, Communication and Evaluation (BRACE) | ■ Drug Utilization Research |
| ■ Databases | ■ Medical Devices |
| | ■ Rare Diseases |



1:00pm – 2:30pm

CONCURRENT SESSIONS: ORAL PRESENTATIONS**Around the Benefit Risk Assessment, Communication, & Evaluation Cycle**

Ballroom B

Moderators: Meredith Smith & Annalisa Rubino

1:00pm

Patient-, Disease- and Treatment Related Factors That Impact Values Attached to Drug Effects: A Preferences Study among Patients with Type 2 Diabetes [447]

Sonia Roldan, Douwe Postmus, Sieta De Vries, Peter Mol, Hans Hillege. (Netherlands)

1:15pm

Impact of Medicines Regulatory Risk Communications in the United Kingdom on Prescribing and Clinical Outcomes: Systematic Review, Re-Analysis and Meta-Analysis [448]

Daniel R Morales, Bruce Guthrie, Tobias Dreischulte, Chris Weatherburn. (United Kingdom)

1:30pm

Risk Minimisation Studies Outcomes and Process Indicators [449]

Esther Artime, Nawab Qizilbash. (Spain)

1:45pm

Ivabradine Drug Utilization Study in Five European Countries: A Pass to Assess Effectiveness of Risk-Minimization Measures [450]

Linda Salem, Alexandre Malouvier, Jon Blathford, Elena Rivero-Ferrer, Nicolas Deltour, Emmanuelle Jacquot. (France)

2:00pm

Comparative Effectiveness of Risk Mitigation Strategies to Prevent Fetal Exposure to Mycophenolate [451]

Amir Sarayani, Yasser Albogami, Mohannad Elkhider, Juan M Hincapie-Castillo, Babette A Brumback, Almut G. Winterstein. (United States)

2:15pm

Post-Authorisation Amendments to Additional Risk Minimisation Measure Requirements of Medicines Authorised in the EU: A Cohort Study [452]

Reynold D Francisca, Emna Baba, Christina E Hoeve, Inge M Zomerdijk, Miriam C Sturkenboom, Sabine M Straus. (Netherlands)

Diabetes: Outcomes and Safety

201A

Moderators: Philip Hunt & Catherine Johannes

1:00pm

Effect of a Novel Pharmacist-Delivered Behavioral Intervention for Patients with Poorly-Controlled Diabetes: The Enhancing Outcomes through Goal Assessment and Generating Engagement in Diabetes Mellitus Pragmatic, Database-Randomized Controlled Trial [453]

Julie Lauffenburger, Roya Ghazinouri, Saira Jan, Sagar Makanji, Christina Ferro, Jennifer Lewey, Eric Wittbrodt, Jessica Lee, Nancy Haff, Constance Fontanet, Niteesh Choudhry. (United States)

1:15pm

Reduced Healthcare Utilization in Patients Using Empagliflozin: An Interim Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study [454]

Mehdi Najafzadeh, Ajinkya Pawar, Anouk Déruaz-Luyet, Kimberly G Brodovicz, Anastasia Ustyugova, Lily G Bessette, Nileesa Gautam, Sebastian Schneeweiss, Elisabetta Patorno. (United States)

1:30pm

The Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists in Preventing Hospitalizations for Chronic Lower Respiratory Disease [455]

Yasser Albogami, Kenneth Cusi, Michael Daniels, Yu-Jung Jenny Wei, Almut Winterstein. (United States)

1:45pm

Risk Factors for Progression to Vision Threatening Diabetic Retinopathy [456]

Brian L VanderBeek, Yafeng Li, J Clay Bavinger, Yinxi Yu. (United States)

2:00pm

Dipeptidyl Peptidase-4 Inhibitors and Risk of Inflammatory Bowel Disease: Real World Evidence in US Adults [457]

Tiansheng Wang, Jeff Y Yang, John B Buse, Virginia Pate, Huilin Tang, Edward Barnes, Robert S Sandler, Til Stürmer. (United States)

2:15pm

Dipeptidyl Peptidase-4 Inhibitors and the Risk of Bullous Pemphigoid among Patients with Type 2 Diabetes: A Population-Based Cohort Study [458]

Antonios Douros, Julie Rouette, Hui Yin, Oriana Hoi Yun Yu, Kristian B. Filion, Laurent Azoulay. (Canada)

Main Conference | Tuesday, August 27

1:00pm – 2:30pm

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)**Lightning Forum**

201B

Methods in Geriatric Pharmacoepidemiology**Moderators:** Mary Ritchey, FISPE, & Lisa Pont, FISPE,

1:00pm

Identifying Drug Classes Whose Initiation May Be a Proxy for Frailty [459]

Henry T Zhang, Robert J Glynn, Til Stürmer. (United States)

1:05pm

Validation of a Five-Year Mortality Prediction Model among US Medicare Beneficiaries [460]

Rachael K Ross, Tzy-Mey Kuo, Michele Jonsson Funk, Jennifer L Lund. (United States)

1:10pm

The Impact of Polypharmacy Definitions on the Estimation of Polypharmacy Prevalence in Older Individuals: A Population-Based Evaluation [461]

Marie-Eve Gagnon, Housseem Missaoui, Bernard Candas, Guillaume Boucher, Marc Simard, Caroline Sirois. (Canada)

1:15pm

Measuring Frailty in Administrative Claims Data: Comparative Performance of Four Claims-Based Frailty Measures in the United States Medicare Data [462]

Dae Kim, Elisabetta Patorno, Ajinkya Pawar, Hemin Lee, Sebastian Schneeweiss, Robert Glynn. (United States)

1:20pm

Panel Discussion: Methods in Geriatric Pharmacoepidemiology**Machine Learning for Risk Prediction****Moderators:** Mary Ritchey, FISPE, & Olaf Klungel, FISPE

1:30pm

Predictive Modeling in Patients with Heart Failure: A Comparison of Machine Learning and Traditional Statistical Approaches [463]

Rishi J Desai, Shirley Wang, Muthiah Vaduganathan, Sebastian Schneeweiss. (United States)

1:35pm

Performance of Machine Learning Algorithms for Hysterectomy Risk Prediction among Women with Endometriosis in the United States [464]

Bradley Saul, Ryan D Kilpatrick, Leah J McGrath, Diane Reams, Lani Wegrzyn, Stephanie E. Chiuve, M Alan Brookhart. (United States)

1:40pm

Inferring Mortality in Claims Data [465]

Dana Y Teltsch, Feng Zhang, Amanda M Kelly, Dawn G Albright. (United States)

1:45pm

Federated Learning for Predicting Clinical Events with Distributed Patient Data Sets [466]

Yoonyoung Park, Issa Sylla, Amar K Das, Olivia Choudhury. (United States)

1:50pm

Panel Discussion: Machine Learning for Risk Prediction**Opioid Method Research****Moderators:** Mary Ritchey, FISPE, & Vincent Lo Re, FISPE

2:00pm

Using Machine Learning to Predict Risk of Opioid Overdose in Medicare [467]

Weihsuan Jenny Lo-Ciganic, James L Huang, Hao H Zhang, Jeremy C Weiss, Yonghui Wu, Chian K Kwoh, Julie M Donohue, Jerry Cochran, Adam J Gordon, Daniel C Malone, Courtney C Kuza, Walid F Gellad. (United States)

2:05pm

Dual-Trajectories of Opioid and Gabapentinoid Use and Risk of Subsequent Drug Overdose among United States Medicare Beneficiaries [468]

Lili Zhou MS, Sandipan Bhattacharjee PhD, C Kent Kwoh MD, Patrick J Tighe MD, Gary M Reisfield MD, Daniel C Malone PhD, Marion Slack PhD, Wei-Hsuan Jenny Lo-Ciganic PhD. (United States)

2:10pm

Estimates of Prolonged Opioid Use Following Surgery Vary by Orders of Magnitude across Various Definitions [469]

Jessica C Young, Jennifer M Wu, Virginia Pate, Michele Jonsson Funk. (United States)

2:15pm

Concurrent Use of Opioids and Strong Metabolic Inhibitors and the Risk of Serious Infections [470]

Andrew D Wiese, Marie R Griffin, C Michael Stein, William Schaffner, Robert A Greevy, Edward F Mitchel, Carlos G Grijalva. (United States)

2:20pm

Panel Discussion: Opioid Methods Research



1:00pm – 2:30pm

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)**How to Analyze Complex Longitudinal Exposures**

201C

Moderators: Daniel Prieto-Alhambra, FISPE, & Mollie Wood

1:00pm

Methods to Account for Time-Varying Medication Use When Developing a Model for Patient Prognosis [471]

Romin Pajouheshnia, Noah Schuster, Rolf Groenwold, Linda Peelen. (Netherlands)

1:15pm

Using the Reverse Waiting Time Distribution with Random Index Dates to Estimate Prescription Durations with Seasonal Variation [472]

Katrine Bødkergaard Nielsen, Randi Marie Selmer, Jesper Hallas, Lars Jøran Kjerpeseth, Anton Pottegård, Eva Skovlund, Henrik Støvring. (Denmark)

1:30pm

Exploring Longitudinal Trajectories to Model Paternal Exposure in Evaluating Risk of Adverse Outcomes in Their Offspring [473]

Minna Vehkala, Ruben Hermans, Silvia Narduzzi, Deborah Layton. (United Kingdom)

1:45pm

Using Machine Learning Algorithms to Predict Medication Initiations and Discontinuations [474]

Hoa V Le, Chi Truong. (United States)

2:00pm

Assessing Differences in Treatment Effects: Interactions with Propensity Score Splines [475]

David J Graham, Jiemin Liao, Elande Baro, Rongmei Zhang, Michael Wernecke, Yuqin Wei, Mao Hu, Sandia Akhtar, Thomas E MaCurdy, Jeffrey A Kelman, Frank E Harrell. (United States)

2:15pm

A Challenge of Real World Data: How to Assign Individuals to a Treatment Strategy When Their Data Are Consistent with Several Treatment Strategies at Baseline [476]

Xabier Garcia de Albeniz, John Hsu, Miguel A Hernan. (Spain)

Validity of RWE Data in Pregnancy

202AB

Moderators: Vera Ehrenstein & Gretchen Bandoli

1:00pm

Development and Validation of Algorithms to Estimate Live Birth Gestational Age in Medicaid Analytic Extract Data [477]

Yanmin Zhu, Thuy N Thai, Brian T Bateman, Sonia Hernandez-Diaz, Jessica M Franklin, Loreen Straub, Almut G Winterstein, Kathryn J Gray, Yandong Qiang, Wei Hua, Lockwood G Taylor, Krista F Huybrechts. (United States)

1:15pm

Utility of Prenatal Tests to Estimate Pregnancy Start in Sentinel [478]

Lockwood G Taylor, Steven T Bird, Danijela Stojanovic, Sengwee Toh, Elnara Fazio-Eynullayeva, Andrew Petrone, Jennifer G Lyons. (United States)

1:30pm

Estimation of the Beginning of Pregnancies Ending in Stillbirths [479]

Tania Schink, Ulrike Haug. (Germany)

1:45pm

Validation of ICD-9-CM Coding Algorithms to Identify Non-Live Birth Outcomes in an Automated Database [480]

Yanmin Zhu, Kathryn Gray, Brian T Bateman, Sonia Hernandez-Diaz, Loreen Straub, Rebecca M Reimers, Beryl Manning-Geist, Elizabeth Yoselevsky, Yandong Qiang, Lockwood G Taylor, Wei Hua, Krista Huybrechts. (United States)

2:00pm

Immortal Time Bias in Comparative Drug Safety Studies in Pregnancy [481]

Kristian B Filion, Colin Dormuth, Pauline Reynier, J. Michael Paterson, Robert W Platt, Samy Suissa. (Canada)

2:15pm

Comparing the Use of Propensity and Disease Risk Scores in Signal Detection for Prematurity on Medico-Administrative Database [482]

Romain Demailly, Sylvie Escolano, Françoise Haramburu, Pascale Tubert-Bitter, Ismail Ahmed. (France)



**Our mission is clear.
We are pioneers
in neuroscience.**

We're proud
to support the
**35th Annual International
Conference of
Pharmacoepidemiology
and Therapeutic Risk
Management**

Caring Deeply. Working Fearlessly. Changing Lives.™

Founded in 1978, Biogen is one of the world's oldest independent biotechnology companies.

www.biogen.com



HOW DO WE USE DATA TO IMPROVE HEALTH CARE,
RIGHT FROM THE BEGINNING?

HOW

WE KNOW HOW. WE ARE THE HOW.

Understanding the impact of medication interventions during pregnancy can improve the health and well-being of women and babies. That's the purpose of the Optum® Dynamic Assessment of Pregnancies and Infants (DAPI).

DAPI leverages claims and electronic health record (EHR) data to better answer questions of exposure and outcomes regarding pregnancies and infant health.

Learn more about DAPI while at ICPE 2019 — visit us at booth #302–304.

Visit optum.com/epidemiology to explore how Optum Epidemiology is advancing public health through rigorous research and the development of elegant data tools.



1:00pm – 2:30pm

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)

Don't Tell the Antivaxxers, Vaccines Work!

204C

Moderators: Catherine Cohet & Patricia Saddier

1:00pm

Pneumococcal Vaccine Safety Surveillance Using Three Statistical Methods: Disproportionality Analysis, Tree-Based Scan Statistics, and Empirical Bayes Geometric Mean [483]

Hyesung Lee, Ju Hwan Kim, Ju-Young Shin. (Korea, Republic of)

1:15pm

Early Season Self-Controlled Risk Interval Analyses of Guillain-Barré Syndrome Risk Following Influenza Vaccination Using Claims Delay Adjustment [484]

Mao Hu, Silvia Perez-Vilar, Michael Wernecke, Deepa Arya, Jeffrey Kelman, Steve Chu, Tom MaCurdy, Richard Forshee. (United States)

1:30pm

Comparative Effectiveness of High-Dose versus Standard-Dose Influenza Vaccine among Patients on Chronic Hemodialysis [485]

Anne M Butler, J Bradley Layton, Vikas R Dharnidharka, John M Sahrman, David J Weber, Leah J McGrath. (United States)

1:45pm

Effect of Age on Relative Effectiveness of High-Dose versus Standard-Dose Influenza Vaccines among US Medicare Beneficiaries Ages 65 Years and Older [486]

Yun Lu, Yoganand Chillarige, Hector Izurieta, Yuqin Wei, Wenjie Xu, Michael Lu, Heng-Meng Sung, Arnstein Lindaas, Michael Wernecke, Thomas MaCurdy, Jeffrey Kelman, Richard A Forshee. (United States)

2:00pm

Risk of Pneumonia after Varicella Vaccination [487]

Chia-Hung Liu, Yi-Chen Juan, Yen-Yum Yang, Yi-Chun Yeh, Wan-Ting Huang, K Arnold Chan. (Taiwan)

2:15pm

No Increased Risk of Kawasaki Disease among Young Children in 28 Days after PCV13 Vaccination [488]

Meghan A Baker, Bethany Baer, Martin Kulldorff, Lauren Zichittella, Rebecca Reindel, Sandra DeLuccia, Hana Lipowicz, Katherine Freitas, Robert Jin, W Katherine Yih. (United States)



2:40pm – 3:50pm

Annual Meeting of ISPE Members & Awards Ceremony

Ballroom B

Annual Meeting

- **Call to Order & Presidential Address**
Alison Bourke, FISPE, President
- **Financial Report**
Krista Huybrechts, FISPE, Vice President Finance
- **New Business**

Awards Ceremony

- **The Ronald D. Mann Best Paper Awards for Manuscripts** Published in *Pharmacoepidemiology and Drug Safety* (PDS), 2018, Vol.27
 - **Presenters**
Brian Strom, FISPE, Editor-in-Chief
Vincent Lo Re, III, FISPE, Regional Editor for the Americas
Hubert GM Leufkens, FISPE, Regional Editor for Europe
Byung Joo Park, FISPE, Regional Editor for Asia-Pacific & ROW
Leah Webster, Journals Publishing Manager, Health Sciences, Wiley
 - **Honorable Mentions**
Risk of Acute Myocardial Infarction with Real-World NSAIDs Depends on Dose and Timing of Exposure
Michele Bally; Marie-Eve Beauchamp; Michal Abrahamowicz; Lyne Nadeau; James Brophy
 - Comparative Effectiveness and Safety of Antiplatelet Drugs in Patients with Diabetes Mellitus and Acute Coronary Syndrome**
Julia Spöndlin; Joshua J. Gagne; Jennifer Lewey; Elisabetta Paterno; Sebastian Schneeweiss; Rishi J. Desai
 - **First Prize**
Methods for Addressing “Innocent Bystanders” When Evaluating the Safety of Concomitant Vaccines
Shirley V. Wang; Abdurrahman Abdurrob; Julia Spöndlin; Edwin Lewis; Sophia R Newcomer; Bruce H Fireman; Matthew F Daley; Jason M Glanz; Jonathan Duffy; Eric S Weintraub; Martin Kulldorff

ISPE Awards

- **Sustained Service Award**
Abraham Hartzema, FISPE
- **Distinguished Service Award**
Mark H Epstein
- **Emerging Leader Award**
Irene Berita Murimi-Worstell

ICPE 2019 Awards

- **The Andrew McAfee Award**
(Best abstract submitted by a researcher or student/post-doc living in a developing country)
Hailong Li, Peking University Health Science Center, Beijing, China
Drug Safety Signal Detection in a Chinese Regional Healthcare Database Using the Tree-Based Scan Statistic and Comparison to 3 Other Statistical Methods [824]
Hailong Li, Lingli Zhang, Siyan Zhan. (China)
- **The John Snow Award**
(Best abstract submitted by a female researcher or student living in a developing country)
Luciane Cruz Lopes, University of Sorocaba, Sorocaba, Sao Paulo, Brazil
Data Sources for Drug Utilization Research in Latin American (LATAM) Countries [222]
Luciane Cruz Lopes, Maribel Salas, Claudia G Osorio-de-Castro, Angela Costa, Maruja Crisante, André O Baldoni, Anahi Dreser, Lucila I Castro-Pastrana, Juan C Sánchez-Salgado, Yesenia R Tanta, Edward Mezones-Holguin, Edgard N Delgado, Gustavo H Marin, Martin Cañas, Monica Tarapués, Carlos Durán, Ismael Olmos, Marta M Fonteles, Silvio Barberato-Filho, Daniel M Mota, Diana L Galicia, Tais F Galvao, Marcus T Silva, Robert V Stichele, Juan Roldan, Bjorn Wettermark, Cristiane C Bergamaschi, María B Mena, Natalia Medero, Elisangela C Lima, Livia L Marengo, Ocelli I Lira, Sanni Ali, Yared Santa-Ana-Tellez, Raquel H Comoglio, Vera L Luiza, Izabela Fulone, Lauren G Mazzei, María Belén Mena, Monique Elsevier. (Brazil)



2:40pm – 3:50pm

Annual Meeting of ISPE Members & Awards Ceremony (continued)

Ballroom B

Student Awards**Best Methods Award**

Michael Andrew Webster-Clark, University of North Carolina at Chapel Hill, Chapel Hill, United States

A Little off the Sides: Propensity Score Trimming in the Presence of Heterogeneity [25]

Michael Webster-Clark, Robert Glynn, Til Stürmer. (United States)

Third Best Abstract

Juan Hincapie-Castillo, University of Florida, Gainesville, United States

Use of Joinpoint Regression in Drug Utilization Research: Post-Tonsillectomy Codeine Use in Pediatrics, United States (2005-2016) [509]

Juan M Hincapie-Castillo, Patrick J Antonelli, Almut G Winterstein. (United States)

Second Best Abstract

Thuy N Thai & Amir Sarayani, College of Pharmacy, University of Florida, Gainesville, United States

Risk of Pregnancy Loss in Patients Exposed to Mycophenolate Compared to Azathioprine: A Retrospective Cohort Study [53]

Thuy N Thai, Amir Sarayani, Xi Wang, Yasser Albogami, Sonja Rasmussen, Almut G Winterstein. (United States)

The Stanley A. Edlavitch Award

(Best abstract submitted by a student/post-doc)

Amani Hamad, University of Manitoba, Winnipeg, Canada

Early Childhood Antibiotics Use and the Risk of Attention-Deficit/Hyperactivity Disorder: A Population-Based Cohort Study [838]

Amani Hamad, Silvia Alessi-Severini, Salah Mahmud, Marni Brownell, I fan Kuo. (Canada)

Induction of ISPE Fellows

- Gillian Bartlett-Esquillant, FISPE
- Jaclyn L F Bosco, FISPE
- Gerald Joseph Dal Pan, FISPE
- Petra Denig, FISPE

- Andrew N Freedman, FISPE
- Ursula Kirchmayer, FISPE
- Ann W McMahon, FISPE
- Eileen E Ming, FISPE
- Fredrik Nyberg, FISPE
- Matthew W Reynolds, FISPE
- Mary E Ritchey, FISPE
- Leyla Sahin, FISPE
- Ingrida Sketris, FISPE
- Katja Taxis, FISPE
- Veronika J Wirtz, FISPE

ISPE Board Transition**Retiring Board Members & Officers**

- Dorothee B Bartels, FISPE
- Rachel E Sobel, FISPE
- June M Raine
- Olaf Klungel, FISPE
- Jesper Hallas, FISPE

Induction of New Directors

- Debbie Layton, Industry/Service Provider (Europe/Africa)
- Fredrik Nyberg, FISPE, Industry/Service Provider (Europe/Africa)
- Mary Ritchey, FISPE, Industry/Service Provider (Americas)
- Lisa Pont, FISPE, Academic (Asia/Pacific)
- Jennita Reefhuis, Government/Regulatory (Americas)
- Ursula Kirchmayer, FISPE, Government/Regulatory (Europe/Africa)

Installation of 2019-2020 Officers

- Olaf Klungel, FISPE, President Elect
- Wei Zhou, FISPE, Vice President Finance-Elect
- Krista Huybrechts, FISPE, Vice President Finance
- Alison Bourke, FISPE, Immediate Past President
- Almut Winterstein, FISPE, President

Adjournment of Meeting

Main Conference | Tuesday, August 27

3:50pm – 4:15pm

Beak/Posters/Exhibits

Hall A

4:15pm – 5:45pm

CONCURRENT SESSIONS: SYMPOSIA AND WORKSHOPS

4:15pm

Reaplicating Clinical Trial Data Using RWD [489]

Ballroom B

Kai-Li Liaw, David Martin, Jessica Franklin, Miriam Sturkenboom, Solomon Iyasu. (United States)

4:15pm

Data Diversity in Multi-Database Pharmacoepidemiologic Studies and Its Role in Outcome Misclassification: A Curse or a Blessing? [490]

201A

Rosa Gini, Stephan Lanes, Kaat Bollaerts, Gianluca Trifirò, Ursula Kirchmayer, Gillian C Hall. (Italy)

4:15pm

Characterizing Patient Experience Data in Medical Product Development: What Is It, What Is Expected, and How Can You Contribute Based on Anticipated Regulatory Guidance? [491]

201B

Rachael DiSantostefano, Brett Hauber, Laura Lee Johnson, Peter Mol, Cindy Girman. (United States) *Sponsored by the Benefit Risk Assessment, Communication and Evaluation (BRACE) Special Interest Group*

4:15pm

Existing Databases for Drug Utilization Research in Latin American and African Countries [492]

201C

Maribel Salas, Björn Wettermark, Luciane Cruz Lopes, Joseph O Fadare, Olayinka O Ogunleye, Macarius M Donneyong, Dan Kajungu, Anahi C Dreser Mansilla. (United States)

4:15pm

Introducing Lactation Real World Data to ISPE [493]

202AB

Leyla Sahin, Christina Chambers, Laura Shaughnessy, Philip Anderson. (United States)

6:00pm – 7:00pm

Council Meetings (Open to all participants.)**Academic Council**

202AB

Government/Regulatory Council

106AB

Industry/Service Providers Council

204C

Student Council

107B

7:30pm – 11:30pm

Social Evening at the Kimmel Center for the Performing Arts (Ticket required.)

Join your colleagues for an evening of food, music, networking and dancing. A cash bar will be available. The Kimmel Center, 300 S. Broad Street is a 10-minute walk from the Philadelphia Marriott Downtown



Commonwealth Informatics
a genpact company

Visit us at Booth #312
to learn more about our
innovative technologies!



We'll be sharing the latest updates with our software!

CVW is our cloud-based platform that supports the end-to-end process of surveillance, signal evaluation, and risk assessment throughout all stages of the medical life-cycle



Main Conference | Wednesday, August 28

7:00am – 8:00am
Continental Breakfast Hall A

7:00am – 8:00am
Poster Session C Set-up Hall A

7:00am – 8:00am
Spotlight Poster Session C Set-up West Bridge

7:00am – 4:30pm
Registration Registration Bridge East

7:00am – 3:30pm
Speaker Ready Room (Please arrive 24 hours before your presentation start time to upload or check your presentation.) Room 303

7:15am – 8:15am
2020 Scientific Program Committee (Open to all participants) 203 AB

7:30am – 1:45pm
Exhibits/Poster Session B Hall A

7:30am – 4:30pm
Mother's Room Room 300
Sponsored by EPI Excellence, LLC

8:30am– 10:00am
CONCURRENT SESSIONS: ORAL PRESENTATIONS

Around the World with DUR Ballroom B

Moderators: Douglas Steinke & Susana Perez-Gutthann, FISPE

8:30am
Treatment Patterns of Checkpoint Inhibitors in Metastatic Melanoma [817]

Marina A Machado, Cristiano S Moura, Jeffrey R Curtis, Marie Hudson, Sasha Bernatsky. (Canada)

8:45am
Measuring Treatment Intensification in Patients with Type 2 Diabetes: An Electronic Health Records Based Study [818]

Robert J Romanelli, Zachary A Marcum, Qiwen Huang, Jakob S Knudsen, Dominick L Frosch. (United States)

9:00am
Trends in Blood Pressure Thresholds for Initiation of Antihypertensive Treatment in Patients with Type 2 Diabetes [819]

Martina Ambroz, Sieta T deVries, Grigory Sidorenkov, Klaas Hoogenberg, Petra Denig. (Netherlands)

9:15am
Incidence of Direct Oral Anticoagulation Use for Non Valvular Atrial Fibrillation and Characteristics of Users in Six European Countries (2008-2015): A Cross-National Drug Utilization Study [820]

Luisa Ibanez, Mònica Sabaté, Xavier Vidal, Elena Ballarín, Marietta Rottenkolber, Sven Schmiedl, Andreas Heeke, Consuelo Huerta, Elisa Martin Merino, Dolores Montero, Luz M Leon-Muñoz, Christiane Gasse, Nicholas Moore, Cécile Droz, Régis Lassalle, Mia Aakjaer, Morten Andersen, Marie Louise De Bruin, Rolf Groenwold, Rianne Van den Ham, Patrick Souverein, Olaf Klungel, Helga Gardarsdottir. (Spain)

9:30am
Assessment of the Calcium Channel Blocker, Lower Extremity Edema, Loop Diuretic Prescribing Cascade: A Prescription Sequence Symmetry Analysis [821]

Scott M Vouri, Xinji Jiang, Carl Pepine, Laurence Solberg, Daniel C. Malone, Almut Winterstein. (United States)

9:45am
Appropriate Prescribing in Nursing Homes Demonstration Project: A Pragmatic, Cluster-Randomized Trial [822]

Mina Tadrous, Kinwah Fung, Laura Desveaux, Tara Gomes, Monica Taljaard, Noah Ivers. (Canada)

8:30am– 10:00am

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)**Validation and Performance - Methods and Pharmacovigilance**

201A

Moderators: Aaron Kamau & Andres Gomez-Camirero

8:30am

Identifying Signals of Warfarin Drug-Drug Interactions: A Translational Biomedical Informatics Approach Using Real World Clinical Evidence [823]

Meijia Zhou, Lei Wang, Charles E. Leonard, Colleen M Brensinger, Warren B Bilker, Stephen E Kimmel, Todd E Hecht, Lang Li, Sean Hennessy. (United States)

8:45am

Drug Safety Signal Detection in a Chinese Regional Healthcare Database Using the Tree-Based Scan Statistic and Comparison to 3 Other Statistical Methods [824]Hailong Li, Lingli Zhang, Siyan Zhan. (China) *Recipient of The Andrew McAfee Award*

9:00am

Contribution of Natural Language Processing in Predicting Risk of Pleural and Pericardial Effusions in Small Cell Lung Cancer by Line of Therapy [825]

Rui Jiang, Ravi Potluri. (United States)

9:15am

Text Mining to Identify Drug-Drug Interactions (DDIS) in Elderly Patients Admitted to Emergency Department [826]

Iris Pujade, Perrine Duthoit, Grégoire Evrard, Alicia Bel-Létoile, Clément Goehrs, Vianney Jouhet, Sébastien Cossin, Antoine Pariente, Frantz Thiessard, Francesco Salvo, Louis Letinier. (France)

9:30am

Nationwide Adverse Drug Reaction Screening Using High Process Computing [827]

Te-yuan Chyou, Prasad S Nishtala. (New Zealand)

9:45am

Detecting Rare Diseases: A Case Study Using Machine Learning Semi-Supervised Networks to Identify Under-Diagnosed Patients [828]

Yunlong Wang, Christina Mack, Fan Zhang, Yong Cai, Emily Zhao. (United States)

Revolutionary Study Designs

201B

Moderators: Nicolle Gatto, FISPE, & Tobias Gerhard, FISPE

8:30am

Evaluation of Bias in Case-Crossover Analyses of Persistent Drug Exposures [829]

Katsiaryna Bykov, Shirley V Wang, Joshua J Gagne. (United States)

8:45am

Empirical Assessment of Case-Based Methods for the Identification of Drug-Related Health Outcome of Interest in the French Nationwide Healthcare Database (SNDS) [830]

Nicolas Thurin, Régis Lassalle, Patrick Blin, Marine Pénichon, Martijn Schuemie, Joshua J Gagne, Jeremy A Rassen, Jacques Benichou, Alain Weill, Cécile Droz-Perroteau, Nicholas Moore. (France)

9:00am

Using Active Comparators in Self-Controlled Studies [831]

Jesper Hallas, Suzanne Cadarette, Nicole Pratt, Joseph A Delaney, Heather Whitaker, Malcolm Maclure. (Denmark)

9:15am

Development and Application of a Hybrid Matching Algorithm to Refine the Prevalent New-User Cohort Design for Comparative Drug Effect Studies [832]

Chenyi Yang, Shihchen Kuo, Chun-Ting Yang, Edward Chia-Cheng Lai, Huang-Tz Ou. (Taiwan)

9:30am

Classes and Prevalence of Prevalent New Users: An Example in Medicare [833]

Michael Webster-Clark, Til Stürmer, Jessie K Edwards, Ross Simpson, Charles Poole, Jennifer L Lund. (United States)

9:45am

Comparative Performance of Trend-in-Trend Design and Instrumental Variable Methods in an Active Comparator New User Setting [834]

Phyo T Htoo, Michele Jonsson-Funk, Gang Fang, Virginia Pate, John Buse, Jessie K Edwards, Nabarun Dasgupta, Til Stürmer. (United States)



8:30am– 10:00am

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)**Infectiously Interesting**

201C

Moderators: Jennita Reefhuis & Mette Norgaard

8:30am

Concomitant Use of Quinolones and Stimulants and the Risk of Cardiovascular Adverse Events: A Comparative Safety Study [835]

Adel A. Alrwisan, Yu-Jung Wei, Patrick Antonelli, Babette Brumback, Almut Winterstein. (Saudi Arabia)

8:45am

An Unnecessary Risk: Lack of Benefit of Fluoroquinolone Antibiotics in Uncomplicated Exacerbations of Chronic Obstructive Pulmonary Disease [836]

Pierre Ernst, Matthew Dahl, Dan Chateau, Nick Daneman, Jacqueline Quail, Ingrid S Sketris, Anat Fisher, Jianguo Zhang, Shawn Bugden, for the CNODES Investigators. (Canada)

9:00am

Excess Risk of Tendon Rupture Due to Fluoroquinolones with and without Concomitant Corticosteroid Use [837]

Rebecca Persson, Susan Jick. (United States)

9:15am

Early Childhood Antibiotics Use and the Risk of Attention-Deficit/Hyperactivity Disorder: A Population-Based Cohort Study [838]Amani Hamad, Silvia Alessi-Severini, Salah Mahmud, Marni Brownell, I fan Kuo. (Canada) *Recipient of The Edlavitch Award - Best Abstract Submitted by a Student/Post-Doc*

9:30am

Comparative Safety and Cost Assessment of Prescribing Systemic Steroids for Acute Respiratory Tract Infections [839]

Kueiyu Joshua J Lin, Sebastian Schneeweiss, Evan Dvorin, Mehdi Najafzadeh, Aaron S Kesselheim. (United States)

9:45am

Antibiotic Use and Colorectal Cancer Recurrence and Mortality: A Danish Nationwide Prospective Cohort [840]

Veronika Fedirko, Deirdre Cronin-Fenton, Anders Hammerich Riis, Henrik Toft Sørensen, Timothy L. Lash. (United States)

Do Do Do Doac

202AB

Moderator: John Seeger, FISPE & Hiraku Kumamaru

8:30am

Staying on Treatment Matters: Estimating Effects of Dabigatran vs Warfarin in Medicare [841]

Michael Webster-Clark, Til Stürmer, Charles Poole, Ross Simpson, Jessie K Edwards, Jennifer L Lund. (United States)

8:45am

Comparative Effectiveness and Safety of Concomitant Use of Antiplatelets and Anticoagulants in Acute Coronary Syndrome Patients with Atrial Fibrillation [842]

Ghadeer K Dawwas, Eric Dietrich, David Winchester, Almut Winterstein, Richard Segal, Haesuk Park. (United States)

9:00am

Safety and Effectiveness of Direct Oral Anticoagulants versus Vitamin K Antagonists, Results from Three Italian Regions [843]

Ursula Kirchmayer, Silvia Narduzzi, Flavia Mayer, Marco Tuccori, Olivia Leoni, Valeria Belleudi, Antonio Addis, Marina Davoli. (Italy)

9:15am

Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Non-Valvular Atrial Fibrillation: A Multi-Center Observational Cohort Study [844]

Madeleine Durand, Mireille E Schnitzer, Menglan Pang, Greg Carney, Sherif Eltonsy, Kristian B Filion, Anat Fisher, Min

Jun, I fan Kuo, Alexis Matteau, J Michael Paterson, Jacqueline Quail, Christel Renoux, for the CNODES Investigators. (Canada)

9:30am

Comparative Effectiveness and Safety of Direct Acting Oral Anticoagulants and Warfarin in Cancer Patients with Venous Thromboembolism [845]

Ghadeer K. Dawwas, Eric Dietrich, Kyle Davis, Haesuk Park. (United States)

9:45am

Risk of Major Bleeding Associated with the Use of Individual Direct Oral Anticoagulants Compared to Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation: A Meta-Analysis of Results from Multiple Population-Based Cohort Studies Using a Common Protocol in Europe and Canada [846]

Hendrika van den Ham, Patrick Souverein, Olaf Klungel, Robert Platt, Pierre Ernst, Sophie Dell'Aniello, Sven Schmiedl, Birgit Grave, Marietta Rottenkolber, Consuelo Huerta, Elisa Martin Merino, Luz León-Muñoz, Luz León-Muñoz, Dolores Montero, Morten Andersen, Mia Aakjær, Marieke De Bruin, Helga Gardarsdottir. (Netherlands)

8:30am– 10:00am

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)**Vaccine Abstracts Gone Viral!**

204C

Moderator: Ju-Young Shin & Harry Seifert, FISPE

8:30am

Impact of the Publicly Funded Herpes Zoster Immunization Program on Burden of Disease in Ontario, Canada [847]

Mina Tadrous, Daniel McCormack, Diana Martins, Tara Gomes, Jeff Kwong, Sarah Buchan, Tony Antoniou. (Canada)

8:45am

Trends in Human Papillomavirus Vaccination Uptake in Girls and Boys in the United States: Real-World Evidence from 2003 to 2016 [848]

Szu-Ta Chen, Krista F Huybrechts, Brian T Bateman, Sonia Hernández-Díaz. (United States)

9:00am

Vaccination before First Symptom of Central Demyelination [849]

Lamia Grimaldi-Bensouda, Nicolas Morisot, Pegdwende O Dialla, Clémentine Nordon, Lucien Abenheim. (France)

9:15am

Incidence of Outcomes Relevant to Vaccine Safety Monitoring in Europe Using Two Distinct Data Sources: National Healthcare Registries (Sweden) and Electronic Medical Records (UK) [850]

Lina Titievsky, Nils Ekstrom, James Stark, Michael Törnblom, Dan Scott, Rob Maroko, Cassandra Hall-Murray, Peter McMahon, Leif Jörgensen, Mats Rosenlund. (United States)

9:30am

Advance: Towards Near-Real Time Monitoring of Vaccination Coverage, Benefits and Risks Using European Electronic Health Record Databases [851]

Kaatje Bollaerts, Tom De Smedt, Chris McGee, Hanne-Dorthe Emborg, Maria Alexandridou, Marco Villa, Talita Duarte-Salles, Myint Tin Tin Htar, Simon de Lusignan, Claudia Bartolini, Rosa Gini, Lina Titievsky, Miriam Sturkenboom, Vincent Bauchau. (Belgium)

9:45am

Variation in Rotavirus Vaccination Coding in US State Medicaid Data [852]

J Bradley Layton, Anne M Butler, M Alan Brookhart, Catherine A Panozzo. (United States)

10:00am– 10:30am

Break/Posters/Exhibits

Hall A

10:30am– 12:00pm

CONCURRENT SESSIONS: SYMPOSIA & WORKSHOPS

10:30am

Analysis of Data from Distributed Pharmacoepidemiologic Networks [853] Ballroom B

Romin Pajouheshnia, Helga Gardarsdottir, Robert Platt, Darren Toh, Olaf Klungel. (Netherlands)

10:30am

Causal Inference in Pharmacoepidemiology [854] 201A

Laura Pazzagli, Elizabeth A Stuart, Miguel Hernán, Sebastian Schneeweiss. (Sweden)

10:30am

Pharmacoepidemiology and Rare Cancer Research [855] 201BWei Zhou, Leigh Marcus, Anton Pottegård, Bruce Carleton, Andrew Freedman, Hans-Georg Eichler. (United States)
Sponsored by the Rare Disease Special Interest Group

10:30am

Emerging Solutions to Addressing Challenges in Measuring Adherence to Multiple Medications [856] 201CJulie Lauffenburger, Caroline Walsh, Sarah-Jo Sinnott, Jessica Franklin, Petra Denig. (United States) *Sponsored by the Adherence Special Interest Group*

10:30am

Mixing It Up: Implementing Qualitative & Mixed Methods in Pharmacoepidemiology Research [857] 202AB

M Elle Saine, Julia E Szymczak, Irene Petersen, Rachel E Sobel. (United States)



12:00pm– 1:30pm
**Lunch/Poster Session C/
Exhibits**

Hall A

12:00pm– 1:30pm
ISPE Board of Directors Luncheon (Open to ISPE members ; interested members should contact info@pharmacoepi.org if they would like to attend.) **Marriott Salon A**

12:15pm– 1:15pm
Spotlight Poster Session C:

West Bridge

- Medications in Pregnancy & Lactation
- Molecular Epi, Biomarkers & Pharmacogenetics
- Oncology
- Pediatrics
- Vaccines

1:30pm – 3:00pm

CONCURRENT SESSIONS: ORAL PRESENTATIONS

CER of DM Treatments - Effectiveness and Safety

Ballroom B

Moderators: Jodi Segal, FISPE, & Christian Hampp, FISPE

1:30pm

Improved Real-World Outcomes for Type 2 Diabetes Patients on Basal-Bolus Insulin Therapy Switching to Insulin Glargine 300 U/ml vs. Insulin Glargine 100 U/ml and Insulin Detemir [858]

Jasmanda Wu, Timothy S Bailey, Zsolt Bosnyak, Jukka Westerbacka, Rishab A Gupta, Arjun A. Menon, Charlie Nicholls, Lawrence Blonde. (United States)

1:45pm

Metformin Use and Risk of Benign Prostatic Hyperplasia [859]

Mette Nørgaard, Bianka Darvalics, Reimar W Thomsen. (Denmark)

2:00pm

Comparative Cardiovascular and Hypoglycemic Safety of Glimepiride in Type 2 Diabetes: A Population-Based Cohort Study [860]

Antonios Douros, Sophie Dell’Aniello, Oriana Yu, Samy Suissa. (Canada)

2:15pm

Major Adverse Cardiovascular Events Associated with Sodium Glucose Co-Transporters versus Other Antidiabetes Drugs: Population-Based Cohort Study [861]

Colin Dormuth, Xiaoting Ding, Ellen Reynolds, Greg Carney. (Canada)

2:30pm

Comparative Risk Evaluation for Cardiovascular Events Associated with Empagliflozin vs. Dapagliflozin: A Multi-Institutional Cohort Study [862]

Shih-Chieh Shao, Kai-Cheng Chang, Ming-Jui Hung, Yuk-Ying Chan, Hui-Yu Chen, Yea-Huei Kao Yang, Edward Chia-Cheng Lai. (Taiwan)

2:45pm

Empagliflozin Selected Cardiovascular and Safety Outcomes in Routine Care: First Results from Theempagliflozin Comparative Effectiveness and Safety (EMPRISE) Study [863]

Elisabetta Patorno, Ajinkya Pawar, Jessica M Franklin, Mehdi Najafzadeh, Anouk Déruaz-Luyet, Kimberly G Brodovicz, Steven Sambevski, Lily G Bessette, Martin Kulldorff, Sebastian Schneeweiss. (United States)

Generating Real-World Evidence on Biologics: European and U.S. Experiences

201A

Moderator: Amanda Golembesky & Peter Mol

1:30pm

Real-World Data on the Use of Biologics in the Treatment of Colorectal Cancer: Comparison between Three European Databases [864]

Katja Anita Oppelt, Josephina G Kuiper, Ylenia Ingrassiotta, Valentina Ientile, Ron M Herings, Gianluca Trifirò, Ulrike Haug. (Germany)

1:45pm

Drug Survival of Targeted Therapies for Plaque Psoriasis: Evidence from a Large U.S. Claims Database [865]

Nathaniel Hendrix, David Veenstra. (United States)

1:30pm – 3:00pm

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)**Generating Real-World Evidence on Biologics: European and U.S. Experiences** (continued)

201A

Moderator: Amanda Golembesky & Peter Mol

2:00pm

Risk of Serious Infections among New Users of Interleukin-17, Interleukin-12/23 Inhibitors, Compared to Tumor Necrosis Factor (TNF)-alpha Inhibitors, for the Treatment of Psoriasis and Psoriatic Arthritis [866]

Xintong Li, Kathleen M Andersen, Hsien-Yen Chang, Jeffrey R Curtis, G Caleb Alexander. (United States)

2:15pm

Risk of Heart Failure Following Exposure to Non-TNFi Compared to TNFi Biologics in US Patients with Rheumatoid Arthritis [867]

Thomas Bo Jensen, Nicole Tsao, Ajinkya Pawar, Rishi Desai, Seouyoung Kim. (United States)

2:30pm

Risk of Diabetes Treatment Intensification**Associated with Use of Abatacept versus Other Biologic Drugs in Patients with Rheumatoid Arthritis and Diabetes Mellitus [868]**

Sarah Chen, Hemin Lee, Yinzhu Jin, Jun Liu, Seouyoung Kim. (United States)

2:45pm

Intravitreal Anti-Vascular Endothelial Growth Factor Drugs and Risk of Serious Non-Ocular Hemorrhage [869]

Janet Sultana, Francesco Giorgianni, Giulia Scodotto, Valentina Ientile, Pasquale Cananzi, Olivia Leoni, Sebastiano Walter Pollina Addario, Giovanbattista de Sarro, Adele de Francesco, Maria Rosalia Puzo, Christel Renoux, Gianluca Trifiro'. (Italy)

It's Complicated in the Old World

201B

Moderators: Jennifer Lund & Thierry Trenque

1:30pm

Heatwaves and Heat-Sensitizing Medications in Vulnerable Older Adults [870]

J Bradley Layton, Wenhong Li, Lily Wang, Jiacan Yuan, Joshua P Gilman, Daniel B Horton, Soko Setoguchi. (United States)

1:45pm

Opioid Intensification versus Adjuvant Gabapentin Initiation and Risk of Hospitalization for Falls and Fractures in United States Nursing Home Residents [871]

Danni Zhao, Anne Hume, Shao-Hsien Liu, Christine Ulbricht, Matt Alcusky, Giovanni Gambassi, Kate L Lapane. (United States)

2:00pm

Comparative Safety and Effectiveness of Apixaban and Rivaroxaban versus Warfarin among US Nursing Home Residents [872]

Matthew Alcusky, David D McManus, Marc Fisher, Anne L Hume, Jennifer Tjia, Kate L Lapane. (United States)

2:15pm

Statin Use in Older Danes: An Analysis of Discontinuation Patterns [873]

Wade Thompson, Dorte E Jarbøl, Peter Haastrup, Jesper Bo Nielsen, Anton Pottegård. (Denmark)

2:30pm

Does Use of Acetylcholinesterase Inhibitors Prevent or Delay the Prescribing of Psychotropic Medications in People with Dementia? Analyses of the Swedish Dementia Registry (Svedem) [874]

Edwin C Tan, Kristina Johnell, J Simon Bell, Sara Garcia-Ptacek, Johan Fastbom, Peter Nordström, Maria Eriksdotter. (Australia)

2:45pm

Association Rule Analysis to Evaluate Frequent Drug Combinations Associated with Acute Kidney Injury in Older Adults [875]

Prasad Nishtala, Te-yuan Chyou. (United Kingdom)



PHARMALEX

CONFIDENCE BEYOND COMPLIANCE

Pharmacovigilance, Epidemiology and Risk Management (PER)

PharmaLex is a global consulting firm providing right-size services in the life sciences

- ▶ Epidemiology & Drug Safety Studies
- ▶ Rx-to-OTC Switches
- ▶ Risk Evaluation & Mitigation Strategies
- ▶ Rapid response to regulatory needs
- ▶ Claims, EHR & AE database analyses
- ▶ Systematic Literature Reviews

www.pharmalex.com

Meet us at Booth #1116 & enter to win a pair of Apple AirPods

B.R.I.D.G.E. TO DATA® is a useful resource to:

- Search, review and compare database profiles
- Access specialized glossary and interactive maps of databases worldwide

Schedule a personalized demo during ICPE

www.bridgetodata.org

B.R.I.D.G.E. TO DATA® Online service provided by DGI, LLC, a non-profit organization



What science can do

At AstraZeneca, we turn ideas into life changing medicines. Working here means being entrepreneurial, thinking big and working together to make the impossible a reality.

Epidemiologists at AstraZeneca support drug discovery and development as well as commercialisation of pharmaceuticals. Major activities include: critical appraisal and synthesis of relevant epidemiological literature; design, initiation, management, conduct, analysis, and reporting of epidemiological studies, including observational and interventional studies; and development of medical and payer evidence plans to fill critical knowledge gaps, including support to specialised areas (e.g. biomarker development, disease modelling, health economics).

If you are interested in learning more about AstraZeneca, or joining our team, visit www.astrazeneca.com.



1:30pm – 3:00pm

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)**Adherence: In for the Long-Term**

201C

Moderator: Aaron Winn & Jaqueline Hugtenburg

1:30pm

Pharmacy-Based Predictors of Non-Adherence, Non-Persistence, and Re-Initiation of Antihypertensive Drugs among Patients on Oral Diabetes Drugs in the Netherlands [876]

Sofa Dewi Alfian, Petra Denig, André Coelho, Eelko Hak. (Netherlands)

1:45pm

The Social Determinants of Non-Adherence to Antihypertensive Medications [877]

Macarius Donneyong, Paul Juarez, Teng-Jen Chang, Shawntita Sealy-Jefferson, Pamela Salsberry, Bo Lu, Wansoo Im, John Jackson, Michael Fischer. (United States)

2:00pm

Increased Out-of-Pocket Costs Lead to Decreased Adherence and Delayed Treatment Reinitiation of Branded Diabetes Drugs in Medicare Patients [878]

Danielle S Chun, Mugdha Gokhale, Stacie B Dusetzina, Virginia Pate, John B Buse, Emily Gower, Til Stürmer. (United States)

2:15pm

Impact of a Two-Tier Intervention on Statin Prescribing and Adherence Levels Among Latino Patients with Diabetes [83]

Toney Duong, Jose Hernandez (United States)

2:30pm

Does Nonadherence with Antidepressants Differ by Treatment Indication? [880]

Jenna Wong, Siyana Kurteva, Robyn Tamblyn. (United States)

2:45pm

A Group Based Trajectory Modeling to Study Adherence Patterns of Atypical Antipsychotics in Pediatrics and Adolescents: A Retrospective Cohort Study Using Texas Children Health Plan [881]

Swarnava Sanyal, Tyler J Varisco, Soham Yande, Hua Chen. (United States)

Potpourri: What Do You Put on Your Cheesesteak?

202AB

Moderator: David Miller, FISPE & Kourtney Davis

1:30pm

Current Practice in Reporting Exposure in Pharmacoepidemiological Studies [882]

Mirjam Hempenius, Kim Luijken, Anthonius Boer, Olaf H Klungel, Rolf H Groenwold, Helga Gardarsdottir. (Netherlands)

1:45pm

Cause-Specific and All-Cause Mortality Associated with Proton Pump Inhibitors: A Cohort Study [883]

Jeremy P Brown, John Tazare, Kathryn Mansfield, Kevin Wing, Adrian Root, Laurie Tomlinson, Krishnan Bhaskaran, Elizabeth Williamson, Liam Smeeth, Ian Douglas. (United Kingdom)

2:00pm

Survival after Stevens-Johnson Syndrome: A UK-Based Cohort Study [884]

Carole Marxer, Noel Frey, Michael Bodmer, Andreas Bircher, Susan S Jick, Christoph R. Meier, Julia Spoendlin. (Switzerland)

2:15pm

Real World Effects of Medications for Chronic Obstructive Pulmonary Disease: A UK Population-Based Non-Interventional Cohort Study with Validation against Randomised Trial Results [885]

Kevin Wing, Elizabeth Williamson, James Carpenter, Lesley Wise, Sebastian Schneeweiss, Liam Smeeth, Jenni Quint, Ian Douglas. (United Kingdom)

2:30pm

Safety of Colobreathe: Findings from the UK Cystic Fibrosis Registry [886]

Sigal Kaplan, Diana Bilton, Susan C Charman, Andrew Lee, Noreen Caine. (Israel)

2:45pm

Where Should I Submit My Manuscript? Applying Machine Learning to Enhance Communication of Medical Research [887]

Jeremy Rassen. (United States)



1:30pm – 3:00pm

CONCURRENT SESSIONS: ORAL PRESENTATIONS (continued)

Slice and Device

204C

Moderator: Soko Setoguchi, FISPE & Christina Mack

1:30pm

Propensity Score Stratification and Inverse Probability Weighting Compared to Surgical Randomised Clinical Trial Results in Device Epidemiology [888]

Victoria Y Strauss, Albert Prats-Uribe, Klara Berencsi, Andrew Carr, Andrew Judge, Alan Silman, David W Murray, Nigel K Arden, Irene Petersen, Rafael Pinedo-Villanueva, David J Beard, J Mark Wilkinson, Ian Douglas, Jose M Valderas, Sarah Lamb, Daniel Prieto-Alhambra. (United Kingdom)

1:45pm

The Performance of Preference-Based Instrumental Variables to Emulate a Randomised Clinical Trial of Comparative Medical Device Effectiveness [889]

Albert Prats-Uribe, Klara Berencsi, Andrew Carr, Andrew Judge, Alan Silman, David W Murray, Nigel K Arden, Irene Petersen, Rafael Pinedo-Villanueva, David J Beard, J Mark Wilkinson, Ian Douglas, Jose M Valderas, Sarah Lamb, Victoria Y Strauss, Daniel Prieto-Alhambra. (United Kingdom)

2:00pm

Development and Validation of Patient-Level Prediction Models for Adverse Outcomes Following Total Knee Arthroplasty in Osteoarthritic Patients [890]

Ross Williams, Jenna Repts, Ying HE, Peter Rijnbeek, Anthony G Sena, Daniel Prieto-Alhambra, Patrick Ryan. (Netherlands)

2:15pm

Medications, Device Use, and Non-Device Associated Urinary Tract Infections in Hospitalized Patients [891]

Paula D Strassle, Emily E Sickbert-Bennett, Lauren M DiBiase, Jennifer L Lund, Michael Klompas, Paul Stewart, David J Weber. (United States)

2:30pm

Cardinality Matching versus Propensity Score Matching for Causal Inference in Medical Device Research: An Applied Analysis of Minimally-Invasive versus Open Elective Thoracic Segmentectomy [892]

Stephen Johnston, Iftekhhar Kalsekar, David Wei, Annie Lied-Lied, Jose Zubizarreta. (United States)

2:45pm

Self Controlled Case Series in Surgical Epidemiology: Checking the Underlying Assumptions in an Empirical Example [893]

Danielle E Robinson, Ian Douglas, Victoria Y Strauss, Daniel Prieto-Alhambra. (United Kingdom)

3:00pm– 3:15pm

Break

Hall A

Main Conference | Wednesday, August 28

3:15pm – 4:45pm

Hot Topics Session: When You're a Single-Arm Trial or Extension, Can an External Control Make a Good Match?

Ballroom B

Uncontrolled study arms in Phase II/III trials and long-term trial extensions provide an efficient mechanism to gain efficacy and safety data. They may also avoid ethical issues in the use of long-term placebo, feasibility or cost issues around choice of a relevant, effective and safe comparator, while meeting the need for sufficient exposure data for regulatory filing.

While uncontrolled studies offer benefits, there are also risks. The lack of an internal control group poses challenges to the evaluation and interpretation of any unexpected serious adverse events (SAEs) that may occur. The occurrence of even a small number of SAEs, or otherwise clinically important AEs, may engender enough uncertainty with respect to the risk/benefit profile that, additional data may be required pre-submission, lead to cautionary labeling, or prompt further post-marketing study requirements.

This Hot Topics Session will cover issues related to uncontrolled, pre-authorization product development trials and extensions to randomized controlled trials. The session will propose the use of observational, real world evidence (RWE) patient cohorts as a potential method to provide an external control group for these Phase II/III uncontrolled, clinical trials and/or open-label, long-term extensions that may mitigate some of the risks. The 20-minute presentations and 30-minute discussion will include:

1. scope of the use of single-arm, uncontrolled trials in product development and examples where uncontrolled arms have posed a regulatory review issue;
2. methodologic and analytic challenges of using external control cohorts as comparators for safety and/or effectiveness for uncontrolled trials and/or trial extensions, including types of databases, collection of data, analytic issues and ability to control for confounding; and,
3. challenges in interpreting uncontrolled trial data in regulatory filings and regulatory perspectives on use of real world data as external controls to assist in regulatory decision-marking.

Moderators

Nancy Santanello, FISPE, Pharmacoepidemiology Consultant
Barry Gertz, Managing Director, Blackstone Life Sciences

Speakers

Joanne Waldstreicher, Chief Medical Officer, Johnson and Johnson, Raritan, NJ

Peter Stein, Director, Center for Drug Evaluation and Research (CDER), Office of New Drugs (OND), FDA, Silver Spring, MD

Stephen Evans, FISPE, Professor of Pharmacoepidemiology, London School of Hygiene and Tropical Medicine, London, UK

4:45pm– 5:30pm

The Final Word

Ballroom B

35th ICPE Awards

Vincent Lo Re, FISPE, Chair, ICPE 2019 Scientific Program Committee

■ **Review of Abstract Admission Categories**

- Vera Ehrenstein
- Daniel B Horton
- Elaine Morrato
- Mary Ritchey, FISPE
- Rachel Sobel, FISPE
- Walter Straus

■ **Newcomer Track**

- Charles Leonard
- Ian Douglas

■ **Moderator Subcommittee**

- Mary Ritchey, FISPE
- Krista Huybrechts, FISPE
- Lisa Pont, FISPE

■ **Spotlight Poster Sessions**

- J Bradley Layton
- Jennifer Lund

Spotlight Poster Awards

- J Bradley Layton, Chair, Spotlight Poster Sessions

2020 Meetings

Mid-Year Meeting – Orlando

Juan Hincapie-Castillo, 2019 Mid-Year Program Planning Committee

36th ICPE – Berlin

Tobias Gerhard, FISPE, Chair ICPE 2020 Scientific Program Committee
Frank Andersohn, Chair, ICPE 2020 Local Host Committee

Drawing for ICPE 2020 Registrations

Tobias Gerhard, FISPE, Chair ICPE 2020 Scientific Program Committee

Adjournment of the ICPE 2019

Vincent Lo Re, FISPE, Chair, ICPE 2019 Scientific Program Committee





Your Global Observational Studies Partner for Field, Secondary Data and Hybrid Studies for Safety, Market Access/HEOR and Development

LEADER IN EUROPEAN PASS STUDIES

- | Oral presentation at ICPE 2019 | Oral presentations to EMA and EFPIA: 2018 |
- | Publication in 2019 in Expert Opinion in Drug Safety |
- | Prize for novel design at ICPE 2018 | Record of PRAC-approved PASS studies |

LEADER IN MULTI-COUNTRY DATABASE STUDIES

- | New method for competing risk in our Lancet publication |
- | Poster at this conference, using CPRD (Abstract #6863) |

PROPRIETARY EDC PLATFORM

- | Flexibly used for PRAC-approved hybrid PASS studies |



www.oxonepi.com | info@oxonepi.com

VISIT US AT BOOTH #1017


epiexcellence

Too many tasks on your to-do list and too little time? We've been in your shoes.
Epi Excellence can help!

Our 25+ epidemiologists and scientists are readily available to alleviate work overload. Whether you need just a few hours of ad hoc support, a dedicated project team, or full-time contractors, we will take on...

- Literature reviews: simple to complex, narrative to systematic
- Epidemiologic study design, protocols, statistical analysis plans
- Regulatory and medical writing
- Program strategy and project management
- Other tasks, no matter how small

Epi Excellence LLC is a small business, honored to be certified as both a National Women's Business Enterprise and a Minority Business Enterprise.



Eileen E. Ming, MPH, ScD, FISPE
Founder and Principal, Epi Excellence LLC



Proud sponsor of **ICPE's Mother's Room** - Room 300 in the PA Convention Center
and **An Oral History of ISPE/ICPE** - come see the videos playing in the Lounge!

Call or Text: +1 215.920.7680 | Email: eming@epiexcellence.com | Web: epiexcellence.com

OVERVIEW

Poster sessions are designed to give presenters an opportunity to discuss informally their research with colleagues interested in their research. The purpose of the posters is to visually stimulate interest in the research, to present sufficient information for viewers to understand the methods, results, and significance of the research, and to promote conversations and networking among conference participants.

NOTE

Neither ISPE nor the Pennsylvania Convention Center will be responsible for any material left on display overnight or is lost or damaged.

POSTER SESSIONS

Spotlight Poster Sessions (West Bridge) & General Poster Sessions (Hall A) will be displayed in the Pennsylvania Convention Center. There will be a distinct Spotlight Poster Session and General Poster Session each day. All posters for a specific day's session must be removed at the end of that day.

- Monday, August 26, **Session A** - Spotlight Posters/General Posters
- Tuesday, August 27, **Session B** - Spotlight Posters/General Posters
- Wednesday, August 28, **Session C** - Spotlight Posters/General Posters

1. SET UP

7:00am-8:00am; all posters must be in place by 8:00am. The poster area (including floor) must remain clear and clean of tubes.

2. HOURS

Posters will be displayed from 8:00am-5:00pm on Monday and Tuesday, and 8:00am-1:15pm on Wednesday.

3. DISCUSSION TIME

General: Presenters should be at their posters between 12:15pm-1:15pm on Monday (A), between 11:45am-12:45pm on Tuesday (B); and between 12:15pm-1:15pm on Wednesday (C)

Spotlight Sessions: Organized by the ISPE Special Interest Groups (SIGs). Presenters should be at their posters between 12:15pm-1:15pm on Monday (A) and 11:45am-12:45pm on Tuesday (B); and between 12:15pm-1:15pm on Wednesday (C)

Spotlight sessions offer pre-selected presenters the opportunity to share their work and to discuss their results with an audience. When the spotlight session chair and audience stop at your poster, please give a brief, 3-minute, presentation and to answer questions about your research.

Monday

- Adherence
- Asian Pharmacoevidence Network (AsPEN)
- Biologics & Biosimilars
- Comparative Effectiveness Research (CER)
- Geriatric Pharmacoevidence

Tuesday

- Benefit Risk Assessment, Communication & Evaluation (BRACE)
- Databases
- Drug Utilization Research/Health Services Research
- Medical Devices
- Rare Diseases

Wednesday

- Medications in Pregnancy & Lactation
- Molecular Epidemiology/Biomarkers/Pharmacogenetics
- Oncology
- Pediatrics
- Vaccines

Spotlight Session Prizes

A group of judges will select the best posters of each Spotlight Session. The best presenters will receive an invitation to display their posters for the duration of the ICPE. The winners will be announced during The Final Word session on Wednesday afternoon, August 28.

NUMBERING SYSTEM

Each poster board will be numbered. Presenters should attach their posters to the board number corresponding to the number assigned to their poster listed in the **Final Program**. The **POSTER BOARD NUMBER** is the first number listed. The **PUBLICATION NUMBER**, for use in locating abstracts in the **Final Program**, is listed after the abstract title.

EXAMPLE

97 Characteristics of Patients with Depression Who Initiate Antidepressant and Benzodiazepine Therapy Simultaneously, Compared with Antidepressant Monotherapy [176]

Greta A Bushnell, Alice White, Til Stürmer, Bradley N Gaynes, Virginia Pate, Deborah Azrael, Matthew Miller. (United States)

KEY 97 Poster Board Number
176 Publication Number

CALL4POSTERS

Posters ordered through Call4Posters can be picked up at the times and location below.

POSTER PICK UP SCHEDULE

Sunday, August 25	Noon-5:00pm ICPE Registration Desk
Monday, August 26	7:00am-3:00pm Hall A, Booth 216
Tuesday, August 27	7:00am-3:00pm Hall A, Booth 216
Wednesday, August 28	7:00am-8:30am Hall A, Booth 216

SAVE THE DATES!



Poster Session A | Monday, August 26 • 8:00am - 6:00pm

SPOTLIGHT SESSIONS: 12:15Pm - 1:15pm

**Poster Spotlight Session A:
Adherence**
A Secondary Adherence to Oral Anticoagulants. Preliminary Results of a Systematic Review and Meta-Analysis of Real-World Studies [84]

Clara L Rodríguez-Bernal, Salvador Peiró, Anibal García-Sempere, Gabriel Sanfélix-Gimeno. (Spain)

B Persistence and Adherence to Biologics in Patients with Psoriasis: A Nation-Wide New User Cohort Study [85]

Yanfang Liu, Yu-Huei Huang, Choo Hua Goh, Chia-Li Chang, Hong Qiu, Chao-Hsiun Tang. (Singapore)

C Investigating the Impact of Statin Intensity on Patients' Discontinuation of Statin Therapy: A Nationwide Cohort Study [86]

Tanja Mueller, Renata C Macedo do Nascimento, Marion Bennie, Brian Godman, Simon Hurding, Sean MacBride Stewart, Augusto Afonso Guerra Junior, Francisco de Assis Acurcio, Alec Morton, Amanj Kurdi. (United Kingdom)

D Does Single-Tablet Regimen Improve Adherence to Antiretroviral Therapy in Brazil? A Group-Based Trajectory Modeling Analysis of Patients Switching Regimens [87]

Simone Santos, Micheline R Silveira, Celline C Almeida-Brasil, Juliana O Costa, Marcio Cruz, Edna Reis, Francisco Acurcio, Maria das Graças B Ceccato. (Canada)

E Risk Factors for Non-Persistence with Antiplatelet Agents in Patients after a Transient Ischemic Attack [88]

Martin Wawruch, Gejza Wimmer Jr, Jan Murin. (Slovakia)

F Treatment Patterns and Adherence in a UK Primary Care Migraine Population [89]

Eleanor Yelland, Rebecca Ghosh, Tarita Murray-Thomas, Alison Williams, Victoria Hacking. (United Kingdom)

G The Impact of Reduced Copay for Hormonal Therapy on Primary and Secondary Non-Adherence for Breast Cancer Medicare Patients [90]

Aaron N Winn, Nicole Fergestrom, Joan M Neuner. (United States)

**Poster Spotlight Session A:
AsPEN**
H Uncertain Association between Benzodiazepine Use and the Risk of Dementia: Population-Based Matched Cohort Study [91]

Yeon-Hee Baek, Hyesung Lee, Woo Jung Kim, Jee-Eun Chung, Nicole Pratt, Lisa K Ellett, Ju-Young Shin. (Korea, Republic of)

I Risk of Cardiovascular Adverse Events and Domperidone Use: A Case-Crossover Study [92]

Sun Mi Shin, Junqing Li, Hye-Jun Kim, Hyesung Lee, Ju-Young Shin. (Korea, Republic of)

J A Multi-Institutional Health Screening Records Database (hsrd) of Korea: Evaluation of its Characteristics and Representativeness [93]

Yunha Noh, Han Eol Jeong, Hye-Jun Kim, Hanju Ko, Eun-Hee Nah, Ju-Young Shin. (Korea, Republic of)

K The Association Between Use of Opioid Analgesics and Benzodiazepines and the Risk of Death: A Population-Based Case-Crossover Study [94]

Junqing Li, Bo Ram Yang, Ha-Lim Jeon, Ju-Young Shin. (Korea, Republic of)

L Comparative Mortality Risk of Antipsychotic Medications in Elderly Patients with Stroke: Adjusting for Unmeasured Confounders with Stroke Registry Database Using Propensity Score Calibration [95]

Chien-Chou Su, Edward Chia-Cheng Lai, Cheng-Yang Hsieh, Chih-Hung Chen, Huey-Yuan Lin, Sheng-Feng Sung, Yu-Wei Chen, Yea-Huei Kao Yang. (Taiwan)

M Trend of Isoniazid Prophylaxis and Tb Infection for Rheumatoid Arthritis Patients Receiving TNF Inhibitors: A Nationwide Population-Based Analysis [96]

Hsun-Yin Liang, Meng-Yu Weng, Wei-I Huang, Pi-Hui Chao, Wen-Wen Chen, Yea-Huei Kao Yang, Edward Chia-Cheng Lai. (Taiwan)

N Risk of Neuroleptic Malignant Syndrome Among Patients Exposed to Antipsychotics [97]

Esther W Chan, Shijian Lao, Jiayi Zhao, Joseph E Blais, Ian CK Wong, Frank MC Besag, WC Chang, David J Castle. (Hong Kong)

**Poster Spotlight Session A:
Biologics and Biosimilars**
O The Use of Long-Acting Insulin Analogues and the Risk of Colorectal Cancer in Patients with Type 2 Diabetes Mellitus [98]

Richeek Pradhan, Hui Yin, Oriana Hoi Yu, Laurent Azoulay. (Canada)

P Methodologic Considerations for Data Source Selection and Study Design of Non-Interventional Studies Comparing the Safety and Effectiveness of Biosimilars and Reference Biologics: Insulin Glargine Products as a Case Example [99]

Nancy D Lin, Jaclyn L Bosco, Cynthia H Holmes, Catherine M Lockhart, John D Seeger. (United States)

Q Adherence and Discontinuation for Infliximab Biosimilar and Originator Drugs Covered by Public Provincial Insurance in Canada [100]

Cristiano S Moura, Waqqas Afif, Talat Bessissow, Gilles Boire, Vivian P Bykerk, Denis Choquette, Peter Lakatos, Walter P Maksymowych, Larry Svenson, Laura Targownik, Carter Thorne, Sasha Bernatsky. (Canada)

R Abatacept in Rheumatoid Arthritis and the Risk of Cancer: A Disproportionality Analysis in VigiBase [101]

Sibylle De Gernay, Haleh Bagheri, Vanessa Rousseau, François Montastruc. (France)

S Predictors of Infection in Rheumatoid Arthritis Patients Using Anti-Tumor Necrosis Factor Agents [102]

Tasia Liu, Aisling R Caffrey. (United States)

T Blood Utilization Among U.S. Elderly Medicare Beneficiaries in the Institutional Outpatient Setting, During 2007-2018 [103]

Mikhail Menis, Barbee I Whitaker, Yixin Jiao, Madeline Swarr, An-Chi Lo, Jiemin Liao, Thomas E MaCurdy, Jeffrey A Kelman, Steven A Anderson, Richard A Forshee. (United States)

U Identification of Exposure to Reference Biologics and Biosimilars - Use of Medical Claim National Drug Code and Healthcare Common Procedure Coding System Code Modifier [104]

Jie Zhang, Kevin Haynes, Aaron B Mendelsohn, James Marshall, Charlie Barr, Cara McDermott, Annemarie Kline, James Kenney, Katelyn J King, Cynthia Holmes, Huifeng Yun, Kai Yeung, Cate Lockhart. (United States)

V Batch-Level Pharmacovigilance Following Manufacturing Change of Biological Products [105]

Ayad K Ali, John D Ayres. (United States)

Poster Spotlight Session A: Comparative Effectiveness Research (CER)

W Evidence of Residual Confounding in Healthcare Database Studies of Oseltamivir and Influenza Complications [106]

Phyo T Htoo, Gregory Measer, Robert Orr, Justin Bohn, Alfred F Sorbello, Henry Francis, Sarah K Dutcher, Sengwee Darren Toh, Noelle M Cocoros. (United States)

X Use of Statins and Risk of Acute Exacerbations in Patients with Chronic Obstructive Pulmonary Disease [107]

Chia-Hsui Chang, Zhe-Wei Zhan, Yaa-Hui Dong. (Taiwan)

Y Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation [108]

David J Graham, Elande Baro, Rongmei Zhang, Jiemin Liao, Michael Wernecke, Marsha E Reichman, Mao Hu, Onyekachukwu Illoh, Yuqin Wei, Margie R Goulding, Yoganand Chillarige, Mary Ross Southworth, Thomas E MaCurdy, Jeffrey A Kelman. (United States)

Z Replication of Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation in A Cohort Study Using Electronic Primary Care Database [109]

Turki A Althunian, Anthonius de Boer, Rolf H. Groenwold, Katrien O Rengerink, Patrick C. Souverein, Olaf H Klungel. (Saudi Arabia)

AA Carboplatin-Based Chemotherapy (C) Versus Immunotherapy (IO) in Metastatic Urothelial Carcinoma (MUC) [110]

Emily Feld, Joanna Harton, Neal J Meropol, Blythe Adamson, Ravi Parikh, Matthew D. Galsky, Aaron Cohen, Vivek Narayan, John Christodouleas, David J Vaughn, Rebecca A Hubbard, Ronac Mamtani. (United States)

BB Optimal Duration of Anticoagulant Thromboprophylaxis in Total Hip Arthroplasty - New Evidence in 55,540 Patients with Osteoarthritis from The Nordic Arthroplasty Register Association (NARA) Group [111]

Alma Pedersen, Ina Trolle Andersen, Søren Overgaard, Anne Marie Fenstad, Stein Atle Lie, Jan-Erik Gjertsen, Ove Furnes. (Denmark)

CC Causal Inference Modeling in Comparative Effectiveness Research for Antiplatelet Agents [112]

Nicholas Belviso, Herbet Aronow, Ashley Buchanan, Stephen Kogut, Aisling Caffrey, Marilyn Barbour, Xuerong Wen. (United States)

DD Comparing the Safety of Apixaban, Rivaroxaban and Dabigatran: Indirect Treatments Comparisons Using Real-World Studies [113]

Carlos Alves, Diogo Mendes, Francisco Batel Marques. (Portugal)

Poster Spotlight Session A: Geriatric Pharmacoepidemiology

EE Statin Use and Fall-Related Hospitalizations among Residents of Long Term Care Facilities: A Case-Control Study [114]

Kate N Wang, J Simon Bell, Edwin C Tan, Julia F Gilmartin-Thomas, Michael J Dooley, Jenni Ilomäki. (Australia)

Poster Session A | Monday, August 26 • 8:00am - 6:00pm

SPOTLIGHT SESSIONS: 12:15Pm - 1:15pm

- FF Risk of Culpable Traffic Accident by Frailty in Drivers with Advanced Age [115]**
Sun-Young Jung, Byungkwan Hwang, Bo Ram Yang, Mi-Sook Kim, Ye-Jee Kim, Nam-Kyong Choi, Byung-Joo Park, JoongYub Lee. (Korea, Republic of)
- GG Multidose Drug Dispensing and Longitudinal Changes in Psychotropic Prescribing Patterns among Older Adults: National Matched Cohort Study [116]**
Lucas Morin, Samuel Hawley, Jonas W Wastesson, Kristina Johnell, Daniel Prieto-Alhambra. (Sweden)
- HH Danish Health Care Professionals' Attitudes Towards Deprescribing in Older Patients with Limited Life Expectancy: A Qualitative Focus Group Study [117]**
Carina Lundby, Trine Graabæk, Jesper Ryg, Jens Søndergaard, Anton Pottegård, Dorthe Susanne Nielsen. (Denmark)
- II Frailty and Use of Psychotropic Medications in Long-Stay Nursing Home Residents [118]**
Yiyang Yuan, Kate L Lapane, Christine M Ulbricht. (United States)
- JJ Meaningful Measurement Matters: How to Best Define Potentially Inappropriate Medication Use to Target Cognitive Outcomes [119]**
Ashley I Martinez, Erin A Abner, Daniela C Moga. (United States)
- KK Angiotensin Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and the Risk of Suicide: A Nested Case Control Study [120]**
Mina Tadrous, Tony Antoniou, Tara Gomes, Simon Greaves, Selina Manji, David N Juurlink, Sidney H Kennedy, Muhammad M Mamdani. (Canada)
- LL Impact of a New Pharmaceutical Care Model on Polymedication and Potentially Inappropriate Medications in Long Term Care Facilities in Canada [121]**
Carolina Tisnado-Garland, Line Guénette, Edeltraut Kröger, Rachel Rouleau, Caroline Sirois. (Canada)

End Spotlight Sessions A

Poster Session A: Analytical Methods

- 1 Abstract Withdrawn [122]**
- 2 How to Estimate Long-Term Treatment Effects in Multiple Sclerosis Registry Studies [123]**
Arthur Allignol, Tim Spelman, Jonatan Freilich, Meritxell Sabidó, Alan Gillett, Jan Hillert, Emmanuelle Boutmy. (Germany)
- 3 Recommendations for Disproportionality Analysis in Small Databases [124]**
Ola Caster, Yasunori Aoki, Lucie Gattepaille, Birgitta Grundmark. (Sweden)
- 4 Missing Data Techniques in Longitudinal Epidemiologic Research: A Case Study [125]**
Valerie Strezsak, Jin-Liern Hong, Paul Dolin. (United States)
- 5 Prospective Testing of Hypothesis-Free Signal Detection Utilizing a Disturbance Algorithm: Nifedipine Use Case [126]**
Jamie Geier, Qing Liu, Stephen E Schachterle, Kenneth Petronis, Manfred Hauben, Vladyslav Bykoriz, Andrew Bate. (United States)
- 6 Toxicity Latent Classes in Chemotherapy-Refractory, Metastatic Colorectal Cancer Patients Treated with Anti-Epidermal Growth Factor Receptor Monoclonal Antibody: Latent Class Analysis of Clinical Trial Data [127]**
Lidija Latifovic, Wei Xu, Rayjean Hung, Geoffrey Liu. (Canada)
- 7 Identifying Risk Factors for 30-Day Hospital Readmissions among Heart Failure Patients Using Machine-Learning Techniques [128]**
Joseph Menzin, Jordan Menzin, Mark Friedman, Anna Watzker. (United States)
- 8 Replication of Risk Characterization in a Cohort with Women with Advanced ER+/HER2- Breast Cancer Using a New Analytic Tool [129]**
Xiaofeng Zhou, Cynthia de Luise, Patricia Prince, Rongjun Shen, Kaiyi Luo, Anthony Louder, Nicolle M Gatto. (United States)
- 9 Consistency Between Prescription Symmetry Sequence Analysis and Symmetry Analysis Cohort Design: Study Using Claims Data in Japan [130]**
Kiyoshi Kubota, Seiya Suzuki, Yuki Kinoshita, Nobuhiro Ooba, Yasuo Ohashi. (Japan)
- 10 To Censor or not to Censor: Impact of Death Censoring in Estimating Excess Length of Stay in Relation to Nosocomial Infection [131]**
Tomomi Kimura, Toshifumi Sugitani, Stephen Stanhope. (Japan)
- 11 Codelist Proximity Analysis - An Innovative, Data Driven, Semi-Automated System, Underpinned by Neural Networks on the Thin Database, to Create Candidate Clinical Codelists for Cohort Extraction and Data Exploration [132]**
Alison Bourke, Timothy Reason. (United Kingdom)
- 12 Variation in Grace Period Used to Define Exposure to Anticoagulants Impacts Incidence Rates of Major Bleeding in Patients with Atrial Fibrillation [133]**
Liliya Sinyavskaya, Christel Renoux, Madeleine Durand. (Canada)
- 13 Big Data and Real World Evidence: Rapid Cycle Analysis Capability via Emerging Analytic Tools - Insights in Atopic Dermatitis and Lessons for Wider Adoption [134]**
Xiaofeng Zhou, Jamie Geier, Rongjun Shen, Richard Gong, Nicolle M. Gatto, Andrew Bate. (United States)
- 14 Application of Machine Learning Algorithms to a Large Primary Care Database Analysis: Random Forest in Evaluation of Body Weight and other Characteristics as Predictors of Antidepressants Prescribing [135]**
Svetlana Puzhko, Gillian Bartlett, David Barber, Tibor Schuster. (Canada)
- 15 Reproducibility of a Population-Based Cohort Study Characterizing Newly Diagnosed Multiple Myeloma Patients in The UK Using an EHR Database [136]**
Anouchka Seesaghur, Victoria Banks, Joe Maskell, Natalia Petruski-Ivleva, Jocelyn Ruoyi Wang, Pattra W Mattox, David Neasham, Shannon L Reynolds, George Kafatos. (United Kingdom)
- 16 Using Snomed to Automate Clinical Concept Mapping [137]**
Shaun Gupta, Daniel Homola, Frederik B Dieleman, Adam Webber, Orla Doyle, Nadejda Leavitt, John A Rigg. (United Kingdom)
- 17 How to Imply the Needs of Marginal Structural Model to Clinicians: An Application in Parkinson's Disease - From a Junior Statistician's Aspect [138]**
Shih-Wei Chiu, Takuhiro Yamaguchi. (Japan)
- 18 The Feasibility of Federated Analysis for Multi-Site Real World Evidence Studies [139]**
Fiona Grimson, Nicolas Niklas, Ruben Hermans, Lorena Cirneanu, Benedikt Maissenhaelter, Joseph Kim. (United Kingdom)
- 19 A Simulation-Based Comparison of Confounding Adjustment Methods in Observational Studies of Administrative Data [140]**
Imane Benasseur, Jason R Guertin, Madeleine Durand, Anne Holbrook, Alexis Matteau, Brian J Potter, Christel Renoux, Mireille Schnitzer, Jean-Éric Tarride, Denis Talbot. (Canada)

Poster Session A: Burden of Disease - Cancer

- 20 A Real-World Evidence Study of BRCA Mutations and Survival in HER2-Negative Breast Cancer [141]**
 Tapashi Dalvi, Kimmie McLaurin, Josefa Briceno, Beth Nordstrom, James Bennett, Robert Hettle, Brian Murphy, Jenna Collins, Susan McCutcheon. (United States)
- 21 Racial Disparities in Survival among Women who have HER2+ Metastatic Breast Cancer: A Systematic Review and Meta-analysis [142]**
 Emily Patry, Ami Vyas. (United States)
- 22 Metastatic Breast Cancer Sub-Type Classification Using Biomarker and Treatment Information in Electronic Health Records [143]**
 Christopher Craggs, Evelyn M Flahavan, Andy Surinach, Matthew Kent, Thibaut Sanglier. (Switzerland)
- 23 Derivation of Anthropometric-Based Equations to Predict Lean Body Mass Composition of Cancer Patients [144]**
 Macarius Donneyong, Autumn B Carey, Ashley S Felix, Jared Huling, James Odei, Christopher Coss. (United States)
- 24 Characterizing Active Multiple Myeloma Populations Identified by Published Claims-Based Algorithms [145]**
 Laura L Hester, Frank J DeFalco, Dina M Gifkins. (United States)
- 25 Association of In-Hospital Bleeding Events with Subsequent Infection and Mortality among Patients Undergoing Cancer-Directed Surgeries in English Inpatient Hospitals [146]**
 Stephen Johnston, Jing Yuan, Nadine Jamous, Sameer Mistry, Simran Jain, Gaurav Gangoli, Walter Danker, Eric Ammann, Kingsley Hampton. (United States)
- 26 The Incidence of Hematologic Cancers after Breast Cancer. A 35-year Population-Based Cohort Study in Denmark [147]**
 Cathrine Fonnesbech Hjorth, Dora Kormentine Farkas, Lidia Schapira, Suzanne Tamang, Mark Cullen, Henrik Toft Sørensen, Deirdre Cronin-Fenton. (Denmark)
- 27 Safety Event Rates in Large Claims-Based Cohorts of Advanced/Metastatic Cancer Patients after Initiation of Systemic Therapy and Immunotherapy [148]**
 Daniel C Beachler, Francois-Xavier Lamy, Leo J Russo, Jade Dinh, Devon H Taylor, Ruihua Yin, Aziza Jamal-Allial, Patrice Verpillat, Stephan Lanes. (United States)
- 28 Association of Continuity of Care & Mortality for Breast Cancer Patients with Comorbidities [149]**
 Ning Cheng, Jingjing Qian, Joel Farley, Peng Zeng, Chiahung Chou, Richard Hansen. (United States)
- 29 The Association Between Partner Bereavement and First Diagnosis and Mortality of Melanoma: Population-Based Cohort Study [150]**
 Angel YS Wong, Lara Dearing, Harriet J Forbes, Amy Mulick, Kathryn Mansfield, Richard J Silverwood, Henrik T Sørensen, Liam Smeeth, Sigrún AJ Schmidt, Sinéad M Langan. (United Kingdom)
- 30 Incidence and Trends of Melanoma Skin Cancer in The United States, 1999-2016 [151]**
 Phuong Le, Chi Le, Chi Truong, Hoa Le. (United States)
- 31 Characteristics of Patients with Small Cell Lung Cancer in The Real-World Setting: A Systematic Review [152]**
 Asieh Golozar, Mareva Faure, Aurore Bergamasco, Kevin Chen, Teigna Arredondo-Bisonó, Yola Moride. (United States)
- 32 Incidence Estimates and Trends of Non-Melanoma Skin Cancer in The United States, 1999-2016 [153]**
 Chi Le, Phuong Le, Chi Truong, Hoa Le. (United States)
- 33 Real World Treatment Patterns, Adverse Events and Healthcare Resource Utilization and Costs Among Chronic Lymphocytic Leukemia (CLL) Patients in The US [154]**
 Shaum Kabadi, Temitope O Olufade, Lisa Le, Stacey Dacosta Byfield. (United States)
- 34 Risk of Primary Urological and Genital Cancers Following Incident Breast Cancer: A Danish Population-Based Cohort Study [155]**
 Jens Sundbøll, Dóra Farkas, Lidia Schapira, Suzanne Tamang, Mette Nørgaard, Mark Cullen, Deirdre Cronin-Fenton, Henrik T Sørensen. (Denmark)
- 35 Hysterectomy Utilization among Newly Diagnosed Endometrial Cancer Patients by Body Mass Index Category: A Real-World Analysis Using a Claims and Electronic Health Record Database [156]**
 Ellen Thiel, Debra Irwin. (United States)
- 36 Risk of Cancer in Patients with Psoriasis/Psoriatic Arthritis: A Population-Based Study in The Province of British Columbia [157]**
 J. Antonio Avina-Zubieta, Alyssa Dominique, Teresa A Simon, Hamid Tavakoli. (United States)
- 37 Epidemiology of Cholangiocarcinoma in Adults with Type 2 Diabetes in The United Kingdom Clinical Practice Research Datalink [158]**
 Ayad K Ali, Syed W Hassan. (United States)

- 38 Risk of Primary Gastrointestinal Cancers Following Incident Breast Cancer: A Danish Population-Based Cohort Study [159]**
Kasper Adelborg, Dóra K Farkas, Lidia Schapira, Suzanne Tamang, Deirdre C Fenton, Mark Cullen, Henrik T Sørensen. (Denmark)
- 39 International Comparison of Cancer Burden and Medical Outcomes between 11 Asian Countries and 23 Cancer Types (2018): A Linear Multilevel Model Analysis [160]**
Joanne Lo. (Taiwan)
- 40 Use of Claims and Electronic Medical Data to Describe Care Pathway for Newly-Diagnosed Colorectal Cancer Patients [161]**
Juliane Mills, Shady Gendy, Deepa Kumar, Bettina K Rillmann, Margaret S Richards, Jane Quigley. (United States)
- 41 Lymphovascular Invasion: Strong Factor in AA [162]**
Yesenia Rodríguez. (Peru)
- 42 Survival and Prognostic Factors in Patients with Small Cell Lung Cancer: A Systematic Review of Observational Studies [163]**
Mareva Faure, Asieh Golozar, Aurore Bergamasco, Kevin Chen, Teigna Arredondo-Bisonó, Yola Moride. (Canada)
- 43 Trends and Factors Associated with Asthma among U.S. Prostate Cancer Patients in 2007-2014 [164]**
Nan Huo, Jingjing Qian, Kimberly B Garza, Chiahung Chou, Zeng Peng. (United States)
- 44 Age and Race as Determinants for Surgical Treatment of Fibroids: A Retrospective Analysis of a Large United States Electronic Health Record Database [165]**
Georgios Varsos, Fred W Peyerl, Kunal Lodaya, Meng Shen, Laxmi Gannu, Apeksha Shenoy, David K Hayashida, Fabian D'Souza. (United States)

Poster Session A: Burden of Disease - Cardiovascular

- 45 Dynamic Assessment of Stroke Risk among Patients with Atrial Fibrillation in Japan - Evidence from J M D C Inc Database [166]**
Rahul Jain, Lu Zhang, Catherine Richards, Joseph Menzin. (United States)
- 46 Incident Unrecognized Myocardial Infarction among People with Dysglycemia: An Opportunity for Prevention [167]**
Janice C Zgibor, Markku Malmi. (United States)
- 47 Sex Disparities in Cardiovascular Risk and Risk Factor Management in Type 2 Diabetes: A Population-Based Study of The Clinical Practice Research Datalink [168]**
Alison K Wright, Evangelos Kontopantelis, Richard Emsley, Iain Buchan, Mamas A Mamas, Naveed Sattar, Darren M Ashcroft, Martin K Rutter. (United Kingdom)
- 48 Trend in 3-Day, 7-Day and 30-Day Heart Failure Readmission Rates from 2010 to 2015 in The Nationwide Readmissions Database [169]**
Phuong N Pham, Joshua Brown. (United States)
- 49 Incidence of Post-Operative Acute Myocardial Infarction among Adults Undergoing Elective Spinal Fusion, Total Hip and Total Knee Arthroplasty [170]**
Kui Huang, Patrick Arena, Xiaofeng Zhou, Qing Liu, Richard Gong, Sundaresan Murugesan, Jingping Mo. (United States)
- 50 Evaluating The Charlson and Elixhauser Comorbidity Index to Predict Acute Cardiovascular Disease Survival for 1 to 5 Years in Korean National Health Insurance Cohort [171]**
Hee-Jin Kim, Mi-sook Kim, Young-Jin Ko, Sang-shin Park, Nam-kyong Choi. (Korea, Republic of)

- 51 Identification of Incident Atrial Fibrillation Patients Using Health Claims Database [172]**
Rahul Khanna, Robert Nicholas D'angelo, Laura Goldstein, Iftekhar Kalsekar, Stephen Marcello, Robert Yeh, Peter J Zimetbaum. (United States)
- 52 Incidence and Prevalence of Systolic and Diastolic Heart Failure among Obese Patients with Type 2 Diabetes in The United States [173]**
Ayad K Ali, Yu-Jing Huang. (United States)
- 53 Risk Factors for Post-Ablation Early and Late Symptomatic Recurrence of Atrial Fibrillation: Findings from a Real World Database Study [174]**
Shumin Zhang, Iftekhar Kalsekar, Ge Lin, Sashi Yadalam, Lee Ming Boo, Nader Ghaly, Rahul Khanna. (United States)
- 54 Epidemiology of Non Fatal Major Adverse Cardiovascular Events in Children with Diabetes [175]**
Ayad K Ali, Mark C. Lakshmanan. (United States)
- 55 Embolic Events and Unmet Therapeutic Need for Coronary and Peripheral Arterial Disease [176]**
Elisabeth Smits, Edith M Heintjes, Fernie J Penning, M van den Bosch, Ron M Herings. (Netherlands)

Poster Session A: Burden of Disease - Endocrine and Metabolism

- 56 Glycemic Control from 2013 to 2016 among US Adults with Type 2 Diabetes: A National Estimate Stratified on Age, eGFR Category and Comorbidities [177]**
Yuzhi Xi, Tongtong Wang, Carol Koro. (United States)

- 57 Variation in Polycystic Ovary Syndrome Patient Characteristics by Body Mass Index: A Real-World Analysis Using a Claims and Electronic Health Record Linked Database [178]**
Ellen R Thiel, Debra E Irwin. (United States)
- 58 A Comparison of The Burden And Characteristics of Incident Type 2 Diabetes Mellitus Cases in HIV and Non-HIV Cohorts within a US Claims Database [179]**
Harriet Dickinson, Myriam Drysdale, Cassidy Henegar, Marianne Cunnington, Leigh Ragone, Vani Vannappagari. (United Kingdom)
- 59 Potassium Trajectories and Predictors for Repeated Hyperkalemia in High-Risk Patients: A Population-Based Cohort Study [180]**
Sia Kromann Nicolaisen, Kasper Adelborg, Pål Hasvold, Eirini Palaka, Lars Pedersen, Reimar Wernich Thomsen. (Denmark)
- 60 Prevalence and Management of Dyslipidaemias in Adult Renal Transplant Recipients Attending Nephrology Clinic at a Tertiary Hospital in Kenya [181]**
Esbon W Njau, Sylvia A Opanga, Peter N Karimi. (Kenya)
- 61 Temporal Trajectories of Complications of Type 2 Diabetes Mellitus [182]**
Eugene Jeong, Namgi Park, Chan Min Park, Dukyong Yoon. (Korea, Republic of)
- 62 Incidence and Prevalence of Gastrointestinal Stenosis and Obstruction in Patients with Diabetes in The United States [183]**
Ayad K Ali, Brian J DeGuire. (United States)
- 63 A Snapshot of Characteristics Recorded in Electronic Medical Records of Women with Polycystic Ovary Syndrome in Trinetx within Two Years of Diagnosis [184]**
Jayashri Desai, Brian Buysse, Jessica Albano. (United States)
- 64 Comparison of Health Outcomes in Diabetic and Non Diabetic Patients Undergoing Maintenance Haemodialysis [185]**
Savitha R Sanathan, Libina Thomas, Manjunath S Shetty, Kiran K K. (India)
- 65 Identification of Medical Complications and Real-Life Care of Familial and Multifactorial Chylomicronaemia Syndromes: The Esthym Study [186]**
Manon Belhassen, Eric Van Ganse, Marine Ginoux, Maeva Nolin, Hanane Bada, Eric Bruckert, Michel Krempf, Vinciane Rebours, René Valéro, Philippe Moulin. (France)
- 66 Thyroid Disease: A Retrospective Analysis of a Large United States Electronic Health Record Database [187]**
Georgios Varsos, Fred W Peyerl, Xavier Marinaro, Halit Yapici, Matharishwan Naganbabu, Laxmi Gannu, David K Hayashida, Fabian D'Souza. (United States)
- 67 Prevalence of Chronic Kidney Diseases in Patients with Diabetes Mellitus in The Middle East: A Systematic Review and Meta-Analysis [188]**
Abdallah Y Naser, Hassan Alwafi. (Jordan)
- Poster Session A: Burden of Disease - Gastrointestinal and Liver**
- 68 Incidence and Time Course of Surgical Complications by Cancer Stage and Site Among Medicare Patients Undergoing Elective Colorectal Resection for Cancer: An Analysis of The Seer-Medicare Database [189]**
Stephen Johnston, Eric Ammann, Akhil Nayak, Deborah Nagle, Anuprita Patkar, Mary Charlton. (United States)
- 69 Relative Hazard of Chronic Kidney Disease among Patients with Inflammatory Bowel Disease Varies by Age [190]**
Ravy K Vajravelu, Lawrence Copelovitch, Mark T Osterman, Ronac Mamtani, Frank I Scott, James D Lewis, Michelle R. Denburg. (United States)
- 70 Risk and Prognosis of Primary Liver, Gallbladder, Bile Duct, and Pancreatic Cancer after a Negative CT Scan: A Danish Population-Based Nationwide Cohort Study [191]**
Frederikke S Troelsen, Rune Erichsen, Anne Ording, Dóra K Farkas, Deirdre C Fenton, Henrik T. Sørensen. (Denmark)
- 71 Progression from Metabolic Syndrome to Non-Alcoholic Fatty Liver Disease: Analyses in an E.M.R-Claims Database [192]**
Brenna L Brady, Debra E Irwin. (United States)
- 72 Epidemiology and Characteristics of Patients with Hepatocellular Carcinoma and Care in The United States [193]**
Huifen Wang, Ping Sun, Binbing Yu, Iksha Herr, Yunes Doleh. (United States)
- 73 Salt-II: Study of Acute Liver Transplantation in France [194]**
Severine Lignot-Maleyran, Sinem-Ezgi Gulmez, Sophie Micon, Regis Lassalle, Jeremy Jove, Patrick Blin, Cécile Droz-Perroteau, Nicholas Moore. (France)

Poster Session A: Burden of Disease - Nervous System

- 74 Blood Lipids and Risk of Dementia in a Cohort of 1.8 Million People Followed Over Two Decades [195]**
Nawab Qizilbash, Masao Iwagami, John Gregson, Stuart Pocock. (Spain)
- 75 Suicidal Behaviors in Patients Diagnosed with Multiple Sclerosis (MS): A Study in The UK Clinical Practice Research Datalink (CPRD) GOLD [196]**
Rebecca Persson, Sally Lee, Neil Minton, Steve Niemcryk, Anders Lindholm, Susan Jick. (United States)
- 76 Incidence of Venous Thromboembolic Events among Amyotrophic Lateral Sclerosis Patients in a United States Health Insurance Claims Database [197]**
Varant Kupelian, Emma Viscidi, Susan Hall, Li Li, Susan Eaton, Anne Dilley, Nicolas Currier, Toby Ferguson, Laura Fanning. (United States)
- 77 Risk Factors for Suicide and Suicide Attempts among Patients with Treatment Resistant Depression: A Population Based Nested Case-Control Study [198]**
Philip Brenner, Therese M-L Andersson, Antti Tanskanen, Allitia DiBernardo, Gang Li, Lena Brandt, Johan Reutfors. (Sweden)
- 78 Early Signs of Bipolar Disorder in a UK Primary Care Patient Cohort [199]**
Catharine Morgan, Darren M Ashcroft, Roger T Webb, Carolyn A Chew-Graham, Anya Francis, Alison R Yung. (United Kingdom)
- 79 Parkinson Disease Psychosis Prevalence, Associated Comorbidities, and Mortality in The Medicare Population [200]**
Daniel Weintraub, Allison W. Willis, Pilar Torres, Keith Liu, Andrew Shim, Doral Fredericks, George Demos. (United States)
- 80 The Incidence of Stroke among Patients Undergoing Elective Open Posterior Lumbar Fusion Procedures with Multilevel Instrumentation: A Retrospective Cohort Study [201]**
Patrick Arena, Jingping Mo, Charu Sabharwal, Elizabeth Begier, Alejandra Gurtman, Xiaofeng Zhou, Qing Liu, Rongjun Shen, Charles Wentworth, Kui Huang. (United States)
- 81 Incidence of Depression, Anxiety and Self-Directed Violence in Women with Uterine Fibroids [202]**
Stephanie E Chiuvé, Carrie Huisingh, Whitney S Krueger, Deepa Chand, Ryan D Kilpatrick, Lauren A Wise. (United States)
- 82 A Landmark Approach to Estimate the Incidence of Malignancies in Patients Treated for Multiple Sclerosis [203]**
Mette Nørgaard, Emmanuelle Boutmy, Katalin Veres, Caroline Foch, Melinda Magyari, Meritxell Sabidó. (Germany)
- 83 Description of Treatment Resistant Depression in France, from The French Nationwide Claims Database [204]**
Pauline Bosco-Lévy, Angela Grelaud, Patrick Blin, Bernard Astruc, Bruno Falissard, Pierre-Michel Llorca, Dominique Schaetz, Marie-Agnès Bernard, Régis Lassalle, Nicholas Moore, Cécile Droz-Perroteau. (France)
- 84 Revisiting Multiple Sclerosis Prevalence in The 21st Century: Exploration Based on a Large Representative Real-World Cohort in The United States [205]**
Allison Bryant, Michael Behling, Shannon Cerf, Richard Gliklich. (United States)
- 85 Odds of Discharge to Substance Abuse Treatment or Psychiatric Care after Hospitalization for Alcohol or Drug Poisonings, Maryland 2016 [206]**
Aida Kuzucan, Sean Fleming, Linda Simoni-Wastila. (United States)
- 86 Visit Adherence and Visual Acuity in Wet Macular Degeneration [207]**
Brian L VanderBeek, Meera S Ramakrishnan, Yinxi YU. (United States)
- 87 Do Parents' Mental Disorders Affect Child Behaviour via Home Environments, and/or Parents' Education? A Mediation Analysis [208]**
Md Jamal Uddin, Claus Thorn Ekstrøm, Merete Nordentoft. (Bangladesh)
- 88 Epidemiology of Radiation Retinopathy in The United States [209]**
Wenzhen Ge, Lei Chen, Kimberly Reed, Steve Gao. (United States)
- 89 Eye Color and Risk of Ocular Melanoma in Patients with Glaucoma - A Swedish Register Study Combining Data from The Swedish Police Authority's Register on Passport Applications and National Health Registers [210]**
David Hägg, Ingegård Anveden Berglind, Helle Kieler, Marie Linder, Ingvild Odsbu. (Sweden)
- 90 Incidence of Depression, Anxiety and Self-Directed Harm in Women with Endometriosis [211]**
Carrie Huisingh, Stacey A Missmer, Natalia Petruski-Ivleva, Whitney S Krueger, Ryan D Kilpatrick, Deepa Chand, Stephanie E Chiuvé. (United States)

Poster Session A | Monday, August 26 • 8:00am - 6:00pm

- 91 Epidemiology of Acute Medical Events in a Cohort with a Rare Neurodegenerative Disease, Progressive Supranuclear Palsy, after Diagnosis [212]**
Denise M Oleske, Joan Holman, Jorge Zamudio, Robert Diegido, Günter U Höglinger. (United States)
- 92 Predictors of In-Hospital Psychiatric Care among Alcohol- And Drug- Related Hospitalizations in Maryland, 2016 [213]**
Sean Fleming, Aida Kuzucan, Linda Simoni-Wastila. (United States)
- 93 Identifying Psychosis in Patients with Dementia: Not a Hallucination or Delusion, the Challenge Really Exists [214]**
Joan Forn, J Bradley Layton, Mary E Ritchey. (Spain)
- 94 Sociodemographic and Clinical Risk Factors of Treatment-Resistant Depression: A Danish Populations-Based Study [215]**
Frederikke H Gronemann, Martin B Jorgensen, Merete Nordentoft, Per K Andersen, Merete Osler. (Denmark)
- 95 Confounding Variable Capture in Large Healthcare Administrative Claims Databases: A Trend Analysis in The Sentinel System [216]**
Wei Liu, Austin Cosgrove, Sarah K Dutcher, Justin Bohn. (United States)
- 96 The Comparison of Medical Records and Claims for Oral Anti Cancer Agents [217]**
Manvi Sharma, Michael L Johnson, Sharon H Giordano, Holly M Holmes. (United States)
- 97 UK Electronic Health Records (EHR) Databases: Expanding Primary Care Coverage with Clinical Practice Research Datalink (CPRD) Aurum [218]**
Achim Wolf, Daniel Dedman, Jennifer Campbell, Helen Booth, Darren Lunn, Jennifer Chapman, Puja Myles. (United Kingdom)
- 98 Leveraging Heterogeneity of European Healthcare Data Sources to Estimate Validity of Case-Finding Algorithms in Multi-Database Studies where a True Gold Standard is Lacking: Strategy from The Emif Project [219]**
Giuseppe Roberto, Maria Garcia-Gil, Talita Duarte-Salles, Paul Avillach, Elisabeth Smits, Sulev Reisberg, Alessandro Pasqua, Lars Pedersen, Lara Tramontan, Miguel A Mayer, Ron Herings, Miriam Sturkenboom, Peter Rijnbeek, Rosa Gini. (Italy)
- 99 Use of Claims Profile Review to Guide Retrieval of Medical Records in an Observational Cohort Study [220]**
Suvapun Bunniran, Libby Horter, Yihua Xu, Claudia Uribe, Brandon T Suehs. (United States)
- 100 The Potential of German Claims Data to Characterize Real-World Treatment Patterns in Cancer Patients - The Example of Crizotinib [221]**
Sarina Schwarz, Katja Anita Oppelt, Ulrike Haug. (Germany)
- 101 Data Sources for Drug Utilization Research in Latin American (LATAM) Countries [222]**
Luciane Cruz Lopes, Maribel Salas, Claudia G Osorio-de-Castro, Angela Acosta, Maruja Crisante, André O Baldoni, Anahi Dreser, Lucila I Castro-Pastrana, Juan C Sánchez-Salgado, Yesenia R Tanta, Edward Mezones-Holguin, Edgard N Delgado, Gustavo H Marin, Martin Cañas, Monica Tarapués, Carlos Durán, Ismael Olmos, Marta M Fonteles, Silvio Barberato-Filho, Daniel M Mota, Diana L Galicia, Tais F Galvao, Marcus T Silva, Robert V Stichele, Juan Roldan, Bjorn Wettermark, Cristiane C Bergamaschi, María B Mena, Natalia Medero, Elisangela C Lima, Livia L Marengo, Ocelli I Lira, Sanni Ali, Yared Santa-Ana-Tellez, Raquel H Comoglio, Vera L Luiza, Izabela Fulone, Lauren G Mazzei, María Belén Mena, Monique Elsevier. (Brazil)
Recipient of the John Snow Award
- 102 Enrollment Patterns and Health in Claims Data for The Commercially Insured US Population [223]**
Dana Y Teltsch, Elizabeth Cheever, Dawn G Albright, Monica Gierada, Richard Wyss. (United States)
- 103 Characterizing Disease Registries Utilized for Drug Safety Evaluation [224]**
Jeeyun Kim, Rashedul Hasan, Alfred Sorbello, Jacqueline M Major. (United States)
- 104 Non-Small Cell Lung Cancer (ALK+/EGFR+) Data Sources in Europe and Canada: A Landscape Study [225]**
Aurore Bergamasco, Thalia Nikoglou, Michael Lees, Yola Moride. (France)
- 105 Assessment of the Use of Synthetic Data to Support the Generation of Real-world Evidence in Cancer in England [226]**
Ali Abbasi, Ruben Hermans, Fiona Grimson, Joseph Kim, Benjamin Bray, Deborah Layton, Adam Reich. (United Kingdom)
- 106 Health Indicator Recording in UK Primary Care Electronic Health Records: Key Implications for Handling Missing Data [227]**
Irene Petersen, Catherine A Welch, Irwin Nazareth, Kate Walters, Louise Marston, Richard W Morris, James R Carpenter, Tim P Morris, Tra My Pham. (United Kingdom)
- 107 Quantifying the Completeness of Hospital Episode Information Recorded in Primary Care in England Using THIN-HES [228]**
Rosalind Polya, Suvi Hokkanen, Deborah Layton. (United Kingdom)

Poster Session A: Databases

108 Development of an Integrated Research Network to Facilitate Non-interventional Research [229]

Stephanie Reisinger, Ariel Berger, Donny Chen, Steve Chick, Lee Kallenbach, Brad Vernon, Krista Payne. (United States)

109 Rare Disease Epidemiology: A Danish Population-Based Program [230]

Jon Fryzek, Lauren C Bylsma, Henrik T. Sørensen. (United States)

110 The Zuellig Pharma Korea Consortium Database - An On-Site Drug Wholesales Database for Pharmacoepidemiological Studies Using Real-World Data [231]

Han Eol Jeong, In-Sun Oh, Junqing Li, Erwan Vilfeu, Sang A Ryyu, Ju-Young Shin. (Korea, Republic of)

111 Real World Evidence Multi-Database Research in Europe: The EU-ADR Alliance [232]

Natasha Yefimenko. (Spain)

Poster Session A: Data Linkage

112 Does Adding Claims to EMR Data Improve Comorbidity Burden Capture: Concerto Health AI Definitive Oncology Dataset and Symphony Linkage Study [233]

William Wong, Navdeep Pal, Ning Wu, Danny Sheinson, Li Chen, Laura Chu. (United States)

113 Data Enhancement Through Linkage: Health Plan Linkage with Pcornet Clinical Data Research Network [234]

Kevin Haynes, Pi Lin, Juliane Reynolds, Qian Shi, L. Charles Bailey, Hanieh Razzaghi, Jason Block. (United States)

114 Data Enhancement Through Linkage: Health Plan Linkage with Pcornet Patient Powered Research Networks [235]

Abiy Agiro, Xiaoxue Chen, Elizabeth B Clark, Cristina Burroughs, W. Benjamin Nowell, Sara Loud, Kalen Young, Antoine G Sreih, Robert McBurney, Rebecca Sutphen, Jeffrey R Curtis, Peter A Merkel, Kevin Haynes. (United States)

115 CIDACS-RL: A Novel Search Engine-Based Record Linkage System for Huge Datasets with High Accuracy and Scalability [236]

George C Barbosa, Mohamed S Ali, Bruno Araujo, Maria Y Ichihara, Sandra Reis, Samila Sena, Julia M Pescarini, Rosemeire L Fiaccone, Leila D Amorim, Robespierre Pita, Marcos E Barreto, Liam Smeeth, Mauricio L Barreto. (Brazil)

116 Use of ICD Codes and Physician Notes from Electronic Medical Records to Identify Cases of a Rare Disease [237]

Lisa Vinikoor-Imler, Nasha Wang, Henry Krzywy, Anne Dilley. (United States)

117 Enhancing Seer Data Through Public Health Reporting of Pharmacy Claims for Precision Cancer Surveillance [238]

Donna Rivera, Kathleen A Cronin, Kevin C Ward, Jennifer Stevens, Nicola Schussler, Linda Coyle, David Angelaszek, Lynne Penberthy. (United States)

118 The Comorbid Burden of Gout on Health Outcomes: Results from Linking Electronic Health Records to Patient-Reported Outcomes [239]

Stephanie Huynh, Dena Jaffe, Carey Strader, Tom Haskell. (United States)

119 Linking Genomic and Longitudinal Real-World Data: Applications to Drug Development and Pharmacoepidemiology Research [240]

Ali Abbasi, Fiona Grimson, Joanne M Hackett, Sudhir Venkatesan, Valeria Lascano, Yoshiko T Cook, Benjamin Bray, Deborah Layton, Joseph Kim. (United Kingdom)

120 Burden and Concordance of Information on CYP2D6, CYP2C19, and CYP2C9 Related Substrate and Inhibitor Co-Prescriptions from The Lifelines Cohort: The Pharmlines Initiative [241]

Muh. Akbar Bahar, Jens H J Bos, Sander D Borgsteede, Aafje Dotinga, Rolinde A Alingh, Bob Wilffert, Eelko Hak. (Netherlands)

121 Do Oral Antineoplastic Treatment Data Differ between EMR & Claims: Concerto Health AI Definitive Oncology Dataset & Symphony Linkage Study [242]

Laura Chu, Nayan Chaudhary, Li Chen, William Wong. (United States)

122 Combining A Prospective Registry with a Retrospective Medical Chart Review [243]

Sandrine Leroy, Monika Brand, Daniel Rosenberg, Graham Wetherill, Adele Morganti. (Switzerland)

123 Abstract withdrawn [244]

124 Building an Integrated Real-Time Data Ecosystem to Enhance Care Delivery for Asthma Patients in Singapore [245]

Shao Wei Sean Lam, Sumitra Shantakumar, Dave Webb, Cheng Hian Ang, Hao Sen Andrew Fang, Yaoxian Alwin Zhang, Sudha Harikrishnan, See-Hwee Yeo, Pei Yee Tiew, Ngaiap Chuan Tan, Eng Hock Marcus Ong, Julian Thumboo, Des Burke, Chian Min Loo, Siyue Mariko Koh, David Bruce Matchar. (Singapore)

Poster Session A | Monday, August 26 • 8:00am - 6:00pm

125 Initiation of an Innovative Study Combining Digital Patient Generated Data with Health Records to Evolve Understanding of Back Pain [246]

Alison Bourke, Shaun O'Hanlon, Toby Helliwell, Matthew Cooper, Mick Mullane, Stephanie Meleck, Josh Hiller, Jaskiran Dhanjal. (United Kingdom)

Poster Session A: Drug Effectiveness - Cancer
126 Does NA-NSAID Use Reduce the Mortality among Endometrial Cancer Patient? [247]

Cecilie D Sperling, Freija Verdoodt, Gitte L Aalborg, Christian Dehlendorff, Søren Friis, Susanne K Kjaer. (Denmark)

127 Inhibition of the Renin-Angiotensin System and Survival in Patients with Pancreatic Cancer [248]

Jakob Kirkegård, Deirdre Cronin-Fenton. (Denmark)

128 Real-World Assessment of Clinical Outcomes among First-Line (1L) Sunitinib Patients with Metastatic Renal Cell Carcinoma (MRCC) by The International MRCC Database Consortium (IMDC) Risk Group [249]

Lynn Huynh, Marie-France Savard, J Connor Wells, Jeffrey Graham, John Steinharter, Bradley McGregor, Frede Donskov, Georg A Bjarnason, Ulka Vaishampayan, Aaron Hansen, Marco Iafolla, Giovanni Zanotti, Catherine Nguyen, Rose Chang, Mei S Duh, Daniel Y Heng. (United States)

129 Antihistamines and Survival from Ovarian Cancer: A Population-Based Cohort Study and In Vitro Cell Viability Study [250]

Christian Dehlendorff, Freija Verdoodt, Marja Jäätelä, Robert Strauss, Anton Pottegård, Jesper Hallas, Susanne K Kjaer, Søren Friis. (Denmark)

130 Response and Adherence to Nilotinib in Daily Practice (RAND-Study): An In-Depth Observational Study of Patients with Chronic Myeloid Leukemia Treated with Nilotinib [251]

Christel C Boons, Lonneke Timmers, Jeroen J Janssen, Peter E Westerweel, Eleonora L Swart, Harry Hendrikse, Jacqueline Hugtenburg. (Netherlands)

131 Comparative Efficacy and Safety of Immune Checkpoint Inhibitors for Untreated and Treated Advanced Non-Small Cell Lung Cancer: Meta-Analysis and Meta-Regression Analysis [252]

Jason C. Hsu, Yen-Tzu Chen, Joanne Lo, Szu-Chun Yang, Yang-Cheng Lee, Peng-Chan Lin. (Taiwan)

132 Lifestyle Factors and Systemic Breast Cancer Treatment- A Cross-Sectional UK Study [253]

Jessie O Oyinlola, Eleanor Yelland, Puja Myles, Rachael Williams. (United Kingdom)

133 Can we Modulate Response to Preoperative Therapy in Rectal Cancer Patients by ACE Inhibitors? [254]

Anouk J M Rombouts, Niek Hugen, Rob A.H. Verhoeven, Josephina G. Kuiper, Philip M P Poortmans, Hans J H W de Wilt, Iris D Nagtegaal. (Netherlands)

134 Effectiveness of Bevacizumabin Metastatic Colorectal Cancer: The Observational Cohort Study in Indonesia [255]

Erna Kristin, Dwi Endarti, Woro Rukmi Pratiwi, Dwi Aris Nugrahaningsih, Alfi Yasmina, Ratih Puspita Febrinasari. (Indonesia)

135 Performance of Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Men: A Head to Head Comparison Based on A 2014-2017 French Population Study [256]

Lucie-Marie Scailteux, Boris Campillo-Gimenez, Sandrine Kerbrat, Fabien Despas, Sébastien Vincendeau, Frédéric BALUSSON, André Happe, Emmanuel Nowak, Emmanuel Oger. (France)

Poster Session A: Drug Effectiveness - Infections
136 Comparative Effectiveness of Efavirenz and Protease Inhibitors in Patients with Human Immunodeficiency Virus - A Meta-Analysis [257]

Sabina O Nduaguba, Chinyere Okoh, Jamie C Barner, Kentya C Ford, James P Wilson, Kenneth Lawson, James N Barnes, Tasha N Beretvas. (United States)

137 Abstract Withdrawn [258]
138 Continuous Cefazolin Infusion Versus Cefazolin Plus Probenecid for The Ambulatory Treatment of Uncomplicated Cellulitis: A Retrospective Cohort Study [259]

Daniel Landry, Sherif Eltonsy, Luc P. Jalbert, Gabriel Girouard, Jonathan Couture, Mathieu Belanger. (Canada)

139 Factors Associated with Viral Suppression among HIV-Positive Kenyan Gay and Bisexual Men who have Sex with Men [260]

Colin P Kunzweiler. (United States)

Poster Session A: Drug Effectiveness - Nervous System

- 140 Predicting Relapse Episodes in Patients with Multiple Sclerosis Treated with Disease Modifying Therapies in a Large Representative Real-World Cohort in The United States [261]**
Michael Behling, Allison Bryant, Tom Brecht, Shannon Cerf, Richard Gliklich, Zhaohui Su. (United States)
- 141 Edaravone Utilization and Outcomes within a Nationally Integrated Health System [262]**
Michelle Vu, Kathryn Tortorice, Jeanne Tuttle, Xiang-Ming Wei, Diane Dong, Jennifer Zacher, Peter Glassman, Francesca Cunningham. (United States)
- 142 Using Artificial Intelligence and Real-World Data to Identify Drugs to Repurpose for Parkinson's Disease [263]**
Sharon Hensley Alford, Naomi P Visanji, Alix M Lacoste, Piyush Madan, Italo Buleje, Yanyan Han, Connie Marras. (United States)
- 143 Efficacy and Safety of Interventions Used for Management of Diabetic Neuropathy Pain: A Frequentist Network Meta-Analysis [264]**
Dipika Bansal, Mir Mahmood Asrar. (India)
- 144 A Systematic Review of Ketamine for Treatment-Resistant Depression [265]**
Reshmee Patel, Feng-Hua Loh. (United States)
- 145 Investigating the Potential Role of Bdnf and Prl Genotypes on Antidepressant Response in Depression Patients: A Prospective Inception Cohort Study [266]**
Taichi Ochi, Natalya M. Vyalova, Innokentiy S Losenkov, Lyudmila A Levchuk, Anton J Loonen, Fokko J Bosker, German G Simutkin, Nikolay A Bokhan, Bob Wilffert, Svetlana A Ivanova. (Netherlands)

Poster Session A: Drug Utilization - Cancer

- 146 Identification of Weekly or Every-Other-Week Administration Schedules for Cetuximab in the Treatment of Metastatic Colorectal Cancer in US Claims Data [267]**
Michael Batech, Emmanuelle Boutmy, Francois-Xavier Lamy, Philippe Ronga, Shaista Salim, Patrice Verpillat. (Germany)
- 147 Treatment Patterns and Outcomes of 159 Ibrutinib-Treated MCL Patients in the US: A Retrospective Electronic Medical Record Database and Chart Review Study [268]**
Jeff Sharman, Shaum Kabadi, Jamyia Clark, E Susan Amirian, David J Andorsky. (United States)
- 148 Factors Associated with Receipt and Overall Survival of Concurrent Chemoradiotherapy Versus Single Modality Therapy in Unresectable Stage III NSCLC [269]**
Maral DerSarkissian, Kellie Ryan, Mei Sheng Duh, Ambika Satija, Priyanka J Bobbili, Jorge E Gomez. (United States)
- 149 Comparison Of Real-World Treatment Patterns, Persistence, Healthcare Resource Utilization (HRU) and Costs between Octreotide and Lanreotide for the Treatment of Neuroendocrine Tumors (NET) [270]**
Lynn Huynh, Beilei Cai, Dominique Lejeune, Mu Cheng, Angie Lax, Mei S Duh, Wendy Cheng, Michelle K. Kim. (United States)
- 150 Predictors of Granulocyte Colony Stimulating Factor Administration among Metastatic Colorectal Cancer Patients [271]**
Chinelo C Orji, Carolyn M Brown, Russell J Hoverman, Kristin M Richards. (United States)
- 151 Contemporary Chemotherapy Treatment Patterns in Non-Small Cell Lung Cancer Patients: An Analysis of an Optum Claims Data [272]**
Dongmu Zhang, Jerzy E Tyczynski, Bruce A Bach. (United States)
- 152 Trends in the Promotion and Utilization of Programmed Death Receptor-1 Blocking Antibodies [273]**
Shelley Jazowski, Stacie Dusetzina. (United States)
- 153 Patterns and Predictors of First-Line Targeted Therapy Utilization among Older Adults Diagnosed with Metastatic Renal Cell Carcinoma [274]**
Blánaid Hicks, Danielle Chun, Sharon Peacock Hinton, Christine Hsu, Hung-Jui Tan, Jennifer Lund. (United Kingdom)
- 154 Demographics, Clinical Characteristics and Treatment Sequencing in Stage 3 Unresectable Non-Small Cell Lung Cancer Patients: A Cancerlinq Cohort [275]**
Alyssa B Klein, Iksha Herr, Sharon MacLachlan, Danielle Potter. (United States)
- 155 Chemotherapy Patterns, Survival and Healthcare Resource Utilization among Patients with Advanced Small Cell Lung Cancer in Indiana State [276]**
Jinghua He, Changxia Shao, Siu Hui, Zuoyi Zhang, Jarod Baker, Paul Dexter, Sumesh Kachroo, Fan Jin. (United States)
- 156 Use of Electronic Healthcare Data to Study the Real-World Utilization of Target Therapy and Immunotherapy for the Treatment of Lung Cancer: A Systematic Review [277]**
Andrea Spini, Giulia Hyeraci, Francesco Pellicano, Sandra Donnini, Silvano Giorgi, Claudia Bartolini, Rosa Gini, Marina Ziche, Giuseppe Roberto. (Italy)

Poster Session A | Monday, August 26 • 8:00am - 6:00pm

- 157 Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: A Structured Review of Epidemiology, Treatment Guidelines, and Real-World Treatment Practices [278]**
 Monika Raut, Rebekah Borse, Arun Balakumaran, Jitender Takyar, Manu Sehgal. (United States)
- 158 Association between Regular Use of Aspirin and Prevalence of Melanoma in Males: Findings from The 2015 US National Health Interview Survey [279]**
 Ching-Yuan Chang, Chung-Hsuen Wu. (United States)
- 159 Comparison of Availability and Accessibility of Immunology (IO) Drugs for Cancer Treatment among Japan, Korea, China And Taiwan [280]**
 Joanne Lo. (Taiwan)
- 160 Treatment Trends for Localized Prostate Cancer: A Comparison of Androgen Deprivation Therapy and Curative Treatments in The Linked Seer-Medicare Database, 2004-2013 [281]**
 Kate Gelperin, Steven T Bird, Armen Avagyan, Jiemin Liao, Yang-Min Max Ning, Elaine Chang, Daniel Suzman, Paul Kluetz, Hai Lyu, Yixin Jiao, Thomas MaCurdy, Jeffrey A. Kelman, David J Graham. (United States)
- 161 Potential Inappropriate Underdosing in Patients Initiating Non-Vitamin K Oral Anticoagulants: Findings from The French National Healthcare Database [282]**
 Géric Maura, Cécile Billionnet, Jérôme Drouin, Alain Weill, Anke Neumann, Antoine Pariente. (France)
- 162 Trends in Oral Anticoagulants Prescribing in Patients with Type 2 Diabetes Mellitus: A Population-Based Study in The United Kingdom [283]**
 Hassan Alwafi, Li Wei, Abdallah Naser, Pajaree Mongkhon, Gary Tse, Kenneth Man, J Simon Bell, Jenni Ilomaki, Gang Fang, Ian Wong. (United Kingdom)
- 163 Trends in Utilization and Predictors for Initiation of Non-Aspirin Non-Steroidal Anti-Inflammatory Drugs in Patients with Cardiovascular Contraindications [284]**
 Anton Pottegård, Morten Schmidt. (Denmark)
- 164 Oral Anticoagulant (OAC) Prescribing for Stroke Prevention in Older People (Aged 75+) with Atrial Fibrillation (AF) in the UK [285]**
 Anneka Mitchell, Margaret C Watson, Tomas Welsh, Julia Snowball, Anita McGrogan. (United Kingdom)
- 165 Sex Differences in Cardiometabolic Treatment among Patients with Type 2 Diabetes [286]**
 Petra Denig, Sieta T Vries, Eugène Puijtenbroek, Peter GM Mol. (Netherlands)
- 166 Beta-Blocker Choice and Exchangeability in Patients with Heart Failure and Chronic Obstructive Pulmonary Disease: An Italian Register-Based Cohort Study [287]**
 Maurizio Sessa, Annamaria Mascolo, Daniel Bech Rasmussen, Magnus Thorsten Jensen, Kristian Kragholm, Liberata Sportiello, Concetta Rafaniello, Michele Giuseppe Tari, Morten Andersen, Francesco Rossi, Annalisa Capuano. (Denmark)
- 167 Patterns of Use of P2y12 Inhibitors in Patients with Acute Coronary Syndrome in Routine Clinical Practice [288]**
 Zhong Yuan, Jill Hardin, Erica A Voss, Laura L. Hester, James Weaver, Kourtney Davis, Elliot S Barnathan. (United States)
- 168 Exposure to N-Nitrosodimethylamine and N-Nitrosodiethylamine-Contaminated Angiotensin-II Receptor Blockers Products in The United States [289]**
 Efe Eworuke, Emily Welch, Veronica Sansing-Foster, Marie Bradley, Judith Maro. (United States)
- 169 Pharmacological Treatment Patterns in Heart Failure: A Real World Cohort Study [290]**
 Pauline Bosco-Levy, Clélia Favary, Jérémy Jové, Régis Lassalle, Nicholas Moore, Cécile Droz-Perroteau. (France)
- 170 Non-Aspirin Non-Steroidal Anti-Inflammatory Drug Use in The Nordic Countries 2000-2016 from a Cardiovascular Risk Perspective: A Drug-Utilization Study [291]**
 Kasper Bruun Kristensen, Øystein Karlstad, Jaana E Martikainen, Anton Pottegård, Jonas W Wastesson, Helga Zoega, Morten Schmidt. (Denmark)
- 171 Trends in Prescription of Thiazide and Thiazide-Like Diuretics in The United Kingdom [292]**
 Tatiana V Macfarlane, Amy Rogers, Robert W Flynn, Steven V Morant, Isla S Mackenzie, Thomas M MacDonald. (United Kingdom)
- 172 Temporal Changes in The Prevalence of Cardiovascular Drugs Use in Persons with and without Alzheimer's Disease, A Retrospective Cohort Study [293]**
 Mai Vu, Marjaana Koponen, Heidi Taipale, Antti Tanskanen, Jari Tiihonen, Raimo Kettunen, Sirpa Hartikainen, Anna-Maija Tolppanen. (Finland)
- 173 Characteristics of NOAC Users Aged Less Than 65 Years in The Sentinel System [294]**
 Marie C Bradley, Emily C Welch, Efe Eworuke, Rongmei Zhang, Elande Baro, David J Graham, Mayura Shinde. (United States)

Poster Session A: Drug Utilization - Cardiovascular

- 174 Impact of Serious Infection on Continuation of Chronic Disease Medications [295]**
Kanya K Shah, Aisling R Caffrey, Vrishali Lopes. (United States)
- 175 Variation in Patient Characteristics in Atrial Fibrillation Treatment: A Real-World Assessment of Contact Force and Cryoballoon Technology [296]**
Scott J Pollak, Laura Goldstein, Mehmet Daskiran, Iftekhar Kalsekar, Rahul Khanna. (United States)
- 176 Real-World DOAC and VKA Use: The PHARMO-Anticoagulation Cohort [297]**
Elisabeth Smits, Jelle Evers, Fernie J Penning- van Beest, Ron Herings, Irene D Bezemer. (Netherlands)
- 177 Trends in Cardiovascular Drug Use and Cardiovascular Disease Mortality in Serbia [298]**
Ana D Tomas Petrović, Olga Horvat, Zdenko Tomić, Ana Sabo. (Serbia)
- 178 Prescribers' Compliance with Smpc Recommendations for Dabigatran, Rivaroxaban, and Apixaban - A European Comparative Drug Utilization Study [299]**
M Rottenkolber, S Schmiedl, L Ibanez, M Sabaté, E Ballarín, X Vidal, LM Leon-Munoz, C Huerta, E Martin Merino, D Montero, C Gasse, M Andersen, M Aakjær, ML De Bruin, R Gerlach, M Tauscher, PC Souverein, R van den Ham, O Klungel, H Gardarsdottir. (Netherlands)
- 179 Adherence to Prescription Guidelines and Achievement of Treatment Goals among Persons with Coronary Heart Disease - A Cross-Sectional Study [300]**
Elisabeth Pedersen, Beate H Garcia, Anne Elise Eggen, Kjell H Halvorsen, Henrik Schirmer, Marit Waaseth. (Norway)

- 180 Antihypertensive Drug Combinations to Optimize Blood Pressure Control in Black Patients [301]**
Onyinye Akunne, Aduragbenro D Adedapo, Kayode S Adedapo. (South Africa)
- 181 Sacubitril/Valsartn (Entresto) Utilisation and Prescribing Patterns in Northern Ireland: A Repeated, Cross-Sectional Study [302]**
Pamela Boyed, Amanj Kurdi. (United Kingdom)

Poster Session A: Medical Devices

- 182 Pain Relief and Function Restoration after Primary Total Knee Arthroplasty: An Evaluation Using Knee Injury and Osteoarthritis Outcome Score in Real World Data [303]**
Zhenna Huang, Jill Webster Ruppenkamp, Chantal E Holy. (United States)
- 183 Knee Injury and Osteoarthritis Outcome Score Availability Evaluation in Real World Data [304]**
Zhenna Huang, Jill Webster Ruppenkamp, Chantal E Holy. (United States)
- 184 Evaluation of Three Database-Derived Comorbidity Measures to Predict Infections, Extended Length of Stay and Readmissions after Total Knee Replacement [305]**
Abhishek S Chitnis, Zhenna Huang, Shreya Murthy, Chantal E Holy. (United States)
- 185 Association between Early Diagnosis of Post-Surgical Infection and Reoperation Following Total Knee Arthroplasty [306]**
Abhishek S Chitnis, Piyush Nandwani. (United States)

- 186 Early Diagnosis of Post-Surgical Infection and Reoperation Following Total Hip Arthroplasty [307]**
Abhishek S Chitnis, Piyush Nandwani, Chantal E Holy. (United States)
- 187 Similar Epidemiologic Trends on Arthroplasty-Related Adverse Outcomes Suggest Common Modifying Role of Sex/Race-Related Patient Factors in Various Arthroplasties [308]**
Yasameen Azarbaijani, Yelizaveta Torosyan. (United States)
- 188 Surgical Stapler Malfunctions: A Systematic Review of the Literature [309]**
Ilynn Bulatao, Brian Man, George Gibeily, Nilsa Loyo-Berrios, Dongyi (Tony) Du. (United States)
- 189 Safety and Effectiveness of Intrauterine Devices: Gynecological History and Sexual Behaviour of Study Participants from The European Active Surveillance Study on Lcs12 [310]**
Christine Hagemann, Anja Bauerfeind, Klaas Heinemann. (Germany)
- 190 Accuracy of Molecular Diagnostic Tests for Drug-Resistant Tuberculosis Detection in China: A Systematic Review [311]**
Yixin Sun, Le Gao, Hui Xia, Zhirong Yang, Yanlin Zhao, Shitong Huan, Siyan Zhan. (China)
- 191 Comparing Detection of Medical Device Recalls Using Quality Control and Disproportionality Analyses Methods of Spontaneous Complaint Reports [312]**
Gary Chung, Amer Ghanem, Paul Coplan. (United States)

Poster Session A: Methods - Validation Studies

- 192 Physician Adjudication of Angioedema in Patients with Heart Failure on Angiotensin-Converting Enzyme Inhibitor Therapy [313]**
Eric S Johnson, Micah L Thorp, Alan S Go, Mingsum S Lee, Albert YJ Shen, Ken J Park, Katarzyna Budzynska, Abraham Markin, Sue H Sung, Jamie H Thompson, Xiuhai Yang, Jaejin An, Kristi Reynolds, Douglas W Roblin, Andrea E Cassidy-Bushrow, Raymond Schlienger, Sigrid Behr, David H Smith. (United States)
- 193 Validity of Low Birth Weight and Small for Gestational Age in The Medicaid Analytic Extract Database [314]**
Xi Wang, Joshua Brown, Hong Xiao, Ellen M Zimmermann, Almut G Winterstein. (United States)
- 194 Validity of Diagnosis-Based Case Definitions for Chronic Kidney Disease in a Japanese Database [315]**
Tomomi Kimura, Robert Snijder. (Japan)
- 195 Development of Computable Phenotypes to Identify Heart Failure Patients with Preserved Ejection Fraction [316]**
Sarah S Cohen, Veronique L Roger, Susan A Weston, Ruoxiang Jiang, Naimisha Movva, Akeem Yusuf, Alanna M Chamberlain. (United States)
- 196 Validity of Claims-Based Algorithms to Identify Acute Kidney Injury, Acute Liver Injury, Severe Complications of Urinary Tract Infections, Breast Cancer, and Bladder Cancer among Patients with Type 2 Diabetes: A Pilot Study [317]**
Cindy Ke Zhou, Jade Dinh, Heather E Danysh, Catherine Johannes, Lia Gutierrez, Rita Schmid, Alejandro Arana, James A Kaye, Manel Pladevall-Vila, Xabier Garcia-Albeniz, Kelsey Gangemi, Ruihua Yin, Javier Cid Ruzafa, Alicia Gilsenan, Daniel C Beachler. (United States)
- 197 Standardizing EMR Lab Data for Improved Safety Surveillance [318]**
Irene Cosmatos, Jamie Reifsnnyder, Michael Bulgrien, Rich Murray. (United States)
- 198 Suitability of Administrative Claims Databases for Bariatric Surgery Research [319]**
Xiaojuan Li, Sengwee Toh. (United States)
- 199 Description of Bariatric Surgery Coding in The UK Clinical Practice Research Datalink and Hospital Episodes Statistics [320]**
Theresa Burkard, Marlene Rauch, Susan S Jick, Christoph R Meier. (Switzerland)
- 200 Development and Validation of a Predictive Model for Incident Heart Failure in Subjects Under 65 Years Old with Newly Diagnosed Atrial Fibrillation [321]**
Joel Swerdel, Patrick Ryan, Elizabeth Marshall, George Rhoads, William Kostis. (United States)
- 201 Validity of Chemotherapy Procedure Codes in The Danish National Patient Registry: A Validation Study [322]**
Martin Oskar Broe, Thea Otto Mattsson, Anton Pottegård. (Denmark)
- 202 Validation of an Algorithm to Predict Treatment Discontinuation Status in Electronic Health Records [323]**
Jessica Davies, Thibaut Sanglier, Jinjoo Shim, Alexa Hibbert, Michael D Taylor, Ken Carson. (United Kingdom)
- 203 The Predictive Value of Acute Cerebrovascular Codes in The Bifap Primary Care Database [324]**
Elisa Martin-Merino, Luz María León-Muñoz, Arturo Alvarez-Gutierrez, Mar Martín-Pérez, Dolores Montero-Corominas, Consuelo Huerta. (Spain)
- 204 Identifying Active Hepatitis C and Tuberculosis Infection Cases Using United States Medical Claims Data [325]**
Katrina Wilcox Hagberg, Rebecca Persson, Catherine Vasilakis-Scaramozza, Susan S Jick. (United States)
- 205 Identification of Patients with Suicidal Ideation or Attempt in Electronic Health Record Data [326]**
Monica L Bertoia, William M. Spalding, Cynthia M Bulik, Karen S Yee, Li Zhou, Hantao Cheng, Nan Liu, John D Seeger. (United States)
- 206 The Recording and Incidence of Inflammatory Bowel Disease in Girls' Primary Care Medical Records in Spain [327]**
Elisa Martin-Merino, Javier Molina Infante, Mar Martín-Pérez, Dolores Montero-Corominas. (Spain)
- 207 Validity of Atrial Fibrillation in Electronic Medical Records: A Single University Hospital Experience in Japan [328]**
Masato Takeuchi, Koji Kawakami. (Japan)
- 208 Identification of Transfused Individuals in Electronic Health Records and Claims Databases Utilizing Different Coding Systems [329]**
Kinnera Chada, Graça Does, Joyce Obidi, Joann Gruber, Barbee Whitaker, Emily Storch, Alan Williams, Juan M Banda, Saurabh Gombhar, Deepa Balraj, John Price, Jarrah Hamer, Thomas Falconer, Karthik Natarajan, Eldar Allakhverdiiev, Sara Dempster, Nerissa Williams, Christian Reich, Azadeh Shoabi. (United States)

209 Systematic Review of Algorithms Used for Identifying Acute Myocardial Infarction, Ischemic Heart Disease and Stroke in Italian Administrative Healthcare Databases [330]

Giulia Hyeraci, Andrea Spini, Rosa Gini, Claudia Bartolini, Ersilia Lucenteforte, Giovanni Corrao, Federico Rea, Giuseppe Roberto. (Italy)

210 Validation of Major Cardiovascular Events in a Multi-Database Post-Authorization Safety Study of Prucalopride [331]

Miguel Cainzos-Achirica, Ana Ruigómez, Thomas M MacDonald, Luis García-Rodríguez, Joan Fortuny, Robert W Flynn, Estel Plana, Ryan Ziemiecki, Elizabeth B Andrews, Alicia Gilsenan. (United States)

211 How Accurate are ICD-10 Codes in Identifying Cases of Syphilis? [332]

Yenling A Ho, Saurabh Rahurkar, Janet N Arno, Jane Wang, Andrea A Broyles, Brian E Dixon. (United States)

212 Validation of a Complex Algorithm for the Diagnosis of Metastatic Castration-Resistant Prostate Cancer within a Claims Database [333]

Nicolas Thurin, Magali Rouyer, Marine Gross-Goupil, Michel Soulié, Sylvestre Le Moulec, Ludovic De Beaucoudrey, Stéphanie Lamarque, Emmanuelle Bignon, Jeremy Jové, Cécile Droz-Perroteau, Nicholas Moore, Patrick Blin. (France)

213 A Validation Exercise: Identifying Hospitalizations for Heart Failure among Patients with COPD in the CPRD [334]

Nuria Saigi-Morgui, Cristina Rebordosa, Christine Bui, Jaime Aguado, Estel Plana, Javier Nuevo, Sami Z Daoud, Alejandra Lei, Susana Perez-Gutthann, Elena Rivero-Ferrer. (Spain)

Poster Session A: Pediatric Pharmacoepidemiology

214 Psychotropic Co-Medication in Dutch Children and Adolescents Using Psycho-Stimulants; A Prescription Sequence Symmetry Analysis [335]

Alexis M Blaauwhof, Eelko Hak, Jens H Bos, Catharina C Schuiling-Veninga. (Netherlands)

215 Utilization of Neuromuscular Blocking Agents and Their Reversal Agents among Children: A Cerner Database Study [336]

Wenjun Zhong, Sarah Liu, Lori Bash, Carol Koro. (United States)

216 Temporal Trends in Opioid Prescription Dispensing among Commercially Insured Children and Adolescents Undergoing Outpatient Surgery in The United States, 2000-2015 [337]

Shahar Shmuel, Virginia Pate, Jennifer L. Lund, Marisa A. Ryan. (United States)

217 Psychotropic Prevalence among a US Commercially-Insured Youth: 2007-2015 [338]

Kyungwan Hong, O'Mareen Spence, Susan dosReis. (United States)

218 Cough and Cold Medicine Recommendations for Children in The United States, 2002-2015 [339]

Daniel B Horton, Tobias Gerhard, Brian L Strom. (United States)

219 Paediatric Antibiotic Use : A Nationwide Observational Study [340]

Githa Fungie Galistiani, Maria Matuz, Balazs Babarczy, Renata Papp, Agnes Hajdu, Szabolcs Szigeti, Laszlo Korosi, Ria Benko. (Hungary)

220 Drug-Induced Hearing Disorders in Children [341]

Adrien Gainville, Vanessa Rousseau, Florentia Kaguelidou, Leila Chebane, Jean-Louis Montastruc, Geneviève Durrieu. (France)

221 Prescribing Patterns of Antiasthma Medication in Children and Adolescents in Primary Care in France [342]

Isabelle Naiim, Florence Tubach, Sylvie Guillo, Aya Ajrouche, Veronique Houdouin, Yann De Rycke, Florentia Kaguelidou. (France)

222 Application of Phevaluator for Assessment of Pediatric Phenotype Algorithms for Type 1 Diabetes Mellitus Using Diagnostic Predictive Modeling in Observational Claims Databases [343]

Jill Hardin, Rupa Makadia, Joel Swerdel. (United States)

223 Annual Number of Pediatric Inpatient Orthopedic and Neurological Surgeries in The United States Using Different Data Sources [344]

Iona Munjal, Jasmina Ivanova, Bing Cai, Birol Emir, Deepa Malhotra. (United States)

224 Safety and Effectiveness of Piperacillin/Tazobactam (zosyn[®]) for Treatment of Hospital Acquired Pneumonia (hap): Novel Approach to Assessment of Drug Safety in Children [345]

Brian T Fisher, Brittany Haltzman-Cassenti, Muhammad Younus, Margaret Tawadrous, Jennifer Faerber, Amy Stein, Hal Tucker, Jesse Blumenstock, Michele Wible, Muida Menon, Kevin Downes, Ellen Kratz, Rasheeda Lawler, Silke S Harmeyer, John Bradley, Inci, Yildirim, Laila Hussani, Andrea Hahn, Joanna Thomson, Jason Newland, Cindy Terrill, Philip Zachariah. (United States)

225 Estimating Patient Age to Support Ema Paediatric Investigation Plans in The UK Clinical Practice Research Database (cprd) [346]

David J Webb, Harriet A Dickinson, Rachael Williams, John W Logie. (United Kingdom)

- 226 Prevalence and Incidence of Antiasthma Medication Use in Children: A Nationwide Prescription Study in France [347]**
 Isabelle Naiim, Florence Tubach, Sylvie Guillo, Aya Ajrouche, Veronique Houdouin, Yann De Rycke, Florentia Kaguelidou. (France)
- 227 Pediatric Codeine Prescriptions in Outpatient and Inpatient Settings in Korea [348]**
 Dajeong Kim, Inmyung Song, Dongwon Yoon, Ju-Young Shin. (Korea, Republic of)
- 228 Characteristics of Pediatric Patients Prescribed Sertraline: Insights from The Sertraline Pediatric Registry for The Evaluation of Safety [349]**
 Francesca Kolitsopoulos, Sara Ramaker, Scott Compton, Samuel Broderick, John Orazem, Yuliya Lokhnygina, Phil Chappell. (United States)
- 229 Prevalence of Kabuki Syndrome in Europe: A Literature Review and Database Analysis [350]**
 Shreya Dave, Chao Chen. (United States)
- 230 Does Geographic Access to Providers Matter for Pediatric ADHD Treatment Engagement and Medication Adherence? [351]**
 Navneet Upadhyay, Rajender Aparasu, Paul J Rowan, Marc L Fleming, Rajesh Balkrishnan, Hua Chen. (United States)
- 231 Proactive Risk Assessment of Intrathecal Chemotherapy in Paediatric Oncology at Referral Hospital in Kenya: A Cross Sectional Study [352]**
 Major Nyamai, Eric Guantai, Pegotty Mutai, Irene Weru, Sylvia Opanga. (Kenya)
- 232 Antibiotics Utilization in Pediatric Respiratory Tract Infections at Tertiary Care Hospitals in an Indian City [353]**
 Deepthi Chinthakindi, Rahamath Khanam, Afzal Unissa, Srividya Kudikala, Kalpana Swain. (India)
- 233 Comorbidities and Treatments in United States Youth with Chronic Musculoskeletal Pain [354]**
 Matthew T Taylor, Daniel B Horton. (United States)
- 234 Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis with Antiepileptic Drugs in Pediatric Patients [355]**
 Eric P Borrelli, Erica Y Lee, Aisling R Caffrey. (United States)
- 235 Efficacy of Pidotimod in Children: A Systematic Review [356]**
 Qui-sha Yi, Chun-song Yang, Linan Zeng, Li-na Chen, Li-na Qiao, Liang Huang, Hao-xin Song, Mao Lin, Wen-rui Li, Xue Mi, Ling-li Zhang. (China)
- 236 Antibiotics Prescribing among Children Under Five at a Tertiary Healthcare Facility South East Nigeria [357]**
 Charles C Ezenduka. (Nigeria)
- 237 Appropriateness of Postoperative Analgesic Doses among Pediatric Surgical Patients in a Teaching Hospital in Northwest Nigeria [358]**
 Kazeem Adeola Oshikoya, Ibrahim Abayomi Ogunyinka, Comfort Adamaigbo, Christopher Suiyel Lukong, Ahmed Olowo-Okere, Adekunle Azeez Adebayo. (Nigeria)
- 238 Observation Versus Prophylactic Antibiotics in Late Preterm Infants with Premature Rupture of Membranes: A Pragmatic Randomized Controlled Trial [359]**
 Linan Zeng, Lingli Zhang. (China)
- 239 Drug-Related Problems in Pediatric Patients with Respiratory Disease Hospitalized in Rionegro Antioquia, Colombia [360]**
 Jefferson Antonio Buendia, Juanita Rivas. (Colombia)
- 240 Assessment of Clinical Care for Infants with Neonatal Abstinence Syndrome in an Electronic Health Record Database [361]**
 Kelesitse Phiri, Michael Doherty, Robin Clifford, Yuan Fan, John Seeger. (United States)
- 241 Antimicrobial Prescribing in Infants in Indonesia [362]**
 Jarir At Thobari, Cahya Dewi Satria, Yohanes Ridora, Jullie Bines, Jim Buttery, Yati Soenarto. (Indonesia)
- 242 Pharmacist-Conducted Review Prevents Potential Prescribing Errors of Neonatal Parenteral Nutrition: A Cross Sectional Study [363]**
 Sara Hazem, Mohamed K Goma, Khalid Rashid, Mohammad Zaitoun. (Saudi Arabia)
- 243 Outpatient and Inpatient Use of Ribavirin among Children Under 14 Years Old in Yinzhou District, Ningbo, China [364]**
 Lu Xu, Hailong Li, Houyu Zhao, Hongbo Lin, Cuili Liu, Peng Shen, Siyan Zhan. (China)
- 244 The Association between Antipsychotic Polypharmacy and Potential Ades in Pediatric Psychiatric Patients [365]**
 Soo-Min Jeon, Susan Park, Sena An, Hae-Young Park, Jin Won Kwon. (Korea, Republic of)
- 245 Determinants of Aminoglycoside Trough Levels Among Paediatric Patients in a Large Referral Hospital in Kenya: A Prospective Cohort Study [366]**
 Zaietuni Mulaa, Margaret Oluka, Faith Okalebo, Sylvia Opanga, Anastasia Guantai, Loice Achieng, Amanj Ismael Baker Kurdi, Brian Godman, Marion Bennie. (United Kingdom)

246 The Effect of Antipsychotic Polypharmacy on Seizure Incidence in Pediatric Psychiatric Patients [367]

Soo Min Jeon, Susan Park, Sena An, Hae-Young Park, Jin-Won Kwon. (Korea, Republic of)

**Poster Session A:
Pharmacovigilance -
Methods/Data**

247 Data-Driven Identification of Adverse Event Reporting Patterns for Japan in The WHO Global Database [368]

Rika Wakao, Henric Taavola, Lovisa Sandberg, Eiko Iwasa, Rebecca E Chandler, G Niklas Norén. (Sweden)

248 The Utilisation of a New Tool in Signal Management - WHO Drug Standardised Drug Groupings [369]

Rebecca E Chandler, Olof Lagerlund. (Sweden)

249 Identifying Signals of Drug-Drug Interactions Involving Direct-Acting Oral Anticoagulants: A Translational Biomedical Informatics Approach [370]

Meijia Zhou, Lei Wang, Charles E Leonard, Colleen M Brensinger, Warren B Bilker, Stephen E Kimmel, Todd E Hecht, Lang Li, Sean Hennessy. (United States)

250 Knowledge Attitudes and Perceptions on Adverse Drug Events Reporting among Patients and Healthcare Providers in Rural Uganda [371]

Dan Kajungu, Helen Ndagije, Victoria Nambasa, Edward Galiwango. (Uganda)

251 Identifying Patients at Risk of Adverse Outcomes from Inappropriate Polypharmacy [372]

Nashwa Masnoon, Sepehr Shakib, Lisa Kalisch-Ellett, Gillian Caughey. (Australia)

252 Integrating Hypothesis-Free Signal Detection with Real-World Data Into Existing Signal Management Systems: A Prospective Evaluation of Potential Impact [373]

Qing Liu, Manfred Hauben, Kenneth Petronis, Stephen Schachterle, Sundaresan Murugesan, Rongjun Shen, Hannah Sheardown, Jamie Geier, Andrew Bate. (United States)

253 Application of Natural Language Processing Techniques to Extract Insights for Pharmacovigilance from Published Literatures [374]

Shinichi Matsuda, Takumi Ohtomo. (Japan)

254 Applying Prescription Sequence Symmetry Analysis to Detect Unknown Adverse Drug Reactions in a Chinese Claims Database [375]

Yinchu Cheng, Yuansheng Huang, Siyan Zhan. (China)

255 Safety-Signal Detection for Liver Dysfunction Associated with a Drug by Utilizing Mid-Net[®]: Results from Pilot Studies [376]

Sono Sawada, Yoshiaki Fujimura, Michio Kimura, Koichiro Murata, Naoki Nakashima, Masaharu Nakayama, Kazuhiko Ohe, Takao Orii, Eizaburo Sueoka, Takahiro Suzuki, Hideto Yokoi, Chieko Ishiguro, Kaori Yamada, Maori Itoh, Yoshiaki Uyama. (Japan)

256 Adverse Reaction Signal Detection for Statins in a Chinese Regional Healthcare Database Using Tree Based Scan Statistic Method [377]

Hailong Li, Lingli Zhang, Siyan Zhan. (China)

257 High Dimensional Empirical Bayes Screening (ideas) in North American Claims and Va Electronic Medical Records [378]

Jill E Lavigne, Kwan Hur, Bharat Thakkar, John J Mann, Robert D Gibbons. (United States)

258 Characterisation of Drug Interaction Related Signals Leading to EU Regulatory Action and a Methodological Review of Novel Drug Interaction Signal Detection Methods in The Post-Marketing Setting [379]

Debabrata Roy, Lorna Hazell, Vicki Osborne, Saad Shakir. (United Kingdom)

259 Using Innovative Automation to Author Development Safety Update Reports and Enhance Cost-Effectiveness [380]

Jennifer Cichone, Krystle Pianka, Nipa Parikh, Beth Pulaski, Akshay Vashist, Mirza Rahman. (United States)

260 Impact Analyses of European Pharmacovigilance Interventions on Public Health Burden [381]

Samantha Lane, Elizabeth Lynn, Jim Slattery, Saad Shakir. (United Kingdom)

261 Adverse Event Report Forecasting from Custom Engagement Programs [382]

Qing Liu, Robert Davenport, Phillip Eichorn, Quazi Ataher, Andrew Bate. (United States)

262 Evaluating the Process of Standardizing Investigational Drug Substance Names Reported to The United States Food and Drug Administration Adverse Event Reporting System [383]

Maggie Fung, Sonja Brajovic, Nitin Patel, Sherry Chang. (United States)

263 Monitoring of Medicinal Products Authorised Based on a Single-Arm Trial: The Case of a CAR-T Cell Therapy [384]

Torbjorn Callréus, Maurizio Sessa, Tarek El-Galaly, Mats Jerkeman, Morten Andersen. (Denmark)

- 264 Evaluation of Reported Adverse Drug Reactions: A Study from a Regional Spontaneous Database in Saudi Arabia [385]**
Khaledah A Alenzi, Ali F Altebainawi, Abdulrahman Ghalelah, Thamir M Alshammari. (Saudi Arabia)
- 265 Patterns of Adverse Drug Reactions Reported to a Hospital-Based Pharmacovigilance Centre in Bhutan – A Case Series Study [386]**
Choki Dorji, Pramote Tragulpiankit. (Bhutan)
- 266 Increased Risk of Allergic Reactions Associated with Xiyanping Injection: A Prescription Sequence Symmetry Analysis [387]**
Yixin Sun, Yifan Zhou, Siyan Zhan, Yinchu Cheng, Shuangqing Gao, Lang Lv. (China)
- 267 Adverse Drug Reactions Monitoring at The Brazil's Pharmacovigilance System from 2008 to 2013 [388]**
Daniel M Mota, Álvaro Vigo, Ricardo de S Kuchenbecker. (Brazil)
- 268 Mapping Meddra to ICD 9 for Signal Detection with Longitudinal Electronic Data [389]**
Stephen B Schachterle, Qing Liu, Kenneth Petronis, Eric Hung, Sundaresan Murugesan, Richard Gong, Manfred Hauben, Jamie Geier, Andrew Bate. (United States)
- 269 Prevalence of Colorectal Neoplasms and Mortality among New Users of Low-Dose Aspirin with Lower Gastrointestinal Bleeding [390]**
Frederikke S Troelsen, Dóra K Farkas, Anne Ording, Rune Erichsen, Henrik T Sørensen. (Denmark)
- 270 Testosterone Replacement Therapy and the Risk of Prostate Cancer in Men with Late-Onset Hypogonadism [391]**
Christina Santella, Christel Renoux, Hui Yin, Oriana Yu, Laurent Azoulay. (Canada)
- 271 Angiotensin Converting Enzyme Inhibitors and Risk of Lung Cancer: A Nested Case-Control Study [392]**
Kasper Bruun Kristensen, Blánaid Hicks, Laurent Azoulay, Anton Pottegård. (Denmark)
- 272 Low Dose Aspirin Use and Colorectal Cancer Risk [393]**
Hui-Min Diana Lin, Kinwei Arnold Chan, Pareen Vora, Montse Soriano Gabarro. (Taiwan)
- 273 Low-Dose Aspirin Use and Endometrial Cancer Mortality – A Nationwide Cohort Study [394]**
Cecilie D Sperling, Freija Verdoodt, Gitte L Aalborg, Christian Dehlendorff, Søren Friis, Susanne K Kjaer. (Denmark)
- 274 Low-Dose Aspirin Use and Risk of Head and Neck Cancer - A Population-Based Case-Control Study [395]**
Cecilie D de la Cour, Freija Verdoodt, Gitte L Aalborg, Christian von Buchwald, Søren Friis, Christian Dehlendorff, Susanne K Kjær. (Denmark)
- 275 Does Use of Nonaspirin Non-Steroidal Anti-Inflammatory Drugs Reduce the Risk of Head and Neck Cancer in a Population-Based Case-Control Study? [396]**
Cecilie D de la Cour, Christian Dehlendorff, Gitte L Aalborg, Christian von Buchwald, Søren Friis, Freija Verdoodt, Susanne K Kjær. (Denmark)
- 276 Statin Use and Risk of Liver Cancer: Evidence from Two Population-Based Studies [397]**
Kim Tu Tran, Úna McMenamin, Helen Coleman, Chris Cardwell, Peter Murchie, Lisa Iversen, Amanda Lee, Aaron Thrift. (United Kingdom)
- 277 Safety of Menopausal Hormone Therapy in Older Breast Cancer Survivors: A Systematic Review and Meta-Analysis [398]**
Godfrey H Mudhune, Mike Armour, Kate A McBride. (Kenya)
- 278 Clinical Outcomes Associated with Drug-Drug Interactions of Oral Chemotherapeutic Agents: A Comprehensive Evidence-Based Literature Review [399]**
Manvi Sharma, Aisha Vadhariya, Soumya Chikermane, Suma Gopinathan, Mariana Chavez-MacGregor, Sharon H Giordano, Michael L Johnson, Holly M Holmes. (United States)
- 279 Nonsteroidal Anti-Inflammatory Drug Use and Breast Cancer Risk in a Prospective Cohort Study of Postmenopausal Women [400]**
Manon Cairat, Marie Al Rhamoun, Marc Gunter, Gianluca Severi, Laure Dossus, Agnes Fournier. (France)
- 280 Bile Acid Sequestrants and The Risk of Cancer: A Cohort Study in The Clinical Practice Research Datalink [401]**
Youjin Wang, Madhav Thambisetty, Vijay Varma, Shahinaz Gadalla. (United States)
- 281 Intensive Safety Surveillance of Anti-Cancer Medicines Subject to Additional Monitoring: A Pilot Study [402]**
Diogo Mendes, Graça Rigueiro, Rui Sousa Silva, Ana Penedones, Carlos Alves, Gabriela Sousa, Francisco Batel Marques. (Portugal)
- 282 Abstract Withdrawn [403]**

Poster Session A: Pharmacovigilance - Cancer

283 Impact of Antidiabetic Medication Use on Breast Cancer Diagnostic Characteristics [404]
Shahariar Mohammed Fahim, Chiu-Hsieh Hsu, Jingjing Qian, Chiahung Chou. (United States)

284 Inverse Association between Digoxin and Cancers Derived from Real World Data [405]
Satoshi Yokoyama, Yasuhiro Sugimoto, Chihiro Nakagawa, Kouichi Hosomi, Mitsutaka Takada. (Japan)

Poster Session A: Trials

285 Effect of a Clinical Pharmacist Intervention on The Emergency Department Revisits: A Randomized Controlled Trial [406]
Matias F. Martinez, Luis Herrada, Ana Munoz, Camila Chavez, Tamara Sandoval, Marcela Jiron. (Chile)

286 Efficacy Gap Between Phase 2 and Subsequent Phase 3 Trials in Oncology [407]
Rick Vreman, Ana Teresa M Mota, Svetlana V Belitser, Anke M Hövels, Wim G Goettsch, Kit C Roes, Hubert G Leufkens, Aukje K Mantel-Teeuwisse. (Netherlands)

287 Feasibility of Using Electronic Health Records to Identify Patients with Chronic Obstructive Pulmonary Disease to Enroll into Pragmatic Trials [408]
Achim Wolf, Daniel Dedman, Rachael Williams, Jennifer Campbell, Tarita Murray-Thomas, Jennifer Quint, John Logie, Jeanne Pimenta. (United Kingdom)

288 Globalization of Clinical Trials: Variation in Estimated Regional Costs of Pivotal Trials, 2015-2016 [409]
Yao Qiao, G Caleb Alexander, Thomas Moore. (United States)

289 The Pragmatic Trial: Still a Rising Star, or Old News? [410]
Margaret S Richards, Juliane K Mills, Bettina Rillmann. (United States)

290 Variations in Seasonal Influenza Vaccine Effectiveness: A Systematic Review and Meta-Analysis of Test-Negative Design Studies [925]
George N Okoli, Florentin Racovitan, Christiaan H Righolt, Salaheddin M Mahmud. (Canada)

End Poster Session A

Poster Spotlight Session B: Benefit Risk Assessment, Communication & Evaluation (BRACE)

- A Structured Benefit-Risk Assessment of Prophylactic Subcutaneous C1-esterase Inhibitor for Hereditary Angioedema Management [494]**
Ami S Patel, Henrike Feuersenger, Sarah Mycroft, Ingo Pragst, Daniel Wood, Thomas Machnig, Douglas Watson. (United States)
- B Impact of Complex Drug Approval Decision-Making Processes on Safety-Related Regulatory Actions for Drugs Approved by The European Medicines Agency [495]**
Lourens T Bloem, Mariana Karomi, Jarno Hoekman, Svetlana V. Belitser, Hubert G Leufkens, Olaf H Klungel, Aukje K Mantel-Teeuwisse. (Netherlands)
- C The Occupational Hazards of Measuring Risk Tolerance: Convergent Validity in Preference Elicitation [496]**
Sumitra Sri Bhashyam, Kevin Marsh, Adrian Quartel, Ari Gershman. (United Kingdom)
- D Determinants for Safety Issue Coverage by Lay and Social Media [497]**
Esther de Vries, Petra Denig, Sieta T de Vries, Taco B Monster, Jacqueline G Hugtenburg, Peter G. Mol. (Netherlands)
- E Monitoring Benefits and Risks of Medicines for Overactive Bladder in Primary Care; Building a Bridge between Daily Practice and Research [498]**
Karin Hek, Leàn Rolfes, Linda E Flinterman, Saskia Vorstenbosch, Eugène van Puijenbroek, Liset van Dijk, Robert A Verheij. (Netherlands)

- F Effectiveness of Risk Evaluation and Mitigation Strategies to Prevent Maternal Exposure to a Topiramate Weight Loss Product [499]**
Amir Sarayani, Yasser Albogami, Almut G Winterstein. (United States)
- G Agomelatine Post-Authorization Safety Studies Program: Comprehensive Results [500]**
Emmanuelle Jacquot, Valérie Olivier, Christèle Percheron, Fanny Mazens, Nicolas Deltour, Susana Perez-Gutthann. (France)

Poster Spotlight Session B: Databases

- H Area-Level Linkages to Enrich Primary Care Electronic Health Data for Research [501]**
Susan Hodgson, Elizabeth Crellin, Kirsty Syder, Sonam Sadarangani, Shivani Padmanabhan. (United Kingdom)
- I Role of Health Plan Administrative Claims Data in Participant Recruitment for Pragmatic Clinical Trials - An ADAPTABLE (Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness) Example [502]**
Qian Shi, Sonali Shambu, Amanda Marshall, Elaine Rose-Kennedy, Holly Robertson, Mark Paullin, William Schuyler Jones, Mark Cziraky, Kevin Haynes. (United States)
- J Impact of Length of Pre-Index Enrollment Criterion on Patient Characteristics in a Cohort of Heart Failure Patients Using a Large U.S. Medicare Advantage Claims Database [503]**
Shannon L Reynolds, Vinay Mehta, Stephen Stemkowski, Huifang Liang, Efe Eworuke, Dimitri Bennett, Karine Marinier, Matthew W Reynolds. (United States)
- K Predicting the Likelihood of 30-Day Hospital Readmissions among Stroke Patients: An Application of Machine-Learning Techniques [504]**
Jordan Menzin, Mark Friedman, Anna Watzker, Joseph Menzin. (United States)
- L New Automated Signal Detection Methods in Pharmacovigilance Combining Medico-Administrative Database Controls and Spontaneous Reporting Cases [505]**
Émeline Courtois, Pascale Tubert-Bitter, Ismail Ahmed. (France)
- M Total Hip or Knee Replacement Surgery and Risk of Thromboembolic Outcomes: A Retrospective Cohort Study [506]**
Xiaofeng Zhou, Kui Huang, Liu Qing, Patrick Arena, Shen Rongjun, Charles Wentworth, Richard Gong, Sundaresan Murugesan, Andrew Bate, Jingping Mo. (United States)
- N Validation of Cancer Diagnoses in Electronic Health Records in Catalonia: Preliminary Results from The Information System for Research in Primary Care (SIDIAP) [507]**
Martina Recalde, Cyntia B Manzano-Salgado, Yesika Díaz, Diana Puente, Maria del Mar Garcia-Gil, Daniel Prieto-Alhambra, Rafael Marcos-Gragera, Jaume Galceran, Margarita Cynthia Posso Rivera, Francesc Macià, Talita Duarte-Salles. (Spain)
- O Quality and Completeness of Diagnoses Recorded in the New CPRD Aurum Database: Evaluation of Pulmonary Embolism [508]**
Susan Jick, Rebecca Persson, Puja Myles, Elizabeth Crellin, Katrina Wilcox Hagberg, Catherine Vasilakis-Scaramozza. (United States)

Poster Spotlight Session B: Drug Utilization Research

P Use of Joinpoint Regression in Drug Utilization Research: Post-Tonsillectomy Codeine Use in Pediatrics, United States (2005-2016) [509]

Juan M Hincapie-Castillo, Patrick J Antonelli, Almut G Winterstein. (United States)

Student Award Recipient – Third Best Abstract Submitted by a Student/Post-Doc

Q Clinical Evaluation of Benzodiazepine and Z-Drug Use Duration among Adults with Anxiety and Sleep Disorders in Primary Care [510]

Jaden Brandt, Silvia Alessi-Severini, Dan Chateau, Christine Leong. (Canada)

R Use of Non-Insulin Diabetes Medicines after Insulin Initiation: A Retrospective Cohort Study [511]

Yunwen Xu, Scott J Pilla, Caleb G Alexander, Irene B Murimi. (United States)

S Feedback to General Practitioners on Inadequate Statin Prescriptions Results in a Lower Prevalence of Statin Use and no Change in the Incidence of Ischaemic Heart Disease or Stroke: An Interrupted Time Series Analysis [512]

Albert Prats-Urbe, Ermengol Coma, Francesc Fina-Aviles, Mireia Fàbregas, Samuel Hawley, Manuel Medina, Daniel Prieto-Alhambra. (United Kingdom)

T Pregabalin Use Outside Subsidy Restrictions in Australia [513]

Tricia Roujia Chiu, Sallie Pearson, Andrea L Schaffer. (Australia)

U Impact of Tramadol Classification on The Prescribing of Other Pain Medicines Commonly Related to Drug-Misuse Deaths in England [514]

Teng-Chou Chen, Roger D. Knaggs, Li-Chia Chen. (United Kingdom)

V Mortality and Hospitalization Following Initiation of Sacubitril/Valsartan in The Medicare Population [515]

Nicholas S Roetker, Yi Peng, William Eggert, David T Gilbertson. (United States)

Poster Spotlight Session B: Medical Devices

W Negative Control Outcomes to Control for Unmeasured Confounding in Device Safety Research: A Clinical Example [516]

Daniel Prieto-Alhambra, James Weaver, Henry Morgan-Stewart, Anthony Sena, Edward Burn, Patrick Ryan. (United Kingdom)

X Tramadol Analgesic Use as a Screening Tool for Total Hip Arthroplasty Implant Survival: A Population-Based Cohort Study [517]

Tamer T Malak, Andrew Judge, Daniel Prieto-Alhambra. (United Kingdom)

Y Long-Term Outcomes Following Mid-Urethral Mesh Sling Surgery for Stress Urinary Incontinence [518]

Sara Z Dejene, Jennifer M Wu, Virginia Pate, Michele Jonsson-Funk. (United States)

Z Machine Learning for Probabilistic Phenotypes and Exploration of Complex Coding Patterns in Large Real-World Healthcare Databases: An Applied Example in Conversion from Minimally-Invasive to Open Sigmoidectomy [519]

Stephen Johnston, Stephen Fortin, Jenna Reps. (United States)

AA Application of Propensity Scores Odds to Visualize Clinical Equipoise for Robotic Assisted Surgery from 2003 to 2015 [520]

Gary Chung, Art Sedrakyan, Piet Hinoul, Paul Coplan, Andrew Yoo. (United States)

BB Does Operating Room Time Affect the Rate of Superficial, Deep and Organ System Post-Surgical Infections in Total Knee Replacement? [521]

Zhenna Huang, Abhishek S Chitnis, Chantal E Holy, Deepak Krishnan, John Wright. (United States)

CC Utilization of Intrauterine Device in Europe - Prescription Patterns in Routine Medical Practice [522]

Tanja Boehnke, Anja Bauerfeind, Klaas Heinemann. (Germany)

DD Administrative Burden of The Brazilian Rule that Contributes to Price Transparency in the Medical Device Market [523]

Daniel Marques Mota, Júlia de Souza Ferreira, Daniela Martins Ferreira, Gabrielle Cunha Troncoso, Gustavo Cunha Garcia. (Brazil)

Poster Spotlight Session B: Rare Disease

EE Validation of Algorithms for Identifying Pulmonary Hypertension Patients Using Diagnostic Predictive Modeling in Large Claims Databases [524]

Eva-Maria Didden, Daniel Fife, Deborah A Quinn, Lu Wang, Joel N Swerdel. (Switzerland)

FF Incidence of Systemic Sclerosis. An Epidemiological Study in a Large Insured Population in The US [525]

Alexander Michel, Marcela Rivera, Tatsiana Vaitsiakhovich. (Switzerland)

Poster Session B | Tuesday, August 27 • 8:00am - 6:00pm

SPOTLIGHT SESSIONS: 11:45Pm - 12:45pm

GG Incidence of Vaso-Occlusive Crisis and Setting of Care in Patients with Sickle Cell Disease from 2013 through 2017 in The United States [526]
Stephen E Schachterle, Emily Rubinstein, Jingping Mo, Andrew Bate, Richard Gong, Krupa M Sivamurthy, Frank Shafer. (United States)

HH The Use of Real-World Data in Health Technology Assessment of Medications for Rare Diseases [527]
Christina J Qian, Alexis T Mickle, Alison M Deighton, Meagan M Harwood, Shelagh M Szabo. (Canada)

II Identification of Inherited Metabolic Disorders Using Temporal Data and Recurrent Neural Network Models [528]
Sharon Hensley Alford, Piyush Madan, Italo Buleje, Yanyan Han, Shilpa Mahatma. (United States)

JJ Prevalence of Friedreich Ataxia in The United States: Analysis of Two Large US Insurance Claims Databases [529]
Chao Chen, Yizhou Ye, Shreya Davé. (United States)

KK Clinical Manifestation of Adult Onset Still's Disease Using Administrative Claims Database [530]
Sujin Kim, Aleksander Lenert, G Yeon Oh. (United States)

LL Prediction Model for Identifying Patients with Lipodystrophy in Electronic Health Records [531]
Eline Houben, Marina Bakker, Rich Colbaugh, Kristin Glass, Christopher Rudolf, Mike Tremblay. (Netherlands)

End Spotlight Sessions B

Poster Session B: Burden of Disease - Respiratory

- 1 Gender Differences in the Management of Chronic Obstructive Pulmonary Disease: Effect of a Clinical Audit in a Sicilian General Practice Setting [532]**
Valentina Isgrò, Janet Sultana, Valentina Ientile, Andrea Fontana, Umberto Alecci, Riccardo Scoglio, Francesco Magliozzo, Gianluca Trifirò. (Italy)
- 2 Changes in Persistent Asthma Care and Outcomes from 2006 to 2016 in France [533]**
Manon Belhassen, Maeva Nolin, Marine Ginoux, Eric Van Ganse. (France)
- 3 Comorbid Conditions in Chronic Obstructive Pulmonary Disease Patients: A Retrospective Analysis of a Large United States Electronic Health Record Database [534]**
Georgios Varsos, Fred W Peyerl, Meng Shen, Halit Yapici, Laxmi Gannu, Apeksha Shenoy, David K Hayashida, Fabian D'Souza. (United States)
- 4 Assessment of Asthma Severity and Patient Comorbidities: A Retrospective Analysis of a Large United States Electronic Health Record Database [535]**
Georgios Varsos, Fred W Peyerl, Meng Shen, Halit Yapici, Laxmi Gannu, Apeksha Shenoy, David K Hayashida, Fabian D'Souza. (United States)

Poster Session B: Burden of Disease - Other

- 5 Anemia and Clinical Outcomes in Patients with Severe Chronic Kidney Disease: A Danish Population-Based Study [536]**
Gunnar Toft, Uffe Heide-Jorgensen, Heleen van Haalen, Glen James, Katarina Hedman, Henrik Birn, Henrik T Sorensen, Christian F Christiansen, Reimar W Thomsen. (Denmark)

- 6 Duration of Follow-Up of Chronic Condition Cohorts in the Sentinel System [537]**
Emily C Welch, Ting-Ying Huang, Mayura Shinde, Michael D Nguyen, Sarah K Dutcher. (United States)
- 7 Incidence and Prevalence of Alopecia Areata in The US and UK [538]**
Michiyo Yamazaki, Xiaofeng Zhou, Lynne Napatalung, Rachel E Sobel. (United States)
- 8 Do Alopecia Areata Patients Differ by Severity? [539]**
Rachel E Sobel, Michiyo Yamazaki, Lynne Napatalung, Kelsey Gangemi, Daina Esposito. (United States)
- 9 Defining Heat Exposure in A Climate-Drug Interaction Study: A Pharmacoepi Approach [540]**
Soko Setoguchi, Thomas A Nahass, Isao Iwata, John Read, Edward Nommennacher, Brian Strom, Tobias Gerhard, Cecilia Huang, David Robinson. (United States)
- 10 Identification of Risk Factors in Chronic Kidney Disease: A Retrospective Analysis of a Large United States Electronic Health Record Database [541]**
Georgios Varsos, Fred W Peyerl, Apeksha Shenoy, Kunal Lodaya, Xuan Zhang, Laxmi Gannu, David K Hayashida, Fabian D'Souza. (United States)
- 11 Association of Diagnosis Code-Based and Laboratory Results-Based Kidney Disease with Development of Vision Threatening Diabetic Retinopathy [542]**
Yinxi Yu, Brian L VanderBeek, Gui-Shuang Ying, Maureen G Maguire. (United States)

- 12 A Clinico - Epidemiological Study of Acute Poisoning Cases in Emergency Department of Tertiary Care Hospital, Warangal, India [543]**
Sreeja Vydhyam, Shiva Rama Krishna Marka, Vasavi Katkuri. (India)
- 13 Chronic Kidney Disease in the Real-World: Rationale and Design of The Global Discover CKD Program [544]**
Glen James, Eric Wittbrodt, Carol Moreno Quinn, Alaster Allum, Esther Pascual, Jenny Wei, Katarina Hedman, Mary Beth DeYoung, Jennie Medin, Juan-Jesus Carrero, Gary Curhan, Steven Fishbane, Hiddo Heerspink, Eiichiro Kanda, Naoki Kashihara, Mikhail Kosiborod, Mitja Lainscak, Carolyn S P Lam, Roberto Pecoits-Filho, Carol Pollock, Peter Stenvinkel, David Wheeler. (United Kingdom)

Poster Session B: Drug Utilization - Musculoskeletal

- 14 Treatment Patterns of Targeted Therapies among Patients Diagnosed with Rheumatoid Arthritis in The United States [545]**
Jolyon Fairburn-Beech, Ayush V Patel, Rachel E Williams. (United Kingdom)
- 15 A Descriptive Analysis of Florida Medical Marijuana Registry Patients from 2016-2017 [546]**
Brianna Costales, Sascha van Boemmel-Wegmann, Richard Segal. (United States)
- 16 Hydroxychloroquine in Systemic Lupus: Drug Tapering/Discontinuation and Clinical Outcomes [547]**
Celline C Almeida-Brasil, Cristiano S Moura, Evelyne Vinet, Christian A Pineau, Luck Lukusa, Sasha Bernatsky. (Canada)

- 17 TNF-Alpha Inhibitor Treatment Patterns in Patients with Rheumatic Diseases and Those with Inflammatory Bowel Disease [548]**
Rosanne W Meijboom, Helga Gardarsdottir, Matthijs L Becker, Toine C Egberts, Hubert G Leufkens, Thijs J Giezen. (Netherlands)
- 18 Comorbidities, Infections and Treatment Patterns in Psoriasis Patients : A Retrospective Analysis of a Large United States Electronic Health Record Database [549]**
Georgios Varsos, Fred W Peyerl, Meng Shen, Kunal Lodaya, Laxmi Gannu, Apeksha Shenoy, David K. Hayashida, Fabian D'Souza. (United States)
- 19 Characterization of Rheumatoid Arthritis (RA) in Puerto Rico: Prevalence, Demographics, and Prescribing Trends among Beneficiaries of The Government Sponsored Health Care Plan (GSHCP) [550]**
Wenfei Wei, Jose Hernandez. (United States)
- 20 The Importance of Reliable Data Collection: Using Electronic Medical Records to Study Lower Extremity Injuries in Elite Football [551]**
Christina Mack, Mackenzie Herzog, Robert Anderson, Edward Wojtys, Kristin Shiue, Richard Kent, Michael Coughlin. (United States)
- 21 Prescribing Pattern of Janus Kinase Inhibitors Drugs in Rheumatoid Arthritis Patients in Taiwan [552]**
Hsing-Yu Hsu, Yi-Hui Lee, Ching-Ya Huang, Yow-Wen Hsieh. (Taiwan)
- 22 Effect of Reimbursement Restriction Policy on The Use of Benzodiazepines in the Netherlands: An Interrupted Time Series Analysis [553]**
Eibert Heerdink, Lennart J Stoker, Richard T Janssen, Antoine C Egberts. (Netherlands)
- 23 Differences in Patterns of Prescribing Medications for Depression in Obese and Normal Weight Patients [554]**
Svetlana Puzhko, Tibor Schuster, Tracie A Barnett, David Barber, Gillian Bartlett. (Canada)
- 24 Trends in Prescribing and Dispensing of Common Insomnia Drugs as Compared to National Guideline Recommendations [555]**
Jenna Wong, Darren Toh. (United States)
- 25 Long-Term Outcomes of Early Use of Long-Acting Injectable Antipsychotics in Schizophrenia [556]**
Yu-Hsuan Joni Shao, Su-Chen Fang, Cheng-Yi Huang. (Taiwan)
- 26 Concurrent Use of Gabapentin, Benzodiazepines and Opioids: Prevalence and Risk Factors among Commercially Insured United States Adults [557]**
Abisola Olopoenia, Wendy Camelo-Castillo, Sean Fleming, Linda Simoni-Wastila. (United States)
- 27 Real-World Evidence of Disease Progression and Treatment Pattern of Patients Diagnosed With Parkinson's Disease [558]**
Chao Chen, Sudhakar Manne, Shreya Davé. (United States)
- 28 Concomitant Drug Use among Frequent Users of Insomnia Medications: A US Claims Database Study [559]**
Cathy Anne Pinto, Praful Kumar, Johanna Hyacinthe, Ankita Kumar, Zhiwen Liu. (United States)
- 29 Antidepressant Use in Denmark, Germany, Spain, and Sweden from 2009 to 2014: Incidence and Comorbidities of Antidepressant Initiators [560]**
Joan Forn, Anton Pottegård, Tammo Reinders, Beatriz Poblador-Plou, Rosa Morros, Lena Brandt, Miguel Cainzos-Achirica, Maja Hellfritsch, Tania Schink, Alexandra Prados-Torres, Maria Giner-Soriano, David Hägg, Jesper Hallas, Jordi Cortés, Emmanuelle Jacquot, Nicolas Deltour, Susana Perez-Gutthann, Manel Pladevall, Johan Reutfors. (Spain)
- 30 Comparability of Antipsychotic-Treated and Non-treated Patients with Schizophrenia and the Assessment of Mortality in Taiwan [561]**
Darmendra Ramcharran, Chao-Hsiun Tang, Po-Ya Chuang, Hong Qiu, Ching-Wen Wendy Yang, Kuo-Hsuan Chung. (United States)
- 31 Real-World Treatment Patterns among Attention-Deficit/Hyperactivity Disorder Patients who Initiated Extended-Release Treatment [562]**
Jennifer Erensen, Xuezhe Wang, Yingjie Ding, Frank A Corvino, Jaromir Mikl. (United States)
- 32 Use of Antidepressants and Anxiolytics among Patients with Chronic Diseases in The Netherlands [563]**
Jan Maurik van den Heuvel, Charlotte E Pelgrim, Aletta D Kraneveld, Anke-Hilse Maitland - van der Zee. (Netherlands)
- 33 Factors Associated with Deep Brain Stimulation Surgery for Parkinson's Disease: Examining Medication Use and Patient Characteristics [564]**
James A Crispo, Melody Lam, Britney Allen, Lucie Richard, Salimah Z Shariff, Dominique R Ansell, Melanie Squarzolo, Connie Marras, Allison W Willis, Dallas Seitz. (Canada)

- 34 The Utilization of First and Second-Generation Antipsychotic Drugs in Denmark from 1999 to 2017: A Study Using Population-Based Data [565]**
Reeha Sharon, Morten Andersen. (Denmark)
- 35 Real-World Evidence for Treatment Patterns of Patients Diagnosed with Depression in The United States [566]**
David Kern, M Soledad Cepeda, Frank Defalco, Mila Etropolis. (United States)
- 36 Levodopa Misuse/Abuse among Patients with Parkinson's Disease [567]**
Richard S Swain, Patty Greene, Sara Karami, Travis Ready, Tamra Meyer. (United States)
- 37 Regional Variation and Increasing Gabapentinoids Prescribing in England [568]**
Xinchun GU, Teng-Chou Chen, Douglas Steinke, Li-Chia Chen. (United Kingdom)
- 38 Characterization of Gabapentin Use in Kentucky [569]**
GYeon Oh, Svelta Slavova, Patricia R Freeman. (United States)
- 39 New Treatments for Comorbidities after Diagnosis with Multiple Sclerosis (MS): A Study in The UK Clinical Practice Research Datalink (CPRD) GOLD [570]**
Rebecca Persson, Sally Lee, Neil Minton, Steve Niemcryk, Anders Lindholm, Susan Jick. (United States)
- 40 Comorbid Conditions and Medications in Post Traumatic Stress Disorder Patients: A Retrospective Analysis of a Large United States Electronic Health Record Database [571]**
Georgios Varsos, Fred W Peyerl, Kunal Lodaya, Meng Shen, Laxmi Gannu, Xuan Zhang, Apeksha Shenoy, David K Hayashida, Fabian D'Souza. (United States)
- 41 Predictors for Methylphenidate Initiation in Young Individuals in The Netherlands [572]**
Chii Chyi Cheung, Bram Dierckx, Hanan El Marroun, Vincent W Jaddoe, Loes E Visser, Bruno H Stricker. (Netherlands)
- 42 Use of Atypical Antipsychotics in The Brazilian Health System: Profile of Users and Their Self-Perception of Health [573]**
Isabella Figueiredo Zuppo, Cristina Mariano Ruas, Helian Nunes Oliveira, Edna Afonso Reis. (Brazil)
- 43 Benzodiazepine Drugs Utilization Studies at Few Indian Hospitals [574]**
Venkateshwar Rao Jupally, Varun Talla, Satyanarayan Pattnaik. (India)
- Poster Session B: Geriatric Pharmacoepidemiology**
- 44 One-Year Persistence of Potentially Inappropriate Medications Use in Older Adults: A Population-Based Study in Quebec, Canada [575]**
Barbara Roux, Marie-Laure Laroche, Marc Simard, Marie-Ève Gagnon, Caroline Sirois. (France)
- 45 Changes in Schizophrenia Documentation in Nursing Home Residents Varies by Antipsychotic Exposure, Dementia, and Race [576]**
Shekinah A Fashaw, Theresa Shireman, Ellen McCreedy, Kali Thomas. (United States)
- 46 Treatment Patterns among Elderly Patients Diagnosed with Diffuse Large B-Cell Lymphoma in The United States [577]**
Leonardo M Simonella, Per-Olof Thuresson, Andy Surinach, Pavel Napalkov, Frank A Corvino. (United States)
- 47 Attitudes Towards Deprescribing in Older Adults with Limited Life Expectancy: Two Systematic Reviews [578]**
Alaa Burghle, Carina Lundby, Jesper Ryg, Jens Søndergaard, Anton Pottegård, Trine Graabæk, Dorthe Nielsen. (Denmark)
- 48 Potentially Inappropriate Medications and Risk of Autonomy Loss for Activities of Daily Living in the Elderly [579]**
Emilie Hucteau, Pernelle Noize, Antoine Pariente, Catherine Helmer, Karine Pérès. (France)
- 49 Patterns of Antipsychotic Use among Older Adults with Late-Life Psychotic Disorders [580]**
Dallas Seitz, Soham Rej, Simone Vigod, Colleen Maxwell, Tarek Rajji, Simon Davies, Nathan Herrmann, Paul Kurdyak, Paul Nguyen. (Canada)
- 50 Risk of Major Bleeding in Elderly Users of Non-Vitamin K Antagonist Oral Anticoagulants According to Advanced Age [581]**
Min Taek Lee, Hyunji Koo, Sun-Young Jung. (Korea, Republic of)
- 51 Real-World Evidence of Statin Effectiveness in Older Adults [582]**
Michele Jonsson Funk, Mitchell M Conover, Virginia Pate. (United States)
- 52 The Association between Potentially Serious Alcohol Medication Interactions and Falls in Community Dwelling Older Adults: A Longitudinal Irish Study [583]**
Alice Holton, Fiona Boland, Paul Gallagher, Tom Fahey, Frank Moriarty, Rose Anne Kenny, Grainne Cousins. (Ireland)
- 53 Potentially Inappropriate Medications among Chinese Older Adults in Community Healthcare Institutions in Beijing [584]**
Mengyuan Fu, Luwen Shi, Xiaodong Guan. (China)

- 54 Trends in Skeletal-Related Event Hospitalization and Use of Bone Targeting Agents in Older Patients with Bone Metastases from Solid Tumors in The United States: 1994-2015 [585]**
Shuling Li, Haifeng Guo, Suying Li, Rohini K Hernandez, Jiannong Liu, Yi Peng, Alan Fu. (United States)
- 55 Benzodiazepines and Risk of Autonomy Loss for Activities of Daily Living in the Elderly [586]**
Emilie Hucteau, Antoine Pariente, Clément Mathieu, Pernelle Noize, Karine Pérès, Catherine Helmer. (France)
- 56 Drug Use among Older People Admitted to Nursing Homes [587]**
Mette Reilev, Carina Lundby, Helene Hoffmann, Søren P Larsen, John Jensen, Anton Pottegård. (Denmark)
- 57 Receipt of Psychotropic Treatment among Working-Age, Long-Stay Nursing Home Residents with Serious Mental Illness [588]**
Christine M Ulbricht, Yiyang Yuan, Kate L Lapane. (United States)
- 58 Adverse Drug Reactions as Cause of Hospital Admissions in Older Adults in a Teaching Hospital in Chile [589]**
Marcela Jiron, Tamara Sandoval, Carolina Gutierrez. (Chile)
- 59 The Goldilocks of Diabetes Care: A Retrospective Evaluation of Prescribing Practices Related to the Intensity of Glycemic Control among the Elderly Population with Type 2 Diabetes across Canada [590]**
Sai Krishna Gudi, Shawn Bugden, Kevin Friesen, Jamie Falk. (Canada)
- 60 Use of Benzodiazepines and other Sedative Medications among Older Patients in Quebec: A Population-Based Study between 2000-2015 [591]**
Gosselin Emmanuelle, Marc Simard, Caroline Sirois. (Canada)
- 61 Polypharmacy among Older Individuals with Chronic Obstructive Pulmonary Disease: Trends between 2000-2015 in Quebec, Canada [592]**
Caroline Sirois, Amina Ouali, Marc Simard. (Canada)
- 62 SSRI & SNRI Use in Adults & Elderly [593]**
Mikkel Z Ankarfeldt, Espen Jimenez-Solem, Cecilie D Sperling, Janne Petersen. (Denmark)
- 63 Potentially Inappropriate Medication Users with Pre-Clinical Alzheimer's Disease More Susceptible to Anticholinergic Challenge [594]**
Ashley I Martinez, Brooke F Beech, Erin A Abner, Gregory A Jicha, Frederick A Smith, Lynne Eckmann, Mark Huffmyer, Daniela C Moga. (United States)
- 64 Computer Support and Collaboration in the Older Person's Medication Use [595]**
Kerstin B Jorsater-Blomgren. (Sweden)
- 65 Translation, Cultural Adaptation, and Psychometric Properties of the Danish Version of the Revised Patients' Attitudes Towards Deprescribing Questionnaire [596]**
Carina Lundby, Trine Simonsen, Jesper Ryg, Jens Søndergaard, Anton Pottegård, Henrik Hein Lauridsen. (Denmark)
- 66 Potentially Inappropriate Medication Use in Older Adults in Quebec, Canada: A Population-Based Cohort Study [597]**
Barbara Roux, Caroline Sirois, Marc Simard, Marie-Ève Gagnon, Marie-Laure Laroche. (France)
- 67 Identification of Potential Drug-Related Problems and Drug-Related Risk Factors in Home-Dwelling Older Adults [598]**
Ana I Plácido, Maria Teresa Herdeiro, Fátima Roque. (Portugal)
- 68 Drug Burden of Polypharmacy and Anticholinergic/Sedative Drugs and Physical/Cognitive/Mental Related Outcomes of the Community-Dwelling Elderly People: The Kawasaki Well-Being Project [599]**
Ringo Asano, Asahi Tanaka, Yasumichi Arai, Takumi Hirata, Yukiko Abe, Yuko Oguma, Hisashi Urushihara. (Japan)
- 69 Prescription Pattern for Geriatrics A Case Study of Jos University Teaching Hospital Nigeria [600]**
Rachel U Odesanya, Juliet Igbanugo. (Nigeria)
- 70 Use of Cardiovascular Drugs among Older People in Greece Consuming More Than Five Drugs Daily [601]**
Paraskevi Papaioannidou, Maria Michailidou. (Greece)
- 71 Effect of Adverse Drug Reactions on Length of Stay in Older Adults in a Teaching Hospital in Chile [602]**
Carolina Gutierrez, Tamara Sandoval, Marcela Jiron. (Chile)
- 72 Usefulness of a New Clinical Pharmacology Service in a Single Center to Optimize Drug Therapy in the Elderly in Colombia [603]**
Jefferson Antonio Buendia, Carlos Rodriguez, Andres Felipe Zuluaga. (Colombia)
- 73 Physicians' Knowledge of Appropriate Prescribing for the Elderly - A Survey among Family and Internal Medicine Physicians in Nigeria [604]**
Joseph O Fadare, Abimbola M Obimakinde, Okezie O Enwere, Olufemi O Desalu, Raphael O Ibidapo. (Nigeria)

Poster Session B: Health Economics/Outcomes Research

- 74 Cost-Effectiveness of Adjuvant Whole Breast Irradiation [605]**
Kyrian Ezendu, Askal Ali, Vakaramoko Diaby. (United States)
- 75 Impact of Drug Insurance Type (private/public) on the Cost of Drugs of Quebecers [606]**
Michel Chamoun. (Canada)
- 76 Mind the Gap: A Comparison of Encounter Location and Medical Costs During the One-Month Periods Immediately before and after a Short Gap in United States Medicaid Healthcare Coverage [607]**
Harriet Dickinson, John Logie, George Mu. (United Kingdom)
- 77 Utilization Patterns, Expenditures, and Estimated Savings Associated with Analog or Human Insulin Products in the Medicare Part D Program [608]**
Jing Luo, Aaron Kesselheim. (United States)
- 78 Depression Treatment, Healthcare Expenditures, and Depression Severity in Patients with Depression Using Patient Health Questionnaire-9 Scores to Assess Depression Severity [609]**
Elizabeth R Packnett, Debra E Irwin. (United States)
- 79 Cost Effectiveness Analysis of Rivaroxaban Compared to Warfarin and Aspirin for Stroke Prevention Atrial Fibrillation in The Indonesian Healthcare Setting [610]**
Erna Kristin, Iwan Dwiprahasto, Dwi Endarti, Rizaldy Taslim Pinzon, Alfi Yasmina, Jarir At Thobari, Woro Rukmi Pratiwi, Yolanda Dyah Kartika, Christiana Trijayanti. (Indonesia)
- 80 Accuracy of Budget Impact Estimations of New Oncology Drugs in The Netherlands [611]**
Joost W Geenen, Mark Jut, Cornelis Boersma, Olaf H Klungel, Anke M Hövels. (Netherlands)
- 81 The Impact of Cost-Related Medication Nonadherence on Out-Of-Pocket Costs and Productivity among Cancer Survivors [612]**
Xiaomo Xiong, Minghui Li, Kevin Lu. (United States)
- 82 Opportunity Costs of Receiving Palliative Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) [613]**
Erin Bange, Abigail Doucette, Peter Gabriel, Robin Wang, Andrzej P Wojcieszynski, Bethany Mooney, Ben Boursi, Kim Anna Reiss, Ronac Mamtani. (United States)
- 83 Healthcare Resource Use and Economic Burden of Respiratory Illness Among Extremely Preterm Infants in The Netherlands [614]**
Eline Houben, Csaba Siffel, Jetty Overbeek, Fernie Penning-van Beest, Sujata P Sarda. (Netherlands)
- 84 Healthcare Costs and Resource Utilization Associated with Select Severe Adverse Events in Patients with Metastatic Urothelial Cancer Treated with First-Line Systemic Therapies [615]**
Rahul Shenolikar, François Laliberté, Yunes Doleh, Cristi Cavanaugh, Maral DerSarkissian, Petros Grivas. (Canada)
- 85 An Analysis of the Effectiveness Outcomes of Economic Studies Evaluating Ophthalmic Drugs: A Systematic Review [616]**
Inês Ribeiro, Francisco Batel Marques, Carlos Alves. (Portugal)
- 86 Economic Evaluation of Bevacizumab Added to Chemotherapy for Metastatic Colorectal Cancer (mCRC) in Indonesia [617]**
Erna Kristin, Dwi Endarti, Rizaldy Taslim Pinzon, Woro Rukmi Pratiwi, Dwi Aris Nugrahaningsih, Alfi Yasmina, Didik Setiawan, Ratih Puspita Febrinasari, Tri Murti Andayani. (Indonesia)
- 87 How Different Regulatory Systems Recognize and Reward Pharmaceutical Innovation - A Comparative Analysis of Intellectual Property (IP) Protection, Marketing Authorization and Pricing/Reimbursement Systems with a Focus on Oncology [618]**
Nahila Justo, Linus Jönsson, Nils Wilking. (Sweden)
- 88 Opioid Use, Healthcare Expenditures, and Pain Severity in Osteoarthritis Patients Using Patient Reported Pain Scores to Assess Pain Severity [619]**
Elizabeth R Packnett, Debra E Irwin. (United States)
- 89 Analysis of the Price Difference Rate between Essential and Non-Essential Medicines in China [620]**
Xinzhao Cai, Zhi Cui, Zhiting Liu, Ying Bian. (Macao)
- 90 The Cost of Hospitalization and Length of Stay Due to Hypoglycemia in Patients with Diabetes Mellitus: A Cross-Sectional Study [621]**
Abdallah Y Naser, Sinaa Alaqeel, Hassan Alwafi. (Jordan)
- 91 The Devil you Should Know: Adjustment for Confounding Bias is Rare in Observational Economic Evaluations in Cardiology [622]**
Jason R Guertin, Blanchard Conombo, Raphaël Langevin, Frédéric Bergeron, Anne Holbrook, Brittany Humphries, Alexis Matteau, Brian J Potter, Christel Renoux, Jean-Eric Tarride, Madeleine Durand. (Canada)

Poster Session B | Tuesday, August 27 • 8:00am - 6:00pm

- 92 Incidence and Treatment-Related Economic Burden Of HPV-Related Cervical, Vulvar, Vaginal, and Anal Cancers in The US [623]**
Vimalanand S Prabhu, Jinghua He, Christine Velicer, Teesta Banerjee, Smita Kothari. (United States)
- 93 Cost Analysis of Hepatitis C Treatments in Saudi Arabia [624]**
Sondus Issam Ata, Mohammed Al-Owairdhi, Taif Khalid Albassri, Fatimah Al-Hussain, Sara Al-Hassan, Abdulaziz Al-Shehri, Fahad Al-Nutaify, Tariq Mohammed Alhawassi. (Saudi Arabia)
- 94 Assessment of Incidence and Severity of Drug Related Problems in Patients with Chronic Diseases and Pharmacist Intervention in Net Cost Savings [625]**
Adepu Ramesh, Manohar Gopal. (India)
- 97 Confounding Effect of Smoking on the Association between Fluoroquinolone and Risk of Aortic Aneurysm [628]**
Mingfeng Zhang, Monique Falconer, Lockwood Taylor. (United States)
- 98 Antidepressant Medication, Suicidal Behavior and Violent Crime in a Cohort of Danish Patients with Affective Disorders [629]**
Merete Osler, Marie Wium-Andersen, Ida Wium-Andersen, Frederikke Gronemann, Martin Jørgensen, Maarten Rozing. (Denmark)
- 99 Use of External Comparators for Health Technology Assessment Submissions - An Analysis of HTA Accelerator [630]**
Dony Patel, Fiona Grimson, Elena Mihaylova, Yulia Chan, Deborah Layton. (United Kingdom)
- 100 Assessment of Channeling among Initiators of Suvorexant Compared to other Insomnia Drugs [631]**
Cathy Anne Pinto, Praful Kumar, W Joseph Herring, Johanna Hyacinthe, Ankita Kumar, Mani Lakshminarayanan, Zhiwen Liu. (United States)
- 101 Lurking Berkson's Bias in Pharmacoepidemiology: Tales of Colliders [632]**
Nicole M Bailey, Andy R Wilson, Aaron W Kamauu. (United States)
- 102 Analytic and Design Approaches to Unmeasured Confounding by Body Mass Index [633]**
Tracy L Kinsey, Til Stürmer, Michele Jonsson Funk, Charles Poole, Ross J Simpson, Robert J Glynn. (United States)
- 103 Multiple Risk Factor Control and Risk of Cardiovascular Events and Mortality in People with Type 2 Diabetes in The UK [634]**
Alison K Wright, Fabian Suarez Ortega, Jeremy Walker, Evangelos Kontopantelis, Iain Buchan, Richard Emsley, Naveed Sattar, Darren M Ashcroft, Sarah Wild, Martin K Rutter. (United Kingdom)
- 104 Evaluation of Confounding by Smoking and Obesity in a Study of Pancreatic and Thyroid Cancer Incidences in Patients Treated with Exenatide, an Administrative Healthcare Database Investigation Supplemented with Medical Records [635]**
Caihua Liang, Monica L Bertoia, C. Robin Clifford, Yan Ding, Qing Qiao, Joshua J Gagne, David D Dore. (United States)
- 105 Using Different Look Back Periods to Calculate The Charlson Comorbidity Index (CCI) in NVAF Patients Treated with Oral Anticoagulants (OACs) [636]**
Sophie Graham, Anna Schultze, Beth Nordstrom, Faisal Mehmud, Sreeram Ramagopalan. (United Kingdom)
- 106 Missing the Trees for the Forest Plots: Where Subgroups Fall Short [637]**
Michael Webster-Clark, Daniel Westreich, John A Baron, Michele Jonsson-Funk. (United States)
- 107 Post-Surgery Infection and Subsequent Mortality among Hip Fracture Surgery Patients: Different Methods for Dealing with Time-Varying Confounding in a Danish Population Based Cohort Study, 2004-2016 [638]**
Nickolaj R Kristensen, George Luta, Lars Pedersen, Vera Ehrenstein, Alma B Pedersen. (Denmark)

Poster Session B: Methods - Study Design, Bias, and Confounding

- 95 Possible Channeling Bias in the Evaluation of Cardiovascular Risk of Triptans: The Importance of Comparator Selection in Observational Research [626]**
Hu Li, Xiang Zhang, Robert Goodloe, Maurice Vincent. (United States)
- 96 Cohort Study of the Relative Incidence of Major Cardiovascular Events among Patients Initiating Prucalopride Versus a Matched Comparator Cohort in a Multinational Study: Study Design and Comparability of Cohorts [627]**
Joan Fortuny, Alicia Gilsenan, Miguel Cainzos-Achirica, Oscar F Cantero, Robert W Flynn, Luis Garcia-Rodriguez, Bianca Kollhorst, Pär Karlsson, Love Linnér, Thomas M MacDonald, Estel Plana, Ana Ruigómez, Tania Schink, Ryan Ziemiecki, Elizabeth B. Andrews. (United States)

- 108 Indication Bias in the Study of Comparative Effectiveness of Direct Oral Anticoagulants in the Prevention of Stroke [639]**
Lamiaie Grimaldi-Bensouda, Jean Ferrières, Didier Leys, Jean-Marc Davy, Mikel Martinez, Nicolas Morisot, Pegdwende O Dialla, Didier Smadja, Norbert Nighoghossian, Jacques Bénichou, Clémentine Nordon, Emmanuel Touzé, Lucien Abenheim. (France)
- 109 Challenges in Conducting a Multinational European Study of Severe Hypersensitivity Reactions among Recipients of Intravenous Iron [640]**
Lia Gutierrez, Irene D Bezemer, Jochen Dress, Vera Ehrenstein, Michael Forstner, Carla Franzoni, Regis Lassalle, Marie Linder, Cecile Droz-Perroteau, Ingvald Odsbu, Jetty A Overbeek, Susana Perez-Gutthann, Federica Edith Pisa, Katherine Rascher, Lawrence Rasouliyan, Jonas Reinold, Kenneth Rothman, Nuria Saigi-Morgui, Mathias Schaller, Elisabeth Smits, Antje Timmer, Gunnar Toft, Gero von Gersdorff, Joan Fortuny. (Spain)
- 110 Bias Reduction with Multiple Imputation of Lab Results From a Limited Internal Sample [641]**
Tiansheng Wang, Magdalene M Assimon, Virginia Pate, Emily W Gower, Jennifer L Lund, Michele L Jonsson-Funk, Michele L Jonsson-Funk, John B Buse, Til Stürmer. (United States)
- 111 Comparison of New User Definitions in Multi-Specialty EMR Data [642]**
Jeffrey Curtis, Lang Chen, James Oates, Cassie Clinton, Fenglong Xie, Shuo Yang, Tim Beukelman. (United States)
- 112 A Simple Method to Find Applicable Lengths of Washout Periods for Identifying New Users in Pharmacoepidemiologic Study [643]**
Nai-Yu Chen, Chien-Chou Su, Edward Chia-Cheng Lai. (Taiwan)
- 113 Impact of Non-Adjustment for Smoking Status During Pregnancy and Pre-Pregnancy Obesity on the Association between Gestational Antidepressant Use and Risk of Low Birth Weight Infants [644]**
Jin-Ping Zhao, Odile Sheehy, Anick Berard. (Canada)
- 114 Case Validation of Cutaneous Lymphoma to Minimise Protopathic Bias [645]**
Lia Gutierrez, Helen Booth, Daniel Dedman, Elizabeth Crellin, James A Kaye, Carla Franzoni, Alejandro Arana, Marcus Schmitt-Egenolf, Anders Sundström, Camilla Byström. (Spain)
- 115 Unmeasured Confounders May Cause Underestimation of Anti-Osteoporotic Drug Effects in Postmenopausal Women with Osteoporosis in Taiwan [646]**
Pin-Tsen Yeh, Yea-Huei Kao Yang, Edward Chia-Cheng Lai. (Taiwan)
- 116 Misclassification of Case-Control Studies in PubMed [647]**
Stephen Kim. (United States)
- 117 Gender and Authorship in Pharmacoepidemiology: Studying The Authorship Patterns of Canadian Network for Observational Drug Effect Studies Research [648]**
Melissa Helwig, Keri McCaffrey, Robyn Traynor, Elaine Burland, Ingrid S Sketris, Samuel A Stewart. (Canada)
- 118 Performance of Genetic Risk Scores as an Instrumental Variable in Pharmacoepidemiology [649]**
Md Jamal Uddin, Claus Thorn Ekstrøm, Merete Nordentoft. (Bangladesh)
- 119 Outcome Classification Methodology and Heterogeneity of Association between BMI and COPD in the UK Biobank Cohort [650]**
Jonathan M Davitte, Jessica L Chao, Oksana Kirichek. (United States)
- 120 Outcome Definition Influences the Relationship between Genetic Polymorphisms of ERCC1, ERCC2, SLC22A2 and Cisplatin Nephrotoxicity in Adult Testicular Cancer Patients [651]**
Zulfan Zazuli, Leila S Otten, Britt I Drogemoller, Galen E Wright, Susanne J Vijverberg, Rosalinde Masereeuw, Colin J Ross, Geoffrey Liu, Bruce C Carleton, Anke Hilse Maitland-van der Zee. (Netherlands)
- Poster Session B: Opioids**
- 121 Uptake of The Ontario Naloxone Program for Pharmacies [652]**
Mina Tadrous, Diana Martins, Beatrice Choremis, Tonya Campbell, Tony Antoniou, Tara Gomes. (Canada)
- 122 Opioid Prescription Patterns among Patients Diagnosed with Rheumatoid Arthritis in United States [653]**
Jolyon Fairburn-Beech, Ayush V Patel, Rachel Williams. (United States)
- 123 Opioid Prescribing and Health Outcomes in Indiana, USA before and after Release of Centers for Disease Control and Prevention Opioid Prescribing Guidelines [654]**
Sariya Udayachalerm, David R Foster, Michael D Murray. (United States)
- 124 Assessing the Impact of Opioid Prescribing Guidelines for Dentists in Ontario, Canada [655]**
Qi Guan, Tonya Campbell, Diana Martins, Mina Tadrous, David Juurlink, Michael Paterson, Muhammad Mamdani, David Mock, Tara Gomes. (Canada)
- 125 A Comparison of Opioid-Involved Fatalities Captured in The National Poison Data System and in Death Certificate Literal Text Data [656]**
Celeste Mallama, James Trinidad, Richard Swain, Yueqin Zhao, Corinne Woods, Jana McAninch. (United States)

- 126 Persistent Opioid Prescribing after Minor Surgery in Trinetx [657]**
 Brian Buysse, Jayashri Desai, Jessica Albano. (United Kingdom)
- 127 Differences in Opioid Prescriptions among Age Categories of Older Adults [658]**
 Yvette M Weesie, Liset van Dijk, Tjard Schermer, François Schellevis, Hubert G Leufkens, Elisabeth J Rook, Karin Hek. (Netherlands)
- 128 Risk Factors for New and Persistent Chronic Opioid Use after Hip Fracture Surgery: A Danish Nationwide Cohort Study from 2005 to 2016 [659]**
 Nina M. Edwards, Claus Varnum, Søren Overgaard, Lone Nikolajsen, Alma B Pedersen. (Denmark)
- 129 Prescription Opioid Use and Dose Trajectories before Diagnosis of Opioid Use Disorder or Overdose among US Adults [660]**
 Yu-Jung Wei, Cheng Chen, Amir Sarayani, Roger Fillingim, Siegfried Schmidt, Almut Winterstein. (United States)
- 130 Trends in Opioid Use among Commercially Insured Pregnant Women with Severe Maternal Morbidity in The United States, 2007-2015 [661]**
 Aakash Bipin Gandhi, Danya M Qato. (United States)
- 131 Concomitant Use of Z-Drugs with Prescribed Opioid Agents and the Risk of Overdose: A Cohort Study [662]**
 Alejandro Szmulewicz, Brian Bateman, Raisa Levin, Krista Huybrechts. (United States)
- 132 Direct and Indirect Effects of Medication Assisted Therapy on Nonfatal Opioid Overdose Among Patients with Opioid Use Disorder within Prescriber Networks [663]**
 Tianyu Sun, Ashley Buchanan, Hilary Aroke, Jeffrey Bratberg, Jing Wu, Josiah Rich, Joseph Hogan, Stephen Kogut. (United States)
- 133 Abstract withdrawn [664]**
- 134 Concomitant Use of Opioids or Psychotropic Medications among Skeletal Muscle Relaxant Users in The United States: A Cross-Sectional Study [665]**
 Yan Li, Gary M Reisfield, Chris Delcher, Yu-Jung Wei, Joshua Brown, Almut G Winterstein. (United States)
- 135 Predictors of Long-Term Opioid Use in HIV Patients who Initiated Antiretroviral Therapy [666]**
 G Yeon Oh, Emily S Brouwer, Erin L Abner, David W Fardo, Patricia R Freeman, Daniela C Moga. (United States)
- 136 Patterns of Opioid Use among Patients with Cancer-Related Pain Diagnoses [667]**
 Tham T Le, Sean Fleming, Oluwadamilola Onasanya, Danya M Qato, Linda Simoni-Wastila. (United States)
- 137 Opioid Overdose in Patients Treated with Extended-Release Naltrexone: Postmarketing Data from 2006 to 2018 [668]**
 Gary Bloomgren, Made Wenten, Kimberly Marcopul, Prashanthi Vunnava, Marie Liles-Burden, Avani Desai, Sarah Akerman, Maria A Sullivan, James Fratantonio, Priya Jain. (United States)
- 138 Recent Changes in the Prevalence of Rapid Tapering of Opioid Doses in Ontario, Canada [669]**
 Mina Tadrous, Wayne Khuu, Diana Martins, David N Juurlink, J. Michael Paterson, Muhammad M Mamdani, Tara Gomes. (Canada)
- 139 Association of New Opioid Continuation with Surgical Specialty and Type in The United States [670]**
 Omar Mansour, Mark Bicket, Irene Murimi, Christopher Wu, G Caleb Alexander. (United States)
- 140 Opioid and Concomitant Benzodiazepine Outpatient Prescription Claims among Women with Pregnancies in 2014 [671]**
 Elizabeth C Ailes, April D Summers, Shin Y Kim, Kayla N Anderson, Suzanne M Gilboa. (United States)
- 141 How Many Elderly in Norway are Persistent Opioid Users? - A Comparison of Two Approaches to Define Persistent Opioid Use [672]**
 Kristian Svendsen, Beate H Garcia, Kjell H Halvorsen, Lars Småbrekke. (Norway)
- 142 Regional Examination of Increased Buprenorphine in The US (2008 - 2017) [673]**
 Amir Reza Pashmineh Azar, Warren Lam, Alyssa Muchisky, Suhail Kaleem, Laura Lockard, Mark Mandel. (United States)
- 143 Incidence and Persistence of Opioid Use after Surgery among Opioid-Naïve Adults in a Large Commercial US Health Plan [674]**
 Sandra Wu, Xian Zhang, Shawn Boykin, Richard Scranton, Mary Helen Tran. (United States)
- 144 Incidence of Chronic Opioid Use in Seniors [675]**
 Audrey Beliveau, Anne-Marie Castilloux, Cara Tanenbaum, Philippe Vincent, Cristiano Soares de Moura, Sasha Bernatsky, Iris Pujade, Yola Moride. (Canada)

- 145 Trends in the Acquisition and Distribution of Opioid Drugs among Ten Contiguous States [676]**
Michael Belko, Elizabeth Stackhouse, Zoe Landau, Alex Mettler, Christine Murphy, Kristin Feickert, Ceilia Severini, Stephanie Nichols, Kenneth McCall, Brian Piper. (United States)
- 146 Oversight of Extended Release/long Acting (ER/LA) Opioids by The U.S. Food and Drug Administration: A Narrative Review [677]**
James Heyward, Lily Olson, Josh Sharfstein, Peter Lurie, G Caleb Alexander. (United States)

**Poster Session B:
Pharmacovigilance -
Musculoskeletal**

- 147 Antidiabetic Medication, Level of Glycaemic Control, and Risk of Fracture in Patients with Type 2 Diabetes Mellitus: A Nested Case-Control Study [678]**
Sarah H Charlier, Janina Vavanikunnel, Claudia Becker, Susan S Jick, Christian Meier, Christoph R Meier. (Switzerland)
- 148 Risk of Hand Osteoarthritis in New Users of Hormone Replacement Therapy: A Nested Case-Control Analysis [679]**
Theresa Burkard, Marlene Rauch, Julia Spöndlin, Daniel Prieto-Alhambra, Susan S Jick, Christoph R Meier. (Switzerland)
- 149 Association between Fluoroquinolone Use and Achilles Tendon Pathology: Active Comparator New User Investigation [680]**
Mackenzie M. Herzog, Virginia Pate, Jennifer L Lund, Stephen W Marshall. (United States)

- 150 Dose-Dependent Effects of Gabapentin and Pregabalin on the Day of Surgery in Total Hip and Knee Arthroplasties [681]**
Tetsu Ohnuma, Karthik Raghunathan, Sean Moore, Soko Setoguchi, Alan R Ellis, John Whittle, Srinivas Pyati, William E Bryan, Marc J Pepin, Raquel R Bartz, Vijay Krishnamoorthy. (United States)
- 151 Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Fractures: Analysis of the FDA Adverse Event Reporting System Database [682]**
Wenchao Lu, Lulu Sun, Luwen Shi, Tiansheng Wang. (China)

- 152 Assessing the Incidence of Osteosarcoma among Teriparatide Users via Linkage of Data from Medicare Part D and Multiple State Cancer Registries in The United States [683]**
Alicia Gilsonan, Kirk Midkiff, David Harris, Lisa McQuay, Shannon Hunter, Nicole Kellier-Steele, Elizabeth Andrews. (United States)

- 153 Risk of Fall Injuries with Concomitant Use of Beta-Blockers and CYP2D6 Inhibitors [684]**
Max Vikström, Karin Leander, Marja-Liisa Dahl, Karin Söderberg-Löfdal. (Sweden)

- 154 Evaluation of Myalgia Related Adverse Event Reports Attributed to Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Inhibitors within the FDA Adverse Events Reporting System (FAERS) [685]**
Yasmin Elsobky, Mohamed A Mekki. (Egypt)

- 155 Association Between SGLT-2 Inhibitors and Lower Extremity Amputation among Patients with Type 2 Diabetes: A Systematic Review [686]**
James Heyward, Omar Mansour, Claire Twose, Hsien-Yen Chang, Sonal Singh, G. Caleb Alexander. (United States)

- 156 Risk of Tendinopathy Associated with Fluoroquinolones: A Systematic Review and Meta-Analysis [687]**
Carlos Alves, Diogo Mendes, Francisco Batel Marques. (Portugal)

- 157 Results of a Long-Term Postmarketing Case Series of Adult Osteosarcoma and Teriparatide in The United States [688]**
Kirk Midkiff, David Harris, Alicia Gilsonan, Nicole Kellier-Steele, David McSorley, Elizabeth Andrews. (United States)

- 158 Statin Use and Muscular Problems: A Cross-Sectional Analysis of The ELSA-Brasil Musculoskeletal Cohort [689]**
Aline F Pedrosa, Bruce B Duncan, Maria de Fátima H Diniz, Luciana A Machado, Rosa W Telles, Sandhi M Barreto, Roberta C Figueiredo. (Brazil)

**Poster Session B:
Pharmacovigilance - Nervous
System**

- 159 Concomitant Opioid and Benzodiazepine or Z-Drug Use: Analysis of The Food and Drug Administration's Adverse Event Reporting System [690]**
Anh Thy H Nguyen, Darren Scheer, Skai Schwartz. (United States)

- 160 Benzodiazepines, Opioids, & Mortality in Hemodialysis Patients [691]**
Mara McAdams DeMarco, Abimereki Muzaale, Sunjae Bae, Matthew Daubresse, Nadia Chu, Dorry Segev. (United States)

- 161 Comparative Safety of Medications for Insomnia and Risk of Suicide Attempt in The Department of Veterans Affairs [692]**
Jill E Lavigne, Kwan Hur, Cathleen M Kane, Anthony Au, Todd M Bishop, Wilfred R Pigeon. (United States)

Poster Session B | Tuesday, August 27 • 8:00am - 6:00pm

- 162 Assessing the Risk of Depression Associated with 5A-Reductase Inhibitor Use : A Population-based Retrospective Cohort Study in Korea [693]**
Bora Yeon, Ah Young Suh, Bonggi Kim, Soo Youn Chung, Soonyoung Han. (Korea, Republic of)
- 163 Switching from Methadone Syrup to Capsule and All-Cause Mortality Risk [694]**
Sandy Maumus-Robert, Joëlle Micallef, Michel Mallaret, Yohann Mansiaux, Nicolas Authier, Maryse Lapeyre-Mestre, Antoine Pariente. (France)
- 164 Impact of the Extension of Maximum Prescription Duration of Methadone Capsule on All-Cause Mortality [695]**
Sandy Maumus-Robert, Maryse Lapeyre-Mestre, Nicolas Authier, Yohann Mansiaux, Michel Mallaret, Joëlle Micallef, Antoine Pariente. (France)
- 165 Trend Analysis of Amphetamine-Class Overdose Deaths in Kentucky [696]**
Patrick J Ward, Svetla Slavova, David Akers. (United States)
- 166 Predictors of Justice System Involvement in Antipsychotic Users in Manitoba, Canada [697]**
Donica Janzen, I fan Kuo, Christine Leong, James Bolton, Silvia Alessi-Severini. (Canada)
- 167 Does Aspirin Use Increase the Risk of Age-Related Macular Degeneration: A Population-Based Comparative Cohort Study [698]**
Wan-Ju Annabelle Lee, Ching-Lan Cheng, Yea-Huei Kao Yang. (Taiwan)
- 168 The Association between Treatment with Montelukast and Migraine - A Symmetry Analysis [699]**
Daniel P Henriksen, Jesper Hallas. (Denmark)
- 169 Excess of All-Cause Mortality Associated with Benzodiazepine Use: A Cohort Study [700]**
Clément Mathieu, Pierre Joly, Hélène Jacqmin-Gadda, Mathilde Wanneveich, Bernard Bégaud, Antoine Pariente. (France)
- 170 Spontaneous Parasomnia Adverse Event Reports Associated with Benzodiazepines and Z-Drugs [701]**
Darren Scheer, Anh Thy H Nguyen, Skai Schwartz. (United States)
- 171 Risk of Death Associated with the Use of Antipsychotic Drugs among Parkinson's Disease with Psychosis [702]**
Hoa V Le, Phuong Le, Chi Truong. (United States)
- 172 Association of Macular Disease with Use of Pentosan Polysulfate Sodium [703]**
Brian L VanderBeek, Alexandra L Li, Yinxi Yu, Neiraj Jain. (United States)
- 173 Stuttering and Methylphenidate [704]**
Thierry Trenque, Brahim Azzouz, Gwladys Claustre, Emmanuelle Herlem, Agathe Trenque, Aurore Morel. (France)
- 174 Use of B2-Adrenoreceptor Agonist and Antagonist Drugs and Risk of Parkinson's Disease [705]**
Franziska Hopfner, Mette Wod, Günter U Höglinger, Morten Blaabjerg, Thomas W Rösler, Gregor Kuhlensäumer, Kaare Christensen, Günther Deuschl, Anton Pottegård. (Denmark)
- 175 Association of the Inhaled Corticosteroids and the Risk of Cataract Requiring Surgery in Adults with Asthma: A Population-Based Study in South Korea [706]**
Na-Young Jeong, Mi-Sook Kim, Chang-Hoon Lee, Heung-Woo Park, Bo Ram Yang, Joongyub Lee, Nam-Kyong Choi. (Korea, Republic of)
- 176 A Safety Signal of Somnambulism with the Use of Antipsychotics: A Pharmacovigilance Disproportionality Analysis [707]**
Amandine Gouverneur, Amandine Ferreira, Cécile Pageot, Camille Morival, Marie Tournier, Antoine Pariente. (France)
- 177 Abstract withdrawn [708]**
- 178 Spontaneous Reporting of Rare Events Associated with Atypical Antipsychotics Using the FDA Adverse Event Reporting System [709]**
Nnadozie Emechebe, Fahad Mukhtar, Darren Scheer, Arshiya Patel, Abhishek Wadhawan, Skai Schwartz, Janice Zgibor. (United States)
- 179 Disproportionality Analysis of Emotional and Mood Disturbances with Statins Using The Food and Drug Administration Adverse Event Reporting System [710]**
Catherine Patterson, Mikel Alberdi, Darren Scheer. (United States)
- 180 Impulse Control Disorders Associated with Dopamine Agonists in Patients with Prolactinomas: A Literature Review [711]**
Anindit Chhibber, William Barbeau, Marco Bortolato, Nakyung Jeon. (United States)
- 181 Risk of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Associated with Anticonvulsants in a Japanese Population [712]**
Toshiki Fukasawa, Hayato Takahashi, MD, PhD, Nanae Tanemura, PhD, Masayuki Amagai, MD, PhD, Hisashi Urushihara, DrPH. (Japan)
- 182 Risk of Extrapyrimalidal Syndromes Associated with Antipsychotic Polypharmacy: A Retrospective Study Based on Spontaneous Reporting System Databases [713]**
Kouichi Hosomi, Hiroki Kagoyama, Satoshi Yokoyama, Mitsutaka Takada. (Japan)

- 183 Risk of Suicide Attempt and the Use of Antidepressants in Taiwan [714]**
Chih-ying Tsai, Yea-Huei Kao Yang, Kao Yang, Edward Chia-Cheng Lai. (Taiwan)
- 184 Comparative Risk of Mortality among Individual Antipsychotics in Patients with Dementia [715]**
Shi-Jie Lai, Chien-Chou Su, Chin-Yao Shen, Edward Chia-Cheng Lai. (Taiwan)
- 185 Oral Antidiabetes Drugs and Risk of Stroke [716]**
Lamiae Grimaldi-Bensouda, Nicolas Morisot, Pegdwende O Dialla, Clémentine Nordon, Lucien Abenheim. (France)
- 186 Trazodone Use and Risk of Dementia: A Population-Based Cohort Study [717]**
Ruth Brauer, Wallis Lau, Joseph F Hayes, Kenneth K Man, David P Osborn, Robert Howard, Joseph Kim, Ian C Wong. (United Kingdom)
- 187 Risk of Bullous Pemphigoid after Initiating Dipeptidyl Peptidase 4-Inhibitor Versus 2nd Generation Sulfonylurea: Multi-Database Cohort Study [718]**
Hemin Lee, Hye Jin Chung, Ajinkya Pawar, Elisabetta Patorno, Dae Hyun Kim. (United States)
- 188 Risk of Acute Kidney Injury and Chronic Kidney Disease Following Aciclovir and Valaciclovir Therapy [719]**
Lars Christian Lund, Daniel P Henriksen, Peter B Jensen, Kasper B Kristensen. (Denmark)
- 189 Fluoroquinolone Adverse Drug Events: Results of an Active Surveillance Project [720]**
Nathan Sylvain, Sherrie Aspinall, Fran Cunningham, Kelly Echevarria, Rongping Zhang, Diane Dong, Peter Glassman, Matthew Goetz. (United States)
- 190 Under-Reporting of Adverse Drug Reaction: Pharmacovigilance Awareness and Challenges among Resident Doctors [721]**
Hala Shokr, Didi Ahmed, Youstra El-adwy. (United Kingdom)
- 191 Calcium Channel Blocker Induced Lymphedema among Breast Cancer Patients: A Nested Case Control Study [722]**
Mrinmayee Lakkad, Amanda Stolarz, Jacob Painter. (United States)
- 192 Incidence of Depression and Anemia amongst Users of Hormonal Treatments for Endometriosis - Final Results from The VIPOS Study [723]**
Klaas Heinemann, Sabine Moehner, Kerstin Becker, Jens Lange. (Germany)
- 193 The Role of Dose Escalation in New Users of Lamotrigine Inducing Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis: Results from The German Registry [724]**
Sophie Diederich, Maren Paulmann, Maja Mockenhaupt. (Germany)
- 194 Cutaneous Allergy as Potential Long-Term Effect of Hormonal Intrauterine Systems [725]**
Jill Huppert, Chunliu Zhan, Yasameen Azarbaijani, Yelizaveta Torosyan. (United States)
- 195 Population-Level Impact of Low-Dose Aspirin on the Prevention of Cardiovascular Disease, Colorectal Cancer and Safety Outcomes in Europe: A Micro-Simulation Model [726]**
Kaatje Bollaerts, Pareen Vora, Elodie Sole, Jorne Bicler, Katsiaryna Holl, Ruth Langley, Angel Lanas, Luis A Rodríguez, Thomas Verstraeten, Montse Soriano-Gabarró. (Belgium)
- 196 Safety of Dietary Supplements Use among Cancer Patients: A Systematic Review of Clinical Trials [727]**
Zhen Zeng, Ahmed Ullah Mishuk, Kadajah Edwards, Chiahung Chou, Jingjing Qian. (China)
- 197 Population Based Estimates of Community Based Adverse Drug Reactions (ADRs) in The Kingdom of Saudi Arabia [728]**
Rasha A Almubark, Thamir M Alshammari, Amani S Alqahtani, Nasser F BinDhim. (Saudi Arabia)
- 198 Mortality Due to Adverse Drug Reactions: An Analysis of an International Pharmacovigilance Database [729]**
Gwladys Claustre, Aurore Morel, Brahim Azzouz, Emmanuelle Herlem, Thierry Trenque. (France)
- 199 Evaluation of Ethnic Differences in Incidence of Severe Cutaneous Adverse Reactions in East Asians [730]**
Tsugumichi Sato, Ching-Lan Cheng, Heung-Woo Park, Yea-Huei Kao Yang, Min-Suk Yang, Mizuki Fujita, Takuya Imatoh, Yuji Kumagai, Masahiro Tohkin, Yoshiro Saito, Kimie Sai. (Japan)
- 200 Medication Related Hospital Admissions to a Tertiary Care Teaching Hospital: A Prospective Cross Sectional Study [731]**
Ramesh Madhan, Patil Aishwarya, Anjali James, Grishma G John, Melwala Mihir, Chalasani Sri Harsha. (India)
- 201 Frozen in Time; Contemporizing Generic Labels [732]**
Lester Reich, Barbara De Bernardi, Douglas Ross, Karilyn Halloran, Ma Fides Binasoy, Nicholas Manuel Gonzales, Philip Arena, Ravi Nair, Tricia Racanelli. (United States)

**Poster Session B:
Pharmacovigilance - Potpourri**

- 202 Prospective Cohort Study of Adverse Drug Reactions on all Admissions to Internal Medicine: Prevalence, Incidence and Risk Factors [733]**
 Aduragbenro D Adedapo, Waheed Adededeji, IfetiOluwanimi A Adedapo, Kayode S Adedapo. (Nigeria)
- 203 Real World Data Pharmacoepidemiological Study on the Prevalence of Potential Drug-Drug Interactions in Thessaloniki, Greece [734]**
 Panagiotis Nikolaos Lalagkas, Georgios Poulentzas, Labros Tsiolis, Eleftherios Berberoglou, Christos Kontogiorgis, Theodoros Constantinides, Dimitra Hadjipavlou-Litina. (Greece)
- 204 Patient Exposure During Pre-Market Trials and Relationship with Post-Market Safety Outcomes [735]**
 Sanae Cherkaoui, Ellen Pinnow, Ilynn Bulatao, Brendan Day, Manish Kalaria, Sonja Brajovic, Gerald Dal Pan. (United States)
- 205 Adverse Drug Reactions on Female Fertility: A Study in VigiBase [736]**
 Daphné Toledano, Mélanie Araujo, Jean-Louis Montastruc, Christine Damase-Michel, Justine Benevent, Isabelle Lacroix. (France)
- 206 The Characteristics of Drug Information Inquiries in an Ethiopian University Hospital: A Two Year Prospective Observational Study [737]**
 Yonas Getaye Tefera, Begashaw Melaku Gebresillassie, Asnakew Achaw Ayele, Yared Belete Belay, Yohannes Kelifa Emiru. (Ethiopia)
- Poster Session B: Pregnancy and Lactation - Methods**
- 207 Validation of Maternal Self-Reported Pregnancy Complications Using Web-Based Questionnaires in a Prospective Cohort Study [738]**
 Pim Beekers, Hussein Jamaladin, Joris van Drongelen, Nel Roeleveld, Marleen M van Gelder. (Netherlands)
- 208 Validation of a Comorbidity Index for Use in Obstetric Patients: A Nationwide Cohort Study [739]**
 Mette Bliddal, Sören Möller, Christina Vinter, Katrine Rubin, Joshua Gagne, Anton Pottegård. (Denmark)
- 209 Social Media Monitoring on the Safety of Medication Use During Pregnancy: A Case Study from The Netherlands [740]**
 Marleen M van Gelder, Annemarije Rog, Sebastian J Bredie, Wietske Kievit, Hedvig Nordeng, Tom H van de Belt. (Netherlands)
- 210 Implementation of ICD-10-CM Z3A% Codes in Real-World Evidence Studies of Pregnancy Outcomes [741]**
 Aziza Jamal-allial, Jade Dinh, Shiva K. Vojjala, Stephan Lanes. (United States)
- 211 Use of Adverse Events Spontaneous Reporting for Drug Safety Surveillance in Pregnancy [742]**
 Wan-Ting Hsu, Sonia Hernández-Díaz. (United States)
- 212 Every Mother Counts: Target Sample Size Estimates for Pregnancy Exposure Registries [743]**
 Emily W Bratton, Katherine M Lee, William G Hawkes, Suzanne N Landi, Kristen A Hahn. (United States)
- 213 Calculating Prevalence of Spontaneous Abortion in Pregnancy Registries: Slippery Slope [744]**
 Deborah Covington, Kristin Veley, Rebecca Buus, Paige Churchill. (United States)
- 214 Development of Pregnancy Identification and Trimester Algorithm in US Claims Data [745]**
 Keele E Wurst, Anna Ehlinger. (United States)
- 215 Timing of Routine Prenatal Screening Tests Relative to the Last Menstrual Period Estimated from an ICD-10 Based Algorithm [746]**
 Kelesitse Phiri, Robin Clifford, Michael Doherty, Yuan Fan, Florence Wang, John Seeger. (United States)
- 216 Evaluation of a Pregnancy and Trimester Algorithm in US Claims Data [747]**
 Keele E Wurst, Anna Ehlinger. (United States)
- 217 Study of the Association of Uterine Perforation and IUD Expulsion with Breastfeeding and Postpartum Timing at IUD Insertion (APEX IUD)- Study Size Estimation to Actuality [748]**
 Catherine W Saltus, Jennifer Gatz, Mary E Ritchey, Laura E Ichikawa, Mary Anne Armstrong, Amy L Alabaster, Maqdooda Merchant, Richard Lynen, Alex Asiimwe, Jiaxiao M Shi, Darios T Getahun, Fagen Xie, Vicki Y Chiu, Mary S Anthony. (United States)
- 218 Prevalence of Cyp2C19 Genetic Polymorphisms in 26 Population Affecting Safety or Efficacy of Medications [749]**
 Mohitosh Biswas. (Bangladesh)
- 219 Medication Related Problems among Post-Renal Transplant Patients at the Renal Unit of a Referral Hospital in Kenya: A Cross Sectional Study [750]**
 Sylvia Opanga, Cyrus Kariuki. (Kenya)

Poster Session B: Pregnancy and Lactation - Medications and Birth Defects

220 20 Years of Major and Minor Malformations in Danish Health Registries: A Descriptive Study [751]

Per Damkier, Mette Bliddal, Anton Pottegård, Jesper Hallas, Anne Broe. (Denmark)

221 In Utero Exposure to Antibiotics and Risk of Congenital Malformations: A Population-Based Study [752]

Per Damkier, Louise M Brønning, Johan F Korch-Frandsen, Anne Broe. (Denmark)

222 Asthma Medication Use and Risk of Birth Defects: National Birth Defects Prevention Study 1997-2011 [753]

Meredith M Howley, Eleni A Papadopoulos, Carla Van Bennekom, Alissa R Van Zutphen, Suzan L Carmichael, JeanPierre W Munsie, Michele L Herdt, Marilyn L Browne. (United States)

223 Phthalate Exposure from Drugs during Pregnancy and Risk of Preterm Birth and Small for Gestational Age [754]

Anne Broe, Anton Pottegård, Jesper Hallas, Thomas P Ahern, Ronald F Lamont, Per Damkier. (Denmark)

224 Estimating the Causal Effect of Prenatal Lead on Prepulse Inhibition: A Prospective Study in Children and Adolescents [755]

Kale Kponee-Shovein, Marc G. Weisskopf, Rachel Grashow, Ran S. Rotem, Brent A. Coull, Lourdes Schnaas, Carmen Hernández-Chávez, Brisa Sanchez, Karen Peterson, Howard Hu, Mauricio Hernandez-Avila, Martha M. Téllez-Rojo. (United States)

225 Oral Corticosteroids During Pregnancy and Offspring Risk of Congenital Heart Defects - A Nationwide Cohort Study [756]

Amalie B Schmidt, Marie Lund, Giulia Corn, Nina Øyen, Jan Wohlfahrt, Mads Melbye. (Denmark)

226 The Safety of Amoxicillin and Clavulanic Acid Use during the First Trimester of Pregnancy [757]

Sharon Daniel, Maya Doron, Boris Fishman, Gideon Koren, Eitan Lunenfeld, Amalia Levy. (Israel)

227 Maternal Early Pregnancy Use of Specific Antidepressant Medications and Risk for Birth Defects [758]

Kayla N. Anderson, Jennifer N Lind, Regina Simeone, William V Bobo, Tiffany Riehle-Colarusso, Kara N Polen, Jennita Reefhuis. (United States)

Poster Session B: Pregnancy and Lactation - Drug Exposure and Outcomes

228 Effect of N-Acetylcysteine Supplementation on Women Undergoing Assisted Reproductive Techniques: A Systematic Review and Meta-Analysis [759]

Nagita Devi, Divya Bujimalla, Dipika Bansal. (India)

229 In Utero Opioid Exposure and Risk of ADHD in Childhood: A Scandinavian Registry Study [760]

Marte Handal, Svetlana Skurtveit, Ingvild Odsbu, Helle Kieler, Mette Nørgaard, Buket Öztürk, Angela Lupatelli, Hedvig Nordeng, Ingunn Olea Lund, Sonia Hernandez-Diaz, Mollie Wood, Milada Mahic. (Norway)

230 Outcome Measurement in Pregnancy Exposure Registries: A Preliminary Review of Publicly Available Resources [761]

Suzanne N Landi, Jessica R Probst, Katherine M Lee, Elsa Garcia, Kristen Hahn. (United States)

231 Risk of Early Neurodevelopmental Outcomes Associated with Prenatal Exposure to Antiepileptic Drugs: A Nationwide Cohort Study Based on The French National Healthcare Databases [762]

Pierre-Olivier Blotière, Sara Miranda, Alain Weill, Mahmoud Zureik, Rosemary Dray-Spira. (France)

232 Fetal Outcomes Associated with Maternal Asthma: Evidence from a Large Healthcare Database in The United States [763]

Jennifer Yland, Brian T Bateman, Krista F Huybrechts, Michael Schatz, Keele E Wurst, Sonia Hernandez-Diaz. (United States)

233 Risk of Attention Deficit Hyperactivity Disorder in Childhood after Exposure to Serotonergic Antidepressants in Pregnancy [764]

Angela Lupatelli, Milada Mahic, Marte Handal, Eivind Ystrom, Ted Reichborn-Kjennerud, Hedvig Nordeng. (Norway)

234 Prenatal Antibiotics Use and the Risk of Attention Deficit Hyperactivity Disorder [765]

Amani Hamad, Silvia Alessi-Severini, Salah Mahmud, Marni Brownell, I fan Kuo. (Canada)

235 The Association between Exposure to Interferon-Beta During Pregnancy and Birth Measurements in Offspring of Women with Multiple Sclerosis [766]

Sarah Burkill, Pia Vattulainen, Yvonne Geissbuehler, Meritxell Sabidó, Catrinel Popescu, Kiliansa Suzart-Woischnik, Jan Hillert, Sven Cnattingus, Miia Artama, Auli Verkköiemä-Ahola, Kjell-Morten Myhr, Pasi Korhonen, Scott Montgomery, Shahram Bahmanyar. (Sweden)

Poster Session B | Tuesday, August 27 • 8:00am - 6:00pm

- 236 Determinants of Missing or Delayed Prenatal Screening in Florida, New Jersey, and Texas Medicaid Populations 1999 to 2010 [767]**
Thuy N Thai, Carl Henriksen, Kathryn J Gray, Brian T Bateman, Sonia Hernandez-Diaz, Yanmin Zhu, Loreen Straub, Krista F Huybrechts, Almut G Winterstein. (United States)
- 237 Prevalence of Ectopic Pregnancy among an Under-Represented Population in Electronic Health Records: Results of the 2011-2015 National Survey of Family Growth [768]**
Jenny Lee, Juliane Schoendorf, Alex Asiimwe, Asieh Golozar. (Netherlands)
- 238 Preconception Use of Asthma Medication and Fecundability: A Prospective Study [769]**
Holly M Crowe, Lauren A Wise, Amelia K Wesselink, Kenneth J Rothman, Henrik T Sørensen, Ellen M Mikkelsen, Elizabeth E Hatch. (United States)
- 239 Prenatal and Infant Exposure to Paracetamol and Ibuprofen and the Risk of Asthma in Children at 24 Months of Age: Findings from a Cohort Study [770]**
Alexandra Boing, Andrea Dâmaso Bertoldi, Isabel Cristina Emmerick. (United States)
- 240 Use of Iron Salts, Hemoglobin Levels in Gestation and the Development of Diabetes Mellitus Gestacional in The 2015 Pelotas Birth Cohort, Brazil [771]**
Vanessa Iribarrem Miranda, Tatiane da Silva Dal Pizzol, Marysabel Pinto Silveira, Sotero Serrate Mengue, Mariângela Freitas Silveira, Andréa Dâmaso Bertoldi. (United States)
- 241 Safety Outcomes among Infants Exposed to Omalizumab via Breastfeeding: Results from The Xolair Pregnancy Registry (EXPECT) [772]**
Sandra Lopez Leon, D G Kaufman, M Howard, S Mukhopadhyay, Robert Fogel. (United States)
- 242 Prenatal Drug Exposure in Children Using Psychiatric Care: A Study Conducted in the POMME Cohort [773]**
Justine Benevent, Mélanie Araujo, Caroline Hurault-Delarue, Jean-Louis Montastruc, Isabelle Lacroix, Christine Damase-Michel. (France)
- 243 Antibiotic Use During Pregnancy and Infancy and the Possible Impact on Overweight in Early Childhood. Analysis from 2015 Pelotas Birth Cohort, Brazil [774]**
Andrea Bertoldi, Thaynã Flores, Isabel Emmerick, Alexandra Boing, Mariângela Silveira. (United States)
- 244 Trends in Use of Antiepileptic Drugs during Pregnancy [775]**
E Houben, E A P Steegers, R M C Herings. (Netherlands)
- 245 Inflammatory Bowel Disease Treatment in Pregnancy in The US and Sweden [776]**
Gabriella Broms, Sonia Friedman, Seoyoung Kim, Gregory Brill, Mollie Wood, Sonia Hernandez-Diaz, Brian Bateman, Krista Huybrechts, Rishi J Desai. (Sweden)
- 246 Switching Patterns of Antidiabetic Medications during Pregnancy in Women with Pre-Gestational Diabetes in Publicly or Privately Insured US Populations [777]**
Nicole Tsao, Sonia Hernandez-Diaz, Brian Bateman, Seanna Vine, Krista Huybrechts. (United States)
- 247 Use of Sildenafil and other PDE-5 Inhibitors among Pregnant Women in Scandinavia [778]**
Helle Kieler, Anders Engeland, Anne Broe, Per Damkier, Kari Furu, Pär Karlsson. (Sweden)
- 248 Hypertensive Disorders of Pregnancy and Utilization of Antihypertensive Therapies [779]**
Elena Dudukina, Uffe Heide-Jørgensen, Edith R Bahmanyar, Henrik T Sørensen, Vera Ehrenstein. (Denmark)
- 249 Use of Anti-Migraine Medications among Commercially Insured Pregnant Women in the United States [780]**
Mollie Wood, Sonia Hernandez-Diaz. (United States)
- 250 The Association between Annual Hospital Delivery Volume and Discharge Opioid Prescriptions after Vaginal Deliveries [781]**
Jea Young Min, Sarah Osmundson, Ed Mitchel, Andrew Wiese, Marie R Griffin, Robert E Hawley, Stephen Patrick, Carlos G Grijalva. (United States)
- 251 Phosphodiesterase-5 (PDE5) Inhibitor Use among Pregnant Women and Women of Child-Bearing Age in The Sentinel Distributed Data Network [782]**
Wei Liu, Mayura Shinde, Corinne Woods, Nicole Haug, Jie Li, Justin A Mathew, Christine P Nguyen, Grace P Chai, David Moeny, Talia Menzin. (United States)
- 252 Exposure to Fosfomycin Trometamol During Pregnancy: A Descriptive Study Using The EFEMERIS Database [783]**
Mélanie Araujo, Justine Bénévnt, Diane Sicard, Caroline Hurault-Delarue, Jean Louis Montastruc, Isabelle Lacroix, Christine Damase-Michel. (France)

Poster Session B: Pregnancy and Lactation - Drug Utilization

- 253 Prescription Patterns Before, During and After Pregnancy among Dutch Women: A Drug Utilization Study [784]**
Olivia N Gussinklo, Alexis M Blaauwhof, Jens H Bos, Catharina Schuiling-Veninga. (Netherlands)
- 254 Spontaneous Reporting Systems as Proxy for Drug Utilization in Pregnancy: The Example of Insulin Maternal Exposure [785]**
Ayad K. Ali, Sirel Gurbuz. (United States)
- 255 The French Pregnancy Cohort: Prevalence and Trend of Medication Use During Pregnancy in The French Population [786]**
A Berard, F Abbas-Chorfa, B Kassai, T Vial, KA Nguyen, O Sheehy, AM Schott. (Canada)
- 256 A Systematic Review on Prescribing Patterns of Antidepressants Before, During, and After Pregnancy [787]**
Jet W Scheffers, Holly Dorning, Irene Petersen. (Netherlands)
- 257 Maternal Early Pregnancy Antidepressant Use by Medication Class and Birth Defect Risk [788]**
Kayla N Anderson, Jennifer N Lind, Regina Simeone, William V Bobo, Tiffany Riehle-Colarusso, Kara N Polen, Jennita Reefhuis. (United States)
- 258 Prevalence and Trends in Depression and Anxiety, Antidepressant Use and Key Maternal Conditions during Pregnancy, 1998-2015 [789]**
Maëlle Dandjinou, Odile Sheehy, Simone Vigod, Anick Bérard. (Canada)
- 259 Asthma Medication Use During Pregnancy: Does Timing of Asthma Diagnosis Matter? [790]**
Simone Issa. (Canada)

- 260 Antihypertensive Drug Use among Pregnancies in South Korea, 2003-2013 [791]**
Yunha Noh, Ju-Young Shin. (Korea, Republic of)
- 261 Knowledge of The New Food and Drug Administration Pregnancy and Lactation Labeling Rule (PLLR) Among Physicians and Pharmacists [792]**
Ghada Alem, Mary K Maneno, Monika Daftary, La'Marcus Wingate, Earl Ettienne, Adaobi Anyiwo. (United States)
- 262 Direct-Acting Oral Anticoagulants (DOACs) In Pregnancy: New Insight from VigiBase® [793]**
Maurizio Sessa, Annamaria Mascolo, Torbjörn Callréus, Annalisa Capuano, Francesco Rossi, Morten Andersen. (Denmark)
- 263 Complications and Medication Patterns in Preeclampsia Patients: A Retrospective Analysis of a Large United States Electronic Health Record Database [794]**
Georgios Varsos, Fred W Peyerl, Meng Shen, Kunal Lodaya, Laxmi Gannu, Apeksha Shenoy, David K Hayashida, Fabian D'Souza. (United States)
- 264 Use of Medicines by Mothers and Duration of Breastfeeding in 2015 Pelotas (Brazil) Birth Cohort Study [795]**
Barbara H Lutz, Andrea D Bertoldi, Isabel C Emmerick, Mariangela F Silveira, Diego G Bassani. (United States)
- 265 Antimalarial Prescription Pattern among Pregnant Women Attending Antenatal Clinic in a Nigerian Tertiary Hospital [796]**
Rachel U Odesanya, Gdwin Atibili. (Nigeria)

Poster Session B: Vaccines

- 266 Monitoring of Adverse Events Following Zoster Vaccine (Shingrix) in Department of Veterans Affairs [797]**
Kwan Hur, Lucy Pandey, Bharat Thakkar, Rongping Zhang, Michelle Eskridge, Cedric Salone, Peter Glassman, Chester Good, Francesca Cunningham. (United States)
- 267 Tetanus, Diphtheria, Acellular Pertussis (Tdap) Vaccination During Pregnancy and Risk of Pertussis in the Newborn in Publicly and Privately Insured Mother-Infant Pairs in The United States [798]**
Katrina Mott, Krista Huybrechts, Helen Mogun, Sonia Hernández-Díaz. (United States)
- 268 Influence of Comorbidity Status on Seasonal Influenza Vaccine Effectiveness in Canada: A Systematic Review and Meta-Analysis of Test-Negative Design Studies [799]**
George N Okoli, Florentin Racovitan, Christiaan H Righolt, Salaheddin M Mahmud. (Canada)
- 269 Coverage Rates, Completeness, and Timeliness of Recommended Basic Immunizations in Swiss Preschool Children: A Descriptive Analysis Using Claims Data [800]**
Rahel Schneider, Daphne Reinau, Nadine Schur, Eva Blozik, Mathias Früh, Andri Signorell, Matthias Schwenkglenks, Christoph R Meier. (Switzerland)
- 270 Signal Detection of Human Papillomavirus Vaccines Using The Korea Adverse Events Reporting System Database, 2005-2016 [801]**
Jung Ran, Ji-Young Yang, Hye-Jun Kim, Ju Hwan Kim, Ju-Young Shin. (Korea, Republic of)



- 271 Monitoring the Safety of High-Dose, Trivalent Influenza Vaccine in The Vaccine Adverse Event Reporting System (VAERS), 2010-2018 [802]**
Pedro Moro, Paige Lewis, Maria Cano. (United States)
- 272 Variation in Vaccination for Respiratory Infections and Associated Outcomes across Long-Term Care Facilities [803]**
Elliott Bosco, Andrew R Zullo, Kevin W McConeghy, Patience Moyo, Robertus van Aalst, Ayman Chit, Stefan Gravenstein, Vincent Mor. (United States)
- 273 Causality Assessment of Fatal Outcomes Following Vaccination Errors Reported in Eudravigilance [804]**
Christina E Hoeve, Marcel S Kwa, Kartini Gadroen, Anja Haren, Miriam C Sturkenboom, Sabine M Straus. (Netherlands)
- 274 Adverse Events Following Adenovirus Type 4 and Type 7 Live Oral Vaccine in The Vaccine Adverse Event Reporting System (VAERS), United States, October 2011-July 2018 [805]**
Michael M McNeil, Iwona Paradowska-Stankiewicz, Elaine R Miller, Paige Lewis, Srihari Seshadri, Limone C Collins, Maria V Cano. (United States)
- 275 3 Years of Post-Licensure Safety Data on a Live Attenuated Tetravalent Dengue Vaccine (CYD-TDV) [806]**
Andrey Rojas, Owen Haney, Lydie Marcelon, Alena Khromava. (United States)
- 276 Vaccination and Risk of Atrial Fibrillation in The Active Component United States Military [807]**
Michael M McNeil, Susan K Duderstadt, Jennifer F Sabatier, Gina G Ma, Jonathan Duffy. (United States)
- 277 Pandemrix Exposure and the Risk of Narcolepsy in Children and Adults: Validation Study Comparing Results from Patient-File-Verified and Register-Based Data in Finland [808]**
Miia Artama, Jukka Jokinen, Hanna Nohynek, Arto Palmu. (Finland)
- 278 Relative Effectiveness of Cell-Cultured and Egg-Based Influenza Vaccines among The U.S. Elderly, 2018-19 [809]**
Hector S Izurieta, Yoganand Chillarige, Jeffrey Kelman, Yuqin Wei, Yun Lu, Wenjie Xu, Michael Lu, Douglas Pratt, Michael Wernecke, Thomas MaCurdy, Richard Forshee. (United States)
- 279 Safety of Trivalent Adjuvanted Influenza Vaccine (aIV3; Flud), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016-June 2018 [810]**
Penina Haber, Pedro Moro, Carmen Ng, Graça M Does, Lewis Page, Maria Cano. (United States)
- 280 Opportunities and Challenges for Near Real Time Monitoring (NRTM) of Vaccine Exposures and Outcomes in the Participating Databases of the ADVANCE Consortium [811]**
Lina Titievsky, Miriam Sturkenboom, Kaatje Bollaerts, Tom de Smedt, Giorgia Danieli, Talita Duarte-Salles, Hanne-Dorthe Emborg, Rosa Gini, Johnny Kahlert, Simon de Lusignan, Elisa Martin, Chris McGee, Lara Tramontan, Vincent Bauchau. (United States)
- 281 Uptake of Papanicolaou Testing by HPV Vaccination Status [812]**
Gabriel Chodick, Amy Leader, Eduardo Schejter, Sharon Larson. (Israel)
- 282 BCG Vaccination against Mycobacterium Tuberculosis Infection in Pediatrics: A Systematic Literature Review and Meta-Analysis [813]**
Md Azharuddin, Mohammad Adil, Pinaki Ghosh, Prem Kapur, Manju Sharma. (India)
- 283 Effect of Expanding Pharmacist's Prescriptive Authority on Influenza and Pneumococcal Vaccination Rates in The United States [814]**
Ahmed I Fahmy, Adel Abou-Ali. (Egypt)
- 284 Trends in Overall Vaccine-Related Adverse Event Reports and Vaccination during Pregnancy, 2000-2016 [815]**
Dongwon Yoon, Ju Hwan Kim, Hyesung Lee, Ju-Young Shin. (Korea, Republic of)
- 285 Detection of Adverse Events after Pneumococcal Vaccines Immunization from Korea Adverse Events Reporting System Database, 2005-2016 [816]**
Kwan Soo Kim, Hyun Jeong Kim, In-Sun Oh, Min Soo Park, Ju-Young Shin. (Korea, Republic of)

End Poster Session B

**Poster Spotlight Session C:
Medications in Pregnancy and Lactation**

- A Use of Ondansetron during Pregnancy and Risks of Spontaneous Abortion, Stillbirth and Major Congenital Malformation: An International, Multi-Centre Cohort Study [894]**
Colin Dormuth, Brandace Winquist, Anat Fisher, Fangyun Wu, Pauline Reynier, Matthew Dahl, Zhihai Ma, Xinya Lu, Jianguo Zhang, Colette Raymond, Kristian B. Filion, Robert W Platt, Carolina Moriello, J Michael Paterson, CNODES Investigators. (Canada)
- B Medically Assisted Reproduction and the Risk of Being Born Small for Gestational Age [895]**
Jessica Gorgui, Odile Sheehy, Jacquetta Trasler, William Fraser, Anick Bérard. (Canada)
- C Ondansetron Use in Early Pregnancy and Late Pregnancy Outcomes [896]**
Elizabeth A Suarez, Kim Boggess, Stephanie M Engel, Jennifer L Lund, Til Stürmer, Michele Jonsson Funk. (United States)
- D Misoprostol as an Adjunct to Oxytocin can Reduce Postpartum Haemorrhage among Pregnant Women Delivering in Bamenda Cameroon, 2015-2016: A Propensity Score-Matched Retrospective Chart Review [897]**
Frederick Morfaw, Mercy Fundoh, Christopher Pisoh, Bi Ayaba, Lawrence Mbuagbaw, Laura N Anderson, Lehana Thabane. (Canada)
- E Maternal Opioid Use and Infant Birth Defects in RI Medicaid Enrolled Population [898]**
Emily Murray, Nicholas Belviso, Xuerong Wen. (United States)

- F Crowdsourcing as a Novel Method to Assess the Impact of Drug Exposure on Belimumab Pregnancy Registry Enrollment [899]**
Kim Gemzoe, Jeffery L Painter, Jeanne Pimenta, Greg Powell. (United Kingdom)
- G Discontinuation of Anti Psoriasis Drug Treatments During Pregnancy. The PSO MOTHER Cohort Study [900]**
Valeria Belleudi, Francesca Poggi, Serena Perna, Luigi Naldi, Renata Bortolus, Alessandro Rosa, Ursula Kirchmayer, Marina Davoli, Antonio Addis. (Italy)
- H Long-Term Neurodevelopmental Outcomes in Children with Prenatal Opioid Exposure [901]**
Nicholas Belviso, Kimford Meador, Oluwadolapo Lawal, Debra Erickson-Owens, Brian Quilliam, Shuang Wang, Kelly Matson, Aisling Caffrey, Xuerong Wen. (United States)

**Poster Spotlight Session C:
Molecular Epidemiology, Biomarkers, and Pharmacogenetics**

- I Projected Impact of Pharmacogenetics on Veteran Pain Management [902]**
Catherine Chanfreau-Coffinier, Julie A Lynch, Leland E Hull, David W Oslin, Scott L DuVall, Sony Tuteja. (United States)
- J Mountin' an Expedition to Find the Truth: Alps Bayesian Pathway Modeling of Tamoxifen Pharmacogenetics [903]**
Thomas P Ahern, Lindsay Collin, James Baurley, Anders Kjærsgaard, Peer M Christiansen, Kristina B Christensen, Per Damkier, Bent Ejlersen, Maret L Maliniak, Kristina L Lauridsen, Rebecca J Nash, Stephen Hamilton-Dutoit, Deirdre P Cronin-Fenton, Timothy L Lash. (United States)
- K Insurance Coverage of Pharmacogenomic Testing [904]**
Heather Anderson, Kristy Crooks, David Kao, Christina Aquilante. (United States)
- L β_2 -Adrenergic Receptor Haplotypes and Risk Of Exacerbations in Asthmatic Children and Young Adults Treated with Long-Acting β_2 -agonists: A Meta-Analysis in The PiCA Consortium [905]**
Leila Karimi, Susanne J. Vijverberg, Marjolein Engelkes, Natalia Hernandez-Pacheco, Niloufar Farzan, Patricia Soares, Ben R Francis, Maria Pino-Yanes, Celeste Eng, Somnath Mukhopadhyay, Maximilian Schieck, Michael Kabesch, Esteban G Burchard, Colin N A Palmer, Steve Turner, Hettie M. Janssens, Anke-Hilse Maitland-Van Der Zee, Katia M. Verhamme. (Netherlands)
- M Prevalence of KRAS, NRAS, and BRAF Gene Mutations in Metastatic Colorectal Cancer (mCRC) Patients: A Systematic Literature Review and Meta-Analysis [906]**
Lauren C Bylsma, Elizabeth D. Levin-Sparenberg, Kimberly Lowe, Laura Sangare, Jon Fryzek, Dominik D. Alexander. (United States)
- N The Role of ABCG1 Gene DNA Methylations in Lipid Profiles and Therapeutic Efficacy of Simvastatin in Chinese Patients with Hyperlipidemia [907]**
Shanqun Jiang, Yi-Hsiang Hsu. (China)
- O Identifying Two Gene Clusters that May Serve as a Gene Signature and Biomarker of Atopic Dermatitis and Can Predict Pimecrolimus Efficacy and Pharmacoepidemiology [908]**
Anas Khaleel. (Jordan)

Poster Session C | Wednesday, August 28 • 8:00am - 6:00pm

SPOTLIGHT SESSIONS: 12:15Pm - 1:15pm

- P Assessment of Stakeholder Perspectives of The Clinical Utility of Pharmacogenomics in Solid Organ Transplantation [909]**
 Kimberly M Deininger, Jacinda N Tran, Shirley M Tsunoda, Gordon K Young, Yee Ming Lee, Heather Anderson, Robert L Page, Jan D Hirsch, Christina L Aquilante. (United States)

Poster Spotlight Session C: Oncology

- Q Hormone Replacement Therapy and the Risk of Melanoma in Post-Menopausal Women [910]**
 Blánaid Hicks, Kasper Bruun Kristensen, Sidsel Arnspang Pedersen, Lisbet Rosenkrantz Hölmich, Anton Pottegård. (United Kingdom)

- R First-Line Treatment of Breast Cancer and the Risk of Hematologic Malignant Neoplasms [911]**
 Marie Joelle Jabagi. (France)

- S Corticosteroids and Risk of Hospitalization for Infection among Cancer Patients Treated with Programmed Cell Death Receptor/Ligand 1 (PD-1/PD-L1) Inhibitors [912]**
 Signe Sørup, Bianka Darvalics, Leo Russo, Dina Oksen, Francois-Xavier Lamy, Patrice Verpillat, Henrik T Sørensen, Deirdre Cronin-Fenton. (Dominica)

- T Comparative Safety and Healthcare Expenditures Associated with Frontline Therapy for Chronic Myeloid Leukemia [913]**
 Ashley L Cole, Benyam Muluneh, Jennifer Lund, William Wood, Jennifer Elston Lafata, Stacie Dusetzina. (United States)

- U Safety and Cost-Effectiveness Analysis of Ponatinib Versus other Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in The United States [914]**
 Xiaomeng Yue, Ana Hincapie, Bin Huang, Jeff J Guo. (United States)

- V Use of Antibiotics against Urinary Tract Infections and Risk of Bladder Cancer: A Danish Nationwide Case-Control Study [915]**
 Anton Pottegård, Kasper B Kristensen, Søren Friis, Jesper Hallas, Jørgen B Jensen, Mette Nørgaard. (Denmark)

- W Association Between Concomitant Hydrochlorothiazide and Cyclophosphamide Use, and Chemotherapy Regimen Discontinuation in Breast Cancer Patients [916]**
 Christine D Hsu, Sharon Peacock Hinton, Til Stürmer, Michele Jonsson Funk, Katherine E Reeder-Hayes, Hanna K Sanoff, Jennifer L Lund. (United States)

Poster Spotlight Session C: Pediatrics

- X Early-Life Antibiotics Use Increases the Risk of Asthma and Eczema: A Discordant Twin Study [917]**
 Elise M. Slob, Chantal J Kats, Susanne J Vijverberg, Mariëlle W Pijnenburg, Toos C van Beijsterveldt, Gerard H Koppelman, Dorret I Boomsma, Anke H Maitland-van der Zee. (Netherlands)

- Y Patterns of Prescription Opioid Use among Commercially Insured United States Youth and Young Adults with Co-Morbid Chronic Pain and Mental Health Conditions [918]**
 Abisola Olopoenia, Julia Slejko, Linda Simoni-Wastila, Wendy Camelo-Castillo. (United States)

- Z Outcomes Associated with Antidepressant Augmentation: A Group-Based Trajectory Modeling with Propensity Score Approach [919]**
 O'Mareen Spence, Susan dosReis. (United States)

- AA A Latent Class Growth Analysis of Antidepressant Dose Trajectories and Treatment Augmentation in Youth [920]**
 O'Mareen Spence, Gloria Reeves, Susan dosReis. (United States)

- BB Selective Serotonin Reuptake Inhibitors and Type 2 Diabetes in Adolescents and Youths [921]**
 Jenny W Sun, Brian T Bateman, Sonia Hernandez-Diaz, Sebastien Haneuse, Florence T Bourgeois, Krista F Huybrechts. (United States)

- CC Trends in Antidepressant Use among Children and Adolescents: A Scandinavian Drug Utilization Study [922]**
 Rikke Wesselhoeft, Peter Bjørdstrup Jensen, Ardesheer Talati, Johan Reutfors, Kari Furu, Katrine Strandberg-Larsen, Per Damkier, Anton Pottegård, Mette Bliddal. (Denmark)

- DD Oral Glucocorticoids and Venous Thromboembolism in Children [923]**
 Daniel B Horton, Fenglong Xie, Lang Chen, Melissa L Mannion, Jeffrey R Curtis, Brian L Strom, Timothy Beukelman. (United States)

- EE Psychotropic Drug Prescribing to Children with Attention Deficit/Hyperactivity Disorder in The United States, 2002-2016 [924]**
 Daniel B Horton, Brian L Strom, Matthew T Taylor, Tobias Gerhard. (United States)

**Poster Spotlight Session C:
Vaccines**

FF The Risk of Arthus Reaction Following Tdap Vaccination: Vaccine Adverse Event Reporting System and a Review of Literature [926]

Vitali Pool, Larissa Mege, Adel Abou-Ali. (United States)

GG Skin Necrosis Following 23-Valent Pneumococcal Polysaccharide Vaccination [927]

Deborah L Thompson, Graca M Does, Jaspal Ahluwalia, Deepa P Arya, Manette Niu. (United States)

HH Safety Surveillance of The Four-Component Meningococcal Group B Vaccine (Bexsero®): Vaccine Adverse Event Reporting System (VAERS), January 2015 - June 2018 [928]

Silvia Perez-Vilar, Graça M Does, Paige W. Lewis, Carmen S Ng, John R. Su, Maria V Cano, Jonathan M Duffy. (United States)

II Bacille Calmette Guerin Vaccine Safety Surveillance in the Korea Adverse Event Reporting System Using Tree-Based Scan Statistics and Traditional Data Mining Methods [929]

Ju Hwan Kim, Hyesung Lee, Ju-Young Shin. (Korea, Republic of)

JJ Signal Detection for Vaccine Safety in the Vaccine Adverse Event Reporting System Using Change Point Models [930]

Jing Huang, Jingcheng Du, Susan S Ellenberg, Sean Hennessy, Cui Tao, Yong Chen. (United States)

KK A Simulation Study of the Statistical Power and Signaling Characteristics of an Early Season Sequential Test for Influenza Vaccine Safety [931]

Richard A Forshee, Mao Hu, Deepa Arya, Silvia Perez-Vilar, Steven A Anderson, An-Chi Lo, Madeline Swarr, Michael Wernecke, Tom MaCurdy, Steve Chu, Jeffrey Kelman. (United States)

End Spotlight Sessions C

Poster Session C: Adherence

1 Adherence to Controller Therapy in Chronic Obstructive Pulmonary Disease: Real Life Setting [932]

Leila Karimi, Esmé J Baan, Tiana Geeraerd, Johan Van Der Lei, Bruno H C Stricker, Guy G Brusselle, Lies Lahousse, Katia M Verhamme. (Netherlands)

2 Are Patients Adherent to Benzodiazepine Treatment? Results of a Retrospective Cohort Study in Primary Care in Spain [933]

Mar Martín-Pérez, Veronica Bryant, Elisa Martín-Merino, Dolores Montero-Corominas, Consuelo Huerta. (Spain)

3 Drug Refill Patterns of Suvorexant and other Insomnia Medications: A US Administrative Claims Database Study [934]

Cathy Anne Pinto, Praful Kumar, William J Herring, Johanna Hyacinthe, Ankita Kumar, Mani Lakshminarayanan, Zhiwen Liu. (United States)

4 Comparative Persistence of Non-Vitamin-K Oral Anticoagulants and Phenprocoumon in Patients with Non-Valvular Atrial Fibrillation - Results from The Reloaded Study [935]

Niklas Schmedt, Reinhold Kreutz, Sebastian Kloss, Dirk Enders, Dennis Häckl, Hendrik Bonnemeier. (Germany)

5 Reality Check: The Mismatch of Time to Bisphosphonate Benefit and Real World Persistence [936]

Kevin J Friesen, Jamie Falk, Shawn Bugden. (Canada)

6 The Unintended Consequences of Cost-Related Medication Nonadherence: Cancer Survivors May Substitute Less Expensive Care with More Costly Services [937]

Kevin Lu, Xiaomo Xiong, Minghui Li. (United States)

7 Patient Adherence and Persistence to Oral Targeted Therapies for Hematologic Malignancies: A Retrospective Cohort Study Among Managed Care Enrollees [938]

Krish Patel, Vinjamuri Sai Sudhir, Shaum Kabad, Joanna C Huang, Sanchita Porwal, Kushan Thakkar, John M Pagel. (United States)

8 Abstract Withdrawn [939]

9 Racioethnic and Provider Specialty Differences in Adherence Trajectories among Medicaid Insured Children with Attention Deficit Hyperactivity Disorder [940]

Jagadeswara Rao Earla, Susan Abugosh, Hua Chen. (United States)

10 Adherence Trajectories in Asthmatic Patients [941]

Esmé Baan, Leila Karimi, Astrid Heeremans, Guy Brusselle, Miriam Sturkenboom, Hettie M Janssens, Lies Lahousse, Johan C de Jongste, Katia Verhamme. (Netherlands)

11 Factors Associated with Inhaled Corticosteroid Non-Adherence in Pregnant Women with Asthma: A Cross-Sectional Analysis [942]

Annelies L Robijn, Megan E Jensen, Peter G Gibson, Vanessa E Murphy. (Australia)

12 Patterns of Adherence to Prescribed Opioids: The Differential Between Opioid Naïve and Opioid Existing Patients of Different Age Groups [943]

Che Suraya Zin, Nor Hidayah Taufek, Mazlila Meor Ahmad. (Malaysia)

13 Statin Adherence and Risk of Diabetes among The United States Department of Veterans Affairs Hospital Patient Population [944]

Skai W Schwartz, Darren Scheer, Pragati Ghimire-Aryal, Kenneth Taylor, Anh T Nguyen, Nnadozie Emechebe, Phillip Foulis. (United States)

14 Impacts of Multi-Dimensional Interventions on Medication Adherence Among Type 2 Diabetes Mellitus Patients in a Nigerian Black Population [945]

Olayinka O Ogunleye, Modupe Oyawole. (Nigeria)

15 Impact of Intensity of Statin Therapy on Patients' Persistence to Treatment: A Scottish Population-Based Study [946]

Tanja Mueller, Renata C Macedo do Nascimento, Marion Bennie, Brian Godman, Simon Hurding, Sean MacBride Stewart, Augusto Afonso Guerra Junior, Francisco de Assis Acurcio, Alec Morton, Amanj Kurdi. (United Kingdom)

16 Post Option B+ Programme in Nigeria: Schedule Adherence among Pregnant Women with HIV [947]

Olumuyiwa Omonaiye, Snezana Kusljic, Pat Nicholson, Elizabeth Manias. (Australia)

17 Antiretroviral Treatment Non-Adherence and Virological Failure in Côte D'Ivoire: A Cross-sectional Study [948]

Mariam Mama Djima, Jocelyne Moisan, Jean-Pierre Gregoire, Serge Paul Eholie, Didier Koumavi Ekouevi. (Côte D'Ivoire)

18 Associations between Refill and Guideline Adherence to Lipid-Lowering Medications and Risk of Cardiovascular Event and Mortality among Patients with Type 2 Diabetes in Sweden [949]

Sofia A Karlsson, Björn Eliasson, Stefan Franzén, Mervete Miftaraj, Ann-Marie Svensson, Karolina Andersson Sundell. (Sweden)

19 Early Discontinuation of Antidepressant Use by Dutch Soldiers [950]

Eibert R Heerdink, Debbie G Janssen, Antoine C Egberts, Erik Vermetten. (Netherlands)

Poster Session C: Benefit-Risk Assessment, Communication, and Evaluation [BRACE]

- 20 Risk Minimization Effectiveness for Mirabegron in The Netherlands, Spain, UK and Finland [951]**
Edith Heintjes, Daniel Prieto-Alhambra, Elisabeth Smits, Helen Booth, Daniel Dedman, Fabian Hoti, Minna Vehkala, Fernie J Penning-van Beest, Irene D Bezemer. (Netherlands)
- 21 Considerations when Applying a Structured Benefit-Risk Assessment to Drug Delivery Combination Products [952]**
Alicia W Gilsean, Mary E Ritchey, Brett Hauber, Elizabeth B Andrews. (United States)
- 22 Effectively Communicating Small Probability Drug Risks to Patients, A Systematic Review [953]**
Esther Yoon. (United States)
- 23 Are the Risk Minimization Measures for Diclofenac Effective? A Pre-Post Comparison Based on German Claims Data [954]**
Oliver Scholle, Bianca Kollhorst, Ulrike Haug. (Germany)
- 24 Differences among Parents when Weighing Benefits and Risks of Potential Treatments to Delay Insulin Dependence in Type-1 Diabetes in Children [955]**
Rachael L DiSantostefano, Jessie Sutphin, Kathleen Gallaher, Joseph Hedrick, Carol Mansfield. (United States)
- 25 Assessment of Colobreathe Risk Minimisation Measures in The European Union: A Cross-Sectional Study [956]**
Sigal Kaplan, Oliver Patino, Carolyn Rainville, Terri Madison. (Israel)
- 26 Prevalence of Antibiotic Use, Knowledge and Attitudes Towards Antibiotic-Free Meat, Pennsylvania - 2016 [957]**
Nkuchia M M'ikanatha, Rachel A Smith, Lisa Dettinger, Heather Tate. (United States)
- 27 Assessment of the Effectiveness of Risk Evaluation and Mitigation Strategies for Dulaglutide: 18- And 36-Month Prescriber Surveys [958]**
Ayad K Ali, John J Kaiser, Ingrid E Hensley. (United States)
- 28 Characteristics of Risk Evaluation and Mitigation Strategies (REMS) Assessment Plans: A Review of REMS with ETASU (2014-2018) Using RE-AIM [959]**
Gita A. Toyserkani, Linda Huynh, Elaine H Morrato. (United States)
- 29 Evaluation of the Effectiveness of Risk Minimisation Measures Targeting Physicians on Prescribing Practices of Thiocolchicoside Containing Medicinal Products for Systemic Use [960]**
Sophie Laurence Jouaville, Carole Ehrhardt, Marie-Laure Kürzinger, Hanka de Voogd, Massoud Toussi. (France)
- 30 Patient Registries - Has the European Medicines Agency Patient Registry Initiative had an Impact on Post-Authorisation Mandates? [961]**
Bettina K Rillmann, Juliane Mills, Meg Richards. (Germany)
- 31 Medical Benefit-Risk Assessment: Creating The Value-Tree An Experience From Six Case Studies [962]**
Christine E Hallgreen, Shahrul Mt-Isa, Ed Waddingham, Kimberly Hockley, Deborah Ashby. (Denmark)
- 32 Direct Healthcare Professional Communications: Awareness, Effectiveness and Distribution Preferences in Saudi Arabia [963]**
Amal Alshatri Almotiry, Zainab Alhassar, Zainab Kazim, Wala'a Aldebasi, Najla Alabdulkarim, Adel Alharf. (Saudi Arabia)
- 33 Applying CIRS-BRAT Framework in a Regulatory Setting: Updated Benefit Risk Assessment for Fibrinogen Concentrate in the Setting of Complex Cardiac Surgery [964]**
Alicia W Gilsean, Andres Brainsky, Susan Colilla. (United States)
- 34 Impact of European Benefit-Risk Reassessment Procedures on Drug Prescribing Practices in Denmark [965]**
Christine E Hallgreen, Morten Andersen, Marie L De Bruin. (Denmark)
- 35 Do Conflicts of Interest Predict Interpretation of Drug Safety Research? An Analysis of Authors' Opinions on Venous Thromboembolic Risks of Oral Contraceptives [966]**
Barbara Mintzes. (Australia)
- 36 Post Market Safety Communications for Sodium Glucose Co-Transporter 2 Inhibitors. An International Case Study of Regulatory Decision-Making [967]**
Alice L Bhasale, Barbara Mintzes, Ameet Sarpatwari. (Australia)
- 37 Risk Assessment (R A) in Pulmonary Arterial Hypertension (P A H) - Overview and Comparison [968]**
Rose Ong, Lilla Di Scala, Camille Du Roure, Rainer Zimmermann, Daniel Rosenberg. (Switzerland)
- 38 What's the Harm? Exploring Evidence of Risk, Seriousness of Harm and Prescriber Advice in Medicine Safety Advisories [969]**
Lucy Perry, Alice Bhasale, Alice Fabbri, Joel Lexchin, Lorri Puil, Barbara Mintzes. (Australia)

39 Risk Communication in Community Pharmacies - Impact on Self-Medication [970]

Hristina Lebanova, Radiana Staynova. (Bulgaria)

Poster Session C: Biologics/ Biosimilars

40 Efficacy and Safety of Tyrosine-Kinase Inhibitors as First-Line Therapy in EGFR Mutant-harboring Advanced Non-Small Cell Lung Cancer Patients: A Network Meta-Analysis [971]

Abdullah Alanazi, Ismaeel Yunusa, Tewodros Eguale. (United States)

41 Use of Postapproval Safety Studies in the Evaluation of Safety Concerns Listed in The European Risk Management Plan of Two Mature TNF Inhibitors [972]

Suzan Esslinger, Marijo Otero-Lobato, Wim Noël, Johnnie Lee, Michael Clark, Anja Geldhof. (Netherlands)

42 Use of Immune Checkpoint Inhibitors and Risk of Immune-Related Adverse Events Among Patients with Advanced Melanoma: A Systematic Review and Network Meta-analysis [973]

Ching-Yuan Chang, Ching-Yu Wang, Haesuk Park, Wei-Hsuan Lo-Ciganic. (United States)

43 Utilization of Pcsk9 Inhibitors in an Italian Region During the First Year of Access to National Healthcare Service Reimbursement [974]

Carlo Piccinni, Ippazio Cosimo Antonazzo, Aldo Pietro Maggioni, Antonella Pedrini, Silvia Calabria, Giulia Ronconi, Letizia Dondi, Nello Martini, Giuseppe Roberto, Tiziana Sampietro, Francesco Sbrana, Beatrice Dal Pino, Federico Bigazzi, Giuseppa Lo Surdo, Elisabetta Volpi, Stefania Biagini, Rosa Gini. (Italy)

44 Trends in Biologic Utilization for the Management of Juvenile Idiopathic Arthritis in The United States, 1997-2018 [975]

Kathleen M Andersen, Daniah Basodan, Xintong Li, G. Caleb Alexander. (United States)

45 Rates of Major Adverse Cardiovascular Events (MACE) and Revascularization among Patients with Psoriasis or Psoriatic Arthritis Treated with Apremilast, Biologics, DMARDs, and Corticosteroids in The US MarketScan Database [976]

Rebecca Persson, Katrina W Hagberg, Ellen Qian, Catherine Vasilakis-Scaramozza, Steve Niemcryk, Michael Peng, Maria Paris, Anders Lindholm, Susan Jick. (United States)

46 Biosimilar Safety Dashboard to Assess Switching in Veterans [977]

Francesca Cunningham, Ashir Shurmunov, Diane Dong, Cedric Salone, Jennifer Zacher, Peter Glassman. (United States)

47 Biosimilar Use in The United States: An Analysis of Filgrastim and Infliximab [978]

Sarah K Dutcher, Efe Eworuke, Elnara Fazio-Eynullayeva, Elizabeth Dee, Michael D Nguyen, Catherine A Panozzo. (United States)

48 Post-Market Safety Outcomes for Original Therapeutic Biologics Approved by The Food and Drug Administration between 2002 and 2014 [979]

Ilynn Bulatao, Ellen Pinnow, Brendan Day, Sanae Cherkaoui, Manish Kalaria, Sonja Brajovic, Gerald Dal Pan. (United States)

49 Social Media Data Analysis with Population-Based Methods: A Pilot Investigation of Mild Hypersensitivity among Users of Subcutaneously Administered Monoclonal Antibodies [980]

Stephen E Schachterle, Dina Tresnan, Manfred Hauben, Sundaresan Murugesan, Rachel E Sobel, Andrew Bate, Robert Reynolds. (United States)

50 A Survey among Health Care Professionals to Assess Their Knowledge and Understanding on Darzalex® (daratumumab) Educational Materials Regarding the Risk of Interference for Blood Typing in 12 European Countries [981]

Mathieu Rosé, Intissar Bourahla, Alessandro Ghiddi, Assem Al-Akabawi, Edmond Chan, Massoud Toussi. (France)

51 Effectiveness and Safety of Eculizumab in the Treatment of Paroxysmal Nocturnal Hemoglobinuria: Systematic Review and Meta-Analysis [982]

Carolina Zampirolli Dias, Isabella de Figureiredo Zuppo, Mariana Michel Barbosa, Pâmela Santos Azevedo, Marina Morgado Garcia, Vânia Eloisa Araujo, Juliana Alvares-Teodoro, Francisco Assis Acurcio, Augusto Afonso Guerra-Junior. (Brazil)

52 Switching from Infliximab-Originator to Infliximab-Biosimilar in Rheumatologic Patients: the Clinical Impact in Tuscan Region, Italy [983]

Irma Convertino, Marco Tuccori, Ersilia Lucenteforte, Marta Mosca, Giuseppe Turchetti, Valentina Lorenzoni, Leopoldo Trieste, Sara Ferraro, Luca Leonardi, Giuseppe Roberto, Nicoletta Luciano, Corrado Blandizzi, Rosa Gini. (Italy)

- 53 The Incidence of Infusion Reactions Associated with Monoclonal Antibody Drugs Targeting the Epidermal Growth Factor Receptor in Metastatic Colorectal Cancer Patients: A Systematic Literature Review and Meta-Analysis [984]**
Lauren C. Bylsma, Rebecca Dean, Kimberly Lowe, Christina Gillezeau, Laura Sangare, Dominik D. Alexander, Jon Fryzek. (United States)
- 54 Prescribing Patterns from Medical Chart Abstraction of Patients Administered Lipegfilgrastim: A Pilot Study in Europe [985]**
Sigal Kaplan, Nicole Lang, Maja Gasparic, Carolyn Rainville, George Haralabopoulos, Emanuele Borroni. (Israel)
- 55 Prescribing Practices Associated with Biologic Therapies for Psoriasis [986]**
Megan H Noe, Daniel B Shin, David J Margolis, Joel M Gelfand. (United States)
- 56 Vemurafenib Associated Drug Reaction with Eosinophilia and Systemic Symptoms: Exploration of Novel Adverse Effect Using Disproportionality Analysis [987]**
Neha Reddy, Subeesh Viswam, Beulah Elsa, Anusha Bellapu, Vasista Sharma, Stephy Chacko. (India)
- 57 Evaluation of Thrombocytopenia and Hemorrhage Associated with Secukinumab [988]**
Mona Almaghrabi, Adel Alrwisan. (Saudi Arabia)
- 58 Younger Age is the Main Determinant for First-Line Biological Treatment in Rheumatoid Arthritis [989]**
Laura Angelici, Antonio Addis, Nera Agabiti, Marina Davoli, Valeria Belleudi. (Italy)

- 59 Racial Disparities Associated with Risks of Erythropoiesis-Stimulating Agents in Cancer Patients after Medicare Reimbursement Policy Change [990]**
Minghui Li, Kevin Lu. (United States)
- 60 Incidence Rate of Serious Infections in Patients with Ulcerative Colitis with or without Systemic Therapy in The United States [991]**
Huifang Liang, Raghava X Danwada, Dongmu Zhang, Rachel W Duan. (United States)
- 61 Safety Profile of Two TNF- α Inhibitors Adalimumab and Golimumab: An Analysis of FAERS Database 2012-2018 [992]**
Kelsey Byers, Xiaomeng Yue, Jeff Guo. (United States)
- 62 Trends in the Utilization of Short-Acting Filgrastim Following The United States Market Launch of the First Biosimilar [993]**
Shelley Jazowski, Stacie Dusetzina. (United States)
- 63 Oral Kinase Inhibitors, Biologics and Serious Infection in Rheumatoid Arthritis [994]**
Benjamin A Bates, Joshua P Gilman, Poonam P Gandhi, Edward Nonnenmacher, Matthew Taylor, Haoqian Chen, Soko Setoguchi. (United States)
- 64 Premedication and the Risk for Infusion Related Reactions among Patients Receiving Monoclonal Antibody Therapy: A Systematic Review and Meta-Analysis [995]**
Francis Mawanda, Joseph D Orchowski, Emily F Shafer, Paul A Ardayfio. (United States)
- 65 Medication Persistence in the First Line of Biological Drugs in Rheumatoid Arthritis [996]**
Jéssica Barreto dos Santos, Augusto Afonso Guerra Junior, Michael Ruberson da Silva, Alessandra Maciel Almeida, Francisco de Assis Acurcio, Juliana Alvares-Teodoro. (Brazil)

Poster Session C: Burden of Disease - Infections

- 66 Antimicrobial Resistance in Non-Typhoidal Salmonella from Retail Poultry Meat by Antibiotic Usage-Related Production Claims - United States, 2005-2015 [997]**
Xin Yin, Nkuchia M M'ikanatha, Heather Tate. (United States)
- 67 Respiratory Viral Testing and Antimicrobial De-Escalation among Hospitalized Patients at a Tertiary Care Facility, 2015-2016: A Matched Cohort Study Series [998]**
Alan C Kinlaw, Emily J Ciccone, Melissa B Miller, David J Weber, Jonathan J Juliano, Ravi Jhaveri, Zachary Willis. (United States)
- 68 Comparing Hospital and Primary Care Physicians' Attitudes to Antibiotic Resistance [999]**
João C Nunes, António Teixeira Rodrigues, Adolfo Figueiras, Fátima Roque, Maria T Herdeiro. (Portugal)
- 69 The Role of Comorbidities, Infections, and Treatments in Sepsis: A Retrospective Analysis of a Large United States Electronic Health Record Database [1000]**
Georgios Varsos, Fred W Peyerl, Meng Shen, Kunal Lodaya, Halit Yapici, Laxmi Gannu, Apeksha Shenoy, David K Hayashida, Fabian D'Souza. (United States)
- 70 Single Nucleotide Polymorphisms of Pfdhfr and Pfdhps: Implications on Prophylactic Malaria Control Measures in Maiduguri, Northeast Nigeria [1001]**
Sulayman Tunde Balogun, Umar Kyari Sandabe, Olufunke Adebola Sodipo, Kenneth O Okon, Ayodele Oluwasoji Akanmu, Fatai Adewale Fehintola. (Nigeria)

- 71 Association between Phosphate Disturbance and Mortality among Critically Ill Patients with Sepsis and Septic Shock [1002]**
Albatoul Al Meshari, Shmeylan Al Harbi, Hassan Al Dorzi, Yassin Arabi, Hani Tamim, Sheryl Abdukahil. (Saudi Arabia)
- 72 CD4+ Count and Antiretroviral Therapy Contributing to Patterns of Prolonged Amenorrhea Among Women with or At-Risk of the Human Immunodeficiency Virus [1003]**
Laura M. Bozzi, O'Mareen Spence, Susan dosReis. (United States)
- 73 Bacteriological Study and Antibacterial Susceptibility of Ludwig's Angina [1004]**
Md Mehedi Hasan, Naima Ahmed Tamanna, Md Jamal Uddin. (Bangladesh)
- 74 Epidemiology of Respiratory Syncytial Virus-Associated Illnesses in Young Children [1005]**
Ann W McMahan, Noelle Cocoros, Amol Purandare, Nicole Haug, Michael Nguyen, Prabha Viswanathan. (United States)
- 75 Identification of Ordinal Endpoints Indicating Influenza Complications: A Feasibility Study Relevant to The Study of Medical Countermeasures [1006]**
Austin C Cosgrove, Nicole R Haug, Catherine A Panozzo, Gregory T Measer, Robert P Orr, Alfred F Sorbello, Henry Francis, Crystal J Garcia, Sarah K Dutcher, Noelle M Cocoros. (United States)
- 76 Hospitalizations Due to Klebsiella Pneumoniae Pneumonia in The United States [1007]**
Naimisha Movva, Paul Warrenner, Bret Sellman, Jon Fryzek. (United States)
- 77 Abstract Withdrawn [1008]**
- 78 A Conceptual Model to Evaluate Disease-Related Stigma and Access to Healthcare among Patients with Hepatitis C Virus Infection [1009]**
M Elle Saine, Vincent Lo Re III, Julia E Szymczak. (United States)
- 79 Geospatial Analysis of Gonorrhea Incidence, Antibiotic Resistance and Internet Usage [1010]**
Simon F Semus, Fanny S Mitrani-Gold. (United States)
- 80 Describing the Epidemiology of Cold and Flu in Hypertensive Patients in The US by Analysing with Novel Observational Health Data Sciences and Informatics (OHDSI) Tools [1011]**
Beth K Russell, Pareen Vora, Montse Soriano-Gabarro, Charlene Ng. (United Kingdom)
- 81 Aerobic Micro-Organisms and Antibiotic Sensitivity: A Study on Head and Neck Space Infection [1012]**
Md Mehedi Hasan, Naima Ahmed Tamanna, Md Jamal Uddin. (Bangladesh)
- 82 Patient Characteristics and Current Management of Systemic Lupus Erythematosus Patients in a Large, Representative US-Based Real World Registry Cohort [1013]**
Kathleen Mortimer, Kathryn Starzyk, Thomas Brecht, Shannon Cerf, Phillip Ballentine, Richard Gliklich. (United States)
- 83 Predictors for Poor Drug-Resistant Tuberculosis Treatment Outcomes in The Netherlands: A Retrospective Cohort Study [1014]**
Ivan Surya Pradipta, Natasha van't Boveneind-Vrubleuskaya, Onno Akkerman, Hans Wouters, Jan-Willem Alffenaar, Eelko Hak. (Netherlands)
- 84 Risk of Venous Thromboembolic Events in Adult Patients with Systemic Lupus Erythematosus: Systematic Review and Meta-Analysis [1015]**
Nick Pooley, Jinoos Yazdany, Julia Langham, Lindsay Nicholson, Sue Langham, Nina Embleton, Xia Wang, Barnabas Desta, Volkan Barut, Edward R. Hammond. (United States)
- 85 Bariatric Surgery Increases the Risk of Major Osteoporotic Fracture: A Self-Controlled Case Series Patients from the CRPD Gold Database Linked to HES [1016]**
Danielle E Robinson, Ian Douglas, Garry D Tan, Cyrus Cooper, Antonella Delmestri, M Kassim Javaid, Andrew Judge, Victoria Y Strauss, Daniel Prieto-Alhambra. (United Kingdom)
- 86 Characteristics and Symptom Severity Of 21,101 Patients Reporting Systemic Lupus Erythematosus in The PatientsLikeMe Online Health Community [1017]**
Elisabeth Nyman, Edward Hammond, Tim Vaughan, Barnabas Desta, Xia Wang, Volkan Barut, Cathy Emmas. (United Kingdom)
- 87 Systemic Lupus Erythematosus (SLE) Disease Characteristics Associated with the Type I Interferon Gene Signature: Baseline Data of the SLE Prospective Observational Cohort Study (SPOCS) [1018]**
Edward R Hammond, Martin Aringer, Laurent Arnaud, Christine Peschken, Jacob Knagenhjelm, Volkan Barut, Xia Wang, Barnabas Desta, Raj Tummala, David Ginkel, Richard Furie, Eric F. Morand. (United States)
- 88 Prevalence and Incidence of Venous Thromboembolism among Patients with Rheumatoid Arthritis in Japan [1019]**
Tomoko Kobayashi, Atsushi Nishikawa, Krista M Schroeder, Ayad K Ali. (Japan)

Poster Session C: Burden of Disease - Musculoskeletal

- 89 The Effect of Concomitant Diabetes on RA-related Outcomes: Results from the ACR's RISE Registry [1020]**
Huifeng Yun, Fenglong Xie, Lang Chen, Shuo Yang, Leticia Ferri, Evo Alemao, Jeffrey R Curtis. (United States)
- 90 Temporal Trends in the Incidence of Non-traumatic Lower Limb Amputation in Patients with Type 1 Diabetes Mellitus in The United States from 2008 to 2016 [1021]**
Sampada K Gandhi, Chuntao Wu, Zoran Doder, Xinyu Li, Juhaeri Juhaeri. (United States)
- 91 Availability of Disease Activity Measures from Systemic Lupus Erythematosus Patients in a Large, Representative US-based Real World Registry Cohort [1022]**
Kathleen Mortimer, Kathryn Starzyk, Thomas Brecht, Shannon Cerf, Phillip Ballentine, Richard Gliklich. (United States)
- 92 Characterizing Differences in Pain Score Reporting among Patients Newly Diagnosed with Rheumatoid Arthritis in The U.S. Using Optum™ Integrated Claims-EHR Data [1023]**
Jonathan M Davitte, Ayush V Patel, Rachel E Williams. (United States)
- 93 Pre-operative Predictors of Post-operative Pain Relief: Pain Score Modeling Following Spinal Fusion Surgery [1024]**
Zhenna Huang, Chantal E. Holy, Jill Webster Ruppenkamp, Katherine Corso, Deepak Krishnan, John Pracyk. (United States)
- 94 Burden of Illness in Patients with Systemic Sclerosis in The United Kingdom [1025]**
Alicia V Gayle, Nils Schoof, Margarida Alves, Deborah Carke, Christina Raab, Prithwiraj Das, Toby Maher. (United Kingdom)
- 95 Evaluation of Discriminative Ability of Commonly Used Indices to Predict Outcomes after Spinal Fusion Surgery [1026]**
Zhenna Huang, Jill Webster Ruppenkamp, Deepak Krishnan, Chantal E Holy. (United States)
- 96 Evaluation of Discriminative Ability of Commonly Used Indices to Predict Outcomes after Fracture Repair Surgery [1027]**
Zhenna Huang, Jill Webster Ruppenkamp, Chantal E Holy, Deepak Krishnan. (United States)
- Poster Session C: Drug Effectiveness - Cardiovascular Diseases**
- 97 Ivabradine for the Treatment of Heart Failure: A Systematic Review and Meta-analysis [1028]**
Hadir Aljohani, Hadeel Alkofide, Hanin Aljohani. (Saudi Arabia)
- 98 Trends in Ambulatory Analgesic Use Over an 8 Year Period in Patients after Myocardial Infarction Using a Nationwide Claims Database [1029]**
Eunyoung Kim, SuHeun Lee, Sunyoung Jung, MinGue Lee, HaeGee Kim. (Korea, Republic of)
- 99 The Effects of Initiation of Secondary Prevention Pharmacotherapy on 1-year Mortality after Stroke [1030]**
Tiantian Ma, Ian Wong, Cate Whittlesea, Li Wei. (United Kingdom)
- 100 Relationship between Daily Versus Evening/Bedtime Statin Dosing and Changes in Low-Density Lipoprotein Cholesterol [1031]**
Zachary Marcum, Claire Huang, Robert Romanelli. (United States)
- 101 Comparative Effectiveness Study of Combined Antihypertensive Medications for Nigerians [1032]**
Charles E Okafor, Chinwe V Ukwe, Maxwell O Adibe, Benedict Anisiuba, Samuel O Ike, Geoffery Nwuruku. (Nigeria)
- 102 Anti-Hypertensive Drugs and Endothelial Function: Results from The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) [1033]**
Isabella Schettini, Sandy Barreto, Brant Luisa, Antônio Ribeiro, Danyelle Rios, Roberta Figueiredo. (Brazil)
- 103 Does the Comparative Effectiveness of First Line Anti-hypertensive Drugs Differ According to Age? [1034]**
Sarah-Jo J Sinnott, Ian J Douglas, Elizabeth Williamson, Liam Smeeth, Laurie Tomlinson. (United Kingdom)
- 104 Does the Comparative Effectiveness of First Line Anti-hypertensive Drugs Vary by Gender? [1035]**
Sarah-Jo Sinnott, Ian J Douglas, Elizabeth Williamson, Liam Smeeth, Laurie A Tomlinson. (United Kingdom)
- 105 Risk Factors of Major Bleeding in Patients Prescribed Rivaroxaban in Primary Care in England [1036]**
Debabrata Roy, Sandeep Dhanda, Lesley Wise, Saad Shakir. (United Kingdom)
- 106 Comparative Effectiveness of First Line Anti-hypertensive Drugs: Variation by Ethnicity [1037]**
Sarah-Jo J Sinnott, Ian J Douglas, Elizabeth Williamson, Liam Smeeth, Laurie A Tomlinson. (United Kingdom)

Poster Session C: Drug Effectiveness - Musculoskeletal Diseases

107 Improvements in Disease Activity Scores Associated with bDMARD Use by Rheumatoid Arthritis Patients in a Large US-based Real World Cohort [1038]

Kathleen Mortimer, Anna Swenson, Thomas Brecht, Brian Strubel, Shannon Cerf, Anna Lafontant, Richard Gliklich. (United States)

108 Real-World Effectiveness of Methotrexate, Cyclosporin, Acitretin and Fumaric Acid Esters for Psoriasis: Does Treatment History Matter? [1039]

Kayleigh J Mason, on behalf of the BADBIR Study Group. (United Kingdom)

Poster Session C: Drug Effectiveness - Other Diseases

109 Comparative Effectiveness of Long-term Lifestyle and Pharmacological Interventions for Primary Prevention of Type 2 Diabetes: A Network Meta-analysis of Randomized Controlled Trials [1040]

Huilin Tang, Jin Xia, Keming Yang, Yiqing Song. (United States)

110 Evaluation on Therapeutic Equivalence of Generic and Brand-name Controlled-release Doxazosin [1041]

Ju-Ling Chen, Ching-Lan Cheng, Yea-Huei Kao Yang. (Taiwan)

111 Real-world Safety and Effectiveness of Onabotulinumtoxin A Treatment of Crow's Feet Lines and Glabellar Lines: Results of a Korean 4-year Postmarketing Surveillance Study [1042]

Dong Jin Yi, Seongjin Hwang, JunHyuk Son, Irina Yushmanova, Krystal Anson Spenta, Suzanne St. Rose. (Korea, Republic of)

Poster Session C: Drug Utilization - Infections

112 Treatment Patterns of Systemic Antifungal Dispensation in Hospitals in England: An Analysis of The Health Treatment Insights Database [1043]

Orlagh U Carroll, Rachel L Tham, Benjamin D Bray, Hassy Dattani, Deborah Layton. (United Kingdom)

113 Impact of Fluoroquinolone Pre-authorization on Ceftriaxone Use and Resistance in a Large Academic Hospital in South East United States of America [1044]

Adeniyi J Idigo, Rachael A Lee, Bryan Jr. Allen, Matthew L Brown, Howard W Wiener, Russell L Griffin, Sadeep Shrestha. (United States)

114 National Medication Use Evaluation of Combination Antibiotic-corticosteroid Ophthalmic Products for Acute Conjunctivitis [1045]

Michelle Vu, Nathan Sylvain, Glenn Cockerham, Muriel Burk, Chester B Good, Peter Glassman, Xiang-Ming Wei, Diane Dong, Francesca Cunningham. (United States)

115 Trends in Pharmacotherapy for Uncomplicated Urinary Tract Infections in The United States, 2007-2016 [1046]

Julia B Ward, Brian R Matlaga, Casey Pierce, John Lim, Kevin C Abbott, Tamara Bavendam, Ziya Kirkali, Lydia Feinstein. (United States)

116 Regional Variation in the Potentially Inappropriate First Line Use of Fluoroquinolones in Canada: A Key to Antibiotic Stewardship? [1047]

Audray St-Jean, Dan Chateau, Matthew Dahl, Pierre Ernst, Nick Daneman, Ingrid S. Sketris, Jianguo Zhang, Fawziah Lalji, Jacqueline Quail, Shawn Bugden, for the CNODES Investigators. (Canada)

117 Dolutegravir Exposure among Women of Child-bearing Potential Living with HIV and During Early Pregnancy - A Drug Utilization Study [1048]

James P Trinidad, Talia Menzin, Elizabeth Dee, Monique Falconer, Mayura Shinde. (United States)

118 Prevalence of Isoniazid Preventive Therapy Use and Factors Predicting Its Use among HIV-Infected Patients in a Nigerian Teaching Hospital [1049]

Abdulwasiu A Busari, Kaseem A Oshikoya, Olamide A Olanrewaju, Ibrahim A Oreagba. (Nigeria)

119 Utilization of Direct Acting Antivirals for the Treatment of Hepatitis C in the Province of Manitoba, Canada [1050]

Silvia Alessi-Severini, Carole Taylor, Samantha Myers, I fan Kuo. (Canada)

120 Ceftolozane-tazobactam Utilization in The National Veterans Affairs Healthcare System [1051]

Jaelyn A Cusumano, Emily Bodo, Vrishali Lopes, Kevin W McConeghy, Laura A Puzniak, Eilish McCann, Kerry L LaPlante, Aisling R Caffrey. (United States)

121 Antibiotics Utilization in Ghana Using Real World Claims Data [1052]

Daniel Ankrah, Ruby Mensah, Francis Asenso-Boadi, Lydia Dsane-Selby. (Ghana)

122 Temporal Trends in the Dispensation of Systemic Antifungal Therapy in Hospitals in England: An Analysis of The Health Treatment Insights Database [1053]

Rachel L Tham, Orlagh U Carroll, Benjamin D Bray, Hassy Dattani, Deborah Layton, Joseph Kim. (United Kingdom)

123 Antibiotics Utilization Review in a Nigerian Tertiary Hospital [1054]

Tarilate C Temedie-Asogwa. (Nigeria)

- 124 Abstract Withdrawn [1055]**
- 125 Characteristics and Timing of Treatment among Patients with Influenza-Like Illness [1056]**
Crystal J Garcia, Nicole R Haug, Catherine A Panozzo, Austin C Cosgrove, Henry Francis, Alfred F Sorbello, Robert P Orr, Gregory T Measer, Sarah K Dutcher, Noelle M Cocoros. (United States)
- 126 Use of Non-HIV Medication among People Receiving Antiretroviral Treatment in Côte d'Ivoire, a Cross Sectional Study [1057]**
Mariam Mama Djima, Didier Koumavi Ekouevi, Jean-Pierre Grregoire, Boris Tchounga, Patrick Ahuatchi Coffie, Viet-Thi Tran, Franck Y. Toure, Jocelyne Moisan. (Côte D'Ivoire)
- 127 Strategy to Improve Hepatitis C Treatment Drug Use in Colombia [1058]**
Angela Viviana Perez Gomez, Aurelio Mejia, Antonio Trujillo, Johnny David Contreras. (United States)
- 128 Indications for Otic Quinolone Use in South Korea [1059]**
Kiyon Rhew, Phuong T Tran, Xi Wang, Patrick J Antonelli, Almut G Winterstein. (United States)
- 129 Trends of Antibacterial-effect Traditional Chinese Medicine Consumption in Secondary and Tertiary Hospitals in China: An Analysis of Pharmaceutical Sales Data, 2011-2015 [1060]**
Yue Zhou, Haishaerjiang Washouer, Xiaodong Guan, Luwen Shi. (China)
- 130 Drug Utilization Evaluation of Antimicrobial Agents at a Tertiary Care Hospital: Point Prevalence Survey [1061]**
Zabiuddin Ahad Mohammed, Chiranjay Mukhopadhyay, Muralidhar Varma, Vandana Kalwaje Eshwara. (India)
- 131 Antimicrobial Prescribing Patterns and Compliance with Treatment Guidelines in Critical Care Unit at a National Referral Hospital in Kenya [1062]**
Emmah Obegi, Margaret Oluka, Faith Okalebo, Sylvia Opanga, Dorothy Aywak, Anastasia Guantai, Loice Achieng, Amanj Ismael Baker Kurdi, Brian Godman, Marion Bennie. (United Kingdom)
- Poster Session C: Drug Utilization - Endocrine and Metabolism**
- 132 Visualizing Drug Treatment Pathways in Type 2 Diabetes [1063]**
Amanda R Patrick, Sheila Nemeth, Sruthi Adimadhyam. (United States)
- 133 Utilisation of Dulaglutide in Primary Care in England: Interim Results from a Post Authorisation Safety Study [1064]**
Miranda Davies, Lorna Hazell, Sandeep Dhanda, Vicki Osborne, Ayad K Ali, Saad Shakir. (United Kingdom)
- 134 European Multi-Country Drug Utilization Study of Dulaglutide [1065]**
Ayad K Ali, Karen E Wells, Mathieu Rosé, Massoud Toussi. (United States)
- 135 Utilisation of Exenatide Once-weekly (bydureon®) in Primary Care in England: Results from a PASS [1066]**
Sandeep Dhanda, Vicki Osborne, Debabrata Roy, Saad Shakir. (United Kingdom)
- 136 Determinants for Initial Treatment Choice in Diabetic Macular Edema [1067]**
Brian VanderBeek, Kurt Scavelli, Yinxi Yu. (United States)
- 137 Gender Differences in Reported Adverse Drug Reactions at Different Time Periods after Drug Initiation [1068]**
Sieta T de Vries, Petra Denig, Peter G M Mol, Eugène P van Puijtenbroek. (Netherlands)
- 138 Drug-utilization Study Examining Characteristics of Patients Prescribed Add-on Treatment to Metformin [1069]**
Juan Carlos Bazo-Alvarez, Irene Petersen, Irwin Nazareth, Manuj Sharma. (United Kingdom)
- 139 Utilization of Prescription Anti-Obesity Drugs in The U.S. Food and Drug Administration's (FDA) Sentinel System, 2008-2017 [1070]**
Sara Azimi-Bolourian, Emily C Welch, Candace C Fuller, Rajani Rajbhandari, Christian Hampp, Michael D Nguyen. (United States)
- 140 Utilization Pattern and Adherence to Novel Anti-Obesity Medications: A Retrospective Study in a Privately Insured Population [1071]**
Amir Sarayani, Phuong Pham, Sascha van Boemmel-Wegmann, Almut G Winterstein. (United States)
- 141 Antidiabetic Therapy De-intensification from a Physician Perspective and Factors Affecting their Prescribing: A Cross-sectional Study [1072]**
Abdallah Y Naser, Badi Alenazi. (Jordan)
- 142 Are Medication Adherence and Total Healthcare Cost Associated with Generic and Brand Levothyroxine Initiation [1073]**
Nan Huo, Jingjing Qian. (United States)

Poster Session C: Drug Utilization - Gastrointestinal and Liver

- 143 Proton Pump Inhibitor (PPI) Use in Australia: Evaluating National Quality Use of Medicines Initiatives [1074]**
 Claudia Bruno, Sallie-Anne Pearson, Benjamin Daniels, Nicholas Buckley, Helga Zoega. (Australia)
- 144 National Trends in Proton Pump Inhibitors (PPIS) Use and Patient Factors Associated with PPIs Use in The United States: 2002-2015 [1075]**
 Ahmed Ullah Mishuk, Richard Hansen, Li Chen, Philippe Gaillard, Jingjing Qian. (United States)
- 145 Use of Proton Pump Inhibitors and Mortality Among Icelandic Prostate Cancer Patients [1076]**
 Óskar Hálfðánarson, Anton Pottegård, Sigrún H Lund, Margret H Ogmundsdottir, Helga M Ogmundsdottir, Helga Zoëga. (Iceland)
- 146 Utilisation of linaclotide in United Kingdom [1077]**
 Nafeesa Dhalwani, Anna Schultze, Robert Donaldson, Ahunna Ukah, Darren Weissman, Jim Wang, Javier Cid Ruzafa. (United Kingdom)

Poster Session C: Drug Utilization - Methods, Interventions, and Implementations

- 147 Bone Mineral Density Testing after Initiation of Androgen Deprivation Therapy for Prostate Cancer [1078]**
 Jason Hu, Alice Dragomir. (Canada)
- 148 Prestop: Patients Perspective on Discontinuation of CML TKI-Treatment [1079]**
 Vashti N Tromp, Lonneke Timmers, Leanne Koningen, Jeroen J Janssen, Peter E Westerweel, Inge G Geelen, Jan Jong, Christel C Boons, Jacqueline G Hugtenburg. (Netherlands)
- 149 Design of a Centrally Aggregated Medication Use Evaluation: Anticholinergics in Dementia [1080]**
 Madeline McCarren, Muriel Burk, Ronald L Carico, Peter A Glassman, Chester B Good, Francesca E Cunningham. (United States)
- 150 Retrospective Interrupted Time Series Examining Hypertension and Diabetes Treatment Affordability and Government Expenditures Following Changes in Patient Cost Sharing in The "Farmacia Popular" Program in Brazil [1081]**
 Isabel C Emmerick, Monica R Campos, Rondineli M da Silva, Luisa A Chaves, Andréa D Bertoldi, Dennis Ross-Degnan, Vera L Luiza. (United States)
- 151 Real-world Impact on Pharmacological Management of Type 2 Diabetes Following a Drug Subsidy Decision: A Joinpoint Regression on Utilization Data in Singapore, 2014-2017 [1082]**
 Jiandong Sun, Kwong Ng. (Singapore)
- 152 A Rapid Monitoring Tool to Provide Near Real-time Evaluation after a New Drug Policy Implementation [1083]**
 Anat Fisher, Greg Carney, Colin R Dormuth. (Canada)
- 153 To Study the Impact of Educational Intervention on Drug Utilization of Reserve Antibiotics [1084]**
 Zabiuddin Ahad Mohammed, Muralidhar Varma, Chiranjay Mukhopadhyay, Vandana Kalwaje Eshwara. (India)
- 154 Development of the AbbVie Automated Commercial Exposure System [1085]**
 Chris Schneiderman, Robert Gregg, Seema Atre, Raghava Danwada, Nancy Liu, John A Saunders, Brian Stavlo. (United States)

- 155 Association between Adherence to Guideline-Recommended Preventive Medications and In-Hospital Mortality among Non-Reperused ST-Elevation Myocardial Infarction Patients Admitted to a Tertiary Care Academic Center in a Developing Country [1086]**
 Sylvi Irawati, Surya Dharma, Katja Taxis, Nguyen Thang, Nunung Nursyarofah, Bob Wilffert, Eelko Hak. (Netherlands)
- 156 Abstract Withdrawn [1087]**
- 157 Pre- and Post-Intervention Study to Assess the Impact of the Use of Consensus Validated Criteria Explicit Criteria on Prescribing of Potentially Inappropriate Medication and Subsequent Adverse Drug Events-Related Hospitalization in Pakistani Elderly [1088]**
 Faizan Mazhar, Shahzad Akram. (Italy)
- 158 Intervention to Improve Penicillin Prescribing in Primary Care: A Controlled Interrupted Time-Series Study [1089]**
 António Teixeira Rodrigues, Fátima Roque, Maria Piñeiro-Lamas, Amílcar Falcão, Adolfo Figueiras, Maria Teresa Herdeiro. (Portugal)
- 159 Patterns of Utilization of Specific Insulin Formulations and Non-Insulin Antidiabetic Therapies Before, During, and After Implementation of a Health Plan Insulin Switching Intervention [1090]**
 Jing Luo, Nazleen Khan, Joshua Gagne, Aaron Kesselheim. (United States)
- 160 The Impact of Interprofessional Education (IPE) on the Outcomes of Pharmacy Practice Experiences [1091]**
 Emily Murray, Xuerong Wen, Celia MacDonnell, Matthew Lacroix, Yang Li, Erica Estus, Michelle Caetano, Barbara Sweeney, Dara LoBuono, Phillip Clark. (United States)

- 161 Perceptions of Saudis Toward Generic Drugs Use [1092]**
Malak S Almofada, Lamyia S Alnaim, Edward B DevoI, Asma A AlHussaini, Aljawhara A AlShahrani, Hessah I AlSuwaidan. (Saudi Arabia)

Poster Session C: Drug Utilization - Policy

- 162 Impact of the October 2016 Policy Change on the Delivery of MedsCheck Annual and MedsCheck Diabetes Services in Ontario Community Pharmacies [1093]**
Ahmad Shakeri, Lisa Dolovich, Lori MacCallum, John-Michael Gamble, Limei Zhou, Suzanne M. Cadarette. (Canada)
- 163 Global Overview of the Relative Consumption of Access Antibiotics within WHO AWaRe Categories [1094]**
Verica Ivanovska, Wenjing Tao, Arno Muller. (Switzerland)
- 164 Reduction in Use of Cyproterone/ethinylestradiol (diane-35 and Generics) after Risk Minimisation Measures in The Netherlands, UK and Italy [1095]**
Irene D Bezemer, Elisabeth Smits, Fernie J Penning-van Beest, Luis A. García Rodríguez, Lucía Cea Soriano, Francesco Lapi, Monica Simonetti, Alex Asiimwe, Dalia Shash, Ron M Herings. (Netherlands)
- 165 Influence of Change in Treatment Policy and ART Regimen in HIV Positive Patients on Treatment Out Comes: An Observation from South Indian State Funded Hospital [1096]**
Varun Talla, Satyanarayana Pattnaik, Jupally Venkateshwar Rao, Vamshi Krishna, Chandrasekar V, Hari Krishna, Sandeep D. (India)

- 166 Impact of Drug Safety Warnings and Cost-Sharing Policies on Osteoporosis Drug Utilization in Spain: A Major Reduction but with the Persistence of Over and Underuse. Data from The ESOSVAL Cohort 2009-2015 [1097]**
Isabel Hurtado-Navarro, Anibal García-Sempere, Clara Rodríguez-Bernal, José Sanfélix-Genovés, Salvador Peiró, Gabriel Sanfeliix-Gimeno. (Spain)
- 167 Impact of European Label Changes for Systematic Diclofenac Products: Post-Referral Prescribing Trends for Initiation of Systemic Diclofenac Products and Time Series Regression [1098]**
Daniel R Morales, Tom MacDonald, Steve Morant, Martin Ernst, Jesper Hallas, Lisa Smits, Ron Herings, Lizzie Nicholson, Marion Bennie, Li Wei, Rob Flynn. (United Kingdom)
- 168 Are NHIS Clients Served Inferior and Sub-standard Medicines? Using Standard WHO RUM Indicators to Determine Quality of Care Under the NHIS in Ghana [1099]**
Daniel K Arhinful, Daniel N Ankrah. (Ghana)
- 169 Impact of European Label Changes for Systematic Diclofenac Products: Post-referral Prescribing Trends in Switching to Alternative Products Following Diclofenac Discontinuation [1100]**
Daniel R Morales, Tom MacDonald, Steve Morant, Martin Ernst, Jesper Hallas, Lisa Smits, Ron Herings, Lizzie Nicholson, Marion Bennie, Marion Bennie, Li Wei, Rob Flynn. (United Kingdom)
- 170 Policies Influencing Access to New Targeted Oncologic Drugs in Ecuadorian Hospitals: An Interrupted Time Series Analysis [1101]**
Carlos E Durán, Monique Elseviers, Robert Vander Stichele, Sylvie Rottey, Patricia Granja. (Ecuador)

- 171 The Part D Enhanced Medication Therapy Management Model: Monitoring Findings as the Model Enters Year Two [1102]**
Karin Johnson, Corey Triebwasser, Ilene Harris, Paul Dowell, Tracy Haidar, Zippora Kiptanui, Olivia Bundschuh, Catherine Cooke, Nicole Brandt. (United States)
- 172 China Pharmacovigilance Under Reformed Drug Regulations [1103]**
Li Zhang, Haibo Song, Ying He, Jialin Cong, Jukai Huang. (China)

Poster Session C: Drug Utilization - Polypharmacy and Appropriateness of Use of Medications

- 173 Trends in Polypharmacy and Dispensed Drugs among Adults in The Netherlands as Compared to The United States [1104]**
Monika P Oktor, Petra Denig, Jens H Bos, Catharina C Schuiling-Veninga, Eelko Hak. (Netherlands)
- 174 Polypharmacy Risk Among Five-Year Cancer Survivors [1105]**
Christine D Hsu, Jennifer L Lund, Hazel Nichols. (United States)
- 175 Variation in Belgian Polypharmacy : Trends 2013-2016 [1106]**
Victoria A Fuchs, Gabriela Boyle, Nina Kouevi-Gath, Carine De Vriese, Fati Kirakoya-Samadoulougou. (Belgium)
- 176 Comparing Prescribing Practices of Primary Care Providers Using Formulary Selectivity Index, as One Measure of Conservative Prescribing [1107]**
Tewodros Eguale, Ismaeel Yunusa, Ihtisham Sultan, Lynn Volk, Diana Norwich, Maria Mirica, William Galanter, Bruce Lambert, Gordon Schiff. (United States)

- 177 Trends in Inappropriate Outpatient Antibiotic Use in The United States [1108]**
Mahek Garg, Haesuk Park. (United States)
- 178 A New Tool to Evaluate and Promote Rational Use of Pharmacotherapy Available to All Danish General Practitioners [1109]**
Ulrik Hesse, Katrine Agergaard, Ghousia Javid, Pernille Juul Kristensen, Maja Laursen. (Denmark)
- 179 Which Part of Unplanned Hospital Readmissions within 30 Days of Discharge is Medication Related and Potentially Preventable? [1110]**
Elien Uitvlugt, Marjo Janssen, Eva Kneepkens, Bart van den Bemt, Patricia van den Bemt, Fatma Karapinar. (Netherlands)
- 180 Appropriateness of Otic Quinolone Use among Privately Insured Patients in The United States [1111]**
Phuong T Tran, Kiyon Rhew, Xi Wang, Almut G Winterstein, Patrick J Antonelli. (United States)
- 181 Self-Medication Practices in Rural Communities, Alexandria, Egypt: Prevalence, Perception and Attitude [1112]**
Hala Shokr, Mohamed Mekrawy, Ola Fahmy. (United Kingdom)
- 182 Disparities in All-Cause Mortality with Potentially Inappropriate Medication Use: Analysis of the Reasons for Geographic and Racial Differences in Stroke Study [1113]**
Md Motiur Rahman, George Howard, Jingjing Qian, Kimberly Garza, Ash Abebe, Richard Hansen. (United States)
- 183 Antidepressants Use and Persistence in Tuscany: A Large Regional Drug-Utilization Study [1114]**
Ippazio Cosimo Antonazzo, Giuseppe Roberto, Elisabetta Poluzzi, Rosa Gini. (Italy)
- 184 Prevalence of Polypharmacy in Japan [1115]**
Hiraku Kumamaru, Nobutomo Matsui, Kohta Sakuma, William YH Kuan, Hiroaki Miyata. (Japan)
- 185 Medication Errors Associated with the Use of Antibiotics in Critical Care Units [1116]**
Ramesh Madhan, Awthamefule Urechi, Chalasani Sri Harsha. (India)
- 186 Distribution and Storage of Medications in Households from Mexico City [1117]**
Ramiro Sánchez-Huesca, Vanessa S Mejía-Esquivel. (Mexico)
- 187 Insights of the Health Care Work Force on Establishing a Medication Error Reporting System in a Tertiary Care Teaching Hospital: A Survey Questionnaire [1118]**
Chalasani Sri Harsha, Madhan Ramesh. (India)
- 188 Polypharmacy and Associated Factors in Primary Healthcare Users of The Unified Health System in Minas Gerais State, Brazil [1119]**
Thais A Moreira, Juliana A Teodoro, Mariana M Barbosa, Renata C Nascimento, Augusto A Guerra-Júnior, Francisco A Acurcio. (Brazil)
- 189 Reasons for Self-Medication with Antibiotics Among People with Secondary Education or Higher in Hyderabad, India: A Cross-Sectional Study [1120]**
Mansour Mahmoud, Wajid Syed, Mohammed Al-Arifi, Fawziah Almana, Atta Naqvi. (Saudi Arabia)
- 190 Non-Prescription Paracetamol: Patients' Knowledge and Habits [1121]**
Michael Petrides, Christos Kontogiorgis, Christos Petrou, Evangelia Nena, Maria Papavasili, Aliko Peletidi, Theodoros Konstantinidis. (Cyprus)
- 191 Drug Overload in HIV Management: An Indian Countryside Clinical Picture [1122]**
Vamshi Krishna Sirigadhi, Sandeep Digijarala, Hari Krishna Aanathoju, Varun Talla, Venkateswar Rao Jupally, Satyanarayana Pattnaik, Chandrashekhar Valupadas. (India)
- Poster Session C: Drug Utilization - Respiratory**
- 192 Prevalence of Long-Term Oral Corticosteroid Use in Asthma Evaluated from Different Angles [1123]**
Trung N Tran, Sharon MacLachlan, Michael Ganz, Wesley Hicks. (United States)
- 193 A Longitudinal Observational Study Describing the Prescribing of, and Persistence with, Multiple-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease in The United States [1124]**
Leah B Sansbury, Lisa Wittenhagen, Yi Ba, Priyanka Joseph, Robyn Mueller, Suren Samarasinghe, Grace Lomax. (United States)
- 194 Discontinuation of Therapy among COPD Patients who Experience an Improvement in Exacerbation Status [1125]**
Mette Reilev, Kasper B Kristensen, Jens Søndergaard, Daniel P Henriksen, Wade Thompson, Anton Pottegård. (Denmark)
- 195 Utilization Pattern of Chronic Lung Disease Treatment Prior to the Start of Respiratory Syncytial Virus Season [1126]**
Yoonyoung Choi, H Cody Meissner, Christian Hampp, Haesuk Park, Babett Brumback, Almut G Winterstein. (United States)

- 196 Assessment of Inhalation Techniques Employed by Asthma and COPD Patients in Warangal Region, India [1127]**
Rajashekar Bollu, Sai Phani Maddipatla, Ashok Eggiri, Shakeer Shaik, Baikunta Prusty Korada. (India)

Poster Session C: Drug Utilization - Potpourri

- 197 Utilization of Olodaterol and Indacaterol in Europe [1128]**
Cristina Rebordosa, Eline Houben, Kristina Laugesen, Joelle Asmar, Jukka T Montonen, Jaume Aguado, Jetty Overbeek, Vera Ehrenstein, Laura Wallace, Alicia Gilsenan. (Spain)

- 198 A Day in the Life: Prescription Medicine Use in Australia [1129]**
Benjamin Daniels, Claire Wylie, Sallie-Anne Pearson, Jonathan Brett, Nicholas Buckley. (Australia)

- 199 Use of Ovarian Suppression with Endocrine Therapy among Premenopausal Women with Breast Cancer in The United States, 2001-2016 [1130]**
Sophie E Mayer, Jennifer L Lund, Virginia Pate, Katherine E Reeder-Hayes. (United States)

- 200 Type and Characteristics of Drug Information Inquiries in Ethiopia University Hospital: 2 Year Prospective Observational Study [1131]**
Yonas Getaye Tefera, Begashaw Gebresillassie, Asnakew Achaw Ayele, Yared Belay, Yohannes Kelifa Emiru. (Ethiopia)

- 201 Over-the-Counter Drugs: A Pharmacoepidemiological Study in Greece During the Financial Crisis [1132]**
OTheodora Tatsiou, Georgios Poulentzas, Panagiotis Nikolaos Lalagkas, Eleftherios Berberoglou, Christos Kontogiorgis, Theodoros Constantinides, Dimitra Hadjipavlou-Litina. (Greece)

- 202 Glucocorticosteroids for the Treatment of Anaphylaxis: A Systematic Review [1133]**
Xiaotong Li, Yajuan Xiong, Suodi Zhai. (China)

- 203 Pharmacoepidemiology Capacity Building in The Latin American and African Regions [1134]**
Maribel Salas, Wendy Camelo Castillo, Lucia D Juarez, Chengchen Zhang, Ariel Arias, Kwame Appenteng, Macarius M. Donneyong, Nicolas Thurin, Luciane C. Lopes, Diana Gomez Galicia, Johanita Burger, Daniel Ankrah, Olayinka Ogunleye, Joseph O Fadare, Juan-David Rueda, Martie Lubbe, Aida Kuzucan, Chioma S Ejekam, Miriam del Carmen Garcia Estrada, Jorgelina Bernet, Luis Alesso, Raquel Herrera Comoglio, Lisa Pont, Norma Angelica Rodriguez, Ilse Truter. (United States)

Poster Session C: Patient-Reported Outcomes and Quality of Life

- 204 Association between Self-Assessed NYHA Functional Class and Quality of Life in a Cohort of Portuguese Heart Failure Patients: The PRIME Study [1135]**
Maria Cary, José Pedro Guerreiro, Mariana Romão, António Teixeira Rodrigues, Marta Afonso-Silva, Pedro Laires. (Portugal)

- 205 Assessment of Health Related Quality of Life of HIV Positive Patients in Warangal Region (India) [1136]**
Navya Sri Gurrum, Navya Poka, Nagalaxmi Valluri, Venkateshwar Rao Jupally, Swethanjali K. (India)

- 206 Validated Instruments of Quality of Life (QoL) in Acute Myeloid Leukemia (AML) Patients [1137]**
Maribel Salas, Maggie Elsharkawy, Angelika Wientzek-Fleischmann, Zahidul Islam, Nora Tu, Aikaterini Bilitou, Ulf Stellmacher. (United States)

- 207 Patient Participation in PCORnet Patient-Powered Research Networks through Payer-Initiated Member Outreach [1138]**
Xiaoxue Chen, Abiy Agiro, W Benjamin Nowell, Sara Loud, Robert McBurney, Kalen Young, Rebecca Sutphen, Elizabeth Bourquardez Clark, Cristina Burroughs, Jeffrey R Curtis, Antoine Sreih, Peter A Merkel, Kevin Haynes. (United States)

- 208 Concordance of Pharmacist vs Patient Responses Regarding Counseling in Community Pharmacy - A Quantitative Assessment [1139]**
Camelia Bucsa, Mihaela Udrea, Daniel Leucuta, Marius Bojita. (Romania)

- 209 What Is the Availability of Follow-Up Pain Score in Real World Databases and Who are These Patients? [1140]**
Zhenna Huang, Jill Webster Ruppenkamp, Chantal E Holy. (United States)

- 210 Health Related Quality of Life and Its Determinants in Asthmatic Patients at a Tertiary Teaching and Referral Hospital in Kenya [1141]**
Mary Consept Alubisia, Sylvia Opana, George Arthur Mugendi. (Kenya)

- 211 Generalizability of Patient-Reported Survey Data Linked with Electronic Health Records [1142]**
Stephanie Huynh, Carey Strader, Jennifer L Nguyen, Tom Haskell. (United States)

- 212 Attitudes and Perceptions Towards Hypoglycaemia in Patients with Diabetes Mellitus: A Multinational Cross-Sectional Study [1143]**
Abdallah Y Naser, Ian CK Wong, Cate Whittlesea, Hassan Alwafi, Amjad Abuirmeileh, Fawaz Turkistani, Nedaa S Bokhari, Maedeh Y Beykloo, Dalal Al-Taweel, Zahra K Alsairafi, Mai B Almane, Li Wei. (Jordan)

213 Anti-Diabetic Drug Utilization Knowledge and Glycemic Index Control in Patients with Uncontrolled Diabetes Mellitus [1144]

Naima Ahmed Tamanna, Md Mehedi Hasan, Md Jamal Uddin. (Bangladesh)

214 Educational Intervention to Improve Knowledge and Skills of Drug Addiction Prevention Amongst Health Professionals and Opinion Leaders in Lagos [1145]

Ibrahim A Oreagba, Tajudeen Abiola, Azuka C Opara. (Nigeria)

Poster Session C: Pharmacovigilance - Cardiovascular

215 Risk of Major Bleeding Associated with the Use of Direct Oral Anticoagulants Compared to Vitamin K Antagonists in Patients with Atrial Fibrillation: A European Multi-Country Population-Based Cohort Study [1146]

Patrick C Souverein, Hendrika A Van den Ham, Consuelo Huerta, Elisa Martin Merino, Dolores Montero, Luz M León-Muñoz, Sven Schmiedl, Marietta Rottenkolber, Morten Andersen, Mia Aakjær, Marie L De Bruin, Olaf H Klungel, Helga Gardarsdottir. (Netherlands)

216 Adverse Drug Event Reporting among Patients Who Discontinued Empagliflozin or Apixaban in The Veterans Health Administration [1147]

Paul M Fina, Francesca E Cunningham, Xinhua Zhao, Peter A Glassman, Von R Moore, Anthony Au, Sherrie L. Aspinall. (United States)

217 Complementary Use of US FDA Adverse Event Reporting System and Sentinel Distributed Database to Characterize Non-Vitamin K Oral Anticoagulants Associated Cutaneous Small Vessel Vasculitis [1148]

Mohamed Mohamoud, Casie Horgan, Veronica Sansing-Foster, Elizabeth Dee, Justin Bohn, Oren Shapira, Mihaela Jason, Efe Eworuke, Monica Munoz, Danijela Stojanovic, Lois La Grenade. (United States)

218 Fluoroquinolone Use and Serious Arrhythmias: A Nationwide Case-Crossover Study [1149]

Lorenzo Porta, Meng-tse Gabriel Lee, Wan-Ting Hsu, Tzu-Chun Hsu, Chien-Chang Lee. (United States)

219 A Self Controlled Case Series of Fluoroquinolone Exposure and the Risk of Aortic Aneurysm or Dissection [1150]

Ajit A Londhe, Chantal Holy, James Weaver, Sergio Fonseca, Angelina Villasis, Daniel Fife. (United States)

220 Acetylcholinesterase Inhibitors, Cardiosuppressive Drugs, and Adverse Cardiac Events in Patients with Dementia [1151]

Izumi Sato, Isao Iwata, Edward Chia-Cheng Lai, Soko Setoguchi. (United States)

221 Concomitant Use of Dronedarone and Dabigatran is Not Associated with Increased Risk of Major Bleeding [1152]

Chuntao Wu, Rania Boiron, Juhaeri Juhaeri. (United States)

222 Hospitalization for Heart Failure among Patients Using Acridinium Bromide and Other COPD Medications: A Post-authorisation Safety Study in the CPRD [1153]

Estel Plana, Elena Rivero-Ferrer, Jaume Aguado, Nuria Saigi-Morgui, Javier Nuevo, Sami Z Daoud, Alejandra Lei, Susana Perez-Gutthann, Cristina Rebordosa. (Spain)

223 Major Bleeding Risk Associated with Oral Anticoagulant in Real Clinical Practice. A Multicentre Population-Based Prospective Cohort Study Over a Period Years [1154]

Jacques Bouget, Frédéric Balusson, Maxime Maignan, Laure Pavageau, Pierre-Marie Roy, Karine Lacut, Lucie-Marie Scailteux, Emmanuel Nowak, Emmanuel Oger. (France)

224 Heart Failure and AKI after Hospital Admission with AKI Among Patients Taking ACE Inhibitors and ARBs [1155]

Patrick Bidulka, Fotini Kalogirou, Edward Kingdon, Krishnan Bhaskaran, Liam Smeeth, Laurie Tomlinson, Dorothea Nitsch. (United Kingdom)

225 The Cardiovascular Safety of Anti-Obesity Drugs [1156]

Einat Gorelik, Ilan Matok, Boris Gorelik, Reem Masarwa, Amichai Perlman, Bruria Hirsh-Racah. (Israel)

226 Can Enzyme-Inducing AEDs and DOACs Be Co-prescribed? Assessing Concordance Between Drug Compendia for Proposed Interactions [1157]

Emily K Acton, Allison W Willis, Michael Gelfand, Scott E Kasner. (United States)

227 Celecoxib and Cardiovascular Safety: Replicating Clinical Trial Evidence from Real World Data [1158]

Ayad K Ali, Stephen P Motsko. (United States)

228 Oral Fluoroquinolones Use and Risk of Aortic Aneurysm and Dissection: A Meta-Analysis of Epidemiological Studies [1159]

Md Salman Hussain, Abul Kalam Najmi. (India)

229 Use of Drugs from the Crediblemeds® List and Risk of Sudden Cardiac Death: A Population-Based Cohort Study [1160]

Marten E Van den Berg, Katia M Verhamme, Bruno H Stricker. (Netherlands)

230 Gender Differences in the Adverse Events Induced by Cardiovascular Drugs: Using National Adverse Event Reporting and Health Insurance Database [1161]

Han-Heui Park, Dongwon Yoon, Ju Hwan Kim, Ju-Young Shin. (Korea, Republic of)

- 231 Risk of Bradyarrhythmia Related to Ticagrelor: A Systematic Review and Meta-analysis [1162]**
Iris Pujade, Justine Perino, Clément Mathieu, Mickael Arnaud, Francesco Salvo. (France)
- 232 Use of Pregabalin and Worsening Heart Failure: A Nationwide Cohort Study [1163]**
Marie Lund, Gry Juul Poulsen, Björn Pasternak, Niklas Worm Andersson, Mads Melbye, Henrik Svanström. (Denmark)
- 233 DPP-4 Inhibitors and Risk of Venous Thromboembolism: Analysis of The FDA Adverse Event Reporting System Database [1164]**
Wenchao Lu, Dandan Li, Jingkai Wei, Lulu Sun, Tiansheng Wang. (China)
- 234 Major Cardiovascular Events in Adults on Antiretroviral Therapy in a South African HIV Management Programme [1165]**
Johannes P Mouton, René de Waal, Morna Cornell, Gary Maartens, Karen Cohen. (South Africa)
- 235 Antiplatelet Agents and Risk of Stroke [1166]**
Lamiae Grimaldi-Bensouda, Nicolas Morisot, Pegdwende O Dialla, Clémentine Nordon, Lucien Abenheim. (France)
- 236 A Plausible Causal Link between Antiretroviral Therapy and Increased Blood Pressure in Patients on Highly Active Antiretroviral Therapy: A Propensity Score-matched Analysis [1167]**
Edmund T Nartey, Raymond A Tetteh. (Ghana)
- 237 Pharmacogenetic Modeling of Metformin on Stroke, Myocardial Infarction and Cardiovascular Mortality [1168]**
Marten E Van den Berg, Katia M Verhamme, Bruno H Stricker. (Netherlands)
- 238 Association between the Risk of Venous Thrombosis and Antidepressants: A Meta-Analysis [1169]**
Kiyon Rhew, Victoria Z Reams, Joshua D Brown, Almut G Winterstein. (United States)
- 239 Abstract Withdrawn [1170]**
- 240 Spironolactone Reduces the Risk of Mortality and Hospitalization in Veterans with Heart Failure with Preserved Ejection Fraction [1171]**
Katherine E Kurgansky, Rachel Parker, Luc Djousse, Jacob Joseph, David Gagnon. (United States)
- 241 Antidepressants Use and the Risk of Brain Hemorrhage [1172]**
Seonji Kim, Young-Jin Ko, Bo Ram Yang, Kyoungsoon Park, Mi-sook Kim, Byung-joo Park. (Korea, Republic of)
- 242 The Association between Direct Oral Anticoagulants and Gynaecological Bleeding in Women v. Standard Therapy: A Systematic Review [1173]**
Sandeep Dhanda, Vicki Osborne, Saad Shakir. (United Kingdom)
- 243 Adverse Drug Reactions Of Antihypertensive Products [1174]**
Matveev Alexandr, Krashennnikov Anatoly, Egorova Elena, Dormidor Arthur. (Russian Federation)
- 244 Comparative Effects of Sodium-glucose Cotransporter 2 Inhibitors on Serum Electrolyte Levels in Patients with Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials [1175]**
Huilin Tang, Qi Dai, Jingjing Zhang, Yiqing Song. (United States)
- 245 Antipsychotic Dose and Weight Gain: Long-Term Evidence from a Retrospective Study Using Electronic Health Records [1176]**
Juan Carlos Bazo-Alvarez, Tim P Morris, James R Carpenter, Joseph F Hayes, Irene Petersen. (United Kingdom)
- 246 Comparative Risk of Polycystic Ovary Syndrome in Young Female Patients Newly Initiating Anti-psychotic Medications [1177]**
Ying-Shan Chung. (Taiwan)
- 247 Impact of Levothyrox Formulation Change on Health and Healthcare Use in France [1178]**
Sandrine Colas, Marion Bertrand, Clara Bouche, Lise Duranteau, Mathilde Francois, Vanessa Pauly, Elisabeth Polard, Mahmoud Zureik, Rosemary Dray-Spira. (France)
- 248 The Association between Receptor Affinity and Metabolic Side Effects Profile of Antipsychotics and Major Adverse Cardiac and Cerebrovascular Events: A Case/Non-Case Study in VigiBase [1179]**
João Pedro Aguiar, Filipa Alves da Costa, Ana Paula Martins, Toine Egberts, Hubert G Leufkens, Patrick Souverein. (Portugal)
- 249 Identifying Type 2 Diabetes Patients at Risk for Hypoglycemic Events: Dealing with Class Imbalance [1180]**
Stijn Crutzen, Sunil Belur Nagaraj, Katja Taxis, Petra Denig. (Netherlands)
- 250 Abstract Withdrawn [1181]**
- 251 Antidepressant-Induced Hyponatremia: A Pharmacoepidemiological-Pharmacodynamic Analysis of Suspected Adverse Drug Reactions Reported to The US FAERS Database [1182]**
Faizan Mazhar, Marco Pozzi, Marta Gentili, Emilio Clementi, Sonia Radice, Carla Carnovale. (Italy)

**Poster Session C:
Pharmacovigilance - Endocrine
and Metabolism**

252 Hyperkalemia Risk with Spironolactone in Patients with Heart Failure Using Loop Diuretics [1183]

Alex Secora, Jung-Im Shin, Yao Qiao, G Caleb Alexander, Josef Coresh, Morgan Grams. (United States)

253 Monitoring the Safety of Exenatide Once-Weekly (Bydureon®) in Primary Care in England: Results from a PASS [1184]

Sandeep Dhanda, Vicki Osborne, Debabrata Roy, Saad Shakir. (United Kingdom)

254 Incidence and Risk Factors for Hypoglycemia in Patients with Diabetes Hospitalised in a Quaternary Care Centre in South India [1185]

Jeeva Joseph, Suja Abraham. (India)

255 Incretin Mimetic Drugs (GLP-1 Receptor Agonists and DPP-4 Inhibitors) and Associated Adverse Events and Renal Outcomes: A Pharmacoepidemiologic Analysis Using The FAERS Database [1186]

Hamza Alshannaq, Jeff Jianfei Guo. (United States)

256 Diabetes Management Protocol: Impact In The Incidence of Hypoglycemia [1187]

Suja Abraham. (India)

257 Risk and Signals of Ketoacidosis among Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: Analysis of Post Marketing FDA Adverse Event Reporting System (FAERS) Database, 2013-2018 [1188]

Thamir M Alshammari, Maram A Al-Otaiby, Fatemah A Anofal, Khaledah A Alenazi. (Saudi Arabia)

**Poster Session C:
Pharmacovigilance -
Gastrointestinal and Liver**

258 Pancreatic Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis [1189]

Huilin Tang, Keming Yang, Aihua Wang, Xin Li, Yiqing Song, Jiali Han. (United States)

259 Acute Pancreatitis Associated with Opioid Use: A Nested Case-Control Study [1190]

Iris Pujade, Francesco Salvo, Anne-Marie Castilloux, Audrey Béliveau, Yola Moride. (France)

260 Cinacalcet Use and Risk of Gastrointestinal Bleeding in Secondary Hyperparathyroidism Patients Receiving Maintenance Hemodialysis [1191]

Tzu-Chieh Lin, Haifeng Guo, Paul Dluzniewski, Yi Peng, Dave Gilbertson, Brian Bradbury, Kimberly Nieman, Michael Sprafka, Jiannong Liu. (United States)

261 Measuring the Risk of Liver Injury in UK Primary Care Patients Prescribed a Second Course of Flucloxacillin: A Cohort Study Using the Clinical Practice Research Datalink (CPRD) [1192]

Patrick Bidulka, Ian Douglas, Louise Pealing, Kevin Wing. (United Kingdom)

262 Main Drug Classes Dispensed Prior to Hospital Admission for Acute Liver Injury [1193]

Adeline Grolleau, Stephanie Duret, Nicolas Thurin, Mai Duong, Regis Lassalle, Patrick Blin, Sinem-Ezgi Gulmez, Nicholas Moore. (France)

263 Antibiotic Exposure Prior to Hospital Admission for Acute Liver Injury [1194]

Adeline Grolleau, Stephanie Duret, Nicolas Thurin, Mai Duong, Regis Lassalle, Patrick Blin, Cecile Droz, Sinem-Ezgi Gulmez, Nicholas Moore. (France)

264 Antidepressant and Anxiolytic-Hypnotic Exposure Prior to Hospital Admission for Acute Liver Injury [1195]

Adeline Grolleau, stephanie Duret, Nicolas Thurin, Mai Duong, Regis Lassalle, Patrick Blin, Cecile Droz, SinemEzgi Gulmez, Nicholas Moore. (France)

265 Abstract Withdrawn [1196]

266 Drug-induced Liver Injury Associated with Antituberculosis and/or Antiretroviral Therapy: A Case Series from a Prospective Registry in The Western Cape, South Africa [1197]

Hannah M Gunter, Shaazia Allie, Annemie Stewart, Munir Pirmohamed, Karen Cohen. (South Africa)

267 A Multifactorial Algorithm to Automate Screening of Drug-Induced Liver Injury Cases in Clinical and Post-marketing Settings [1198]

Osman Turkoglu, Ritu Gupta, Alvin Estilo, Liliam Pineda Salgado, Rajesh Pandey, Mirza Rahman. (United States)

268 Analysis of 172 Cases with Drug-Induced Liver Injury between 2017 and 2018 in a General Hospital in Central China [1199]

Hong Cheng, Wannan Yan. (China)

269 Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists and Risk of Mortality in Critically Ill Patients - A Pilot Analysis of Multi-institutional Study [1200]

Hsing-Chun Hsieh, Tsung-Hsuan Lin, Mei-Chuan Lee, Hui-Chen Su, Shih-Chieh Shao, Chien-Chou Su, Edward Chia-Cheng Lai. (Taiwan)

270 NSAID and Analgesic Exposure Prior to Hospital Admission for Acute Liver Injury [1201]

Nicholas Moore, Adeline Grolleau, Stephanie Duret, Nicolas Thurin, Mai Duong, Regis Lassalle, Patrick Blin, Sinem Ezgi Gulmez, Cecile Droz-Perroteau. (France)

Poster Session C: Pharmacovigilance - Infections

271 Rates and Predictors of Post-Surgical Infections for Common Surgical Approaches [1202]

Abhishek S Chitnis, Katherine Corso, Zhenna Huang, Piyush Nandwani, Chantal E Holy. (United States)

272 The Role of Sleeping Pills in the Development of Shingles in Veterans [1203]

Pragati Ghimire-Aryal, Skai W Schwartz, Darren Scheer, Kenneth Taylor, Yuri Sebastião, W McDowell Anderson, Philip R Foulis. (United States)

273 Medication Related Problems and Associated Risk Factors among HIV/AIDS Patients on Antiretroviral Therapy at a National Referral Hospital in Kenya: A Cross-sectional Study [1204]

Sylvia Opanga, Peris W Thuo. (Kenya)

274 Medication Related Problems Among HIV/AIDS Patients on Antiretroviral Therapy at a National Referral Hospital in Kenya [1205]

Sylvia Opanga, Peris Wambui Thuo. (Kenya)

275 Rare Adverse Effects Analysis of New Generation Hepatitis C Medications Using EMR and FAERS Data [1206]

Chongliang Luo, Xinyuan Zhang, Liu Yang, Jingcheng Du, Jiayi Tong, Jing Huang, Cui Tao, Yong Chen. (United States)

276 Tenofovir-Associated Renal Toxicity in a Cohort of HIV-infected Patients in Ghana [1207]

Edmund T Nartey, Raymond A Tetteh. (Ghana)

Poster Session C: Pharmacovigilance - Respiratory

277 The Effects of Amoxicillin on Acute COPD Exacerbations in the Outpatient Setting: A Retrospective Cohort Study Based on Real-World Data [1208]

Yuanyuan Wang, Jens H Bos, Catharina C Schuiling-Veninga, Bob Wilffert, Eelko Hak. (Netherlands)

278 Risk of Interstitial Lung Disease among Patients Treated for Atrial Fibrillation with Selected Anti-Arrhythmic Drugs in Two Healthcare Databases [1209]

Arlene K Tave, Earl Goehring, Vibha Desai, Chuntao Wu, Rhonda Bohn, Sally Tamayo, Nicholas Sicignano, Juhaeri Juhaeri, Judith K Jones, Sheila Weiss. (United States)

279 Risk of Developing Chronic Obstructive Pulmonary Disease or Lung Cancer in Smokers Taking Enzyme-Inducing Antiepileptic Drugs [1210]

Daphne Reinau, Anne Leuppi-Taegtmeier, Susan S Jick, Christoph R Meier. (Switzerland)

Poster Session C: Propensity Scores

280 A Comparison of Outcome-Related Diagnostics for Propensity Scores [1211]

Emily Granger, Jamie C Sergeant, Mark Lunt. (United Kingdom)

281 A Systematic Review of the Use of Propensity Scores in Cardiovascular Literature [1212]

Julie Rouette, Michelle Samuel, Brice Batomen, Joanne Kim, Robert W Platt, James Brophy, Jay S Kaufman. (Canada)

282 Comparisons of Propensity Score-based Estimates in the Presence of Treatment Effect Modification [1213]

M Sanni Ali, Daniel Prieto-Alhambra, Ian Douglas, Liam Smeeth. (United Kingdom)

283 Propensity Score Matching with Bootstrapping and "Divide and Recombine" Approaches in Huge Data [1214]

Gabriela Lima Borges, M Sanni Ali, Mauricio L Barreto, Liam Smeeth, Rosemeire Leovigildo Fiaccone. (Brazil)

284 Improving Confounder Adjustment: Translating High-Dimensional Propensity Score Principles to United Kingdom Electronic Health Records [1215]

John Tazare, Liam Smeeth, Stephen J Evans, Elizabeth Williamson, Ian J Douglas. (United Kingdom)

285 Evaluation of Observational Study Data with Multi-level Propensity Scores: The Planning Process [1216]

Mary E Ritchey, Mary Anne Armstrong, Shannon Hunter, Jiaxiao M Shi, Darios T Getahun, Fagen Xie, Christoph Dierig. (United States)

286 Deep Learning-Based Propensity Score Computation: Cohort Study in Second Line Treated Advanced Non-small Cell Lung Cancer (ANSCLC) Patients [1217]

Janick Weberpals, Tim Becker, Fabian Schmich, Dominik Rüttinger, Fabian Theis, Anna Bauer-Mehren. (Germany)

End Poster Session C

Abstract Index

Pub. #	Poster #	Presentation Time	Room	Format
Monday, August 26, 2019				
What Does Replicable and Robust Non-Randomized Database Evidence Look Like?				
1		10:30 AM	Ballroom B	Symposia
How Do We Assess When Electronic Health Records or Claims Databases are Fit For a Specific Research or Regulatory Purpose?				
2		10:30 AM	201 A	Symposia
When Artificial Intelligence Meets Pharmacoepidemiology				
3		10:30 AM	201 B	Symposia
Pregnancy Registries And Pregnancy Outcome Studies In Healthcare Databases: Trends And Complementary Research Approaches				
4		10:30 AM	201 C	Symposia
Drugs and Germs: Dirty Details About Pharmacoepidemiology And The Microbiome				
5		10:30 AM		202 AB
Show Us Your Money: Health Economics and Policy Symposia				
6		1:30 PM	Ballroom B	Oral
7		1:45 PM	Ballroom B	Oral
8		2:00 PM	Ballroom B	Oral
9		2:15 PM	Ballroom B	Oral
10		2:30 PM	Ballroom B	Oral
11		2:45 PM	Ballroom B	Oral
Winning The Immunity Challenge				
12		1:30 PM	201 A	Oral
13		1:45 PM	201 A	Oral
14		2:00 PM	201 A	Oral
15		2:15 PM	201 A	Oral
16		2:30 PM	201 A	Oral
17		2:45 PM	201 A	Oral
Medications and Birth Defects				
18		1:30 PM	201 B	Oral
19		1:45 PM	201 B	Oral
20		2:00 PM	201 B	Oral
21		2:15 PM	201 B	Oral
22		2:30 PM	201 B	Oral
23		2:45 PM	201 B	Oral

Pub. #	Poster #	Presentation Time	Room	Format
Confounding Methods				
24		1:30 PM	201 C	Oral
25		1:45 PM	201 C	Oral
26		2:00 PM	201 C	Oral
27		2:15 PM	201 C	Oral
28		2:30 PM	201 C	Oral
29		2:45 PM	201 C	Oral
Not All Bad News on CVD Safety				
30		1:30 PM	202 AB	Oral
31		1:45 PM	202 AB	Oral
32		2:00 PM	202 AB	Oral
33		2:15 PM	202 AB	Oral
34		2:30 PM	202 AB	Oral
35		2:45 PM	202 AB	Oral
Wear and Tear, Bad to the Bone and the Good Stuff				
36		1:30 PM	204 C	Oral
37		1:45 PM	204 C	Oral
38		2:00 PM	204 C	Oral
39		2:15 PM	204 C	Oral
40		2:30 PM	204 C	Oral
41		2:45 PM	204 C	Oral
The Ascension Of Real-World Evidence: Can (and Should) We Establish Thresholds For Validity?				
42		3:30 PM	Ballroom B	Symposia
Heterogeneity And Validity In National And International Multi-Database Pharmacoepidemiologic Studies (MPES): Lessons Learned In North America, Europe, And Asia				
43		3:30 PM	201 A	Symposia
Thinking Globally While Acting Locally: Developing Time-on-Treatment Data In International Settings				
44		3:30 PM	201 B	Symposia
Machine Learning To Improve Causal Inference In Pharmacoepidemiology				
45		3:30 PM	201 C	Symposia
Measuring, Mapping, And Meshing Of Genotype And Phenotype Data Across Large Datasets: Challenges Of Combining And Mining Genotype And Phenotype Data				
46		3:30 PM	202 AB	Symposia
Where is the Unbiased Comparison?				
47		5:15 PM	Ballroom B	Oral
48		5:30 PM	Ballroom B	Oral

Pub. #	Poster #	Presentation Time	Room	Format
Monday, August 26, 2019 (continued)				
49		5:45 PM	Ballroom B	Oral
50		6:00 PM	Ballroom B	Oral
51		6:15 PM	Ballroom B	Oral
52		6:30 PM	Ballroom B	Oral
How Do Exposed Pregnancies End?				
53		5:15 PM	201 A	Oral
54		5:30 PM	201 A	Oral
55		5:45 PM	201 A	Oral
56		6:00 PM	201 A	Oral
57		6:15 PM	201 A	Oral
58		6:30 PM	201 A	Oral
Still Asking the Same Questions? Who, What, Where, When, How				
59		5:15 PM	201 B	Oral
60		5:30 PM	201 B	Oral
61		5:45 PM	201 B	Oral
62		6:00 PM	201 B	Oral
63		6:15 PM	201 B	Oral
64		6:30 PM	201 B	Oral
SGLT2 and Risk (?)				
65		5:15 PM	201 C	Oral
66		5:30 PM	201 C	Oral
67		5:45 PM	201 C	Oral
68		6:00 PM	201 C	Oral
69		6:15 PM	201 C	Oral
70		6:30 PM	201 C	Oral
Mental Health and Medicines				
71		5:15 PM	202 AB	Oral
72		5:30 PM	202 AB	Oral
73		5:45 PM	202 AB	Oral
74		6:00 PM	202 AB	Oral
75		6:15 PM	202 AB	Oral
76		6:30 PM	202 AB	Oral
Risky Business in Cancer				
77		5:15 PM	204 C	Oral
78		5:30 PM	204 C	Oral
79		5:45 PM	204 C	Oral

Pub. #	Poster #	Presentation Time	Room	Format
80		6:00 PM	204 C	Oral
81		6:15 PM	204 C	Oral
82		6:30 PM	204 C	Oral
Poster Spotlight Session A: Adherence				
84	A	12:15 PM – 1:15 PM	West Bridge	Poster
85	B	12:15 PM – 1:15 PM	West Bridge	Poster
86	C	12:15 PM – 1:15 PM	West Bridge	Poster
87	D	12:15 PM – 1:15 PM	West Bridge	Poster
88	E	12:15 PM – 1:15 PM	West Bridge	Poster
89	F	12:15 PM – 1:15 PM	West Bridge	Poster
90	G	12:15 PM – 1:15 PM	West Bridge	Poster
Poster Spotlight Session A: AsPEN				
91	H	12:15 PM – 1:15 PM	West Bridge	Poster
92	I	12:15 PM – 1:15 PM	West Bridge	Poster
93	J	12:15 PM – 1:15 PM	West Bridge	Poster
94	K	12:15 PM – 1:15 PM	West Bridge	Poster
95	L	12:15 PM – 1:15 PM	West Bridge	Poster
96	M	12:15 PM – 1:15 PM	West Bridge	Poster
97	N	12:15 PM – 1:15 PM	West Bridge	Poster
Poster Spotlight Session A: Biologics and Biosimilars				
98	O	12:15 PM – 1:15 PM	West Bridge	Poster
99	P	12:15 PM – 1:15 PM	West Bridge	Poster
100	Q	12:15 PM – 1:15 PM	West Bridge	Poster
101	R	12:15 PM – 1:15 PM	West Bridge	Poster
102	S	12:15 PM – 1:15 PM	West Bridge	Poster
103	T	12:15 PM – 1:15 PM	West Bridge	Poster
104	U	12:15 PM – 1:15 PM	West Bridge	Poster
105	V	12:15 PM – 1:15 PM	West Bridge	Poster
Poster Spotlight Session A: Comparative Effectiveness Research (CER)				
106	W	12:15 PM – 1:15 PM	West Bridge	Poster
107	X	12:15 PM – 1:15 PM	West Bridge	Poster
108	Y	12:15 PM – 1:15 PM	West Bridge	Poster
109	Z	12:15 PM – 1:15 PM	West Bridge	Poster
110	AA	12:15 PM – 1:15 PM	West Bridge	Poster
111	BB	12:15 PM – 1:15 PM	West Bridge	Poster
112	CC	12:15 PM – 1:15 PM	West Bridge	Poster
113	DD	12:15 PM – 1:15 PM	West Bridge	Poster

Abstract Index



Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

Monday, August 26, 2019 (continued)

Poster Spotlight Session A: Geriatric Pharmacoepidemiology

114	EE	12:15 PM – 1:15 PM	West Bridge	Poster
115	FF	12:15 PM – 1:15 PM	West Bridge	Poster
116	GG	12:15 PM – 1:15 PM	West Bridge	Poster
117	HH	12:15 PM – 1:15 PM	West Bridge	Poster
118	II	12:15 PM – 1:15 PM	West Bridge	Poster
119	JJ	12:15 PM – 1:15 PM	West Bridge	Poster
120	KK	12:15 PM – 1:15 PM	West Bridge	Poster
121	LL	12:15 PM – 1:15 PM	West Bridge	Poster

Poster Session A: Analytical Methods

122	1	8:00 AM – 6:00 PM	Hall A	With-drawn
123	2	8:00 AM – 6:00 PM	Hall A	Poster
124	3	8:00 AM – 6:00 PM	Hall A	Poster
125	4	8:00 AM – 6:00 PM	Hall A	Poster
126	5	8:00 AM – 6:00 PM	Hall A	Poster
127	6	8:00 AM – 6:00 PM	Hall A	Poster
128	7	8:00 AM – 6:00 PM	Hall A	Poster
129	8	8:00 AM – 6:00 PM	Hall A	Poster
130	9	8:00 AM – 6:00 PM	Hall A	Poster
131	10	8:00 AM – 6:00 PM	Hall A	Poster
132	11	8:00 AM – 6:00 PM	Hall A	Poster
133	12	8:00 AM – 6:00 PM	Hall A	Poster
134	13	8:00 AM – 6:00 PM	Hall A	Poster
135	14	8:00 AM – 6:00 PM	Hall A	Poster
136	15	8:00 AM – 6:00 PM	Hall A	Poster
137	16	8:00 AM – 6:00 PM	Hall A	Poster
138	17	8:00 AM – 6:00 PM	Hall A	Poster
139	18	8:00 AM – 6:00 PM	Hall A	Poster
140	19	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session A: Burden of Disease - Cancer

141	20	8:00 AM – 6:00 PM	Hall A	Poster
142	21	8:00 AM – 6:00 PM	Hall A	Poster
143	22	8:00 AM – 6:00 PM	Hall A	Poster
144	23	8:00 AM – 6:00 PM	Hall A	Poster
145	24	8:00 AM – 6:00 PM	Hall A	Poster
146	25	8:00 AM – 6:00 PM	Hall A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

147	26	8:00 AM – 6:00 PM	Hall A	Poster
148	27	8:00 AM – 6:00 PM	Hall A	Poster
149	28	8:00 AM – 6:00 PM	Hall A	Poster
150	29	8:00 AM – 6:00 PM	Hall A	Poster
151	30	8:00 AM – 6:00 PM	Hall A	Poster
152	31	8:00 AM – 6:00 PM	Hall A	Poster
153	32	8:00 AM – 6:00 PM	Hall A	Poster
154	33	8:00 AM – 6:00 PM	Hall A	Poster
155	34	8:00 AM – 6:00 PM	Hall A	Poster
156	35	8:00 AM – 6:00 PM	Hall A	Poster
157	36	8:00 AM – 6:00 PM	Hall A	Poster
158	37	8:00 AM – 6:00 PM	Hall A	Poster
159	38	8:00 AM – 6:00 PM	Hall A	Poster
160	39	8:00 AM – 6:00 PM	Hall A	Poster
161	40	8:00 AM – 6:00 PM	Hall A	Poster
162	41	8:00 AM – 6:00 PM	Hall A	Poster
163	42	8:00 AM – 6:00 PM	Hall A	Poster
164	43	8:00 AM – 6:00 PM	Hall A	Poster
165	44	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session A: Burden of Disease - Cardiovascular

166	45	8:00 AM – 6:00 PM	Hall A	Poster
167	46	8:00 AM – 6:00 PM	Hall A	Poster
168	47	8:00 AM – 6:00 PM	Hall A	Poster
169	48	8:00 AM – 6:00 PM	Hall A	Poster
170	49	8:00 AM – 6:00 PM	Hall A	Poster
171	50	8:00 AM – 6:00 PM	Hall A	Poster
172	51	8:00 AM – 6:00 PM	Hall A	Poster
173	52	8:00 AM – 6:00 PM	Hall A	Poster
174	53	8:00 AM – 6:00 PM	Hall A	Poster
175	54	8:00 AM – 6:00 PM	Hall A	Poster
176	55	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session A: Burden of Disease - Endocrine and Metabolism

177	56	8:00 AM – 6:00 PM	Hall A	Poster
178	57	8:00 AM – 6:00 PM	Hall A	Poster
179	58	8:00 AM – 6:00 PM	Hall A	Poster
180	59	8:00 AM – 6:00 PM	Hall A	Poster
181	60	8:00 AM – 6:00 PM	Hall A	Poster
182	61	8:00 AM – 6:00 PM	Hall A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

Monday, August 26, 2019 (continued)

183	62	8:00 AM – 6:00 PM	Hall A	Poster
184	63	8:00 AM – 6:00 PM	Hall A	Poster
185	64	8:00 AM – 6:00 PM	Hall A	Poster
186	65	8:00 AM – 6:00 PM	Hall A	Poster
187	66	8:00 AM – 6:00 PM	Hall A	Poster
188	67	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session A: Burden of Disease - Gastrointestinal and Liver

189	68	8:00 AM – 6:00 PM	Hall A	Poster
190	69	8:00 AM – 6:00 PM	Hall A	Poster
191	70	8:00 AM – 6:00 PM	Hall A	Poster
192	71	8:00 AM – 6:00 PM	Hall A	Poster
193	72	8:00 AM – 6:00 PM	Hall A	Poster
194	73	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session A: Burden of Disease - Nervous System

195	74	8:00 AM – 6:00 PM	Hall A	Poster
196	75	8:00 AM – 6:00 PM	Hall A	Poster
197	76	8:00 AM – 6:00 PM	Hall A	Poster
198	77	8:00 AM – 6:00 PM	Hall A	Poster
199	78	8:00 AM – 6:00 PM	Hall A	Poster
200	79	8:00 AM – 6:00 PM	Hall A	Poster
201	80	8:00 AM – 6:00 PM	Hall A	Poster
202	81	8:00 AM – 6:00 PM	Hall A	Poster
203	82	8:00 AM – 6:00 PM	Hall A	Poster
204	83	8:00 AM – 6:00 PM	Hall A	Poster
205	84	8:00 AM – 6:00 PM	Hall A	Poster
206	85	8:00 AM – 6:00 PM	Hall A	Poster
207	86	8:00 AM – 6:00 PM	Hall A	Poster
208	87	8:00 AM – 6:00 PM	Hall A	Poster
209	88	8:00 AM – 6:00 PM	Hall A	Poster
210	89	8:00 AM – 6:00 PM	Hall A	Poster
211	90	8:00 AM – 6:00 PM	Hall A	Poster
212	91	8:00 AM – 6:00 PM	Hall A	Poster
213	92	8:00 AM – 6:00 PM	Hall A	Poster
214	93	8:00 AM – 6:00 PM	Hall A	Poster
215	94	8:00 AM – 6:00 PM	Hall A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

Poster Session A: Databases

216	95	8:00 AM – 6:00 PM	Hall A	Poster
217	96	8:00 AM – 6:00 PM	Hall A	Poster
218	97	8:00 AM – 6:00 PM	Hall A	Poster
219	98	8:00 AM – 6:00 PM	Hall A	Poster
220	99	8:00 AM – 6:00 PM	Hall A	Poster
221	100	8:00 AM – 6:00 PM	Hall A	Poster
222	101	8:00 AM – 6:00 PM	Hall A	Poster
223	102	8:00 AM – 6:00 PM	Hall A	Poster
224	103	8:00 AM – 6:00 PM	Hall A	Poster
225	104	8:00 AM – 6:00 PM	Hall A	Poster
226	105	8:00 AM – 6:00 PM	Hall A	Poster
227	106	8:00 AM – 6:00 PM	Hall A	Poster
228	107	8:00 AM – 6:00 PM	Hall A	Poster
229	108	8:00 AM – 6:00 PM	Hall A	Poster
230	109	8:00 AM – 6:00 PM	Hall A	Poster
231	110	8:00 AM – 6:00 PM	Hall A	Poster
232	111	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session A: Data Linkage

233	112	8:00 AM – 6:00 PM	Hall A	Poster
234	113	8:00 AM – 6:00 PM	Hall A	Poster
235	114	8:00 AM – 6:00 PM	Hall A	Poster
236	115	8:00 AM – 6:00 PM	Hall A	Poster
237	116	8:00 AM – 6:00 PM	Hall A	Poster
238	117	8:00 AM – 6:00 PM	Hall A	Poster
239	118	8:00 AM – 6:00 PM	Hall A	Poster
240	119	8:00 AM – 6:00 PM	Hall A	Poster
241	120	8:00 AM – 6:00 PM	Hall A	Poster
242	121	8:00 AM – 6:00 PM	Hall A	Poster
243	122	8:00 AM – 6:00 PM	Hall A	Poster
244	123	8:00 AM – 6:00 PM	Hall A	With- drawn
245	124	8:00 AM – 6:00 PM	Hall A	Poster
246	125	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session A: Drug Effectiveness - Cancer

247	126	8:00 AM – 6:00 PM	Hall A	Poster
248	127	8:00 AM – 6:00 PM	Hall A	Poster
249	128	8:00 AM – 6:00 PM	Hall A	Poster
250	129	8:00 AM – 6:00 PM	Hall A	Poster

Abstract Index

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

Monday, August 26, 2019 (continued)

251	130	8:00 AM – 6:00 PM	Hall A	Poster
252	131	8:00 AM – 6:00 PM	Hall A	Poster
253	132	8:00 AM – 6:00 PM	Hall A	Poster
254	133	8:00 AM – 6:00 PM	Hall A	Poster
255	134	8:00 AM – 6:00 PM	Hall A	Poster
256	135	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session A: Drug Effectiveness - Infections

257	136	8:00 AM – 6:00 PM	Hall A	Poster
258	137	8:00 AM – 6:00 PM	Hall A	With-drawn
259	138	8:00 AM – 6:00 PM	Hall A	Poster
260	139	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session A: Drug Effectiveness - Nervous System

261	140	8:00 AM – 6:00 PM	Hall A	Poster
262	141	8:00 AM – 6:00 PM	Hall A	Poster
263	142	8:00 AM – 6:00 PM	Hall A	Poster
264	143	8:00 AM – 6:00 PM	Hall A	Poster
265	144	8:00 AM – 6:00 PM	Hall A	Poster
266	145	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session A: Drug Utilization - Cancer

267	146	8:00 AM – 6:00 PM	Hall A	Poster
268	147	8:00 AM – 6:00 PM	Hall A	Poster
269	148	8:00 AM – 6:00 PM	Hall A	Poster
270	149	8:00 AM – 6:00 PM	Hall A	Poster
271	150	8:00 AM – 6:00 PM	Hall A	Poster
272	151	8:00 AM – 6:00 PM	Hall A	Poster
273	152	8:00 AM – 6:00 PM	Hall A	Poster
274	153	8:00 AM – 6:00 PM	Hall A	Poster
275	154	8:00 AM – 6:00 PM	Hall A	Poster
276	155	8:00 AM – 6:00 PM	Hall A	Poster
277	156	8:00 AM – 6:00 PM	Hall A	Poster
278	157	8:00 AM – 6:00 PM	Hall A	Poster
279	158	8:00 AM – 6:00 PM	Hall A	Poster
280	159	8:00 AM – 6:00 PM	Hall A	Poster
281	160	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session A: Drug Utilization - Cardiovascular

282	161	8:00 AM – 6:00 PM	Hall A	Poster
283	162	8:00 AM – 6:00 PM	Hall A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

284	163	8:00 AM – 6:00 PM	Hall A	Poster
285	164	8:00 AM – 6:00 PM	Hall A	Poster
286	165	8:00 AM – 6:00 PM	Hall A	Poster
287	166	8:00 AM – 6:00 PM	Hall A	Poster
288	167	8:00 AM – 6:00 PM	Hall A	Poster
289	168	8:00 AM – 6:00 PM	Hall A	Poster
290	169	8:00 AM – 6:00 PM	Hall A	Poster
291	170	8:00 AM – 6:00 PM	Hall A	Poster
292	171	8:00 AM – 6:00 PM	Hall A	Poster
293	172	8:00 AM – 6:00 PM	Hall A	Poster
294	173	8:00 AM – 6:00 PM	Hall A	Poster
295	174	8:00 AM – 6:00 PM	Hall A	Poster
296	175	8:00 AM – 6:00 PM	Hall A	Poster
297	176	8:00 AM – 6:00 PM	Hall A	Poster
298	177	8:00 AM – 6:00 PM	Hall A	Poster
299	178	8:00 AM – 6:00 PM	Hall A	Poster
300	179	8:00 AM – 6:00 PM	Hall A	Poster
301	180	8:00 AM – 6:00 PM	Hall A	Poster
302	181	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session A: Medical Devices

303	182	8:00 AM – 6:00 PM	Hall A	Poster
304	183	8:00 AM – 6:00 PM	Hall A	Poster
305	184	8:00 AM – 6:00 PM	Hall A	Poster
306	185	8:00 AM – 6:00 PM	Hall A	Poster
307	186	8:00 AM – 6:00 PM	Hall A	Poster
308	187	8:00 AM – 6:00 PM	Hall A	Poster
309	188	8:00 AM – 6:00 PM	Hall A	Poster
310	189	8:00 AM – 6:00 PM	Hall A	Poster
311	190	8:00 AM – 6:00 PM	Hall A	Poster
312	191	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session A: Methods - Validation Studies

313	192	8:00 AM – 6:00 PM	Hall A	Poster
314	193	8:00 AM – 6:00 PM	Hall A	Poster
315	194	8:00 AM – 6:00 PM	Hall A	Poster
316	195	8:00 AM – 6:00 PM	Hall A	Poster
317	196	8:00 AM – 6:00 PM	Hall A	Poster
318	197	8:00 AM – 6:00 PM	Hall A	Poster
319	198	8:00 AM – 6:00 PM	Hall A	Poster
320	199	8:00 AM – 6:00 PM	Hall A	Poster



Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

Monday, August 26, 2019 (continued)

321	200	8:00 AM – 6:00 PM	Hall A	Poster
322	201	8:00 AM – 6:00 PM	Hall A	Poster
323	202	8:00 AM – 6:00 PM	Hall A	Poster
324	203	8:00 AM – 6:00 PM	Hall A	Poster
325	204	8:00 AM – 6:00 PM	Hall A	Poster
326	205	8:00 AM – 6:00 PM	Hall A	Poster
327	206	8:00 AM – 6:00 PM	Hall A	Poster
328	207	8:00 AM – 6:00 PM	Hall A	Poster
329	208	8:00 AM – 6:00 PM	Hall A	Poster
330	209	8:00 AM – 6:00 PM	Hall A	Poster
331	210	8:00 AM – 6:00 PM	Hall A	Poster
332	211	8:00 AM – 6:00 PM	Hall A	Poster
333	212	8:00 AM – 6:00 PM	Hall A	Poster
334	213	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session A: Pediatric Pharmacoepidemiology

335	214	8:00 AM – 6:00 PM	Hall A	Poster
336	215	8:00 AM – 6:00 PM	Hall A	Poster
337	216	8:00 AM – 6:00 PM	Hall A	Poster
338	217	8:00 AM – 6:00 PM	Hall A	Poster
339	218	8:00 AM – 6:00 PM	Hall A	Poster
340	219	8:00 AM – 6:00 PM	Hall A	Poster
341	220	8:00 AM – 6:00 PM	Hall A	Poster
342	221	8:00 AM – 6:00 PM	Hall A	Poster
343	222	8:00 AM – 6:00 PM	Hall A	Poster
344	223	8:00 AM – 6:00 PM	Hall A	Poster
345	224	8:00 AM – 6:00 PM	Hall A	Poster
346	225	8:00 AM – 6:00 PM	Hall A	Poster
347	226	8:00 AM – 6:00 PM	Hall A	Poster
348	227	8:00 AM – 6:00 PM	Hall A	Poster
349	228	8:00 AM – 6:00 PM	Hall A	Poster
350	229	8:00 AM – 6:00 PM	Hall A	Poster
351	230	8:00 AM – 6:00 PM	Hall A	Poster
352	231	8:00 AM – 6:00 PM	Hall A	Poster
353	232	8:00 AM – 6:00 PM	Hall A	Poster
354	233	8:00 AM – 6:00 PM	Hall A	Poster
355	234	8:00 AM – 6:00 PM	Hall A	Poster
356	235	8:00 AM – 6:00 PM	Hall A	Poster
357	236	8:00 AM – 6:00 PM	Hall A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

358	237	8:00 AM – 6:00 PM	Hall A	Poster
359	238	8:00 AM – 6:00 PM	Hall A	Poster
360	239	8:00 AM – 6:00 PM	Hall A	Poster
361	240	8:00 AM – 6:00 PM	Hall A	Poster
362	241	8:00 AM – 6:00 PM	Hall A	Poster
363	242	8:00 AM – 6:00 PM	Hall A	Poster
364	243	8:00 AM – 6:00 PM	Hall A	Poster
365	244	8:00 AM – 6:00 PM	Hall A	Poster
366	245	8:00 AM – 6:00 PM	Hall A	Poster
367	246	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session A: Pharmacovigilance - Methods/Data

368	247	8:00 AM – 6:00 PM	Hall A	Poster
369	248	8:00 AM – 6:00 PM	Hall A	Poster
370	249	8:00 AM – 6:00 PM	Hall A	Poster
371	250	8:00 AM – 6:00 PM	Hall A	Poster
372	251	8:00 AM – 6:00 PM	Hall A	Poster
373	252	8:00 AM – 6:00 PM	Hall A	Poster
374	253	8:00 AM – 6:00 PM	Hall A	Poster
375	254	8:00 AM – 6:00 PM	Hall A	Poster
376	255	8:00 AM – 6:00 PM	Hall A	Poster
377	256	8:00 AM – 6:00 PM	Hall A	Poster
378	257	8:00 AM – 6:00 PM	Hall A	Poster
379	258	8:00 AM – 6:00 PM	Hall A	Poster
380	259	8:00 AM – 6:00 PM	Hall A	Poster
381	260	8:00 AM – 6:00 PM	Hall A	Poster
382	261	8:00 AM – 6:00 PM	Hall A	Poster
383	262	8:00 AM – 6:00 PM	Hall A	Poster
384	263	8:00 AM – 6:00 PM	Hall A	Poster
385	264	8:00 AM – 6:00 PM	Hall A	Poster
386	265	8:00 AM – 6:00 PM	Hall A	Poster
387	266	8:00 AM – 6:00 PM	Hall A	Poster
388	267	8:00 AM – 6:00 PM	Hall A	Poster
389	268	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session A: Pharmacovigilance - Cancer

390	269	8:00 AM – 6:00 PM	Hall A	Poster
391	270	8:00 AM – 6:00 PM	Hall A	Poster
392	271	8:00 AM – 6:00 PM	Hall A	Poster
393	272	8:00 AM – 6:00 PM	Hall A	Poster
394	273	8:00 AM – 6:00 PM	Hall A	Poster

Abstract Index

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

Monday, August 26, 2019 (continued)

395	274	8:00 AM – 6:00 PM	Hall A	Poster
396	275	8:00 AM – 6:00 PM	Hall A	Poster
397	276	8:00 AM – 6:00 PM	Hall A	Poster
398	277	8:00 AM – 6:00 PM	Hall A	Poster
399	278	8:00 AM – 6:00 PM	Hall A	Poster
400	279	8:00 AM – 6:00 PM	Hall A	Poster
401	280	8:00 AM – 6:00 PM	Hall A	Poster
402	281	8:00 AM – 6:00 PM	Hall A	Poster
403	282	8:00 AM – 6:00 PM	Hall A	With-drawn
404	283	8:00 AM – 6:00 PM	Hall A	Poster
405	284	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session A: Trials

406	285	8:00 AM – 6:00 PM	Hall A	Poster
407	286	8:00 AM – 6:00 PM	Hall A	Poster
408	287	8:00 AM – 6:00 PM	Hall A	Poster
409	288	8:00 AM – 6:00 PM	Hall A	Poster
410	289	8:00 AM – 6:00 PM	Hall A	Poster
925	290	8:00 AM – 6:00 PM	Hall A	Poster

Tuesday, August 27, 2019

A Mummer's Parade of Analytic Methods

411		8:00 AM	Ballroom B	Oral
412		8:15 AM	Ballroom B	Oral
413		8:30 AM	Ballroom B	Oral
414		8:45 AM	Ballroom B	Oral
415		9:00 AM	Ballroom B	Oral
416		9:15 AM	Ballroom B	Oral

To Bleed or not to Bleed

417		8:00 AM	201 A	Oral
418		8:15 AM	201 A	Oral
419		8:30 AM	201 A	Oral
420		8:45 AM	201 A	Oral
421		9:00 AM	201 A	Oral
422		9:15 AM	201 A	Oral

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

We All Need Validation

423		8:00 AM	201 B	Oral
424		8:15 AM	201 B	Oral
425		8:30 AM	201 B	Oral
426		8:45 AM	201 B	Oral
427		9:00 AM	201 B	Oral
428		9:15 AM	201 B	Oral

What a Pain: Are We Making Progress With Opioids?

429		8:00 AM	201 C	Oral
430		8:15 AM	201 C	Oral
431		8:30 AM	201 C	Oral
432		8:45 AM	201 C	Oral
433		9:00 AM	201 C	Oral
434		9:15 AM	201 C	Oral

CNS Drugs in Pregnancy

435		8:00 AM	202 AB	Oral
436		8:15 AM	202 AB	Oral
437		8:30 AM	202 AB	Oral
438		8:45 AM	202 AB	Oral
439		9:00 AM	202 AB	Oral
440		9:15 AM	202 AB	Oral

Your Brain on Drugs: Pharmacoepidemiology of CNS Agents

441		8:00 AM	204 C	Oral
442		8:15 AM	204 C	Oral
443		8:30 AM	204 C	Oral
444		8:45 AM	204 C	Oral
445		9:00 AM	204 C	Oral
446		9:15 AM	204 C	Oral

Around the Benefit Risk Assessment, Communication, & Evaluation Cycle

447		1:00 PM	Ballroom B	Oral
448		1:15 PM	Ballroom B	Oral
449		1:30 PM	Ballroom B	Oral
450		1:45 PM	Ballroom B	Oral
451		2:00 PM	Ballroom B	Oral
452		2:15 PM	Ballroom B	Oral

Pub. #	Poster #	Presentation Time	Room	Format
Tuesday, August 27, 2019 (continued)				
Diabetes: Outcomes and Safety				
453		1:00 PM	201 A	Oral
454		1:15 PM	201 A	Oral
455		1:30 PM	201 A	Oral
457		2:00 PM	201 A	Oral
458		2:15 PM	201 A	Oral
Lightning Forum - Methods in Geriatric Pharmacoepidemiology				
459		1:00 PM	201 B	Lightning Forum
460		1:05 PM	201 B	Lightning Forum
461		1:10 PM	201 B	Lightning Forum
462		1:15 PM	201 B	Lightning Forum
Lightning Forum - Machine Learning for Risk Prediction				
463		1:30 PM	201 B	Lightning Forum
464		1:35 PM	201 B	Lightning Forum
465		1:40 PM	201 B	Lightning Forum
466		1:45 PM	201 B	Lightning Forum
Lightning Forum - Opioid Method Research				
467		2:00 PM	201 B	Lightning Forum
468		2:05 PM	201 B	Lightning Forum
469		2:10 PM	201 B	Lightning Forum
470		2:15 PM	201 B	Lightning Forum
How to Analyze Complex Longitudinal Exposures				
471		1:00 PM	201 C	Oral
472		1:15 PM	201 C	Oral
473		1:30 PM	201 C	Oral
474		1:45 PM	201 C	Oral
475		2:00 PM	201 C	Oral
476		2:15 PM	201 C	Oral

Pub. #	Poster #	Presentation Time	Room	Format
Validity of RWE Data in Pregnancy				
477		1:00 PM	202 AB	Oral
478		1:15 PM	202 AB	Oral
479		1:30 PM	202 AB	Oral
480		1:45 PM	202 AB	Oral
481		2:00 PM	202 AB	Oral
482		2:15 PM	202 AB	Oral
Don't Tell The Antivaxxers, Vaccines Work!				
483		1:00 PM	204 C	Oral
484		1:15 PM	204 C	Oral
485		1:30 PM	204 C	Oral
486		1:45 PM	204 C	Oral
487		2:00 PM	204 C	Oral
488		2:15 PM	204 C	Oral
Replicating Clinical Trial Data Using RWD				
489		4:15 PM	Ballroom B	Symposia
Data Diversity In Multi-Database Pharmacoepidemiologic Studies And Its Role In Outcome Misclassification: A Curse Or A Blessing?				
490		4:15 PM	201 A	Symposia
Characterizing Patient Experience Data In Medical Product Development: What Is It, What Is Expected, And How Can You Contribute Based On Anticipated Regulatory Guidance?				
491		4:15 PM	201 B	Symposia
Existing Databases For Drug Utilization Research In Latin American And African Countries				
492		4:15 PM	201 C	Symposia
Introducing Lactation Real World Data To ISPE				
493		4:15 PM	202 AB	Symposia
Poster Spotlight Session B: Benefit Risk Assessment, Communication & Evaluation (BRACE)				
494	A	11:45 AM – 12:45 PM	West Bridge	Poster
495	B	11:45 AM – 12:45 PM	West Bridge	Poster
496	C	11:45 AM – 12:45 PM	West Bridge	Poster
497	D	11:45 AM – 12:45 PM	West Bridge	Poster
498	E	11:45 AM – 12:45 PM	West Bridge	Poster
499	F	11:45 AM – 12:45 PM	West Bridge	Poster
500	G	11:45 AM – 12:45 PM	West Bridge	Poster
Poster Spotlight Session B: Databases				
501	H	11:45 AM – 12:45 PM	West Bridge	Poster

Abstract Index

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

Tuesday, August 27, 2019 (continued)

502	I	11:45 AM – 12:45 PM	West Bridge	Poster
503	J	11:45 AM – 12:45 PM	West Bridge	Poster
504	K	11:45 AM – 12:45 PM	West Bridge	Poster
505	L	11:45 AM – 12:45 PM	West Bridge	Poster
506	M	11:45 AM – 12:45 PM	West Bridge	Poster
507	N	11:45 AM – 12:45 PM	West Bridge	Poster
508	O	11:45 AM – 12:45 PM	West Bridge	Poster

Poster Spotlight Session B: Drug Utilization Research

509	P	11:45 AM – 12:45 PM	West Bridge	Poster
510	Q	11:45 AM – 12:45 PM	West Bridge	Poster
511	R	11:45 AM – 12:45 PM	West Bridge	Poster
512	S	11:45 AM – 12:45 PM	West Bridge	Poster
513	T	11:45 AM – 12:45 PM	West Bridge	Poster
514	U	11:45 AM – 12:45 PM	West Bridge	Poster
515	V	11:45 AM – 12:45 PM	West Bridge	Poster

Poster Spotlight Session B: Medical Devices

516	W	11:45 AM – 12:45 PM	West Bridge	Poster
517	X	11:45 AM – 12:45 PM	West Bridge	Poster
518	Y	11:45 AM – 12:45 PM	West Bridge	Poster
519	Z	11:45 AM – 12:45 PM	West Bridge	Poster
520	AA	11:45 AM – 12:45 PM	West Bridge	Poster
521	BB	11:45 AM – 12:45 PM	West Bridge	Poster
522	CC	11:45 AM – 12:45 PM	West Bridge	Poster
523	DD	11:45 AM – 12:45 PM	West Bridge	Poster

Poster Spotlight Session B: Rare Disease

524	EE	11:45 AM – 12:45 PM	West Bridge	Poster
525	FF	11:45 AM – 12:45 PM	West Bridge	Poster
526	GG	11:45 AM – 12:45 PM	West Bridge	Poster
527	HH	11:45 AM – 12:45 PM	West Bridge	Poster
528	II	11:45 AM – 12:45 PM	West Bridge	Poster
529	JJ	11:45 AM – 12:45 PM	West Bridge	Poster
530	KK	11:45 AM – 12:45 PM	West Bridge	Poster
531	LL	11:45 AM – 12:45 PM	West Bridge	Poster

Poster Session B: Burden of Disease - Respiratory

532	1	8:00 AM – 6:00 PM	Hall A	Poster
533	2	8:00 AM – 6:00 PM	Hall A	Poster
534	3	8:00 AM – 6:00 PM	Hall A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

535	4	8:00 AM – 6:00 PM	Hall A	Poster
-----	---	-------------------	--------	--------

Poster Session B: Burden of Disease - Other

536	5	8:00 AM – 6:00 PM	Hall A	Poster
537	6	8:00 AM – 6:00 PM	Hall A	Poster
538	7	8:00 AM – 6:00 PM	Hall A	Poster
539	8	8:00 AM – 6:00 PM	Hall A	Poster
540	9	8:00 AM – 6:00 PM	Hall A	Poster
541	10	8:00 AM – 6:00 PM	Hall A	Poster
542	11	8:00 AM – 6:00 PM	Hall A	Poster
543	12	8:00 AM – 6:00 PM	Hall A	Poster
544	13	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session B: Drug Utilization - Musculoskeletal

545	14	8:00 AM – 6:00 PM	Hall A	Poster
546	15	8:00 AM – 6:00 PM	Hall A	Poster
547	16	8:00 AM – 6:00 PM	Hall A	Poster
548	17	8:00 AM – 6:00 PM	Hall A	Poster
549	18	8:00 AM – 6:00 PM	Hall A	Poster
550	19	8:00 AM – 6:00 PM	Hall A	Poster
551	20	8:00 AM – 6:00 PM	Hall A	Poster
552	21	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session B: Drug Utilization - Nervous system

553	22	8:00 AM – 6:00 PM	Hall A	Poster
554	23	8:00 AM – 6:00 PM	Hall A	Poster
555	24	8:00 AM – 6:00 PM	Hall A	Poster
556	25	8:00 AM – 6:00 PM	Hall A	Poster
557	26	8:00 AM – 6:00 PM	Hall A	Poster
558	27	8:00 AM – 6:00 PM	Hall A	Poster
559	28	8:00 AM – 6:00 PM	Hall A	Poster
560	29	8:00 AM – 6:00 PM	Hall A	Poster
561	30	8:00 AM – 6:00 PM	Hall A	Poster
562	31	8:00 AM – 6:00 PM	Hall A	Poster
563	32	8:00 AM – 6:00 PM	Hall A	Poster
564	33	8:00 AM – 6:00 PM	Hall A	Poster
565	34	8:00 AM – 6:00 PM	Hall A	Poster
566	35	8:00 AM – 6:00 PM	Hall A	Poster
567	36	8:00 AM – 6:00 PM	Hall A	Poster
568	37	8:00 AM – 6:00 PM	Hall A	Poster
569	38	8:00 AM – 6:00 PM	Hall A	Poster
570	39	8:00 AM – 6:00 PM	Hall A	Poster



Pub. #	Poster #	Presentation Time	Room	Format
Tuesday, August 27, 2019 (continued)				
571	40	8:00 AM – 6:00 PM	Hall A	Poster
572	41	8:00 AM – 6:00 PM	Hall A	Poster
573	42	8:00 AM – 6:00 PM	Hall A	Poster
574	43	8:00 AM – 6:00 PM	Hall A	Poster
Poster Session B: Geriatric Pharmacoepidemiology				
575	44	8:00 AM – 6:00 PM	Hall A	Poster
576	45	8:00 AM – 6:00 PM	Hall A	Poster
577	46	8:00 AM – 6:00 PM	Hall A	Poster
578	47	8:00 AM – 6:00 PM	Hall A	Poster
579	48	8:00 AM – 6:00 PM	Hall A	Poster
580	49	8:00 AM – 6:00 PM	Hall A	Poster
581	50	8:00 AM – 6:00 PM	Hall A	Poster
582	51	8:00 AM – 6:00 PM	Hall A	Poster
583	52	8:00 AM – 6:00 PM	Hall A	Poster
584	53	8:00 AM – 6:00 PM	Hall A	Poster
585	54	8:00 AM – 6:00 PM	Hall A	Poster
586	55	8:00 AM – 6:00 PM	Hall A	Poster
587	56	8:00 AM – 6:00 PM	Hall A	Poster
588	57	8:00 AM – 6:00 PM	Hall A	Poster
589	58	8:00 AM – 6:00 PM	Hall A	Poster
590	59	8:00 AM – 6:00 PM	Hall A	Poster
591	60	8:00 AM – 6:00 PM	Hall A	Poster
592	61	8:00 AM – 6:00 PM	Hall A	Poster
593	62	8:00 AM – 6:00 PM	Hall A	Poster
594	63	8:00 AM – 6:00 PM	Hall A	Poster
595	64	8:00 AM – 6:00 PM	Hall A	Poster
596	65	8:00 AM – 6:00 PM	Hall A	Poster
597	66	8:00 AM – 6:00 PM	Hall A	Poster
598	67	8:00 AM – 6:00 PM	Hall A	Poster
599	68	8:00 AM – 6:00 PM	Hall A	Poster
600	69	8:00 AM – 6:00 PM	Hall A	Poster
601	70	8:00 AM – 6:00 PM	Hall A	Poster
602	71	8:00 AM – 6:00 PM	Hall A	Poster
603	72	8:00 AM – 6:00 PM	Hall A	Poster
604	73	8:00 AM – 6:00 PM	Hall A	Poster
Poster Session B: Health Economics/Outcomes Research				
605	74	8:00 AM – 6:00 PM	Hall A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
606	75	8:00 AM – 6:00 PM	Hall A	Poster
607	76	8:00 AM – 6:00 PM	Hall A	Poster
608	77	8:00 AM – 6:00 PM	Hall A	Poster
609	78	8:00 AM – 6:00 PM	Hall A	Poster
610	79	8:00 AM – 6:00 PM	Hall A	Poster
611	80	8:00 AM – 6:00 PM	Hall A	Poster
612	81	8:00 AM – 6:00 PM	Hall A	Poster
613	82	8:00 AM – 6:00 PM	Hall A	Poster
614	83	8:00 AM – 6:00 PM	Hall A	Poster
615	84	8:00 AM – 6:00 PM	Hall A	Poster
616	85	8:00 AM – 6:00 PM	Hall A	Poster
617	86	8:00 AM – 6:00 PM	Hall A	Poster
618	87	8:00 AM – 6:00 PM	Hall A	Poster
619	88	8:00 AM – 6:00 PM	Hall A	Poster
620	89	8:00 AM – 6:00 PM	Hall A	Poster
621	90	8:00 AM – 6:00 PM	Hall A	Poster
622	91	8:00 AM – 6:00 PM	Hall A	Poster
623	92	8:00 AM – 6:00 PM	Hall A	Poster
624	93	8:00 AM – 6:00 PM	Hall A	Poster
625	94	8:00 AM – 6:00 PM	Hall A	Poster
Poster Session B: Methods - Study Design, Bias, and Confounding				
626	95	8:00 AM – 6:00 PM	Hall A	Poster
627	96	8:00 AM – 6:00 PM	Hall A	Poster
628	97	8:00 AM – 6:00 PM	Hall A	Poster
629	98	8:00 AM – 6:00 PM	Hall A	Poster
630	99	8:00 AM – 6:00 PM	Hall A	Poster
631	100	8:00 AM – 6:00 PM	Hall A	Poster
632	101	8:00 AM – 6:00 PM	Hall A	Poster
633	102	8:00 AM – 6:00 PM	Hall A	Poster
634	103	8:00 AM – 6:00 PM	Hall A	Poster
635	104	8:00 AM – 6:00 PM	Hall A	Poster
636	105	8:00 AM – 6:00 PM	Hall A	Poster
637	106	8:00 AM – 6:00 PM	Hall A	Poster
638	107	8:00 AM – 6:00 PM	Hall A	Poster
639	108	8:00 AM – 6:00 PM	Hall A	Poster
640	109	8:00 AM – 6:00 PM	Hall A	Poster
641	110	8:00 AM – 6:00 PM	Hall A	Poster
642	111	8:00 AM – 6:00 PM	Hall A	Poster

Abstract Index

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

Tuesday, August 27, 2019 (continued)

643	112	8:00 AM – 6:00 PM	Hall A	Poster
644	113	8:00 AM – 6:00 PM	Hall A	Poster
645	114	8:00 AM – 6:00 PM	Hall A	Poster
646	115	8:00 AM – 6:00 PM	Hall A	Poster
647	116	8:00 AM – 6:00 PM	Hall A	Poster
648	117	8:00 AM – 6:00 PM	Hall A	Poster
649	118	8:00 AM – 6:00 PM	Hall A	Poster
650	119	8:00 AM – 6:00 PM	Hall A	Poster
651	120	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session B: Opioids

652	121	8:00 AM – 6:00 PM	Hall A	Poster
653	122	8:00 AM – 6:00 PM	Hall A	Poster
654	123	8:00 AM – 6:00 PM	Hall A	Poster
655	124	8:00 AM – 6:00 PM	Hall A	Poster
656	125	8:00 AM – 6:00 PM	Hall A	Poster
657	126	8:00 AM – 6:00 PM	Hall A	Poster
658	127	8:00 AM – 6:00 PM	Hall A	Poster
659	128	8:00 AM – 6:00 PM	Hall A	Poster
660	129	8:00 AM – 6:00 PM	Hall A	Poster
661	130	8:00 AM – 6:00 PM	Hall A	Poster
662	131	8:00 AM – 6:00 PM	Hall A	Poster
663	132	8:00 AM – 6:00 PM	Hall A	Poster
664	133	8:00 AM – 6:00 PM	Hall A	Withdrawn
665	134	8:00 AM – 6:00 PM	Hall A	Poster
666	135	8:00 AM – 6:00 PM	Hall A	Poster
667	136	8:00 AM – 6:00 PM	Hall A	Poster
668	137	8:00 AM – 6:00 PM	Hall A	Poster
669	138	8:00 AM – 6:00 PM	Hall A	Poster
670	139	8:00 AM – 6:00 PM	Hall A	Poster
671	140	8:00 AM – 6:00 PM	Hall A	Poster
672	141	8:00 AM – 6:00 PM	Hall A	Poster
673	142	8:00 AM – 6:00 PM	Hall A	Poster
674	143	8:00 AM – 6:00 PM	Hall A	Poster
675	144	8:00 AM – 6:00 PM	Hall A	Poster
676	145	8:00 AM – 6:00 PM	Hall A	Poster
677	146	8:00 AM – 6:00 PM	Hall A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

Poster Session B: Pharmacovigilance - Musculoskeletal

678	147	8:00 AM – 6:00 PM	Hall A	Poster
679	148	8:00 AM – 6:00 PM	Hall A	Poster
680	149	8:00 AM – 6:00 PM	Hall A	Poster
681	150	8:00 AM – 6:00 PM	Hall A	Poster
682	151	8:00 AM – 6:00 PM	Hall A	Poster
683	152	8:00 AM – 6:00 PM	Hall A	Poster
684	153	8:00 AM – 6:00 PM	Hall A	Poster
685	154	8:00 AM – 6:00 PM	Hall A	Poster
686	155	8:00 AM – 6:00 PM	Hall A	Poster
687	156	8:00 AM – 6:00 PM	Hall A	Poster
688	157	8:00 AM – 6:00 PM	Hall A	Poster
689	158	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session B: Pharmacovigilance - Nervous System

690	159	8:00 AM – 6:00 PM	Hall A	Poster
691	160	8:00 AM – 6:00 PM	Hall A	Poster
692	161	8:00 AM – 6:00 PM	Hall A	Poster
693	162	8:00 AM – 6:00 PM	Hall A	Poster
694	163	8:00 AM – 6:00 PM	Hall A	Poster
695	164	8:00 AM – 6:00 PM	Hall A	Poster
696	165	8:00 AM – 6:00 PM	Hall A	Poster
697	166	8:00 AM – 6:00 PM	Hall A	Poster
698	167	8:00 AM – 6:00 PM	Hall A	Poster
699	168	8:00 AM – 6:00 PM	Hall A	Poster
700	169	8:00 AM – 6:00 PM	Hall A	Poster
701	170	8:00 AM – 6:00 PM	Hall A	Poster
702	171	8:00 AM – 6:00 PM	Hall A	Poster
703	172	8:00 AM – 6:00 PM	Hall A	Poster
704	173	8:00 AM – 6:00 PM	Hall A	Poster
705	174	8:00 AM – 6:00 PM	Hall A	Poster
706	175	8:00 AM – 6:00 PM	Hall A	Poster
707	176	8:00 AM – 6:00 PM	Hall A	Poster
708	177	8:00 AM – 6:00 PM	Hall A	Withdrawn
709	178	8:00 AM – 6:00 PM	Hall A	Poster
710	179	8:00 AM – 6:00 PM	Hall A	Poster
711	180	8:00 AM – 6:00 PM	Hall A	Poster
712	181	8:00 AM – 6:00 PM	Hall A	Poster
713	182	8:00 AM – 6:00 PM	Hall A	Poster



Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

Tuesday, August 27, 2019 (continued)

714	183	8:00 AM – 6:00 PM	Hall A	Poster
715	184	8:00 AM – 6:00 PM	Hall A	Poster
716	185	8:00 AM – 6:00 PM	Hall A	Poster
717	186	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session B: Pharmacovigilance - Potpourri

718	187	8:00 AM – 6:00 PM	Hall A	Poster
719	188	8:00 AM – 6:00 PM	Hall A	Poster
720	189	8:00 AM – 6:00 PM	Hall A	Poster
721	190	8:00 AM – 6:00 PM	Hall A	Poster
722	191	8:00 AM – 6:00 PM	Hall A	Poster
723	192	8:00 AM – 6:00 PM	Hall A	Poster
724	193	8:00 AM – 6:00 PM	Hall A	Poster
725	194	8:00 AM – 6:00 PM	Hall A	Poster
726	195	8:00 AM – 6:00 PM	Hall A	Poster
727	196	8:00 AM – 6:00 PM	Hall A	Poster
728	197	8:00 AM – 6:00 PM	Hall A	Poster
729	198	8:00 AM – 6:00 PM	Hall A	Poster
730	199	8:00 AM – 6:00 PM	Hall A	Poster
731	200	8:00 AM – 6:00 PM	Hall A	Poster
732	201	8:00 AM – 6:00 PM	Hall A	Poster
733	202	8:00 AM – 6:00 PM	Hall A	Poster
734	203	8:00 AM – 6:00 PM	Hall A	Poster
735	204	8:00 AM – 6:00 PM	Hall A	Poster
736	205	8:00 AM – 6:00 PM	Hall A	Poster
737	206	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session B: Pregnancy and Lactation - Methods

738	207	8:00 AM – 6:00 PM	Hall A	Poster
739	208	8:00 AM – 6:00 PM	Hall A	Poster
740	209	8:00 AM – 6:00 PM	Hall A	Poster
741	210	8:00 AM – 6:00 PM	Hall A	Poster
742	211	8:00 AM – 6:00 PM	Hall A	Poster
743	212	8:00 AM – 6:00 PM	Hall A	Poster
744	213	8:00 AM – 6:00 PM	Hall A	Poster
745	214	8:00 AM – 6:00 PM	Hall A	Poster
746	215	8:00 AM – 6:00 PM	Hall A	Poster
747	216	8:00 AM – 6:00 PM	Hall A	Poster
748	217	8:00 AM – 6:00 PM	Hall A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

749	218	8:00 AM – 6:00 PM	Hall A	Poster
750	219	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session B: Pregnancy and Lactation - Medications and Birth Defects

751	220	8:00 AM – 6:00 PM	Hall A	Poster
752	221	8:00 AM – 6:00 PM	Hall A	Poster
753	222	8:00 AM – 6:00 PM	Hall A	Poster
754	223	8:00 AM – 6:00 PM	Hall A	Poster
755	224	8:00 AM – 6:00 PM	Hall A	Poster
756	225	8:00 AM – 6:00 PM	Hall A	Poster
757	226	8:00 AM – 6:00 PM	Hall A	Poster
758	227	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session B: Pregnancy and Lactation - Drug Exposure and Outcomes

759	228	8:00 AM – 6:00 PM	Hall A	Poster
760	229	8:00 AM – 6:00 PM	Hall A	Poster
761	230	8:00 AM – 6:00 PM	Hall A	Poster
762	231	8:00 AM – 6:00 PM	Hall A	Poster
763	232	8:00 AM – 6:00 PM	Hall A	Poster
764	233	8:00 AM – 6:00 PM	Hall A	Poster
765	234	8:00 AM – 6:00 PM	Hall A	Poster
766	235	8:00 AM – 6:00 PM	Hall A	Poster
767	236	8:00 AM – 6:00 PM	Hall A	Poster
768	237	8:00 AM – 6:00 PM	Hall A	Poster
769	238	8:00 AM – 6:00 PM	Hall A	Poster
770	239	8:00 AM – 6:00 PM	Hall A	Poster
771	240	8:00 AM – 6:00 PM	Hall A	Poster
772	241	8:00 AM – 6:00 PM	Hall A	Poster
773	242	8:00 AM – 6:00 PM	Hall A	Poster
774	243	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session B: Pregnancy and Lactation - Drug Utilization

775	244	8:00 AM – 6:00 PM	Hall A	Poster
776	245	8:00 AM – 6:00 PM	Hall A	Poster
777	246	8:00 AM – 6:00 PM	Hall A	Poster
778	247	8:00 AM – 6:00 PM	Hall A	Poster
779	248	8:00 AM – 6:00 PM	Hall A	Poster
780	249	8:00 AM – 6:00 PM	Hall A	Poster
781	250	8:00 AM – 6:00 PM	Hall A	Poster

Abstract Index

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

Tuesday, August 27, 2019 (continued)

782	251	8:00 AM – 6:00 PM	Hall A	Poster
783	252	8:00 AM – 6:00 PM	Hall A	Poster
784	253	8:00 AM – 6:00 PM	Hall A	Poster
785	254	8:00 AM – 6:00 PM	Hall A	Poster
786	255	8:00 AM – 6:00 PM	Hall A	Poster
787	256	8:00 AM – 6:00 PM	Hall A	Poster
788	257	8:00 AM – 6:00 PM	Hall A	Poster
789	258	8:00 AM – 6:00 PM	Hall A	Poster
790	259	8:00 AM – 6:00 PM	Hall A	Poster
791	260	8:00 AM – 6:00 PM	Hall A	Poster
792	261	8:00 AM – 6:00 PM	Hall A	Poster
793	262	8:00 AM – 6:00 PM	Hall A	Poster
794	263	8:00 AM – 6:00 PM	Hall A	Poster
795	264	8:00 AM – 6:00 PM	Hall A	Poster
796	265	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session B: Vaccines

797	266	8:00 AM – 6:00 PM	Hall A	Poster
798	267	8:00 AM – 6:00 PM	Hall A	Poster
799	268	8:00 AM – 6:00 PM	Hall A	Poster
800	269	8:00 AM – 6:00 PM	Hall A	Poster
801	270	8:00 AM – 6:00 PM	Hall A	Poster
802	271	8:00 AM – 6:00 PM	Hall A	Poster
803	272	8:00 AM – 6:00 PM	Hall A	Poster
804	273	8:00 AM – 6:00 PM	Hall A	Poster
805	274	8:00 AM – 6:00 PM	Hall A	Poster
806	275	8:00 AM – 6:00 PM	Hall A	Poster
807	276	8:00 AM – 6:00 PM	Hall A	Poster
808	277	8:00 AM – 6:00 PM	Hall A	Poster
809	278	8:00 AM – 6:00 PM	Hall A	Poster
810	279	8:00 AM – 6:00 PM	Hall A	Poster
811	280	8:00 AM – 6:00 PM	Hall A	Poster
812	281	8:00 AM – 6:00 PM	Hall A	Poster
813	282	8:00 AM – 6:00 PM	Hall A	Poster
814	283	8:00 AM – 6:00 PM	Hall A	Poster
815	284	8:00 AM – 6:00 PM	Hall A	Poster
816	285	8:00 AM – 6:00 PM	Hall A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

Wednesday, August 28, 2019

Around the World with DUR

817		8:30 AM	Ballroom B	Oral
818		8:45 AM	Ballroom B	Oral
819		9:00 AM	Ballroom B	Oral
820		9:15 AM	Ballroom B	Oral
821		9:30 AM	Ballroom B	Oral
822		9:45 AM	Ballroom B	Oral

Validation and Performance - Methods and Pharmacovigilance

823		8:30 AM	201 A	Oral
824		8:45 AM	201 A	Oral
825		9:00 AM	201 A	Oral
826		9:15 AM	201 A	Oral
827		9:30 AM	201 A	Oral
828		9:45 AM	201 A	Oral

Revolutionary Study Designs

829		8:30 AM	201 B	Oral
830		8:45 AM	201 B	Oral
831		9:00 AM	201 B	Oral
832		9:15 AM	201 B	Oral
833		9:30 AM	201 B	Oral
834		9:45 AM	201 B	Oral

Infectiously Interesting

835		8:30 AM	201 C	Oral
836		8:45 AM	201 C	Oral
837		9:00 AM	201 C	Oral
838		9:15 AM	201 C	Oral
839		9:30 AM	201 C	Oral
840		9:45 AM	201 C	Oral

Do Do Do Doac

841		8:30 AM	202 AB	Oral
842		8:45 AM	202 AB	Oral
843		9:00 AM	202 AB	Oral
844		9:15 AM	202 AB	Oral
845		9:30 AM	202 AB	Oral
846		9:45 AM	202 AB	Oral

Pub. #	Poster #	Presentation Time	Room	Format
Wednesday, August 28, 2019 (continued)				
Vaccine Abstracts Gone Viral!				
847		8:30 AM	204 C	Oral
848		8:45 AM	204 C	Oral
849		9:00 AM	204 C	Oral
850		9:15 AM	204 C	Oral
851		9:30 AM	204 C	Oral
852		9:45 AM	204 C	Oral
Analysis of Data From Distributed Pharmacoepidemiologic Networks				
853		10:30 AM	Ballroom B	Symposia
Causal Inference in Pharmacoepidemiology - An Important Challenge				
854		10:30 AM	201 A	Symposia
Pharmacoepidemiology and Rare Cancer Research				
855		10:30 AM	201 B	Symposia
Emerging Solutions to Addressing Challenges In Measuring Adherence to Multiple Medications				
856		10:30 AM	201 C	Symposia
Mixing It Up: Implementing Qualitative & Mixed Methods In Pharmacoepidemiology Research				
857		10:30 AM	202 AB	Symposia
CER of DM Treatments - Effectiveness and Safety				
858		1:30 PM	Ballroom B	Oral
859		1:45 PM	Ballroom B	Oral
860		2:00 PM	Ballroom B	Oral
861		2:15 PM	Ballroom B	Oral
862		2:30 PM	Ballroom B	Oral
863		2:45 PM	Ballroom B	Oral
Generating Real-World Evidence on Biologics: European and U.S. Experiences				
864		1:30 PM	201 A	Oral
865		1:45 PM	201 A	Oral
866		2:00 PM	201 A	Oral
867		2:15 PM	201 A	Oral
868		2:30 PM	201 A	Oral
869		2:45 PM	201 A	Oral
It's Complicated in the Old World				
870		1:30 PM	201 B	Oral
871		1:45 PM	201 B	Oral

Pub. #	Poster #	Presentation Time	Room	Format
872		2:00 PM	201 B	Oral
873		2:15 PM	201 B	Oral
874		2:30 PM	201 B	Oral
875		2:45 PM	201 B	Oral
Adherence: In for the Long-Term				
876		1:30 PM	201 C	Oral
877		1:45 PM	201 C	Oral
878		2:00 PM	201 C	Oral
83		2:15 PM	201 C	Oral
880		2:30 PM	201 C	Oral
881		2:45 PM	201 C	Oral
Potpourri: What Do You Put on Your Cheesesteak?				
882		1:30 PM	202 AB	Oral
883		1:45 PM	202 AB	Oral
884		2:00 PM	202 AB	Oral
885		2:15 PM	202 AB	Oral
886		2:30 PM	202 AB	Oral
887		2:45 PM	202 AB	Oral
Slice and Devise				
888		1:30 PM	204 C	Oral
889		1:45 PM	204 C	Oral
890		2:00 PM	204 C	Oral
891		2:15 PM	204 C	Oral
892		2:30 PM	204 C	Oral
893		2:45 PM	204 C	Oral
Poster Spotlight Session C: Medications in Pregnancy and Lactation				
894	A	12:15 PM – 1:15 PM	West Bridge	Poster
895	B	12:15 PM – 1:15 PM	West Bridge	Poster
896	C	12:15 PM – 1:15 PM	West Bridge	Poster
897	D	12:15 PM – 1:15 PM	West Bridge	Poster
898	E	12:15 PM – 1:15 PM	West Bridge	Poster
899	F	12:15 PM – 1:15 PM	West Bridge	Poster
900	G	12:15 PM – 1:15 PM	West Bridge	Poster
901	H	12:15 PM – 1:15 PM	West Bridge	Poster
Poster Spotlight Session C: Molecular, Epidemiology Biomarkers, and Pharmacogenetics				
902	I	12:15 PM – 1:15 PM	West Bridge	Poster
903	J	12:15 PM – 1:15 PM	West Bridge	Poster

Abstract Index



Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

Wednesday, August 28, 2019 (continued)

904	K	12:15 PM – 1:15 PM	West Bridge	Poster
905	L	12:15 PM – 1:15 PM	West Bridge	Poster
906	M	12:15 PM – 1:15 PM	West Bridge	Poster
907	N	12:15 PM – 1:15 PM	West Bridge	Poster
908	O	12:15 PM – 1:15 PM	West Bridge	Poster
909	P	12:15 PM – 1:15 PM	West Bridge	Poster

Poster Spotlight Session C: Oncology

910	Q	12:15 PM – 1:15 PM	West Bridge	Poster
911	R	12:15 PM – 1:15 PM	West Bridge	Poster
912	S	12:15 PM – 1:15 PM	West Bridge	Poster
913	T	12:15 PM – 1:15 PM	West Bridge	Poster
914	U	12:15 PM – 1:15 PM	West Bridge	Poster
915	V	12:15 PM – 1:15 PM	West Bridge	Poster
916	W	12:15 PM – 1:15 PM	West Bridge	Poster

Poster Spotlight Session C: Pediatrics

917	X	12:15 PM – 1:15 PM	West Bridge	Poster
918	Y	12:15 PM – 1:15 PM	West Bridge	Poster
919	Z	12:15 PM – 1:15 PM	West Bridge	Poster
920	AA	12:15 PM – 1:15 PM	West Bridge	Poster
921	BB	12:15 PM – 1:15 PM	West Bridge	Poster
922	CC	12:15 PM – 1:15 PM	West Bridge	Poster
923	DD	12:15 PM – 1:15 PM	West Bridge	Poster
924	EE	12:15 PM – 1:15 PM	West Bridge	Poster

Poster Spotlight Session C: Vaccines

926	GG	12:15 PM – 1:15 PM	West Bridge	Poster
927	HH	12:15 PM – 1:15 PM	West Bridge	Poster
928	II	12:15 PM – 1:15 PM	West Bridge	Poster
929	JJ	12:15 PM – 1:15 PM	West Bridge	Poster
930	KK	12:15 PM – 1:15 PM	West Bridge	Poster
931	LL	12:15 PM – 1:15 PM	West Bridge	Poster

Poster Session C: Adherence

932	1	8:00 AM – 6:00 PM	Hall A	Poster
933	2	8:00 AM – 6:00 PM	Hall A	Poster
934	3	8:00 AM – 6:00 PM	Hall A	Poster
935	4	8:00 AM – 6:00 PM	Hall A	Poster
936	5	8:00 AM – 6:00 PM	Hall A	Poster
937	6	8:00 AM – 6:00 PM	Hall A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

938	7	8:00 AM – 6:00 PM	Hall A	Poster
939	8	8:00 AM – 6:00 PM	Hall A	With-drawn
940	9	8:00 AM – 6:00 PM	Hall A	Poster
941	10	8:00 AM – 6:00 PM	Hall A	Poster
942	11	8:00 AM – 6:00 PM	Hall A	Poster
943	12	8:00 AM – 6:00 PM	Hall A	Poster
944	13	8:00 AM – 6:00 PM	Hall A	Poster
945	14	8:00 AM – 6:00 PM	Hall A	Poster
946	15	8:00 AM – 6:00 PM	Hall A	Poster
947	16	8:00 AM – 6:00 PM	Hall A	Poster
948	17	8:00 AM – 6:00 PM	Hall A	Poster
949	18	8:00 AM – 6:00 PM	Hall A	Poster
950	19	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session C: Benefit-Risk Assessment, Communication, and Evaluation (BRACE)

951	20	8:00 AM – 6:00 PM	Hall A	Poster
952	21	8:00 AM – 6:00 PM	Hall A	Poster
953	22	8:00 AM – 6:00 PM	Hall A	Poster
954	23	8:00 AM – 6:00 PM	Hall A	Poster
955	24	8:00 AM – 6:00 PM	Hall A	Poster
956	25	8:00 AM – 6:00 PM	Hall A	Poster
957	26	8:00 AM – 6:00 PM	Hall A	Poster
958	27	8:00 AM – 6:00 PM	Hall A	Poster
959	28	8:00 AM – 6:00 PM	Hall A	Poster
960	29	8:00 AM – 6:00 PM	Hall A	Poster
961	30	8:00 AM – 6:00 PM	Hall A	Poster
962	31	8:00 AM – 6:00 PM	Hall A	Poster
963	32	8:00 AM – 6:00 PM	Hall A	Poster
964	33	8:00 AM – 6:00 PM	Hall A	Poster
965	34	8:00 AM – 6:00 PM	Hall A	Poster
966	35	8:00 AM – 6:00 PM	Hall A	Poster
967	36	8:00 AM – 6:00 PM	Hall A	Poster
968	37	8:00 AM – 6:00 PM	Hall A	Poster
969	38	8:00 AM – 6:00 PM	Hall A	Poster
970	39	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session C: Biologics/Biosimilars

971	40	8:00 AM – 6:00 PM	Hall A	Poster
972	41	8:00 AM – 6:00 PM	Hall A	Poster
973	42	8:00 AM – 6:00 PM	Hall A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
Wednesday, August 28, 2019 (continued)				
974	43	8:00 AM – 6:00 PM	Hall A	Poster
975	44	8:00 AM – 6:00 PM	Hall A	Poster
976	45	8:00 AM – 6:00 PM	Hall A	Poster
977	46	8:00 AM – 6:00 PM	Hall A	Poster
978	47	8:00 AM – 6:00 PM	Hall A	Poster
979	48	8:00 AM – 6:00 PM	Hall A	Poster
980	49	8:00 AM – 6:00 PM	Hall A	Poster
981	50	8:00 AM – 6:00 PM	Hall A	Poster
982	51	8:00 AM – 6:00 PM	Hall A	Poster
983	52	8:00 AM – 6:00 PM	Hall A	Poster
984	53	8:00 AM – 6:00 PM	Hall A	Poster
985	54	8:00 AM – 6:00 PM	Hall A	Poster
986	55	8:00 AM – 6:00 PM	Hall A	Poster
987	56	8:00 AM – 6:00 PM	Hall A	Poster
988	57	8:00 AM – 6:00 PM	Hall A	Poster
989	58	8:00 AM – 6:00 PM	Hall A	Poster
990	59	8:00 AM – 6:00 PM	Hall A	Poster
991	60	8:00 AM – 6:00 PM	Hall A	Poster
992	61	8:00 AM – 6:00 PM	Hall A	Poster
993	62	8:00 AM – 6:00 PM	Hall A	Poster
994	63	8:00 AM – 6:00 PM	Hall A	Poster
995	64	8:00 AM – 6:00 PM	Hall A	Poster
996	65	8:00 AM – 6:00 PM	Hall A	Poster
Poster Session C: Burden of Disease - Infections				
997	66	8:00 AM – 6:00 PM	Hall A	Poster
998	67	8:00 AM – 6:00 PM	Hall A	Poster
999	68	8:00 AM – 6:00 PM	Hall A	Poster
1000	69	8:00 AM – 6:00 PM	Hall A	Poster
1001	70	8:00 AM – 6:00 PM	Hall A	Poster
1002	71	8:00 AM – 6:00 PM	Hall A	Poster
1003	72	8:00 AM – 6:00 PM	Hall A	Poster
1004	73	8:00 AM – 6:00 PM	Hall A	Poster
1005	74	8:00 AM – 6:00 PM	Hall A	Poster
1006	75	8:00 AM – 6:00 PM	Hall A	Poster
1007	76	8:00 AM – 6:00 PM	Hall A	Poster
1008	77	8:00 AM – 6:00 PM	Hall A	With-drawn
1009	78	8:00 AM – 6:00 PM	Hall A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
1010	79	8:00 AM – 6:00 PM	Hall A	Poster
1011	80	8:00 AM – 6:00 PM	Hall A	Poster
1012	81	8:00 AM – 6:00 PM	Hall A	Poster
Poster Session C: Burden of Disease - Musculoskeletal				
1013	82	8:00 AM – 6:00 PM	Hall A	Poster
1014	83	8:00 AM – 6:00 PM	Hall A	Poster
1015	84	8:00 AM – 6:00 PM	Hall A	Poster
1016	85	8:00 AM – 6:00 PM	Hall A	Poster
1017	86	8:00 AM – 6:00 PM	Hall A	Poster
1018	87	8:00 AM – 6:00 PM	Hall A	Poster
1019	88	8:00 AM – 6:00 PM	Hall A	Poster
1020	89	8:00 AM – 6:00 PM	Hall A	Poster
1021	90	8:00 AM – 6:00 PM	Hall A	Poster
1022	91	8:00 AM – 6:00 PM	Hall A	Poster
1023	92	8:00 AM – 6:00 PM	Hall A	Poster
1024	93	8:00 AM – 6:00 PM	Hall A	Poster
1025	94	8:00 AM – 6:00 PM	Hall A	Poster
1026	95	8:00 AM – 6:00 PM	Hall A	Poster
1027	96	8:00 AM – 6:00 PM	Hall A	Poster
Poster Session C: Drug Effectiveness - Cardiovascular Diseases				
1028	97	8:00 AM – 6:00 PM	Hall A	Poster
1029	98	8:00 AM – 6:00 PM	Hall A	Poster
1030	99	8:00 AM – 6:00 PM	Hall A	Poster
1031	100	8:00 AM – 6:00 PM	Hall A	Poster
1032	101	8:00 AM – 6:00 PM	Hall A	Poster
1033	102	8:00 AM – 6:00 PM	Hall A	Poster
1034	103	8:00 AM – 6:00 PM	Hall A	Poster
1035	104	8:00 AM – 6:00 PM	Hall A	Poster
1036	105	8:00 AM – 6:00 PM	Hall A	Poster
1037	106	8:00 AM – 6:00 PM	Hall A	Poster
Poster Session C: Drug Effectiveness - Musculoskeletal Diseases				
1038	107	8:00 AM – 6:00 PM	Hall A	Poster
1039	108	8:00 AM – 6:00 PM	Hall A	Poster
Poster Session C: Drug Effectiveness - Other Diseases				
1040	109	8:00 AM – 6:00 PM	Hall A	Poster
1041	110	8:00 AM – 6:00 PM	Hall A	Poster
1042	111	8:00 AM – 6:00 PM	Hall A	Poster

Abstract Index

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

Wednesday, August 28, 2019 (continued)**Poster Session C: Drug Utilization - Infections**

1043	112	8:00 AM – 6:00 PM	Hall A	Poster
1044	113	8:00 AM – 6:00 PM	Hall A	Poster
1045	114	8:00 AM – 6:00 PM	Hall A	Poster
1046	115	8:00 AM – 6:00 PM	Hall A	Poster
1047	116	8:00 AM – 6:00 PM	Hall A	Poster
1048	117	8:00 AM – 6:00 PM	Hall A	Poster
1049	118	8:00 AM – 6:00 PM	Hall A	Poster
1050	119	8:00 AM – 6:00 PM	Hall A	Poster
1051	120	8:00 AM – 6:00 PM	Hall A	Poster
1052	121	8:00 AM – 6:00 PM	Hall A	Poster
1053	122	8:00 AM – 6:00 PM	Hall A	Poster
1054	123	8:00 AM – 6:00 PM	Hall A	Poster
1055	124	8:00 AM – 6:00 PM	Hall A	With-drawn
1056	125	8:00 AM – 6:00 PM	Hall A	Poster
1057	126	8:00 AM – 6:00 PM	Hall A	Poster
1058	127	8:00 AM – 6:00 PM	Hall A	Poster
1059	128	8:00 AM – 6:00 PM	Hall A	Poster
1060	129	8:00 AM – 6:00 PM	Hall A	Poster
1061	130	8:00 AM – 6:00 PM	Hall A	Poster
1062	131	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session C: Drug Utilization - Endocrine and Metabolism

1063	132	8:00 AM – 6:00 PM	Hall A	Poster
1064	133	8:00 AM – 6:00 PM	Hall A	Poster
1065	134	8:00 AM – 6:00 PM	Hall A	Poster
1066	135	8:00 AM – 6:00 PM	Hall A	Poster
1067	136	8:00 AM – 6:00 PM	Hall A	Poster
1068	137	8:00 AM – 6:00 PM	Hall A	Poster
1069	138	8:00 AM – 6:00 PM	Hall A	Poster
1070	139	8:00 AM – 6:00 PM	Hall A	Poster
1071	140	8:00 AM – 6:00 PM	Hall A	Poster
1072	141	8:00 AM – 6:00 PM	Hall A	Poster
1073	142	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session C: Drug Utilization - Gastrointestinal and Liver

1074	143	8:00 AM – 6:00 PM	Hall A	Poster
------	-----	-------------------	--------	--------

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

1075	144	8:00 AM – 6:00 PM	Hall A	Poster
1076	145	8:00 AM – 6:00 PM	Hall A	Poster
1077	146	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session C: Drug Utilization - Methods, Interventions, and Implementations

1078	147	8:00 AM – 6:00 PM	Hall A	Poster
1079	148	8:00 AM – 6:00 PM	Hall A	Poster
1080	149	8:00 AM – 6:00 PM	Hall A	Poster
1081	150	8:00 AM – 6:00 PM	Hall A	Poster
1082	151	8:00 AM – 6:00 PM	Hall A	Poster
1083	152	8:00 AM – 6:00 PM	Hall A	Poster
1084	153	8:00 AM – 6:00 PM	Hall A	Poster
1085	154	8:00 AM – 6:00 PM	Hall A	Poster
1086	155	8:00 AM – 6:00 PM	Hall A	Poster
1087	156	8:00 AM – 6:00 PM	Hall A	With-drawn
1088	157	8:00 AM – 6:00 PM	Hall A	Poster
1089	158	8:00 AM – 6:00 PM	Hall A	Poster
1090	159	8:00 AM – 6:00 PM	Hall A	Poster
1091	160	8:00 AM – 6:00 PM	Hall A	Poster
1092	161	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session C: Drug Utilization - Policy

1093	162	8:00 AM – 6:00 PM	Hall A	Poster
1094	163	8:00 AM – 6:00 PM	Hall A	Poster
1095	164	8:00 AM – 6:00 PM	Hall A	Poster
1096	165	8:00 AM – 6:00 PM	Hall A	Poster
1097	166	8:00 AM – 6:00 PM	Hall A	Poster
1098	167	8:00 AM – 6:00 PM	Hall A	Poster
1099	168	8:00 AM – 6:00 PM	Hall A	Poster
1100	169	8:00 AM – 6:00 PM	Hall A	Poster
1101	170	8:00 AM – 6:00 PM	Hall A	Poster
1102	171	8:00 AM – 6:00 PM	Hall A	Poster
1103	172	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session C: Drug Utilization - Polypharmacy and Appropriateness of Use of Medications

1104	173	8:00 AM – 6:00 PM	Hall A	Poster
1105	174	8:00 AM – 6:00 PM	Hall A	Poster
1106	175	8:00 AM – 6:00 PM	Hall A	Poster
1107	176	8:00 AM – 6:00 PM	Hall A	Poster
1108	177	8:00 AM – 6:00 PM	Hall A	Poster



Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

Wednesday, August 28, 2019 (continued)

1109	178	8:00 AM – 6:00 PM	Hall A	Poster
1110	179	8:00 AM – 6:00 PM	Hall A	Poster
1111	180	8:00 AM – 6:00 PM	Hall A	Poster
1112	181	8:00 AM – 6:00 PM	Hall A	Poster
1113	182	8:00 AM – 6:00 PM	Hall A	Poster
1114	183	8:00 AM – 6:00 PM	Hall A	Poster
1115	184	8:00 AM – 6:00 PM	Hall A	Poster
1116	185	8:00 AM – 6:00 PM	Hall A	Poster
1117	186	8:00 AM – 6:00 PM	Hall A	Poster
1118	187	8:00 AM – 6:00 PM	Hall A	Poster
1119	188	8:00 AM – 6:00 PM	Hall A	Poster
1120	189	8:00 AM – 6:00 PM	Hall A	Poster
1121	190	8:00 AM – 6:00 PM	Hall A	Poster
1122	191	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session C: Drug Utilization - Respiratory

1123	192	8:00 AM – 6:00 PM	Hall A	Poster
1124	193	8:00 AM – 6:00 PM	Hall A	Poster
1125	194	8:00 AM – 6:00 PM	Hall A	Poster
1126	195	8:00 AM – 6:00 PM	Hall A	Poster
1127	196	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session C: Drug Utilization - Potpourri

1128	197	8:00 AM – 6:00 PM	Hall A	Poster
1129	198	8:00 AM – 6:00 PM	Hall A	Poster
1130	199	8:00 AM – 6:00 PM	Hall A	Poster
1131	200	8:00 AM – 6:00 PM	Hall A	Poster
1132	201	8:00 AM – 6:00 PM	Hall A	Poster
1133	202	8:00 AM – 6:00 PM	Hall A	Poster
1134	203	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session C: Patient-Reported Outcomes and Quality of Life

1135	204	8:00 AM – 6:00 PM	Hall A	Poster
1136	205	8:00 AM – 6:00 PM	Hall A	Poster
1137	206	8:00 AM – 6:00 PM	Hall A	Poster
1138	207	8:00 AM – 6:00 PM	Hall A	Poster
1139	208	8:00 AM – 6:00 PM	Hall A	Poster
1140	209	8:00 AM – 6:00 PM	Hall A	Poster
1141	210	8:00 AM – 6:00 PM	Hall A	Poster
1142	211	8:00 AM – 6:00 PM	Hall A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

1143	212	8:00 AM – 6:00 PM	Hall A	Poster
1144	213	8:00 AM – 6:00 PM	Hall A	Poster
1145	214	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session C: Pharmacovigilance - Cardiovascular

1146	215	8:00 AM – 6:00 PM	Hall A	Poster
1147	216	8:00 AM – 6:00 PM	Hall A	Poster
1148	217	8:00 AM – 6:00 PM	Hall A	Poster
1149	218	8:00 AM – 6:00 PM	Hall A	Poster
1150	219	8:00 AM – 6:00 PM	Hall A	Poster
1151	220	8:00 AM – 6:00 PM	Hall A	Poster
1152	221	8:00 AM – 6:00 PM	Hall A	Poster
1153	222	8:00 AM – 6:00 PM	Hall A	Poster
1154	223	8:00 AM – 6:00 PM	Hall A	Poster
1155	224	8:00 AM – 6:00 PM	Hall A	Poster
1156	225	8:00 AM – 6:00 PM	Hall A	Poster
1157	226	8:00 AM – 6:00 PM	Hall A	Poster
1158	227	8:00 AM – 6:00 PM	Hall A	Poster
1159	228	8:00 AM – 6:00 PM	Hall A	Poster
1160	229	8:00 AM – 6:00 PM	Hall A	Poster
1161	230	8:00 AM – 6:00 PM	Hall A	Poster
1162	231	8:00 AM – 6:00 PM	Hall A	Poster
1163	232	8:00 AM – 6:00 PM	Hall A	Poster
1164	233	8:00 AM – 6:00 PM	Hall A	Poster
1165	234	8:00 AM – 6:00 PM	Hall A	Poster
1166	235	8:00 AM – 6:00 PM	Hall A	Poster
1167	236	8:00 AM – 6:00 PM	Hall A	Poster
1168	237	8:00 AM – 6:00 PM	Hall A	Poster
1169	238	8:00 AM – 6:00 PM	Hall A	Poster
1170	239	8:00 AM – 6:00 PM	Hall A	With- drawn
1171	240	8:00 AM – 6:00 PM	Hall A	Poster
1172	241	8:00 AM – 6:00 PM	Hall A	Poster
1173	242	8:00 AM – 6:00 PM	Hall A	Poster
1174	243	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session C: Pharmacovigilance - Endocrine and Metabolism

1175	244	8:00 AM – 6:00 PM	Hall A	Poster
1176	245	8:00 AM – 6:00 PM	Hall A	Poster
1177	246	8:00 AM – 6:00 PM	Hall A	Poster

Abstract Index

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

Wednesday, August 28, 2019 (continued)

1178	247	8:00 AM – 6:00 PM	Hall A	Poster
1179	248	8:00 AM – 6:00 PM	Hall A	Poster
1180	249	8:00 AM – 6:00 PM	Hall A	Poster
1181	250	8:00 AM – 6:00 PM	Hall A	With-drawn
1182	251	8:00 AM – 6:00 PM	Hall A	Poster
1183	252	8:00 AM – 6:00 PM	Hall A	Poster
1184	253	8:00 AM – 6:00 PM	Hall A	Poster
1185	254	8:00 AM – 6:00 PM	Hall A	Poster
1186	255	8:00 AM – 6:00 PM	Hall A	Poster
1187	256	8:00 AM – 6:00 PM	Hall A	Poster
1188	257	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session C: Pharmacovigilance - Gastrointestinal and Liver

1189	258	8:00 AM – 6:00 PM	Hall A	Poster
1190	259	8:00 AM – 6:00 PM	Hall A	Poster
1191	260	8:00 AM – 6:00 PM	Hall A	Poster
1192	261	8:00 AM – 6:00 PM	Hall A	Poster
1193	262	8:00 AM – 6:00 PM	Hall A	Poster
1194	263	8:00 AM – 6:00 PM	Hall A	Poster
1195	264	8:00 AM – 6:00 PM	Hall A	Poster
1196	265	8:00 AM – 6:00 PM	Hall A	With-drawn
1197	266	8:00 AM – 6:00 PM	Hall A	Poster
1198	267	8:00 AM – 6:00 PM	Hall A	Poster
1199	268	8:00 AM – 6:00 PM	Hall A	Poster
1200	269	8:00 AM – 6:00 PM	Hall A	Poster
1201	270	8:00 AM – 6:00 PM	Hall A	Poster

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

Poster Session C: Pharmacovigilance - Infections

1202	271	8:00 AM – 6:00 PM	Hall A	Poster
1203	272	8:00 AM – 6:00 PM	Hall A	Poster
1204	273	8:00 AM – 6:00 PM	Hall A	Poster
1205	274	8:00 AM – 6:00 PM	Hall A	Poster
1206	275	8:00 AM – 6:00 PM	Hall A	Poster
1207	276	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session C: Pharmacovigilance - Respiratory

1208	277	8:00 AM – 6:00 PM	Hall A	Poster
1209	278	8:00 AM – 6:00 PM	Hall A	Poster
1210	279	8:00 AM – 6:00 PM	Hall A	Poster

Poster Session C: Propensity Scores

1211	280	8:00 AM – 6:00 PM	Hall A	Poster
1212	281	8:00 AM – 6:00 PM	Hall A	Poster
1213	282	8:00 AM – 6:00 PM	Hall A	Poster
1214	283	8:00 AM – 6:00 PM	Hall A	Poster
1215	284	8:00 AM – 6:00 PM	Hall A	Poster
1216	285	8:00 AM – 6:00 PM	Hall A	Poster
1217	286	8:00 AM – 6:00 PM	Hall A	Poster



NEXT-GENERATION, DATA-DRIVEN HEALTHCARE INSIGHTS & SOLUTIONS

FROM THE POINT OF CARE
TO EVERYDAY LIFE

By leveraging a vast and growing electronic health record ambulatory footprint along with strong provider relationships, Veradigm can transform biopharma research, market access, and real-world insights by aligning in point-of-care workflows. Visit us at [veradigm.com](https://www.veradigm.com) for more information.



Meeting Notes

ADVERTISERS INDEX

- Aarhus University, Department of Clinical Epidemiology 45
- Aetion, Inc. 33
- Amgen, Inc. 21
- Analysis Group. 38
- AstraZeneca 63
- Bayer 23
- BHE 27
- Biogen 52
- Boehringer-Ingelheim International 152
- Commonwealth Informatics 56
- Eli Lilly & Company 18
- EPI Excellence, LLC 68
- Evidera 9
- Harvard Pilgrim Healthcare Institute 23
- HealthCore, Inc. 13
- IBM Watson Health 43
- ICON plc 30
- IQVIA 40
- JMDC, Inc. 19
- Kantar Health 27
- Optum 52
- Oxon Epidemiology 68
- Pfizer 35
- PharmaLex and DGI, LLC 63
- RTI Health Solutions 38
- Servier 40
- United Biosource 30
- Veradigm 147
- Wiley Publications. 154



A series of horizontal dotted lines spanning the width of the page, intended for taking meeting notes.

Meeting Notes



A series of horizontal dotted lines spanning the width of the page, intended for taking meeting notes.



A series of horizontal dotted lines spanning the width of the page, intended for taking meeting notes.



Improving the health of humans and animals...

... is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients' lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry's top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals.

The department Global Epidemiology, Real World Evidence- Center of Excellence contributes substantially to achieving these goals by evaluating patient populations and our products in real world settings and is currently expanding.

Would you like to join our team?

Please send an e-mail to epidemiology@boehringer-ingelheim.com indicating your interest.

www.boehringer-ingelheim.com



International Conference on Pharmacoepidemiology & Therapeutic Risk Management 36TH ICPE/BERLIN ABSTRACTS INVITED

The essential pharmacoepidemiology annual scientific conference is scheduled for Berlin, August 26-30, 2020. Berlin's glamour, grit, culture, architecture, food, and history await you.

KEY DATES

- **December 16, 2019:** Online abstract submission opens. Abstracts are only accepted via the online submission site
- **February 12, 2020:** Abstract submissions closes; abstracts are not accepted past this date in any form
- **March 2, 2020:** ICPE Scholarship submission closes
- **April 2020:** Abstracts reviewed by ISPE's Scientific Program Committee
- **June 19, 2020:** Acceptance notifications issued

All presenters and panelists (workshop/symposia) must register to attend 36th ICPE/Berlin.

STUDENT AWARDS & SCHOLARSHIPS

ISPE grants awards to recognize and encourage student excellence in pharmacoepidemiology and scholarships to help defray conference expenses. Details of awards and scholarships will be available on pharmacoepi.org in December 2019.

SPONSORSHIPS, EXHIBITS & ACADEMIC SHOWCASE

ISPE offers organizations, institutions and academic programs opportunities to support the conference while sharing products and services with attendees. Visit pharmacoepi.org/meetings/36ICPE in December for a conference sponsorship/exhibitor prospectus.



Visit pharmacoepi.org/meetings/36ICPE for conference information.

36TH ICPE
August 26-30, 2020

Estrel Hotel & Congress Center
Berlin, Germany

Official Journal of the International Society for Pharmacoepidemiology

Editor-In-Chief: Professor Brian L. Strom

Pharmacoepidemiology & Drug Safety provides an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology.

**Free online access for ISPE members
via the society website**

Congratulations to the Ronald D. Mann Best Paper Award Winners – 2018

First Prize

Methods for addressing “innocent bystanders” when evaluating safety of concomitant vaccines

Shirley V. Wang; Abdurrahman Abdurrob; Julia Spoendlin; Edwin Lewis; Sophia R. Newcomer; Bruce H. Fireman; Matthew F. Daley; Jason M. Glanz; Jonathan Duffy; Eric S. Weintraub; Martin Kulldorff

Honorable Mention:

Risk of acute myocardial infarction with real-world NSAIDs depends on dose and timing of exposure

Michèle Bally; Marie-Eve Beauchamp; Michal Abrahamowicz; Lyne Nadeau; James Brophy

Honorable Mention:


Comparative effectiveness and safety of antiplatelet drugs in patients with diabetes mellitus and acute coronary syndrome

Julia Spoendlin; Joshua J. Gagne; Jennifer Lewey; Elisabetta Patorno; Sebastian Schneeweiss; Rishi J. Desai

For more information on these top papers and other journal features, please visit:

www.pdsjournal.org

Print ISSN: 1053-8569 • Online ISSN: 1099-1557 • 2019 Volume: 28 • Frequency: Monthly




Impact Factor
2.314

*2017 Journal Citation Reports®

Convention Center Floor Plans

Convention Center 200 Level




NOTE: Shading around columns indicates a minimum clearance of 5' on each side that must be maintained for access to electrical services and fire hose connections.


15' Clearance must be maintained in any direction from emergency exit doorways

Dimensions are approximate verify in field

KEY	
R	Restroom
PE	Public Elevator
FrE	Freight Elevator
C	Concessions
F	Fire Hose Connection
+	First Aid
⬤	Exit Doors
IDE	Heart Defibrillator




Convention Center 300 Level



E	= Elevator
FrE	= Freight Elevator
R	= Rest Room
T	= Telephone
W	= Water Fountain

Marriott Floor Plans

Marriott Level 3 Meeting Rooms



Marriott Level 5 Ballroom

